id	sid	tid	token	lemma	pos
cord-340028-6oicmeam	1	1	key	key	NN
cord-340028-6oicmeam	1	2	:	:	:
cord-340028-6oicmeam	2	1	cord-340028	cord-340028	NNP
cord-340028-6oicmeam	2	2	-	-	HYPH
cord-340028-6oicmeam	2	3	6oicmeam	6oicmeam	CD
cord-340028-6oicmeam	2	4	authors	author	NNS
cord-340028-6oicmeam	2	5	:	:	:
cord-340028-6oicmeam	2	6	Zhavoronkov	Zhavoronkov	NNP
cord-340028-6oicmeam	2	7	,	,	,
cord-340028-6oicmeam	2	8	Alex	Alex	NNP
cord-340028-6oicmeam	2	9	title	title	NN
cord-340028-6oicmeam	2	10	:	:	:
cord-340028-6oicmeam	2	11	Geroprotective	Geroprotective	NNP
cord-340028-6oicmeam	2	12	and	and	CC
cord-340028-6oicmeam	2	13	senoremediative	senoremediative	JJ
cord-340028-6oicmeam	2	14	strategies	strategy	NNS
cord-340028-6oicmeam	2	15	to	to	TO
cord-340028-6oicmeam	2	16	reduce	reduce	VB
cord-340028-6oicmeam	2	17	the	the	DT
cord-340028-6oicmeam	2	18	comorbidity	comorbidity	NN
cord-340028-6oicmeam	2	19	,	,	,
cord-340028-6oicmeam	2	20	infection	infection	NN
cord-340028-6oicmeam	2	21	rates	rate	NNS
cord-340028-6oicmeam	2	22	,	,	,
cord-340028-6oicmeam	2	23	severity	severity	NN
cord-340028-6oicmeam	2	24	,	,	,
cord-340028-6oicmeam	2	25	and	and	CC
cord-340028-6oicmeam	2	26	lethality	lethality	NN
cord-340028-6oicmeam	2	27	in	in	IN
cord-340028-6oicmeam	2	28	gerophilic	gerophilic	NNP
cord-340028-6oicmeam	2	29	and	and	CC
cord-340028-6oicmeam	2	30	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	2	31	infections	infection	NNS
cord-340028-6oicmeam	2	32	date	date	NN
cord-340028-6oicmeam	2	33	:	:	:
cord-340028-6oicmeam	2	34	2020	2020	CD
cord-340028-6oicmeam	2	35	-	-	HYPH
cord-340028-6oicmeam	2	36	03	03	CD
cord-340028-6oicmeam	2	37	-	-	HYPH
cord-340028-6oicmeam	2	38	31	31	CD
cord-340028-6oicmeam	2	39	journal	journal	NN
cord-340028-6oicmeam	2	40	:	:	:
cord-340028-6oicmeam	2	41	Aging	age	VBG
cord-340028-6oicmeam	2	42	(	(	-LRB-
cord-340028-6oicmeam	2	43	Albany	Albany	NNP
cord-340028-6oicmeam	2	44	NY	NY	NNP
cord-340028-6oicmeam	2	45	)	)	-RRB-
cord-340028-6oicmeam	3	1	DOI	DOI	NNP
cord-340028-6oicmeam	3	2	:	:	:
cord-340028-6oicmeam	4	1	10.18632	10.18632	CD
cord-340028-6oicmeam	4	2	/	/	SYM
cord-340028-6oicmeam	4	3	aging.102988	aging.102988	NN
cord-340028-6oicmeam	4	4	sha	sha	NNP
cord-340028-6oicmeam	4	5	:	:	:
cord-340028-6oicmeam	4	6	dafc17c07befd2b040bdf2e79a7bf5eb4b7f7841	dafc17c07befd2b040bdf2e79a7bf5eb4b7f7841	NNP
cord-340028-6oicmeam	4	7	doc_id	doc_id	NNP
cord-340028-6oicmeam	4	8	:	:	:
cord-340028-6oicmeam	4	9	340028	340028	CD
cord-340028-6oicmeam	4	10	cord_uid	cord_uid	NNS
cord-340028-6oicmeam	4	11	:	:	:
cord-340028-6oicmeam	5	1	6oicmeam	6oicmeam	CD
cord-340028-6oicmeam	6	1	The	the	DT
cord-340028-6oicmeam	6	2	recently	recently	RB
cord-340028-6oicmeam	6	3	identified	identify	VBN
cord-340028-6oicmeam	6	4	SARS	SARS	NNP
cord-340028-6oicmeam	6	5	-	-	HYPH
cord-340028-6oicmeam	6	6	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	6	7	betacoronavirus	betacoronavirus	NN
cord-340028-6oicmeam	6	8	responsible	responsible	JJ
cord-340028-6oicmeam	6	9	for	for	IN
cord-340028-6oicmeam	6	10	the	the	DT
cord-340028-6oicmeam	6	11	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	6	12	pandemic	pandemic	NN
cord-340028-6oicmeam	6	13	has	have	VBZ
cord-340028-6oicmeam	6	14	uncovered	uncover	VBN
cord-340028-6oicmeam	6	15	the	the	DT
cord-340028-6oicmeam	6	16	age	age	NN
cord-340028-6oicmeam	6	17	-	-	HYPH
cord-340028-6oicmeam	6	18	associated	associate	VBN
cord-340028-6oicmeam	6	19	vulnerability	vulnerability	NN
cord-340028-6oicmeam	6	20	in	in	IN
cord-340028-6oicmeam	6	21	the	the	DT
cord-340028-6oicmeam	6	22	burden	burden	NN
cord-340028-6oicmeam	6	23	of	of	IN
cord-340028-6oicmeam	6	24	disease	disease	NN
cord-340028-6oicmeam	6	25	and	and	CC
cord-340028-6oicmeam	6	26	put	put	VB
cord-340028-6oicmeam	6	27	aging	age	VBG
cord-340028-6oicmeam	6	28	research	research	NN
cord-340028-6oicmeam	6	29	in	in	IN
cord-340028-6oicmeam	6	30	the	the	DT
cord-340028-6oicmeam	6	31	spotlight	spotlight	NN
cord-340028-6oicmeam	6	32	.	.	.
cord-340028-6oicmeam	7	1	The	the	DT
cord-340028-6oicmeam	7	2	limited	limited	JJ
cord-340028-6oicmeam	7	3	data	datum	NNS
cord-340028-6oicmeam	7	4	available	available	JJ
cord-340028-6oicmeam	7	5	indicates	indicate	VBZ
cord-340028-6oicmeam	7	6	that	that	IN
cord-340028-6oicmeam	7	7	COVID-19	covid-19	PRP
cord-340028-6oicmeam	7	8	should	should	MD
cord-340028-6oicmeam	7	9	be	be	VB
cord-340028-6oicmeam	7	10	referred	refer	VBN
cord-340028-6oicmeam	7	11	to	to	IN
cord-340028-6oicmeam	7	12	as	as	IN
cord-340028-6oicmeam	7	13	a	a	DT
cord-340028-6oicmeam	7	14	gerolavic	gerolavic	NN
cord-340028-6oicmeam	7	15	(	(	-LRB-
cord-340028-6oicmeam	7	16	from	from	IN
cord-340028-6oicmeam	7	17	Greek	Greek	NNP
cord-340028-6oicmeam	7	18	,	,	,
cord-340028-6oicmeam	7	19	géros	géros	FW
cord-340028-6oicmeam	7	20	“	"	``
cord-340028-6oicmeam	7	21	old	old	JJ
cord-340028-6oicmeam	7	22	man	man	NN
cord-340028-6oicmeam	7	23	”	"	''
cord-340028-6oicmeam	7	24	and	and	CC
cord-340028-6oicmeam	7	25	epilavís	epilavís	NNP
cord-340028-6oicmeam	7	26	,	,	,
cord-340028-6oicmeam	7	27	“	"	``
cord-340028-6oicmeam	7	28	harmful	harmful	JJ
cord-340028-6oicmeam	7	29	”	"	''
cord-340028-6oicmeam	7	30	)	)	-RRB-
cord-340028-6oicmeam	7	31	infection	infection	NN
cord-340028-6oicmeam	7	32	because	because	IN
cord-340028-6oicmeam	7	33	the	the	DT
cord-340028-6oicmeam	7	34	infection	infection	NN
cord-340028-6oicmeam	7	35	rates	rate	NNS
cord-340028-6oicmeam	7	36	,	,	,
cord-340028-6oicmeam	7	37	severity	severity	NN
cord-340028-6oicmeam	7	38	,	,	,
cord-340028-6oicmeam	7	39	and	and	CC
cord-340028-6oicmeam	7	40	lethality	lethality	NN
cord-340028-6oicmeam	7	41	are	be	VBP
cord-340028-6oicmeam	7	42	substantially	substantially	RB
cord-340028-6oicmeam	7	43	higher	high	JJR
cord-340028-6oicmeam	7	44	in	in	IN
cord-340028-6oicmeam	7	45	the	the	DT
cord-340028-6oicmeam	7	46	population	population	NN
cord-340028-6oicmeam	7	47	aged	age	VBN
cord-340028-6oicmeam	7	48	60	60	CD
cord-340028-6oicmeam	7	49	and	and	CC
cord-340028-6oicmeam	7	50	older	old	JJR
cord-340028-6oicmeam	7	51	.	.	.
cord-340028-6oicmeam	8	1	This	this	DT
cord-340028-6oicmeam	8	2	is	be	VBZ
cord-340028-6oicmeam	8	3	primarily	primarily	RB
cord-340028-6oicmeam	8	4	due	due	JJ
cord-340028-6oicmeam	8	5	to	to	IN
cord-340028-6oicmeam	8	6	comorbidity	comorbidity	NN
cord-340028-6oicmeam	8	7	but	but	CC
cord-340028-6oicmeam	8	8	may	may	MD
cord-340028-6oicmeam	8	9	be	be	VB
cord-340028-6oicmeam	8	10	partially	partially	RB
cord-340028-6oicmeam	8	11	due	due	JJ
cord-340028-6oicmeam	8	12	to	to	IN
cord-340028-6oicmeam	8	13	immunosenescence	immunosenescence	NNP
cord-340028-6oicmeam	8	14	,	,	,
cord-340028-6oicmeam	8	15	decreased	decrease	VBD
cord-340028-6oicmeam	8	16	immune	immune	JJ
cord-340028-6oicmeam	8	17	function	function	NN
cord-340028-6oicmeam	8	18	in	in	IN
cord-340028-6oicmeam	8	19	the	the	DT
cord-340028-6oicmeam	8	20	elderly	elderly	JJ
cord-340028-6oicmeam	8	21	,	,	,
cord-340028-6oicmeam	8	22	and	and	CC
cord-340028-6oicmeam	8	23	general	general	JJ
cord-340028-6oicmeam	8	24	loss	loss	NN
cord-340028-6oicmeam	8	25	of	of	IN
cord-340028-6oicmeam	8	26	function	function	NN
cord-340028-6oicmeam	8	27	,	,	,
cord-340028-6oicmeam	8	28	fitness	fitness	NN
cord-340028-6oicmeam	8	29	,	,	,
cord-340028-6oicmeam	8	30	and	and	CC
cord-340028-6oicmeam	8	31	increased	increase	VBN
cord-340028-6oicmeam	8	32	frailty	frailty	NN
cord-340028-6oicmeam	8	33	associated	associate	VBN
cord-340028-6oicmeam	8	34	with	with	IN
cord-340028-6oicmeam	8	35	aging	age	VBG
cord-340028-6oicmeam	8	36	.	.	.
cord-340028-6oicmeam	9	1	Immunosenescence	Immunosenescence	NNP
cord-340028-6oicmeam	9	2	is	be	VBZ
cord-340028-6oicmeam	9	3	a	a	DT
cord-340028-6oicmeam	9	4	major	major	JJ
cord-340028-6oicmeam	9	5	factor	factor	NN
cord-340028-6oicmeam	9	6	affecting	affect	VBG
cord-340028-6oicmeam	9	7	vaccination	vaccination	NN
cord-340028-6oicmeam	9	8	response	response	NN
cord-340028-6oicmeam	9	9	,	,	,
cord-340028-6oicmeam	9	10	as	as	RB
cord-340028-6oicmeam	9	11	well	well	RB
cord-340028-6oicmeam	9	12	as	as	IN
cord-340028-6oicmeam	9	13	the	the	DT
cord-340028-6oicmeam	9	14	severity	severity	NN
cord-340028-6oicmeam	9	15	and	and	CC
cord-340028-6oicmeam	9	16	lethality	lethality	NN
cord-340028-6oicmeam	9	17	of	of	IN
cord-340028-6oicmeam	9	18	infectious	infectious	JJ
cord-340028-6oicmeam	9	19	diseases	disease	NNS
cord-340028-6oicmeam	9	20	.	.	.
cord-340028-6oicmeam	10	1	While	while	IN
cord-340028-6oicmeam	10	2	vaccination	vaccination	NN
cord-340028-6oicmeam	10	3	reduces	reduce	VBZ
cord-340028-6oicmeam	10	4	infection	infection	NN
cord-340028-6oicmeam	10	5	rates	rate	NNS
cord-340028-6oicmeam	10	6	,	,	,
cord-340028-6oicmeam	10	7	and	and	CC
cord-340028-6oicmeam	10	8	therapeutic	therapeutic	JJ
cord-340028-6oicmeam	10	9	interventions	intervention	NNS
cord-340028-6oicmeam	10	10	reduce	reduce	VBP
cord-340028-6oicmeam	10	11	the	the	DT
cord-340028-6oicmeam	10	12	severity	severity	NN
cord-340028-6oicmeam	10	13	and	and	CC
cord-340028-6oicmeam	10	14	lethality	lethality	NN
cord-340028-6oicmeam	10	15	of	of	IN
cord-340028-6oicmeam	10	16	infections	infection	NNS
cord-340028-6oicmeam	10	17	,	,	,
cord-340028-6oicmeam	10	18	these	these	DT
cord-340028-6oicmeam	10	19	interventions	intervention	NNS
cord-340028-6oicmeam	10	20	have	have	VBP
cord-340028-6oicmeam	10	21	limitations	limitation	NNS
cord-340028-6oicmeam	10	22	.	.	.
cord-340028-6oicmeam	11	1	Previous	previous	JJ
cord-340028-6oicmeam	11	2	studies	study	NNS
cord-340028-6oicmeam	11	3	showed	show	VBD
cord-340028-6oicmeam	11	4	that	that	IN
cord-340028-6oicmeam	11	5	postulated	postulate	VBN
cord-340028-6oicmeam	11	6	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	11	7	,	,	,
cord-340028-6oicmeam	11	8	such	such	JJ
cord-340028-6oicmeam	11	9	as	as	IN
cord-340028-6oicmeam	11	10	sirolimus	sirolimus	NNP
cord-340028-6oicmeam	11	11	(	(	-LRB-
cord-340028-6oicmeam	11	12	rapamycin	rapamycin	NNP
cord-340028-6oicmeam	11	13	)	)	-RRB-
cord-340028-6oicmeam	11	14	and	and	CC
cord-340028-6oicmeam	11	15	its	-PRON-	PRP$
cord-340028-6oicmeam	11	16	close	close	JJ
cord-340028-6oicmeam	11	17	derivative	derivative	JJ
cord-340028-6oicmeam	11	18	rapalog	rapalog	NN
cord-340028-6oicmeam	11	19	everolimus	everolimus	NNP
cord-340028-6oicmeam	11	20	(	(	-LRB-
cord-340028-6oicmeam	11	21	RAD001	RAD001	NNP
cord-340028-6oicmeam	11	22	)	)	-RRB-
cord-340028-6oicmeam	11	23	,	,	,
cord-340028-6oicmeam	11	24	decreased	decrease	VBD
cord-340028-6oicmeam	11	25	infection	infection	NN
cord-340028-6oicmeam	11	26	rates	rate	NNS
cord-340028-6oicmeam	11	27	in	in	IN
cord-340028-6oicmeam	11	28	a	a	DT
cord-340028-6oicmeam	11	29	small	small	JJ
cord-340028-6oicmeam	11	30	sample	sample	NN
cord-340028-6oicmeam	11	31	of	of	IN
cord-340028-6oicmeam	11	32	elderly	elderly	JJ
cord-340028-6oicmeam	11	33	patients	patient	NNS
cord-340028-6oicmeam	11	34	.	.	.
cord-340028-6oicmeam	12	1	This	this	DT
cord-340028-6oicmeam	12	2	article	article	NN
cord-340028-6oicmeam	12	3	presents	present	VBZ
cord-340028-6oicmeam	12	4	a	a	DT
cord-340028-6oicmeam	12	5	review	review	NN
cord-340028-6oicmeam	12	6	of	of	IN
cord-340028-6oicmeam	12	7	the	the	DT
cord-340028-6oicmeam	12	8	limited	limited	JJ
cord-340028-6oicmeam	12	9	literature	literature	NN
cord-340028-6oicmeam	12	10	available	available	JJ
cord-340028-6oicmeam	12	11	on	on	IN
cord-340028-6oicmeam	12	12	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	12	13	and	and	CC
cord-340028-6oicmeam	12	14	senoremediative	senoremediative	JJ
cord-340028-6oicmeam	12	15	interventions	intervention	NNS
cord-340028-6oicmeam	12	16	that	that	WDT
cord-340028-6oicmeam	12	17	may	may	MD
cord-340028-6oicmeam	12	18	be	be	VB
cord-340028-6oicmeam	12	19	investigated	investigate	VBN
cord-340028-6oicmeam	12	20	to	to	TO
cord-340028-6oicmeam	12	21	decrease	decrease	VB
cord-340028-6oicmeam	12	22	the	the	DT
cord-340028-6oicmeam	12	23	disease	disease	NN
cord-340028-6oicmeam	12	24	burden	burden	NN
cord-340028-6oicmeam	12	25	of	of	IN
cord-340028-6oicmeam	12	26	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	12	27	infections	infection	NNS
cord-340028-6oicmeam	12	28	.	.	.
cord-340028-6oicmeam	13	1	This	this	DT
cord-340028-6oicmeam	13	2	article	article	NN
cord-340028-6oicmeam	13	3	also	also	RB
cord-340028-6oicmeam	13	4	highlights	highlight	VBZ
cord-340028-6oicmeam	13	5	a	a	DT
cord-340028-6oicmeam	13	6	need	need	NN
cord-340028-6oicmeam	13	7	for	for	IN
cord-340028-6oicmeam	13	8	rigorous	rigorous	JJ
cord-340028-6oicmeam	13	9	clinical	clinical	JJ
cord-340028-6oicmeam	13	10	validation	validation	NN
cord-340028-6oicmeam	13	11	of	of	IN
cord-340028-6oicmeam	13	12	deep	deep	JJ
cord-340028-6oicmeam	13	13	aging	age	VBG
cord-340028-6oicmeam	13	14	clocks	clock	NNS
cord-340028-6oicmeam	13	15	as	as	IN
cord-340028-6oicmeam	13	16	surrogate	surrogate	JJ
cord-340028-6oicmeam	13	17	markers	marker	NNS
cord-340028-6oicmeam	13	18	of	of	IN
cord-340028-6oicmeam	13	19	biological	biological	JJ
cord-340028-6oicmeam	13	20	age	age	NN
cord-340028-6oicmeam	13	21	.	.	.
cord-340028-6oicmeam	14	1	These	these	DT
cord-340028-6oicmeam	14	2	could	could	MD
cord-340028-6oicmeam	14	3	be	be	VB
cord-340028-6oicmeam	14	4	used	use	VBN
cord-340028-6oicmeam	14	5	to	to	TO
cord-340028-6oicmeam	14	6	assess	assess	VB
cord-340028-6oicmeam	14	7	the	the	DT
cord-340028-6oicmeam	14	8	need	need	NN
cord-340028-6oicmeam	14	9	for	for	IN
cord-340028-6oicmeam	14	10	,	,	,
cord-340028-6oicmeam	14	11	and	and	CC
cord-340028-6oicmeam	14	12	efficacy	efficacy	NN
cord-340028-6oicmeam	14	13	of	of	IN
cord-340028-6oicmeam	14	14	,	,	,
cord-340028-6oicmeam	14	15	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	14	16	and	and	CC
cord-340028-6oicmeam	14	17	senoremediative	senoremediative	JJ
cord-340028-6oicmeam	14	18	interventions	intervention	NNS
cord-340028-6oicmeam	14	19	and	and	CC
cord-340028-6oicmeam	14	20	provide	provide	VB
cord-340028-6oicmeam	14	21	better	well	JJR
cord-340028-6oicmeam	14	22	protection	protection	NN
cord-340028-6oicmeam	14	23	for	for	IN
cord-340028-6oicmeam	14	24	elderly	elderly	JJ
cord-340028-6oicmeam	14	25	populations	population	NNS
cord-340028-6oicmeam	14	26	from	from	IN
cord-340028-6oicmeam	14	27	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	14	28	infections	infection	NNS
cord-340028-6oicmeam	14	29	.	.	.
cord-340028-6oicmeam	15	1	This	this	DT
cord-340028-6oicmeam	15	2	article	article	NN
cord-340028-6oicmeam	15	3	does	do	VBZ
cord-340028-6oicmeam	15	4	not	not	RB
cord-340028-6oicmeam	15	5	represent	represent	VB
cord-340028-6oicmeam	15	6	medical	medical	JJ
cord-340028-6oicmeam	15	7	advice	advice	NN
cord-340028-6oicmeam	15	8	and	and	CC
cord-340028-6oicmeam	15	9	the	the	DT
cord-340028-6oicmeam	15	10	medications	medication	NNS
cord-340028-6oicmeam	15	11	described	describe	VBN
cord-340028-6oicmeam	15	12	are	be	VBP
cord-340028-6oicmeam	15	13	not	not	RB
cord-340028-6oicmeam	15	14	yet	yet	RB
cord-340028-6oicmeam	15	15	licensed	license	VBN
cord-340028-6oicmeam	15	16	or	or	CC
cord-340028-6oicmeam	15	17	recommended	recommend	VBN
cord-340028-6oicmeam	15	18	as	as	IN
cord-340028-6oicmeam	15	19	immune	immune	JJ
cord-340028-6oicmeam	15	20	system	system	NN
cord-340028-6oicmeam	15	21	boosters	booster	NNS
cord-340028-6oicmeam	15	22	,	,	,
cord-340028-6oicmeam	15	23	as	as	IN
cord-340028-6oicmeam	15	24	they	-PRON-	PRP
cord-340028-6oicmeam	15	25	have	have	VBP
cord-340028-6oicmeam	15	26	not	not	RB
cord-340028-6oicmeam	15	27	undergone	undergo	VBN
cord-340028-6oicmeam	15	28	clinical	clinical	JJ
cord-340028-6oicmeam	15	29	evaluation	evaluation	NN
cord-340028-6oicmeam	15	30	for	for	IN
cord-340028-6oicmeam	15	31	this	this	DT
cord-340028-6oicmeam	15	32	purpose	purpose	NN
cord-340028-6oicmeam	15	33	.	.	.
cord-340028-6oicmeam	16	1	Aging	age	VBG
cord-340028-6oicmeam	16	2	is	be	VBZ
cord-340028-6oicmeam	16	3	a	a	DT
cord-340028-6oicmeam	16	4	complex	complex	JJ
cord-340028-6oicmeam	16	5	,	,	,
cord-340028-6oicmeam	16	6	multifactorial	multifactorial	JJ
cord-340028-6oicmeam	16	7	process	process	NN
cord-340028-6oicmeam	16	8	[	[	-LRB-
cord-340028-6oicmeam	16	9	1	1	CD
cord-340028-6oicmeam	16	10	]	]	-RRB-
cord-340028-6oicmeam	16	11	that	that	WDT
cord-340028-6oicmeam	16	12	leads	lead	VBZ
cord-340028-6oicmeam	16	13	to	to	IN
cord-340028-6oicmeam	16	14	loss	loss	NN
cord-340028-6oicmeam	16	15	of	of	IN
cord-340028-6oicmeam	16	16	function	function	NN
cord-340028-6oicmeam	16	17	and	and	CC
cord-340028-6oicmeam	16	18	is	be	VBZ
cord-340028-6oicmeam	16	19	the	the	DT
cord-340028-6oicmeam	16	20	primary	primary	JJ
cord-340028-6oicmeam	16	21	risk	risk	NN
cord-340028-6oicmeam	16	22	factor	factor	NN
cord-340028-6oicmeam	16	23	for	for	IN
cord-340028-6oicmeam	16	24	major	major	JJ
cord-340028-6oicmeam	16	25	human	human	JJ
cord-340028-6oicmeam	16	26	pathologies	pathology	NNS
cord-340028-6oicmeam	16	27	including	include	VBG
cord-340028-6oicmeam	16	28	cancer	cancer	NN
cord-340028-6oicmeam	16	29	,	,	,
cord-340028-6oicmeam	16	30	diabetes	diabetes	NN
cord-340028-6oicmeam	16	31	,	,	,
cord-340028-6oicmeam	16	32	cardiovascular	cardiovascular	JJ
cord-340028-6oicmeam	16	33	disorders	disorder	NNS
cord-340028-6oicmeam	16	34	,	,	,
cord-340028-6oicmeam	16	35	and	and	CC
cord-340028-6oicmeam	16	36	neurodegenerative	neurodegenerative	JJ
cord-340028-6oicmeam	16	37	diseases	disease	NNS
cord-340028-6oicmeam	16	38	[	[	-LRB-
cord-340028-6oicmeam	16	39	1	1	CD
cord-340028-6oicmeam	16	40	,	,	,
cord-340028-6oicmeam	16	41	2	2	CD
cord-340028-6oicmeam	16	42	]	]	-RRB-
cord-340028-6oicmeam	16	43	.	.	.
cord-340028-6oicmeam	17	1	Although	although	IN
cord-340028-6oicmeam	17	2	there	there	EX
cord-340028-6oicmeam	17	3	is	be	VBZ
cord-340028-6oicmeam	17	4	still	still	RB
cord-340028-6oicmeam	17	5	much	much	JJ
cord-340028-6oicmeam	17	6	debate	debate	NN
cord-340028-6oicmeam	17	7	in	in	IN
cord-340028-6oicmeam	17	8	the	the	DT
cord-340028-6oicmeam	17	9	scientific	scientific	JJ
cord-340028-6oicmeam	17	10	community	community	NN
cord-340028-6oicmeam	17	11	,	,	,
cord-340028-6oicmeam	17	12	proposals	proposal	NNS
cord-340028-6oicmeam	17	13	have	have	VBP
cord-340028-6oicmeam	17	14	been	be	VBN
cord-340028-6oicmeam	17	15	made	make	VBN
cord-340028-6oicmeam	17	16	to	to	TO
cord-340028-6oicmeam	17	17	classify	classify	VB
cord-340028-6oicmeam	17	18	aging	age	VBG
cord-340028-6oicmeam	17	19	as	as	IN
cord-340028-6oicmeam	17	20	a	a	DT
cord-340028-6oicmeam	17	21	disease	disease	NN
cord-340028-6oicmeam	17	22	in	in	IN
cord-340028-6oicmeam	17	23	order	order	NN
cord-340028-6oicmeam	17	24	to	to	TO
cord-340028-6oicmeam	17	25	develop	develop	VB
cord-340028-6oicmeam	17	26	therapeutic	therapeutic	JJ
cord-340028-6oicmeam	17	27	strategies	strategy	NNS
cord-340028-6oicmeam	17	28	to	to	TO
cord-340028-6oicmeam	17	29	prevent	prevent	VB
cord-340028-6oicmeam	17	30	or	or	CC
cord-340028-6oicmeam	17	31	delay	delay	VB
cord-340028-6oicmeam	17	32	the	the	DT
cord-340028-6oicmeam	17	33	onset	onset	NN
cord-340028-6oicmeam	17	34	of	of	IN
cord-340028-6oicmeam	17	35	age	age	NN
cord-340028-6oicmeam	17	36	-	-	HYPH
cord-340028-6oicmeam	17	37	related	relate	VBN
cord-340028-6oicmeam	17	38	illnessess	illnessess	NN
cord-340028-6oicmeam	17	39	[	[	-LRB-
cord-340028-6oicmeam	17	40	3	3	CD
cord-340028-6oicmeam	17	41	]	]	-RRB-
cord-340028-6oicmeam	17	42	[	[	-LRB-
cord-340028-6oicmeam	17	43	4	4	CD
cord-340028-6oicmeam	17	44	]	]	-RRB-
cord-340028-6oicmeam	17	45	[	[	-LRB-
cord-340028-6oicmeam	17	46	5	5	CD
cord-340028-6oicmeam	17	47	]	]	-RRB-
cord-340028-6oicmeam	17	48	.	.	.
cord-340028-6oicmeam	18	1	Increasing	increase	VBG
cord-340028-6oicmeam	18	2	frailty	frailty	NN
cord-340028-6oicmeam	18	3	with	with	IN
cord-340028-6oicmeam	18	4	age	age	NN
cord-340028-6oicmeam	18	5	leads	lead	VBZ
cord-340028-6oicmeam	18	6	to	to	IN
cord-340028-6oicmeam	18	7	an	an	DT
cord-340028-6oicmeam	18	8	increased	increase	VBN
cord-340028-6oicmeam	18	9	risk	risk	NN
cord-340028-6oicmeam	18	10	of	of	IN
cord-340028-6oicmeam	18	11	many	many	JJ
cord-340028-6oicmeam	18	12	diseases	disease	NNS
cord-340028-6oicmeam	18	13	.	.	.
cord-340028-6oicmeam	19	1	These	these	DT
cord-340028-6oicmeam	19	2	diseases	disease	NNS
cord-340028-6oicmeam	19	3	are	be	VBP
cord-340028-6oicmeam	19	4	commonly	commonly	RB
cord-340028-6oicmeam	19	5	referred	refer	VBN
cord-340028-6oicmeam	19	6	to	to	IN
cord-340028-6oicmeam	19	7	as	as	IN
cord-340028-6oicmeam	19	8	age	age	NN
cord-340028-6oicmeam	19	9	-	-	HYPH
cord-340028-6oicmeam	19	10	related	relate	VBN
cord-340028-6oicmeam	19	11	[	[	-LRB-
cord-340028-6oicmeam	19	12	6	6	CD
cord-340028-6oicmeam	19	13	]	]	-RRB-
cord-340028-6oicmeam	19	14	.	.	.
cord-340028-6oicmeam	20	1	Many	many	JJ
cord-340028-6oicmeam	20	2	pathogens	pathogen	NNS
cord-340028-6oicmeam	20	3	are	be	VBP
cord-340028-6oicmeam	20	4	more	more	RBR
cord-340028-6oicmeam	20	5	infectious	infectious	JJ
cord-340028-6oicmeam	20	6	and	and	CC
cord-340028-6oicmeam	20	7	prevalent	prevalent	JJ
cord-340028-6oicmeam	20	8	in	in	IN
cord-340028-6oicmeam	20	9	the	the	DT
cord-340028-6oicmeam	20	10	elderly	elderly	JJ
cord-340028-6oicmeam	20	11	,	,	,
cord-340028-6oicmeam	20	12	[	[	-LRB-
cord-340028-6oicmeam	20	13	7	7	CD
cord-340028-6oicmeam	20	14	]	]	-RRB-
cord-340028-6oicmeam	20	15	[	[	-LRB-
cord-340028-6oicmeam	20	16	8	8	CD
cord-340028-6oicmeam	20	17	]	]	-RRB-
cord-340028-6oicmeam	20	18	[	[	-LRB-
cord-340028-6oicmeam	20	19	9	9	CD
cord-340028-6oicmeam	20	20	]	]	-RRB-
cord-340028-6oicmeam	20	21	[	[	-LRB-
cord-340028-6oicmeam	20	22	10	10	CD
cord-340028-6oicmeam	20	23	]	]	-RRB-
cord-340028-6oicmeam	21	1	and	and	CC
cord-340028-6oicmeam	21	2	may	may	MD
cord-340028-6oicmeam	21	3	be	be	VB
cord-340028-6oicmeam	21	4	referred	refer	VBN
cord-340028-6oicmeam	21	5	to	to	IN
cord-340028-6oicmeam	21	6	as	as	RB
cord-340028-6oicmeam	21	7	gerophilic	gerophilic	NNP
cord-340028-6oicmeam	21	8	(	(	-LRB-
cord-340028-6oicmeam	21	9	from	from	IN
cord-340028-6oicmeam	21	10	Greek	Greek	NNP
cord-340028-6oicmeam	21	11	,	,	,
cord-340028-6oicmeam	21	12	géros	géros	FW
cord-340028-6oicmeam	21	13	"	"	``
cord-340028-6oicmeam	21	14	old	old	JJ
cord-340028-6oicmeam	21	15	man	man	NN
cord-340028-6oicmeam	21	16	"	"	''
cord-340028-6oicmeam	21	17	and	and	CC
cord-340028-6oicmeam	21	18	philia	philia	FW
cord-340028-6oicmeam	21	19	,	,	,
cord-340028-6oicmeam	21	20	"	"	``
cord-340028-6oicmeam	21	21	love	love	NN
cord-340028-6oicmeam	21	22	"	"	''
cord-340028-6oicmeam	21	23	)	)	-RRB-
cord-340028-6oicmeam	21	24	.	.	.
cord-340028-6oicmeam	22	1	Some	some	DT
cord-340028-6oicmeam	22	2	infections	infection	NNS
cord-340028-6oicmeam	22	3	,	,	,
cord-340028-6oicmeam	22	4	including	include	VBG
cord-340028-6oicmeam	22	5	COVID-19	covid-19	CD
cord-340028-6oicmeam	22	6	,	,	,
cord-340028-6oicmeam	22	7	are	be	VBP
cord-340028-6oicmeam	22	8	not	not	RB
cord-340028-6oicmeam	22	9	exclusively	exclusively	RB
cord-340028-6oicmeam	22	10	gerophilic	gerophilic	JJ
cord-340028-6oicmeam	22	11	,	,	,
cord-340028-6oicmeam	22	12	as	as	IN
cord-340028-6oicmeam	22	13	younger	young	JJR
cord-340028-6oicmeam	22	14	people	people	NNS
cord-340028-6oicmeam	22	15	may	may	MD
cord-340028-6oicmeam	22	16	also	also	RB
cord-340028-6oicmeam	22	17	become	become	VB
cord-340028-6oicmeam	22	18	infected	infected	JJ
cord-340028-6oicmeam	22	19	.	.	.
cord-340028-6oicmeam	23	1	However	however	RB
cord-340028-6oicmeam	23	2	,	,	,
cord-340028-6oicmeam	23	3	these	these	DT
cord-340028-6oicmeam	23	4	individuals	individual	NNS
cord-340028-6oicmeam	23	5	have	have	VBP
cord-340028-6oicmeam	23	6	mild	mild	JJ
cord-340028-6oicmeam	23	7	symptoms	symptom	NNS
cord-340028-6oicmeam	23	8	or	or	CC
cord-340028-6oicmeam	23	9	remain	remain	VBP
cord-340028-6oicmeam	23	10	asymptomatic	asymptomatic	JJ
cord-340028-6oicmeam	23	11	,	,	,
cord-340028-6oicmeam	23	12	while	while	IN
cord-340028-6oicmeam	23	13	the	the	DT
cord-340028-6oicmeam	23	14	elderly	elderly	JJ
cord-340028-6oicmeam	23	15	experience	experience	NN
cord-340028-6oicmeam	23	16	substantially	substantially	RB
cord-340028-6oicmeam	23	17	more	more	RBR
cord-340028-6oicmeam	23	18	severe	severe	JJ
cord-340028-6oicmeam	23	19	symptoms	symptom	NNS
cord-340028-6oicmeam	23	20	and	and	CC
cord-340028-6oicmeam	23	21	lethality	lethality	NN
cord-340028-6oicmeam	23	22	.	.	.
cord-340028-6oicmeam	24	1	The	the	DT
cord-340028-6oicmeam	24	2	term	term	NN
cord-340028-6oicmeam	24	3	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	24	4	(	(	-LRB-
cord-340028-6oicmeam	24	5	from	from	IN
cord-340028-6oicmeam	24	6	Greek	Greek	NNP
cord-340028-6oicmeam	24	7	,	,	,
cord-340028-6oicmeam	24	8	géros	géros	FW
cord-340028-6oicmeam	24	9	"	"	``
cord-340028-6oicmeam	24	10	old	old	JJ
cord-340028-6oicmeam	24	11	man	man	NN
cord-340028-6oicmeam	24	12	"	"	''
cord-340028-6oicmeam	24	13	,	,	,
cord-340028-6oicmeam	24	14	and	and	CC
cord-340028-6oicmeam	24	15	epilavís	epilavís	NNP
cord-340028-6oicmeam	24	16	,	,	,
cord-340028-6oicmeam	24	17	"	"	``
cord-340028-6oicmeam	24	18	harmful	harmful	JJ
cord-340028-6oicmeam	24	19	"	"	''
cord-340028-6oicmeam	24	20	)	)	-RRB-
cord-340028-6oicmeam	24	21	may	may	MD
cord-340028-6oicmeam	24	22	more	more	RBR
cord-340028-6oicmeam	24	23	appropriately	appropriately	RB
cord-340028-6oicmeam	24	24	The	the	DT
cord-340028-6oicmeam	24	25	online	online	JJ
cord-340028-6oicmeam	24	26	resources	resource	NNS
cord-340028-6oicmeam	25	1	Our	-PRON-	PRP$
cord-340028-6oicmeam	25	2	World	World	NNP
cord-340028-6oicmeam	25	3	in	in	IN
cord-340028-6oicmeam	25	4	Data	Data	NNP
cord-340028-6oicmeam	25	5	[	[	-LRB-
cord-340028-6oicmeam	25	6	16	16	CD
cord-340028-6oicmeam	25	7	]	]	-RRB-
cord-340028-6oicmeam	25	8	and	and	CC
cord-340028-6oicmeam	25	9	The	the	DT
cord-340028-6oicmeam	25	10	Lancet	Lancet	NNP
cord-340028-6oicmeam	25	11	's	's	POS
cord-340028-6oicmeam	25	12	Global	Global	NNP
cord-340028-6oicmeam	25	13	Burden	Burden	NNP
cord-340028-6oicmeam	25	14	of	of	IN
cord-340028-6oicmeam	25	15	Disease	Disease	NNP
cord-340028-6oicmeam	25	16	[	[	-LRB-
cord-340028-6oicmeam	25	17	17	17	CD
cord-340028-6oicmeam	25	18	]	]	-RRB-
cord-340028-6oicmeam	25	19	provide	provide	VB
cord-340028-6oicmeam	25	20	deep	deep	JJ
cord-340028-6oicmeam	25	21	visual	visual	JJ
cord-340028-6oicmeam	25	22	insight	insight	NN
cord-340028-6oicmeam	25	23	into	into	IN
cord-340028-6oicmeam	25	24	the	the	DT
cord-340028-6oicmeam	25	25	global	global	JJ
cord-340028-6oicmeam	25	26	burden	burden	NN
cord-340028-6oicmeam	25	27	of	of	IN
cord-340028-6oicmeam	25	28	disease	disease	NN
cord-340028-6oicmeam	25	29	by	by	IN
cord-340028-6oicmeam	25	30	cause	cause	NN
cord-340028-6oicmeam	25	31	and	and	CC
cord-340028-6oicmeam	25	32	demographics	demographic	NNS
cord-340028-6oicmeam	25	33	.	.	.
cord-340028-6oicmeam	26	1	In	in	IN
cord-340028-6oicmeam	26	2	2017	2017	CD
cord-340028-6oicmeam	26	3	,	,	,
cord-340028-6oicmeam	26	4	there	there	EX
cord-340028-6oicmeam	26	5	were	be	VBD
cord-340028-6oicmeam	26	6	56	56	CD
cord-340028-6oicmeam	26	7	million	million	CD
cord-340028-6oicmeam	26	8	deaths	death	NNS
cord-340028-6oicmeam	26	9	globally	globally	RB
cord-340028-6oicmeam	26	10	;	;	:
cord-340028-6oicmeam	26	11	over	over	IN
cord-340028-6oicmeam	26	12	two	two	CD
cord-340028-6oicmeam	26	13	-	-	HYPH
cord-340028-6oicmeam	26	14	thirds	third	NNS
cord-340028-6oicmeam	26	15	of	of	IN
cord-340028-6oicmeam	26	16	these	these	DT
cord-340028-6oicmeam	26	17	(	(	-LRB-
cord-340028-6oicmeam	26	18	76	76	CD
cord-340028-6oicmeam	26	19	%	%	NN
cord-340028-6oicmeam	26	20	)	)	-RRB-
cord-340028-6oicmeam	26	21	were	be	VBD
cord-340028-6oicmeam	26	22	in	in	IN
cord-340028-6oicmeam	26	23	people	people	NNS
cord-340028-6oicmeam	26	24	over	over	IN
cord-340028-6oicmeam	26	25	50	50	CD
cord-340028-6oicmeam	26	26	years	year	NNS
cord-340028-6oicmeam	26	27	of	of	IN
cord-340028-6oicmeam	26	28	age	age	NN
cord-340028-6oicmeam	26	29	.	.	.
cord-340028-6oicmeam	27	1	According	accord	VBG
cord-340028-6oicmeam	27	2	to	to	IN
cord-340028-6oicmeam	27	3	the	the	DT
cord-340028-6oicmeam	27	4	online	online	JJ
cord-340028-6oicmeam	27	5	period	period	NN
cord-340028-6oicmeam	27	6	life	life	NN
cord-340028-6oicmeam	27	7	tables	table	NNS
cord-340028-6oicmeam	27	8	put	put	VBN
cord-340028-6oicmeam	27	9	out	out	RP
cord-340028-6oicmeam	27	10	by	by	IN
cord-340028-6oicmeam	27	11	the	the	DT
cord-340028-6oicmeam	27	12	US	US	NNP
cord-340028-6oicmeam	27	13	Social	Social	NNP
cord-340028-6oicmeam	27	14	Security	Security	NNP
cord-340028-6oicmeam	27	15	Administration	Administration	NNP
cord-340028-6oicmeam	27	16	[	[	-LRB-
cord-340028-6oicmeam	27	17	18	18	CD
cord-340028-6oicmeam	27	18	]	]	-RRB-
cord-340028-6oicmeam	27	19	,	,	,
cord-340028-6oicmeam	27	20	the	the	DT
cord-340028-6oicmeam	27	21	annual	annual	JJ
cord-340028-6oicmeam	27	22	chance	chance	NN
cord-340028-6oicmeam	27	23	of	of	IN
cord-340028-6oicmeam	27	24	death	death	NN
cord-340028-6oicmeam	27	25	in	in	IN
cord-340028-6oicmeam	27	26	2015	2015	CD
cord-340028-6oicmeam	27	27	(	(	-LRB-
cord-340028-6oicmeam	27	28	the	the	DT
cord-340028-6oicmeam	27	29	probability	probability	NN
cord-340028-6oicmeam	27	30	of	of	IN
cord-340028-6oicmeam	27	31	dying	die	VBG
cord-340028-6oicmeam	27	32	within	within	IN
cord-340028-6oicmeam	27	33	one	one	CD
cord-340028-6oicmeam	27	34	year	year	NN
cord-340028-6oicmeam	27	35	)	)	-RRB-
cord-340028-6oicmeam	27	36	for	for	IN
cord-340028-6oicmeam	27	37	a	a	DT
cord-340028-6oicmeam	27	38	person	person	NN
cord-340028-6oicmeam	27	39	over	over	IN
cord-340028-6oicmeam	27	40	80	80	CD
cord-340028-6oicmeam	27	41	was	be	VBD
cord-340028-6oicmeam	27	42	5.2	5.2	CD
cord-340028-6oicmeam	27	43	%	%	NN
cord-340028-6oicmeam	27	44	,	,	,
cord-340028-6oicmeam	27	45	increasing	increase	VBG
cord-340028-6oicmeam	27	46	to	to	IN
cord-340028-6oicmeam	27	47	14.8	14.8	CD
cord-340028-6oicmeam	27	48	%	%	NN
cord-340028-6oicmeam	27	49	by	by	IN
cord-340028-6oicmeam	27	50	the	the	DT
cord-340028-6oicmeam	27	51	age	age	NN
cord-340028-6oicmeam	27	52	89	89	CD
cord-340028-6oicmeam	27	53	.	.	.
cord-340028-6oicmeam	28	1	According	accord	VBG
cord-340028-6oicmeam	28	2	to	to	IN
cord-340028-6oicmeam	28	3	estimates	estimate	NNS
cord-340028-6oicmeam	28	4	by	by	IN
cord-340028-6oicmeam	28	5	the	the	DT
cord-340028-6oicmeam	28	6	US	US	NNP
cord-340028-6oicmeam	28	7	Centers	Centers	NNPS
cord-340028-6oicmeam	28	8	for	for	IN
cord-340028-6oicmeam	28	9	Disease	Disease	NNP
cord-340028-6oicmeam	28	10	Control	Control	NNP
cord-340028-6oicmeam	28	11	[	[	-LRB-
cord-340028-6oicmeam	28	12	19	19	CD
cord-340028-6oicmeam	28	13	]	]	-RRB-
cord-340028-6oicmeam	28	14	,	,	,
cord-340028-6oicmeam	28	15	approximately	approximately	RB
cord-340028-6oicmeam	28	16	5,945,690	5,945,690	CD
cord-340028-6oicmeam	28	17	individuals	individual	NNS
cord-340028-6oicmeam	28	18	older	old	JJR
cord-340028-6oicmeam	28	19	than	than	IN
cord-340028-6oicmeam	28	20	65	65	CD
cord-340028-6oicmeam	28	21	had	have	VBD
cord-340028-6oicmeam	28	22	symptomatic	symptomatic	JJ
cord-340028-6oicmeam	28	23	influenza	influenza	NN
cord-340028-6oicmeam	28	24	during	during	IN
cord-340028-6oicmeam	28	25	the	the	DT
cord-340028-6oicmeam	28	26	2017	2017	CD
cord-340028-6oicmeam	28	27	-	-	SYM
cord-340028-6oicmeam	28	28	2018	2018	CD
cord-340028-6oicmeam	28	29	season	season	NN
cord-340028-6oicmeam	28	30	,	,	,
cord-340028-6oicmeam	28	31	resulting	result	VBG
cord-340028-6oicmeam	28	32	in	in	IN
cord-340028-6oicmeam	28	33	3,329,586	3,329,586	CD
cord-340028-6oicmeam	28	34	medical	medical	JJ
cord-340028-6oicmeam	28	35	visits	visit	NNS
cord-340028-6oicmeam	28	36	,	,	,
cord-340028-6oicmeam	28	37	540,517	540,517	CD
cord-340028-6oicmeam	28	38	hospitalizations	hospitalization	NNS
cord-340028-6oicmeam	28	39	,	,	,
cord-340028-6oicmeam	28	40	and	and	CC
cord-340028-6oicmeam	28	41	50,903	50,903	CD
cord-340028-6oicmeam	28	42	deaths	death	NNS
cord-340028-6oicmeam	28	43	.	.	.
cord-340028-6oicmeam	29	1	Hence	hence	RB
cord-340028-6oicmeam	29	2	,	,	,
cord-340028-6oicmeam	29	3	the	the	DT
cord-340028-6oicmeam	29	4	death	death	NN
cord-340028-6oicmeam	29	5	rate	rate	NN
cord-340028-6oicmeam	29	6	for	for	IN
cord-340028-6oicmeam	29	7	those	those	DT
cord-340028-6oicmeam	29	8	hospitalized	hospitalize	VBN
cord-340028-6oicmeam	29	9	with	with	IN
cord-340028-6oicmeam	29	10	influenza	influenza	NN
cord-340028-6oicmeam	29	11	was	be	VBD
cord-340028-6oicmeam	29	12	9.4	9.4	CD
cord-340028-6oicmeam	29	13	%	%	NN
cord-340028-6oicmeam	29	14	for	for	IN
cord-340028-6oicmeam	29	15	patients	patient	NNS
cord-340028-6oicmeam	29	16	over	over	IN
cord-340028-6oicmeam	29	17	65	65	CD
cord-340028-6oicmeam	29	18	.	.	.
cord-340028-6oicmeam	30	1	However	however	RB
cord-340028-6oicmeam	30	2	,	,	,
cord-340028-6oicmeam	30	3	many	many	JJ
cord-340028-6oicmeam	30	4	of	of	IN
cord-340028-6oicmeam	30	5	the	the	DT
cord-340028-6oicmeam	30	6	COVID-19	covid-19	JJ
cord-340028-6oicmeam	30	7	patients	patient	NNS
cord-340028-6oicmeam	30	8	over	over	IN
cord-340028-6oicmeam	30	9	65	65	CD
cord-340028-6oicmeam	30	10	years	year	NNS
cord-340028-6oicmeam	30	11	have	have	VBP
cord-340028-6oicmeam	30	12	one	one	CD
cord-340028-6oicmeam	30	13	or	or	CC
cord-340028-6oicmeam	30	14	more	more	JJR
cord-340028-6oicmeam	30	15	comorbities	comorbitie	NNS
cord-340028-6oicmeam	30	16	[	[	-LRB-
cord-340028-6oicmeam	30	17	20	20	CD
cord-340028-6oicmeam	30	18	]	]	-RRB-
cord-340028-6oicmeam	30	19	,	,	,
cord-340028-6oicmeam	30	20	and	and	CC
cord-340028-6oicmeam	30	21	it	-PRON-	PRP
cord-340028-6oicmeam	30	22	is	be	VBZ
cord-340028-6oicmeam	30	23	often	often	RB
cord-340028-6oicmeam	30	24	difficult	difficult	JJ
cord-340028-6oicmeam	30	25	February	February	NNP
cord-340028-6oicmeam	30	26	11	11	CD
cord-340028-6oicmeam	30	27	,	,	,
cord-340028-6oicmeam	30	28	2020	2020	CD
cord-340028-6oicmeam	30	29	.	.	.
cord-340028-6oicmeam	31	1	The	the	DT
cord-340028-6oicmeam	31	2	figures	figure	NNS
cord-340028-6oicmeam	31	3	are	be	VBP
cord-340028-6oicmeam	31	4	adopted	adopt	VBN
cord-340028-6oicmeam	31	5	and	and	CC
cord-340028-6oicmeam	31	6	generated	generate	VBN
cord-340028-6oicmeam	31	7	from	from	IN
cord-340028-6oicmeam	31	8	[	[	-LRB-
cord-340028-6oicmeam	31	9	12	12	CD
cord-340028-6oicmeam	31	10	]	]	-RRB-
cord-340028-6oicmeam	31	11	(	(	-LRB-
cord-340028-6oicmeam	31	12	http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51	http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51	NNP
cord-340028-6oicmeam	31	13	)	)	-RRB-
cord-340028-6oicmeam	31	14	.	.	.
cord-340028-6oicmeam	32	1	to	to	TO
cord-340028-6oicmeam	32	2	attribute	attribute	VB
cord-340028-6oicmeam	32	3	the	the	DT
cord-340028-6oicmeam	32	4	cause	cause	NN
cord-340028-6oicmeam	32	5	of	of	IN
cord-340028-6oicmeam	32	6	death	death	NN
cord-340028-6oicmeam	32	7	exclusively	exclusively	RB
cord-340028-6oicmeam	32	8	to	to	IN
cord-340028-6oicmeam	32	9	the	the	DT
cord-340028-6oicmeam	32	10	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	32	11	coronavirus	coronavirus	NN
cord-340028-6oicmeam	32	12	.	.	.
cord-340028-6oicmeam	33	1	Currently	currently	RB
cord-340028-6oicmeam	33	2	,	,	,
cord-340028-6oicmeam	33	3	there	there	EX
cord-340028-6oicmeam	33	4	are	be	VBP
cord-340028-6oicmeam	33	5	no	no	DT
cord-340028-6oicmeam	33	6	accurate	accurate	JJ
cord-340028-6oicmeam	33	7	statistics	statistic	NNS
cord-340028-6oicmeam	33	8	linking	link	VBG
cord-340028-6oicmeam	33	9	smoking	smoking	NN
cord-340028-6oicmeam	33	10	status	status	NN
cord-340028-6oicmeam	33	11	,	,	,
cord-340028-6oicmeam	33	12	lifestyle	lifestyle	NN
cord-340028-6oicmeam	33	13	,	,	,
cord-340028-6oicmeam	33	14	and	and	CC
cord-340028-6oicmeam	33	15	behavior	behavior	NN
cord-340028-6oicmeam	33	16	to	to	IN
cord-340028-6oicmeam	33	17	the	the	DT
cord-340028-6oicmeam	33	18	severity	severity	NN
cord-340028-6oicmeam	33	19	and	and	CC
cord-340028-6oicmeam	33	20	lethality	lethality	NN
cord-340028-6oicmeam	33	21	of	of	IN
cord-340028-6oicmeam	33	22	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	33	23	.	.	.
cord-340028-6oicmeam	34	1	Despite	despite	IN
cord-340028-6oicmeam	34	2	this	this	DT
cord-340028-6oicmeam	34	3	,	,	,
cord-340028-6oicmeam	34	4	it	-PRON-	PRP
cord-340028-6oicmeam	34	5	is	be	VBZ
cord-340028-6oicmeam	34	6	possible	possible	JJ
cord-340028-6oicmeam	34	7	that	that	IN
cord-340028-6oicmeam	34	8	these	these	DT
cord-340028-6oicmeam	34	9	factors	factor	NNS
cord-340028-6oicmeam	34	10	,	,	,
cord-340028-6oicmeam	34	11	as	as	RB
cord-340028-6oicmeam	34	12	well	well	RB
cord-340028-6oicmeam	34	13	as	as	IN
cord-340028-6oicmeam	34	14	frailty	frailty	NN
cord-340028-6oicmeam	34	15	and	and	CC
cord-340028-6oicmeam	34	16	comorbidities	comorbiditie	NNS
cord-340028-6oicmeam	34	17	,	,	,
cord-340028-6oicmeam	34	18	play	play	VBP
cord-340028-6oicmeam	34	19	a	a	DT
cord-340028-6oicmeam	34	20	substantial	substantial	JJ
cord-340028-6oicmeam	34	21	role	role	NN
cord-340028-6oicmeam	34	22	.	.	.
cord-340028-6oicmeam	35	1	Gerolavic	gerolavic	JJ
cord-340028-6oicmeam	35	2	diseases	disease	NNS
cord-340028-6oicmeam	35	3	such	such	JJ
cord-340028-6oicmeam	35	4	as	as	IN
cord-340028-6oicmeam	35	5	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	35	6	may	may	MD
cord-340028-6oicmeam	35	7	not	not	RB
cord-340028-6oicmeam	35	8	significantly	significantly	RB
cord-340028-6oicmeam	35	9	increase	increase	VB
cord-340028-6oicmeam	35	10	the	the	DT
cord-340028-6oicmeam	35	11	yearly	yearly	JJ
cord-340028-6oicmeam	35	12	death	death	NN
cord-340028-6oicmeam	35	13	rates	rate	NNS
cord-340028-6oicmeam	35	14	for	for	IN
cord-340028-6oicmeam	35	15	each	each	DT
cord-340028-6oicmeam	35	16	individual	individual	JJ
cord-340028-6oicmeam	35	17	age	age	NN
cord-340028-6oicmeam	35	18	group	group	NN
cord-340028-6oicmeam	35	19	;	;	:
cord-340028-6oicmeam	35	20	however	however	RB
cord-340028-6oicmeam	35	21	,	,	,
cord-340028-6oicmeam	35	22	these	these	DT
cord-340028-6oicmeam	35	23	diseases	disease	NNS
cord-340028-6oicmeam	35	24	substantially	substantially	RB
cord-340028-6oicmeam	35	25	accelerate	accelerate	VBP
cord-340028-6oicmeam	35	26	death	death	NN
cord-340028-6oicmeam	35	27	from	from	IN
cord-340028-6oicmeam	35	28	multiple	multiple	JJ
cord-340028-6oicmeam	35	29	conditions	condition	NNS
cord-340028-6oicmeam	35	30	,	,	,
cord-340028-6oicmeam	35	31	and	and	CC
cord-340028-6oicmeam	35	32	compress	compress	VB
cord-340028-6oicmeam	35	33	the	the	DT
cord-340028-6oicmeam	35	34	process	process	NN
cord-340028-6oicmeam	35	35	to	to	IN
cord-340028-6oicmeam	35	36	less	less	JJR
cord-340028-6oicmeam	35	37	than	than	IN
cord-340028-6oicmeam	35	38	two	two	CD
cord-340028-6oicmeam	35	39	weeks	week	NNS
cord-340028-6oicmeam	35	40	.	.	.
cord-340028-6oicmeam	36	1	Comorbidity	comorbidity	NN
cord-340028-6oicmeam	36	2	is	be	VBZ
cord-340028-6oicmeam	36	3	also	also	RB
cord-340028-6oicmeam	36	4	the	the	DT
cord-340028-6oicmeam	36	5	likely	likely	JJ
cord-340028-6oicmeam	36	6	cause	cause	NN
cord-340028-6oicmeam	36	7	of	of	IN
cord-340028-6oicmeam	36	8	the	the	DT
cord-340028-6oicmeam	36	9	substantial	substantial	JJ
cord-340028-6oicmeam	36	10	differences	difference	NNS
cord-340028-6oicmeam	36	11	in	in	IN
cord-340028-6oicmeam	36	12	death	death	NN
cord-340028-6oicmeam	36	13	rates	rate	NNS
cord-340028-6oicmeam	36	14	among	among	IN
cord-340028-6oicmeam	36	15	different	different	JJ
cord-340028-6oicmeam	36	16	countries	country	NNS
cord-340028-6oicmeam	36	17	due	due	JJ
cord-340028-6oicmeam	36	18	to	to	IN
cord-340028-6oicmeam	36	19	differences	difference	NNS
cord-340028-6oicmeam	36	20	in	in	IN
cord-340028-6oicmeam	36	21	patient	patient	JJ
cord-340028-6oicmeam	36	22	demographics	demographic	NNS
cord-340028-6oicmeam	36	23	,	,	,
cord-340028-6oicmeam	36	24	levels	level	NNS
cord-340028-6oicmeam	36	25	of	of	IN
cord-340028-6oicmeam	36	26	preparedness	preparedness	NN
cord-340028-6oicmeam	36	27	,	,	,
cord-340028-6oicmeam	36	28	when	when	WRB
cord-340028-6oicmeam	36	29	the	the	DT
cord-340028-6oicmeam	36	30	epidemic	epidemic	NN
cord-340028-6oicmeam	36	31	began	begin	VBD
cord-340028-6oicmeam	36	32	locally	locally	RB
cord-340028-6oicmeam	36	33	,	,	,
cord-340028-6oicmeam	36	34	and	and	CC
cord-340028-6oicmeam	36	35	reporting	report	VBG
cord-340028-6oicmeam	36	36	[	[	-LRB-
cord-340028-6oicmeam	36	37	13	13	CD
cord-340028-6oicmeam	36	38	]	]	-RRB-
cord-340028-6oicmeam	36	39	.	.	.
cord-340028-6oicmeam	37	1	Only	only	RB
cord-340028-6oicmeam	37	2	the	the	DT
cord-340028-6oicmeam	37	3	data	datum	NNS
cord-340028-6oicmeam	37	4	available	available	JJ
cord-340028-6oicmeam	37	5	from	from	IN
cord-340028-6oicmeam	37	6	China	China	NNP
cord-340028-6oicmeam	37	7	,	,	,
cord-340028-6oicmeam	37	8	where	where	WRB
cord-340028-6oicmeam	37	9	the	the	DT
cord-340028-6oicmeam	37	10	epidemic	epidemic	NN
cord-340028-6oicmeam	37	11	has	have	VBZ
cord-340028-6oicmeam	37	12	subsided	subside	VBN
cord-340028-6oicmeam	37	13	,	,	,
cord-340028-6oicmeam	37	14	and	and	CC
cord-340028-6oicmeam	37	15	the	the	DT
cord-340028-6oicmeam	37	16	Diamond	Diamond	NNP
cord-340028-6oicmeam	37	17	Princess	Princess	NNP
cord-340028-6oicmeam	37	18	cruise	cruise	NN
cord-340028-6oicmeam	37	19	ship	ship	NN
cord-340028-6oicmeam	37	20	were	be	VBD
cord-340028-6oicmeam	37	21	used	use	VBN
cord-340028-6oicmeam	37	22	for	for	IN
cord-340028-6oicmeam	37	23	this	this	DT
cord-340028-6oicmeam	37	24	study	study	NN
cord-340028-6oicmeam	37	25	.	.	.
cord-340028-6oicmeam	38	1	One	one	CD
cord-340028-6oicmeam	38	2	of	of	IN
cord-340028-6oicmeam	38	3	the	the	DT
cord-340028-6oicmeam	38	4	possible	possible	JJ
cord-340028-6oicmeam	38	5	causes	cause	NNS
cord-340028-6oicmeam	38	6	of	of	IN
cord-340028-6oicmeam	38	7	the	the	DT
cord-340028-6oicmeam	38	8	age	age	NN
cord-340028-6oicmeam	38	9	-	-	HYPH
cord-340028-6oicmeam	38	10	associated	associate	VBN
cord-340028-6oicmeam	38	11	increases	increase	NNS
cord-340028-6oicmeam	38	12	in	in	IN
cord-340028-6oicmeam	38	13	COVID-19	covid-19	JJ
cord-340028-6oicmeam	38	14	infection	infection	NN
cord-340028-6oicmeam	38	15	rate	rate	NN
cord-340028-6oicmeam	38	16	,	,	,
cord-340028-6oicmeam	38	17	severity	severity	NN
cord-340028-6oicmeam	38	18	,	,	,
cord-340028-6oicmeam	38	19	and	and	CC
cord-340028-6oicmeam	38	20	lethality	lethality	NN
cord-340028-6oicmeam	38	21	is	be	VBZ
cord-340028-6oicmeam	38	22	immunosenescence	immunosenescence	JJ
cord-340028-6oicmeam	38	23	.	.	.
cord-340028-6oicmeam	39	1	Immunosenescence	Immunosenescence	NNP
cord-340028-6oicmeam	39	2	is	be	VBZ
cord-340028-6oicmeam	39	3	a	a	DT
cord-340028-6oicmeam	39	4	well	well	RB
cord-340028-6oicmeam	39	5	-	-	HYPH
cord-340028-6oicmeam	39	6	known	know	VBN
cord-340028-6oicmeam	39	7	age	age	NN
cord-340028-6oicmeam	39	8	-	-	HYPH
cord-340028-6oicmeam	39	9	related	relate	VBN
cord-340028-6oicmeam	39	10	process	process	NN
cord-340028-6oicmeam	39	11	contributing	contribute	VBG
cord-340028-6oicmeam	39	12	to	to	IN
cord-340028-6oicmeam	39	13	the	the	DT
cord-340028-6oicmeam	39	14	global	global	JJ
cord-340028-6oicmeam	39	15	burden	burden	NN
cord-340028-6oicmeam	39	16	of	of	IN
cord-340028-6oicmeam	39	17	disease	disease	NN
cord-340028-6oicmeam	39	18	[	[	-LRB-
cord-340028-6oicmeam	39	19	21	21	CD
cord-340028-6oicmeam	39	20	]	]	-RRB-
cord-340028-6oicmeam	39	21	.	.	.
cord-340028-6oicmeam	40	1	It	-PRON-	PRP
cord-340028-6oicmeam	40	2	is	be	VBZ
cord-340028-6oicmeam	40	3	among	among	IN
cord-340028-6oicmeam	40	4	the	the	DT
cord-340028-6oicmeam	40	5	major	major	JJ
cord-340028-6oicmeam	40	6	factors	factor	NNS
cord-340028-6oicmeam	40	7	underlying	underlie	VBG
cord-340028-6oicmeam	40	8	the	the	DT
cord-340028-6oicmeam	40	9	difference	difference	NN
cord-340028-6oicmeam	40	10	between	between	IN
cord-340028-6oicmeam	40	11	younger	young	JJR
cord-340028-6oicmeam	40	12	and	and	CC
cord-340028-6oicmeam	40	13	older	old	JJR
cord-340028-6oicmeam	40	14	populations	population	NNS
cord-340028-6oicmeam	40	15	in	in	IN
cord-340028-6oicmeam	40	16	the	the	DT
cord-340028-6oicmeam	40	17	response	response	NN
cord-340028-6oicmeam	40	18	rate	rate	NN
cord-340028-6oicmeam	40	19	to	to	IN
cord-340028-6oicmeam	40	20	vaccinations	vaccination	NNS
cord-340028-6oicmeam	40	21	and	and	CC
cord-340028-6oicmeam	40	22	the	the	DT
cord-340028-6oicmeam	40	23	virulence	virulence	NN
cord-340028-6oicmeam	40	24	of	of	IN
cord-340028-6oicmeam	40	25	infectious	infectious	JJ
cord-340028-6oicmeam	40	26	diseases	disease	NNS
cord-340028-6oicmeam	40	27	[	[	-LRB-
cord-340028-6oicmeam	40	28	22	22	CD
cord-340028-6oicmeam	40	29	]	]	-RRB-
cord-340028-6oicmeam	40	30	[	[	-LRB-
cord-340028-6oicmeam	40	31	23	23	CD
cord-340028-6oicmeam	40	32	]	]	-RRB-
cord-340028-6oicmeam	40	33	[	[	-LRB-
cord-340028-6oicmeam	40	34	24	24	CD
cord-340028-6oicmeam	40	35	]	]	-RRB-
cord-340028-6oicmeam	40	36	.	.	.
cord-340028-6oicmeam	41	1	Among	among	IN
cord-340028-6oicmeam	41	2	the	the	DT
cord-340028-6oicmeam	41	3	factors	factor	NNS
cord-340028-6oicmeam	41	4	contributing	contribute	VBG
cord-340028-6oicmeam	41	5	to	to	IN
cord-340028-6oicmeam	41	6	immunosenescence	immunosenescence	NNP
cord-340028-6oicmeam	41	7	is	be	VBZ
cord-340028-6oicmeam	41	8	the	the	DT
cord-340028-6oicmeam	41	9	chronic	chronic	JJ
cord-340028-6oicmeam	41	10	involution	involution	NN
cord-340028-6oicmeam	41	11	of	of	IN
cord-340028-6oicmeam	41	12	the	the	DT
cord-340028-6oicmeam	41	13	thymus	thymus	NN
cord-340028-6oicmeam	41	14	gland	gland	NN
cord-340028-6oicmeam	41	15	with	with	IN
cord-340028-6oicmeam	41	16	increased	increase	VBN
cord-340028-6oicmeam	41	17	age	age	NN
cord-340028-6oicmeam	41	18	.	.	.
cord-340028-6oicmeam	42	1	Indeed	indeed	RB
cord-340028-6oicmeam	42	2	,	,	,
cord-340028-6oicmeam	42	3	the	the	DT
cord-340028-6oicmeam	42	4	infection	infection	NN
cord-340028-6oicmeam	42	5	rates	rate	NNS
cord-340028-6oicmeam	42	6	of	of	IN
cord-340028-6oicmeam	42	7	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	42	8	,	,	,
cord-340028-6oicmeam	42	9	separated	separate	VBN
cord-340028-6oicmeam	42	10	by	by	IN
cord-340028-6oicmeam	42	11	age	age	NN
cord-340028-6oicmeam	42	12	,	,	,
cord-340028-6oicmeam	42	13	are	be	VBP
cord-340028-6oicmeam	42	14	correlated	correlate	VBN
cord-340028-6oicmeam	42	15	with	with	IN
cord-340028-6oicmeam	42	16	involution	involution	NN
cord-340028-6oicmeam	42	17	of	of	IN
cord-340028-6oicmeam	42	18	the	the	DT
cord-340028-6oicmeam	42	19	thymus	thymus	NN
cord-340028-6oicmeam	42	20	[	[	-LRB-
cord-340028-6oicmeam	42	21	12	12	CD
cord-340028-6oicmeam	42	22	]	]	-RRB-
cord-340028-6oicmeam	42	23	.	.	.
cord-340028-6oicmeam	43	1	The	the	DT
cord-340028-6oicmeam	43	2	thymus	thymus	NN
cord-340028-6oicmeam	43	3	gland	gland	NN
cord-340028-6oicmeam	43	4	is	be	VBZ
cord-340028-6oicmeam	43	5	most	most	RBS
cord-340028-6oicmeam	43	6	active	active	JJ
cord-340028-6oicmeam	43	7	early	early	RB
cord-340028-6oicmeam	43	8	in	in	IN
cord-340028-6oicmeam	43	9	life	life	NN
cord-340028-6oicmeam	43	10	,	,	,
cord-340028-6oicmeam	43	11	reaching	reach	VBG
cord-340028-6oicmeam	43	12	maximum	maximum	JJ
cord-340028-6oicmeam	43	13	size	size	NN
cord-340028-6oicmeam	43	14	within	within	IN
cord-340028-6oicmeam	43	15	the	the	DT
cord-340028-6oicmeam	43	16	first	first	JJ
cord-340028-6oicmeam	43	17	year	year	NN
cord-340028-6oicmeam	43	18	.	.	.
cord-340028-6oicmeam	44	1	Its	-PRON-	PRP$
cord-340028-6oicmeam	44	2	activity	activity	NN
cord-340028-6oicmeam	44	3	then	then	RB
cord-340028-6oicmeam	44	4	declines	decline	VBZ
cord-340028-6oicmeam	44	5	with	with	IN
cord-340028-6oicmeam	44	6	age	age	NN
cord-340028-6oicmeam	44	7	until	until	IN
cord-340028-6oicmeam	44	8	an	an	DT
cord-340028-6oicmeam	44	9	individual	individual	NN
cord-340028-6oicmeam	44	10	reaches	reach	VBZ
cord-340028-6oicmeam	44	11	40	40	CD
cord-340028-6oicmeam	44	12	to	to	TO
cord-340028-6oicmeam	44	13	50	50	CD
cord-340028-6oicmeam	44	14	,	,	,
cord-340028-6oicmeam	44	15	after	after	IN
cord-340028-6oicmeam	44	16	which	which	WDT
cord-340028-6oicmeam	44	17	there	there	EX
cord-340028-6oicmeam	44	18	are	be	VBP
cord-340028-6oicmeam	44	19	negligible	negligible	JJ
cord-340028-6oicmeam	44	20	traces	trace	NNS
cord-340028-6oicmeam	44	21	of	of	IN
cord-340028-6oicmeam	44	22	the	the	DT
cord-340028-6oicmeam	44	23	thymus	thymus	NN
cord-340028-6oicmeam	44	24	remaining	remain	VBG
cord-340028-6oicmeam	44	25	,	,	,
cord-340028-6oicmeam	44	26	replaced	replace	VBN
cord-340028-6oicmeam	44	27	by	by	IN
cord-340028-6oicmeam	44	28	fibrotic	fibrotic	JJ
cord-340028-6oicmeam	44	29	tissue	tissue	NN
cord-340028-6oicmeam	44	30	[	[	-LRB-
cord-340028-6oicmeam	44	31	25	25	CD
cord-340028-6oicmeam	44	32	]	]	-RRB-
cord-340028-6oicmeam	44	33	.	.	.
cord-340028-6oicmeam	45	1	As	as	IN
cord-340028-6oicmeam	45	2	a	a	DT
cord-340028-6oicmeam	45	3	result	result	NN
cord-340028-6oicmeam	45	4	of	of	IN
cord-340028-6oicmeam	45	5	thymic	thymic	JJ
cord-340028-6oicmeam	45	6	involution	involution	NN
cord-340028-6oicmeam	45	7	,	,	,
cord-340028-6oicmeam	45	8	the	the	DT
cord-340028-6oicmeam	45	9	number	number	NN
cord-340028-6oicmeam	45	10	of	of	IN
cord-340028-6oicmeam	45	11	naïve	naïve	JJ
cord-340028-6oicmeam	45	12	T	t	NN
cord-340028-6oicmeam	45	13	cells	cell	NNS
cord-340028-6oicmeam	45	14	exiting	exit	VBG
cord-340028-6oicmeam	45	15	the	the	DT
cord-340028-6oicmeam	45	16	thymus	thymus	NN
cord-340028-6oicmeam	45	17	decreases	decrease	VBZ
cord-340028-6oicmeam	45	18	significantly	significantly	RB
cord-340028-6oicmeam	45	19	,	,	,
cord-340028-6oicmeam	45	20	with	with	IN
cord-340028-6oicmeam	45	21	substantial	substantial	JJ
cord-340028-6oicmeam	45	22	declines	decline	NNS
cord-340028-6oicmeam	45	23	in	in	IN
cord-340028-6oicmeam	45	24	older	old	JJR
cord-340028-6oicmeam	45	25	age	age	NN
cord-340028-6oicmeam	45	26	[	[	-LRB-
cord-340028-6oicmeam	45	27	26	26	CD
cord-340028-6oicmeam	45	28	]	]	-RRB-
cord-340028-6oicmeam	45	29	.	.	.
cord-340028-6oicmeam	46	1	Besides	besides	IN
cord-340028-6oicmeam	46	2	thymic	thymic	JJ
cord-340028-6oicmeam	46	3	involution	involution	NN
cord-340028-6oicmeam	46	4	,	,	,
cord-340028-6oicmeam	46	5	there	there	EX
cord-340028-6oicmeam	46	6	are	be	VBP
cord-340028-6oicmeam	46	7	many	many	JJ
cord-340028-6oicmeam	46	8	other	other	JJ
cord-340028-6oicmeam	46	9	factors	factor	NNS
cord-340028-6oicmeam	46	10	driving	drive	VBG
cord-340028-6oicmeam	46	11	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	46	12	and	and	CC
cord-340028-6oicmeam	46	13	the	the	DT
cord-340028-6oicmeam	46	14	increase	increase	NN
cord-340028-6oicmeam	46	15	in	in	IN
cord-340028-6oicmeam	46	16	multimorbidity	multimorbidity	NN
cord-340028-6oicmeam	46	17	that	that	WDT
cord-340028-6oicmeam	46	18	occurs	occur	VBZ
cord-340028-6oicmeam	46	19	during	during	IN
cord-340028-6oicmeam	46	20	aging	age	VBG
cord-340028-6oicmeam	46	21	[	[	-LRB-
cord-340028-6oicmeam	46	22	22	22	CD
cord-340028-6oicmeam	46	23	,	,	,
cord-340028-6oicmeam	46	24	27	27	CD
cord-340028-6oicmeam	46	25	,	,	,
cord-340028-6oicmeam	46	26	28	28	CD
cord-340028-6oicmeam	46	27	]	]	-RRB-
cord-340028-6oicmeam	46	28	.	.	.
cord-340028-6oicmeam	47	1	Figure	figure	NN
cord-340028-6oicmeam	47	2	2	2	CD
cord-340028-6oicmeam	47	3	illustrates	illustrate	VBZ
cord-340028-6oicmeam	47	4	the	the	DT
cord-340028-6oicmeam	47	5	hypothesised	hypothesise	VBN
cord-340028-6oicmeam	47	6	reciprocal	reciprocal	JJ
cord-340028-6oicmeam	47	7	relationship	relationship	NN
cord-340028-6oicmeam	47	8	between	between	IN
cord-340028-6oicmeam	47	9	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	47	10	and	and	CC
cord-340028-6oicmeam	47	11	infectious	infectious	JJ
cord-340028-6oicmeam	47	12	disease	disease	NN
cord-340028-6oicmeam	47	13	acquisition	acquisition	NN
cord-340028-6oicmeam	47	14	.	.	.
cord-340028-6oicmeam	48	1	In	in	IN
cord-340028-6oicmeam	48	2	this	this	DT
cord-340028-6oicmeam	48	3	model	model	NN
cord-340028-6oicmeam	48	4	,	,	,
cord-340028-6oicmeam	48	5	age	age	NN
cord-340028-6oicmeam	48	6	-	-	HYPH
cord-340028-6oicmeam	48	7	associated	associate	VBN
cord-340028-6oicmeam	48	8	immunosenescence	immunosenescence	NNP
cord-340028-6oicmeam	48	9	leads	lead	VBZ
cord-340028-6oicmeam	48	10	to	to	IN
cord-340028-6oicmeam	48	11	a	a	DT
cord-340028-6oicmeam	48	12	reduced	reduce	VBN
cord-340028-6oicmeam	48	13	ability	ability	NN
cord-340028-6oicmeam	48	14	to	to	TO
cord-340028-6oicmeam	48	15	resist	resist	VB
cord-340028-6oicmeam	48	16	infection	infection	NN
cord-340028-6oicmeam	48	17	,	,	,
cord-340028-6oicmeam	48	18	while	while	IN
cord-340028-6oicmeam	48	19	infection	infection	NN
cord-340028-6oicmeam	48	20	produces	produce	VBZ
cord-340028-6oicmeam	48	21	biological	biological	JJ
cord-340028-6oicmeam	48	22	damage	damage	NN
cord-340028-6oicmeam	48	23	and	and	CC
cord-340028-6oicmeam	48	24	loss	loss	NN
cord-340028-6oicmeam	48	25	of	of	IN
cord-340028-6oicmeam	48	26	homeostasis	homeostasis	NN
cord-340028-6oicmeam	48	27	.	.	.
cord-340028-6oicmeam	49	1	This	this	DT
cord-340028-6oicmeam	49	2	ultimately	ultimately	RB
cord-340028-6oicmeam	49	3	contributes	contribute	VBZ
cord-340028-6oicmeam	49	4	to	to	IN
cord-340028-6oicmeam	49	5	accelerated	accelerate	VBN
cord-340028-6oicmeam	49	6	aging	aging	NN
cord-340028-6oicmeam	49	7	and	and	CC
cord-340028-6oicmeam	49	8	the	the	DT
cord-340028-6oicmeam	49	9	development	development	NN
cord-340028-6oicmeam	49	10	of	of	IN
cord-340028-6oicmeam	49	11	age	age	NN
cord-340028-6oicmeam	49	12	-	-	HYPH
cord-340028-6oicmeam	49	13	related	relate	VBN
cord-340028-6oicmeam	49	14	diseases	disease	NNS
cord-340028-6oicmeam	49	15	,	,	,
cord-340028-6oicmeam	49	16	and	and	CC
cord-340028-6oicmeam	49	17	further	further	RB
cord-340028-6oicmeam	49	18	accelerates	accelerate	VBZ
cord-340028-6oicmeam	49	19	immunosenescence	immunosenescence	RB
cord-340028-6oicmeam	49	20	.	.	.
cord-340028-6oicmeam	50	1	In	in	IN
cord-340028-6oicmeam	50	2	support	support	NN
cord-340028-6oicmeam	50	3	of	of	IN
cord-340028-6oicmeam	50	4	this	this	DT
cord-340028-6oicmeam	50	5	model	model	NN
cord-340028-6oicmeam	50	6	,	,	,
cord-340028-6oicmeam	50	7	infections	infection	NNS
cord-340028-6oicmeam	50	8	and	and	CC
cord-340028-6oicmeam	50	9	other	other	JJ
cord-340028-6oicmeam	50	10	age	age	NN
cord-340028-6oicmeam	50	11	-	-	HYPH
cord-340028-6oicmeam	50	12	related	relate	VBN
cord-340028-6oicmeam	50	13	diseases	disease	NNS
cord-340028-6oicmeam	50	14	are	be	VBP
cord-340028-6oicmeam	50	15	among	among	IN
cord-340028-6oicmeam	50	16	the	the	DT
cord-340028-6oicmeam	50	17	main	main	JJ
cord-340028-6oicmeam	50	18	causes	cause	NNS
cord-340028-6oicmeam	50	19	of	of	IN
cord-340028-6oicmeam	50	20	death	death	NN
cord-340028-6oicmeam	50	21	in	in	IN
cord-340028-6oicmeam	50	22	the	the	DT
cord-340028-6oicmeam	50	23	developed	develop	VBN
cord-340028-6oicmeam	50	24	world	world	NN
cord-340028-6oicmeam	50	25	and	and	CC
cord-340028-6oicmeam	50	26	in	in	IN
cord-340028-6oicmeam	50	27	developing	develop	VBG
cord-340028-6oicmeam	50	28	countries	country	NNS
cord-340028-6oicmeam	50	29	.	.	.
cord-340028-6oicmeam	51	1	Due	due	IN
cord-340028-6oicmeam	51	2	to	to	IN
cord-340028-6oicmeam	51	3	the	the	DT
cord-340028-6oicmeam	51	4	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	51	5	nature	nature	NN
cord-340028-6oicmeam	51	6	of	of	IN
cord-340028-6oicmeam	51	7	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	51	8	,	,	,
cord-340028-6oicmeam	51	9	the	the	DT
cord-340028-6oicmeam	51	10	classical	classical	JJ
cord-340028-6oicmeam	51	11	preventative	preventative	JJ
cord-340028-6oicmeam	51	12	measures	measure	NNS
cord-340028-6oicmeam	51	13	and	and	CC
cord-340028-6oicmeam	51	14	treatment	treatment	NN
cord-340028-6oicmeam	51	15	strategies	strategy	NNS
cord-340028-6oicmeam	51	16	used	use	VBN
cord-340028-6oicmeam	51	17	for	for	IN
cord-340028-6oicmeam	51	18	targeting	target	VBG
cord-340028-6oicmeam	51	19	infectious	infectious	JJ
cord-340028-6oicmeam	51	20	diseases	disease	NNS
cord-340028-6oicmeam	51	21	may	may	MD
cord-340028-6oicmeam	51	22	not	not	RB
cord-340028-6oicmeam	51	23	be	be	VB
cord-340028-6oicmeam	51	24	as	as	RB
cord-340028-6oicmeam	51	25	effective	effective	JJ
cord-340028-6oicmeam	51	26	,	,	,
cord-340028-6oicmeam	51	27	and	and	CC
cord-340028-6oicmeam	51	28	there	there	EX
cord-340028-6oicmeam	51	29	is	be	VBZ
cord-340028-6oicmeam	51	30	a	a	DT
cord-340028-6oicmeam	51	31	need	need	NN
cord-340028-6oicmeam	51	32	for	for	IN
cord-340028-6oicmeam	51	33	alternative	alternative	JJ
cord-340028-6oicmeam	51	34	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	51	35	and	and	CC
cord-340028-6oicmeam	51	36	senoremediative	senoremediative	JJ
cord-340028-6oicmeam	51	37	strategies	strategy	NNS
cord-340028-6oicmeam	51	38	.	.	.
cord-340028-6oicmeam	52	1	There	there	EX
cord-340028-6oicmeam	52	2	are	be	VBP
cord-340028-6oicmeam	52	3	multiple	multiple	JJ
cord-340028-6oicmeam	52	4	clinical	clinical	JJ
cord-340028-6oicmeam	52	5	trials	trial	NNS
cord-340028-6oicmeam	52	6	in	in	IN
cord-340028-6oicmeam	52	7	progress	progress	NN
cord-340028-6oicmeam	52	8	using	use	VBG
cord-340028-6oicmeam	52	9	established	establish	VBN
cord-340028-6oicmeam	52	10	medical	medical	JJ
cord-340028-6oicmeam	52	11	interventions	intervention	NNS
cord-340028-6oicmeam	52	12	to	to	TO
cord-340028-6oicmeam	52	13	treat	treat	VB
cord-340028-6oicmeam	52	14	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	52	15	,	,	,
cord-340028-6oicmeam	52	16	with	with	IN
cord-340028-6oicmeam	52	17	the	the	DT
cord-340028-6oicmeam	52	18	number	number	NN
cord-340028-6oicmeam	52	19	of	of	IN
cord-340028-6oicmeam	52	20	studies	study	NNS
cord-340028-6oicmeam	52	21	rapidly	rapidly	RB
cord-340028-6oicmeam	52	22	increasing	increase	VBG
cord-340028-6oicmeam	52	23	[	[	-LRB-
cord-340028-6oicmeam	52	24	23	23	CD
cord-340028-6oicmeam	52	25	]	]	-RRB-
cord-340028-6oicmeam	52	26	.	.	.
cord-340028-6oicmeam	53	1	For	for	IN
cord-340028-6oicmeam	53	2	a	a	DT
cord-340028-6oicmeam	53	3	list	list	NN
cord-340028-6oicmeam	53	4	of	of	IN
cord-340028-6oicmeam	53	5	promising	promise	VBG
cord-340028-6oicmeam	53	6	SARS	SARS	NNP
cord-340028-6oicmeam	53	7	-	-	HYPH
cord-340028-6oicmeam	53	8	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	53	9	/	/	SYM
cord-340028-6oicmeam	53	10	COVID-19	covid-19	JJ
cord-340028-6oicmeam	53	11	targets	target	NNS
cord-340028-6oicmeam	53	12	and	and	CC
cord-340028-6oicmeam	53	13	treatment	treatment	NN
cord-340028-6oicmeam	53	14	approaches	approach	NNS
cord-340028-6oicmeam	53	15	,	,	,
cord-340028-6oicmeam	53	16	please	please	UH
cord-340028-6oicmeam	53	17	refer	refer	VB
cord-340028-6oicmeam	53	18	to	to	IN
cord-340028-6oicmeam	53	19	the	the	DT
cord-340028-6oicmeam	53	20	Global	Global	NNP
cord-340028-6oicmeam	53	21	Health	Health	NNP
cord-340028-6oicmeam	53	22	Drug	Drug	NNP
cord-340028-6oicmeam	53	23	Discovery	Discovery	NNP
cord-340028-6oicmeam	53	24	Institute	Institute	NNP
cord-340028-6oicmeam	53	25	's	's	POS
cord-340028-6oicmeam	53	26	portal	portal	NN
cord-340028-6oicmeam	53	27	dedicated	dedicate	VBN
cord-340028-6oicmeam	53	28	to	to	TO
cord-340028-6oicmeam	53	29	COVID-19	covid-19	VB
cord-340028-6oicmeam	53	30	[	[	-LRB-
cord-340028-6oicmeam	53	31	29	29	CD
cord-340028-6oicmeam	53	32	]	]	-RRB-
cord-340028-6oicmeam	53	33	.	.	.
cord-340028-6oicmeam	53	34	 	 	_SP
cord-340028-6oicmeam	54	1	Here	here	RB
cord-340028-6oicmeam	54	2	we	-PRON-	PRP
cord-340028-6oicmeam	54	3	compare	compare	VBP
cord-340028-6oicmeam	54	4	the	the	DT
cord-340028-6oicmeam	54	5	expected	expect	VBN
cord-340028-6oicmeam	54	6	benefit	benefit	NN
cord-340028-6oicmeam	54	7	of	of	IN
cord-340028-6oicmeam	54	8	treatments	treatment	NNS
cord-340028-6oicmeam	54	9	for	for	IN
cord-340028-6oicmeam	54	10	elderly	elderly	JJ
cord-340028-6oicmeam	54	11	populations	population	NNS
cord-340028-6oicmeam	54	12	(	(	-LRB-
cord-340028-6oicmeam	54	13	60	60	CD
cord-340028-6oicmeam	54	14	years	year	NNS
cord-340028-6oicmeam	54	15	and	and	CC
cord-340028-6oicmeam	54	16	older	old	JJR
cord-340028-6oicmeam	54	17	)	)	-RRB-
cord-340028-6oicmeam	55	1	that	that	WDT
cord-340028-6oicmeam	55	2	are	be	VBP
cord-340028-6oicmeam	55	3	currently	currently	RB
cord-340028-6oicmeam	55	4	in	in	IN
cord-340028-6oicmeam	55	5	development	development	NN
cord-340028-6oicmeam	55	6	,	,	,
cord-340028-6oicmeam	55	7	including	include	VBG
cord-340028-6oicmeam	55	8	standard	standard	JJ
cord-340028-6oicmeam	55	9	preventative	preventative	JJ
cord-340028-6oicmeam	55	10	strategies	strategy	NNS
cord-340028-6oicmeam	55	11	such	such	JJ
cord-340028-6oicmeam	55	12	as	as	IN
cord-340028-6oicmeam	55	13	vaccines	vaccine	NNS
cord-340028-6oicmeam	55	14	and	and	CC
cord-340028-6oicmeam	55	15	antivirals	antiviral	NNS
cord-340028-6oicmeam	55	16	targeting	target	VBG
cord-340028-6oicmeam	55	17	SARS	SARS	NNP
cord-340028-6oicmeam	55	18	-	-	HYPH
cord-340028-6oicmeam	55	19	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	55	20	,	,	,
cord-340028-6oicmeam	55	21	and	and	CC
cord-340028-6oicmeam	55	22	the	the	DT
cord-340028-6oicmeam	55	23	potential	potential	JJ
cord-340028-6oicmeam	55	24	added	add	VBN
cord-340028-6oicmeam	55	25	benefit	benefit	NN
cord-340028-6oicmeam	55	26	of	of	IN
cord-340028-6oicmeam	55	27	speculative	speculative	JJ
cord-340028-6oicmeam	55	28	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	55	29	strategies	strategy	NNS
cord-340028-6oicmeam	55	30	such	such	JJ
cord-340028-6oicmeam	55	31	as	as	IN
cord-340028-6oicmeam	55	32	rapalogs	rapalogs	NNP
cord-340028-6oicmeam	55	33	,	,	,
cord-340028-6oicmeam	55	34	NAD+	NAD+	NNP
cord-340028-6oicmeam	55	35	boosters	booster	NNS
cord-340028-6oicmeam	55	36	,	,	,
cord-340028-6oicmeam	55	37	senolytics	senolytic	NNS
cord-340028-6oicmeam	55	38	,	,	,
cord-340028-6oicmeam	55	39	and	and	CC
cord-340028-6oicmeam	55	40	stem	stem	NN
cord-340028-6oicmeam	55	41	cell	cell	NN
cord-340028-6oicmeam	55	42	treatment	treatment	NN
cord-340028-6oicmeam	55	43	.	.	.
cord-340028-6oicmeam	56	1	These	these	DT
cord-340028-6oicmeam	56	2	additional	additional	JJ
cord-340028-6oicmeam	56	3	measures	measure	NNS
cord-340028-6oicmeam	56	4	may	may	MD
cord-340028-6oicmeam	56	5	be	be	VB
cord-340028-6oicmeam	56	6	used	use	VBN
cord-340028-6oicmeam	56	7	in	in	IN
cord-340028-6oicmeam	56	8	isolation	isolation	NN
cord-340028-6oicmeam	56	9	or	or	CC
cord-340028-6oicmeam	56	10	as	as	IN
cord-340028-6oicmeam	56	11	adjuvant	adjuvant	JJ
cord-340028-6oicmeam	56	12	therapies	therapy	NNS
cord-340028-6oicmeam	56	13	to	to	TO
cord-340028-6oicmeam	56	14	reduce	reduce	VB
cord-340028-6oicmeam	56	15	infection	infection	NN
cord-340028-6oicmeam	56	16	risk	risk	NN
cord-340028-6oicmeam	56	17	,	,	,
cord-340028-6oicmeam	56	18	symptom	symptom	NN
cord-340028-6oicmeam	56	19	severity	severity	NN
cord-340028-6oicmeam	56	20	,	,	,
cord-340028-6oicmeam	56	21	or	or	CC
cord-340028-6oicmeam	56	22	improve	improve	VB
cord-340028-6oicmeam	56	23	vaccine	vaccine	NN
cord-340028-6oicmeam	56	24	efficacy	efficacy	NN
cord-340028-6oicmeam	56	25	.	.	.
cord-340028-6oicmeam	57	1	Vaccine	vaccine	NN
cord-340028-6oicmeam	57	2	development	development	NN
cord-340028-6oicmeam	57	3	is	be	VBZ
cord-340028-6oicmeam	57	4	one	one	CD
cord-340028-6oicmeam	57	5	of	of	IN
cord-340028-6oicmeam	57	6	the	the	DT
cord-340028-6oicmeam	57	7	most	most	RBS
cord-340028-6oicmeam	57	8	successful	successful	JJ
cord-340028-6oicmeam	57	9	approaches	approach	NNS
cord-340028-6oicmeam	57	10	for	for	IN
cord-340028-6oicmeam	57	11	combating	combat	VBG
cord-340028-6oicmeam	57	12	viral	viral	JJ
cord-340028-6oicmeam	57	13	diseases	disease	NNS
cord-340028-6oicmeam	57	14	globally	globally	RB
cord-340028-6oicmeam	57	15	,	,	,
cord-340028-6oicmeam	57	16	and	and	CC
cord-340028-6oicmeam	57	17	is	be	VBZ
cord-340028-6oicmeam	57	18	often	often	RB
cord-340028-6oicmeam	57	19	regarded	regard	VBN
cord-340028-6oicmeam	57	20	as	as	IN
cord-340028-6oicmeam	57	21	one	one	CD
cord-340028-6oicmeam	57	22	of	of	IN
cord-340028-6oicmeam	57	23	the	the	DT
cord-340028-6oicmeam	57	24	greatest	great	JJS
cord-340028-6oicmeam	57	25	advances	advance	NNS
cord-340028-6oicmeam	57	26	in	in	IN
cord-340028-6oicmeam	57	27	biomedical	biomedical	JJ
cord-340028-6oicmeam	57	28	science	science	NN
cord-340028-6oicmeam	57	29	and	and	CC
cord-340028-6oicmeam	57	30	integrated	integrate	VBN
cord-340028-6oicmeam	57	31	healthcare	healthcare	NN
cord-340028-6oicmeam	57	32	.	.	.
cord-340028-6oicmeam	58	1	Currently	currently	RB
cord-340028-6oicmeam	58	2	,	,	,
cord-340028-6oicmeam	58	3	there	there	EX
cord-340028-6oicmeam	58	4	are	be	VBP
cord-340028-6oicmeam	58	5	around	around	RB
cord-340028-6oicmeam	58	6	60	60	CD
cord-340028-6oicmeam	58	7	active	active	JJ
cord-340028-6oicmeam	58	8	clinical	clinical	JJ
cord-340028-6oicmeam	58	9	trials	trial	NNS
cord-340028-6oicmeam	58	10	related	relate	VBN
cord-340028-6oicmeam	58	11	to	to	IN
cord-340028-6oicmeam	58	12	a	a	DT
cord-340028-6oicmeam	58	13	SARS	SARS	NNP
cord-340028-6oicmeam	58	14	-	-	HYPH
cord-340028-6oicmeam	58	15	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	58	16	vaccine	vaccine	NN
cord-340028-6oicmeam	58	17	,	,	,
cord-340028-6oicmeam	58	18	most	most	JJS
cord-340028-6oicmeam	58	19	of	of	IN
cord-340028-6oicmeam	58	20	them	-PRON-	PRP
cord-340028-6oicmeam	58	21	taking	take	VBG
cord-340028-6oicmeam	58	22	place	place	NN
cord-340028-6oicmeam	58	23	in	in	IN
cord-340028-6oicmeam	58	24	China	China	NNP
cord-340028-6oicmeam	58	25	[	[	-LRB-
cord-340028-6oicmeam	58	26	30	30	CD
cord-340028-6oicmeam	58	27	]	]	-RRB-
cord-340028-6oicmeam	58	28	.	.	.
cord-340028-6oicmeam	59	1	Broadly	broadly	RB
cord-340028-6oicmeam	59	2	speaking	speak	VBG
cord-340028-6oicmeam	59	3	,	,	,
cord-340028-6oicmeam	59	4	the	the	DT
cord-340028-6oicmeam	59	5	success	success	NN
cord-340028-6oicmeam	59	6	of	of	IN
cord-340028-6oicmeam	59	7	a	a	DT
cord-340028-6oicmeam	59	8	vaccine	vaccine	NN
cord-340028-6oicmeam	59	9	partly	partly	RB
cord-340028-6oicmeam	59	10	depends	depend	VBZ
cord-340028-6oicmeam	59	11	on	on	IN
cord-340028-6oicmeam	59	12	the	the	DT
cord-340028-6oicmeam	59	13	similarity	similarity	NN
cord-340028-6oicmeam	59	14	of	of	IN
cord-340028-6oicmeam	59	15	the	the	DT
cord-340028-6oicmeam	59	16	vaccine	vaccine	NN
cord-340028-6oicmeam	59	17	strain	strain	NN
cord-340028-6oicmeam	59	18	with	with	IN
cord-340028-6oicmeam	59	19	the	the	DT
cord-340028-6oicmeam	59	20	viral	viral	JJ
cord-340028-6oicmeam	59	21	pathogenic	pathogenic	JJ
cord-340028-6oicmeam	59	22	strain	strain	NN
cord-340028-6oicmeam	59	23	in	in	IN
cord-340028-6oicmeam	59	24	question	question	NN
cord-340028-6oicmeam	59	25	.	.	.
cord-340028-6oicmeam	60	1	In	in	IN
cord-340028-6oicmeam	60	2	addition	addition	NN
cord-340028-6oicmeam	60	3	,	,	,
cord-340028-6oicmeam	60	4	an	an	DT
cord-340028-6oicmeam	60	5	individual	individual	NN
cord-340028-6oicmeam	60	6	's	's	POS
cord-340028-6oicmeam	60	7	immune	immune	JJ
cord-340028-6oicmeam	60	8	response	response	NN
cord-340028-6oicmeam	60	9	must	must	MD
cord-340028-6oicmeam	60	10	be	be	VB
cord-340028-6oicmeam	60	11	sufficiently	sufficiently	RB
cord-340028-6oicmeam	60	12	strong	strong	JJ
cord-340028-6oicmeam	60	13	to	to	TO
cord-340028-6oicmeam	60	14	mount	mount	VB
cord-340028-6oicmeam	60	15	a	a	DT
cord-340028-6oicmeam	60	16	reaction	reaction	NN
cord-340028-6oicmeam	60	17	to	to	IN
cord-340028-6oicmeam	60	18	the	the	DT
cord-340028-6oicmeam	60	19	vaccine	vaccine	NN
cord-340028-6oicmeam	60	20	that	that	WDT
cord-340028-6oicmeam	60	21	can	can	MD
cord-340028-6oicmeam	60	22	later	later	RB
cord-340028-6oicmeam	60	23	confer	confer	VB
cord-340028-6oicmeam	60	24	protection	protection	NN
cord-340028-6oicmeam	60	25	against	against	IN
cord-340028-6oicmeam	60	26	the	the	DT
cord-340028-6oicmeam	60	27	pathogen	pathogen	NN
cord-340028-6oicmeam	60	28	,	,	,
cord-340028-6oicmeam	60	29	should	should	MD
cord-340028-6oicmeam	60	30	exposure	exposure	NN
cord-340028-6oicmeam	60	31	occur	occur	VB
cord-340028-6oicmeam	60	32	.	.	.
cord-340028-6oicmeam	61	1	Our	-PRON-	PRP$
cord-340028-6oicmeam	61	2	current	current	JJ
cord-340028-6oicmeam	61	3	strategy	strategy	NN
cord-340028-6oicmeam	61	4	for	for	IN
cord-340028-6oicmeam	61	5	targeting	target	VBG
cord-340028-6oicmeam	61	6	annual	annual	JJ
cord-340028-6oicmeam	61	7	influenza	influenza	NN
cord-340028-6oicmeam	61	8	viral	viral	JJ
cord-340028-6oicmeam	61	9	outbreaks	outbreak	NNS
cord-340028-6oicmeam	61	10	focuses	focus	VBZ
cord-340028-6oicmeam	61	11	on	on	IN
cord-340028-6oicmeam	61	12	effective	effective	JJ
cord-340028-6oicmeam	61	13	vaccination	vaccination	NN
cord-340028-6oicmeam	61	14	based	base	VBN
cord-340028-6oicmeam	61	15	on	on	IN
cord-340028-6oicmeam	61	16	predictions	prediction	NNS
cord-340028-6oicmeam	61	17	of	of	IN
cord-340028-6oicmeam	61	18	strain	strain	NN
cord-340028-6oicmeam	61	19	variants	variant	NNS
cord-340028-6oicmeam	61	20	.	.	.
cord-340028-6oicmeam	62	1	People	People	NNS
cord-340028-6oicmeam	62	2	>	>	XX
cord-340028-6oicmeam	62	3	60	60	CD
cord-340028-6oicmeam	62	4	years	year	NNS
cord-340028-6oicmeam	62	5	of	of	IN
cord-340028-6oicmeam	62	6	age	age	NN
cord-340028-6oicmeam	62	7	with	with	IN
cord-340028-6oicmeam	62	8	chronic	chronic	JJ
cord-340028-6oicmeam	62	9	medical	medical	JJ
cord-340028-6oicmeam	62	10	conditions	condition	NNS
cord-340028-6oicmeam	62	11	,	,	,
cord-340028-6oicmeam	62	12	such	such	JJ
cord-340028-6oicmeam	62	13	as	as	IN
cord-340028-6oicmeam	62	14	type	type	NN
cord-340028-6oicmeam	62	15	2	2	CD
cord-340028-6oicmeam	62	16	diabetes	diabete	NNS
cord-340028-6oicmeam	62	17	or	or	CC
cord-340028-6oicmeam	62	18	cardiovascular	cardiovascular	JJ
cord-340028-6oicmeam	62	19	disease	disease	NN
cord-340028-6oicmeam	62	20	,	,	,
cord-340028-6oicmeam	62	21	direct	direct	JJ
cord-340028-6oicmeam	62	22	immunosuppression	immunosuppression	NN
cord-340028-6oicmeam	62	23	from	from	IN
cord-340028-6oicmeam	62	24	HIV	HIV	NNP
cord-340028-6oicmeam	62	25	,	,	,
cord-340028-6oicmeam	62	26	posttransplant	posttransplant	NN
cord-340028-6oicmeam	62	27	or	or	CC
cord-340028-6oicmeam	62	28	biologic	biologic	JJ
cord-340028-6oicmeam	62	29	treatment	treatment	NN
cord-340028-6oicmeam	62	30	,	,	,
cord-340028-6oicmeam	62	31	pregnant	pregnant	JJ
cord-340028-6oicmeam	62	32	individuals	individual	NNS
cord-340028-6oicmeam	62	33	,	,	,
cord-340028-6oicmeam	62	34	or	or	CC
cord-340028-6oicmeam	62	35	those	those	DT
cord-340028-6oicmeam	62	36	with	with	IN
cord-340028-6oicmeam	62	37	BMI>40	BMI>40	NNS
cord-340028-6oicmeam	62	38	,	,	,
cord-340028-6oicmeam	62	39	are	be	VBP
cord-340028-6oicmeam	62	40	believed	believe	VBN
cord-340028-6oicmeam	62	41	to	to	TO
cord-340028-6oicmeam	62	42	be	be	VB
cord-340028-6oicmeam	62	43	at	at	IN
cord-340028-6oicmeam	62	44	higher	high	JJR
cord-340028-6oicmeam	62	45	risk	risk	NN
cord-340028-6oicmeam	62	46	for	for	IN
cord-340028-6oicmeam	62	47	influenza	influenza	NN
cord-340028-6oicmeam	62	48	infection	infection	NN
cord-340028-6oicmeam	62	49	due	due	IN
cord-340028-6oicmeam	62	50	to	to	IN
cord-340028-6oicmeam	62	51	a	a	DT
cord-340028-6oicmeam	62	52	weakened	weaken	VBN
cord-340028-6oicmeam	62	53	immune	immune	JJ
cord-340028-6oicmeam	62	54	response	response	NN
cord-340028-6oicmeam	62	55	[	[	-LRB-
cord-340028-6oicmeam	62	56	31	31	CD
cord-340028-6oicmeam	62	57	]	]	-RRB-
cord-340028-6oicmeam	62	58	.	.	.
cord-340028-6oicmeam	63	1	Similarly	similarly	RB
cord-340028-6oicmeam	63	2	,	,	,
cord-340028-6oicmeam	63	3	vaccines	vaccine	NNS
cord-340028-6oicmeam	63	4	do	do	VBP
cord-340028-6oicmeam	63	5	not	not	RB
cord-340028-6oicmeam	63	6	provide	provide	VB
cord-340028-6oicmeam	63	7	complete	complete	JJ
cord-340028-6oicmeam	63	8	protection	protection	NN
cord-340028-6oicmeam	63	9	in	in	IN
cord-340028-6oicmeam	63	10	older	old	JJR
cord-340028-6oicmeam	63	11	populations	population	NNS
cord-340028-6oicmeam	63	12	due	due	JJ
cord-340028-6oicmeam	63	13	to	to	IN
cord-340028-6oicmeam	63	14	agerelated	agerelate	VBN
cord-340028-6oicmeam	63	15	declines	decline	NNS
cord-340028-6oicmeam	63	16	in	in	IN
cord-340028-6oicmeam	63	17	immune	immune	JJ
cord-340028-6oicmeam	63	18	function	function	NN
cord-340028-6oicmeam	63	19	and	and	CC
cord-340028-6oicmeam	63	20	accumulation	accumulation	NN
cord-340028-6oicmeam	63	21	of	of	IN
cord-340028-6oicmeam	63	22	multi	multi	JJ
cord-340028-6oicmeam	63	23	-	-	NNS
cord-340028-6oicmeam	63	24	morbidities	morbidity	NNS
cord-340028-6oicmeam	63	25	.	.	.
cord-340028-6oicmeam	64	1	Outbreaks	outbreak	NNS
cord-340028-6oicmeam	64	2	can	can	MD
cord-340028-6oicmeam	64	3	occur	occur	VB
cord-340028-6oicmeam	64	4	in	in	IN
cord-340028-6oicmeam	64	5	elderly	elderly	JJ
cord-340028-6oicmeam	64	6	nursing	nursing	NN
cord-340028-6oicmeam	64	7	homes	home	NNS
cord-340028-6oicmeam	64	8	even	even	RB
cord-340028-6oicmeam	64	9	when	when	WRB
cord-340028-6oicmeam	64	10	vaccination	vaccination	NN
cord-340028-6oicmeam	64	11	rates	rate	NNS
cord-340028-6oicmeam	64	12	reach	reach	VBP
cord-340028-6oicmeam	64	13	80	80	CD
cord-340028-6oicmeam	64	14	-	-	SYM
cord-340028-6oicmeam	64	15	98	98	CD
cord-340028-6oicmeam	64	16	%	%	NN
cord-340028-6oicmeam	64	17	uptake	uptake	NN
cord-340028-6oicmeam	64	18	[	[	-LRB-
cord-340028-6oicmeam	64	19	32	32	CD
cord-340028-6oicmeam	64	20	]	]	-RRB-
cord-340028-6oicmeam	64	21	.	.	.
cord-340028-6oicmeam	65	1	Thus	thus	RB
cord-340028-6oicmeam	65	2	,	,	,
cord-340028-6oicmeam	65	3	even	even	RB
cord-340028-6oicmeam	65	4	when	when	WRB
cord-340028-6oicmeam	65	5	a	a	DT
cord-340028-6oicmeam	65	6	successful	successful	JJ
cord-340028-6oicmeam	65	7	vaccine	vaccine	NN
cord-340028-6oicmeam	65	8	for	for	IN
cord-340028-6oicmeam	65	9	SARS	SARS	NNP
cord-340028-6oicmeam	65	10	-	-	HYPH
cord-340028-6oicmeam	65	11	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	65	12	becomes	become	VBZ
cord-340028-6oicmeam	65	13	available	available	JJ
cord-340028-6oicmeam	65	14	,	,	,
cord-340028-6oicmeam	65	15	a	a	DT
cord-340028-6oicmeam	65	16	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	65	17	agent	agent	NN
cord-340028-6oicmeam	65	18	might	may	MD
cord-340028-6oicmeam	65	19	be	be	VB
cord-340028-6oicmeam	65	20	used	use	VBN
cord-340028-6oicmeam	65	21	in	in	IN
cord-340028-6oicmeam	65	22	combination	combination	NN
cord-340028-6oicmeam	65	23	with	with	IN
cord-340028-6oicmeam	65	24	the	the	DT
cord-340028-6oicmeam	65	25	vaccine	vaccine	NN
cord-340028-6oicmeam	65	26	to	to	TO
cord-340028-6oicmeam	65	27	boost	boost	VB
cord-340028-6oicmeam	65	28	the	the	DT
cord-340028-6oicmeam	65	29	immune	immune	JJ
cord-340028-6oicmeam	65	30	response	response	NN
cord-340028-6oicmeam	65	31	.	.	.
cord-340028-6oicmeam	66	1	Currently	currently	RB
cord-340028-6oicmeam	66	2	in	in	IN
cord-340028-6oicmeam	66	3	most	most	JJS
cord-340028-6oicmeam	66	4	countries	country	NNS
cord-340028-6oicmeam	66	5	,	,	,
cord-340028-6oicmeam	66	6	the	the	DT
cord-340028-6oicmeam	66	7	influenza	influenza	NN
cord-340028-6oicmeam	66	8	vaccine	vaccine	NN
cord-340028-6oicmeam	66	9	formulation	formulation	NN
cord-340028-6oicmeam	66	10	is	be	VBZ
cord-340028-6oicmeam	66	11	determined	determine	VBN
cord-340028-6oicmeam	66	12	6	6	CD
cord-340028-6oicmeam	66	13	-	-	SYM
cord-340028-6oicmeam	66	14	9	9	CD
cord-340028-6oicmeam	66	15	months	month	NNS
cord-340028-6oicmeam	66	16	before	before	IN
cord-340028-6oicmeam	66	17	the	the	DT
cord-340028-6oicmeam	66	18	expected	expect	VBN
cord-340028-6oicmeam	66	19	outbreak	outbreak	NN
cord-340028-6oicmeam	66	20	season	season	NN
cord-340028-6oicmeam	66	21	and	and	CC
cord-340028-6oicmeam	66	22	the	the	DT
cord-340028-6oicmeam	66	23	strains	strain	NNS
cord-340028-6oicmeam	66	24	are	be	VBP
cord-340028-6oicmeam	66	25	based	base	VBN
cord-340028-6oicmeam	66	26	on	on	IN
cord-340028-6oicmeam	66	27	the	the	DT
cord-340028-6oicmeam	66	28	precedent	precedent	NN
cord-340028-6oicmeam	66	29	season	season	NN
cord-340028-6oicmeam	66	30	's	's	POS
cord-340028-6oicmeam	66	31	viruses	virus	NNS
cord-340028-6oicmeam	66	32	.	.	.
cord-340028-6oicmeam	67	1	As	as	IN
cord-340028-6oicmeam	67	2	a	a	DT
cord-340028-6oicmeam	67	3	result	result	NN
cord-340028-6oicmeam	67	4	,	,	,
cord-340028-6oicmeam	67	5	vaccine	vaccine	NN
cord-340028-6oicmeam	67	6	efficacy	efficacy	NN
cord-340028-6oicmeam	67	7	is	be	VBZ
cord-340028-6oicmeam	67	8	expected	expect	VBN
cord-340028-6oicmeam	67	9	to	to	TO
cord-340028-6oicmeam	67	10	differ	differ	VB
cord-340028-6oicmeam	67	11	from	from	IN
cord-340028-6oicmeam	67	12	season	season	NN
cord-340028-6oicmeam	67	13	to	to	IN
cord-340028-6oicmeam	67	14	season	season	NN
cord-340028-6oicmeam	67	15	.	.	.
cord-340028-6oicmeam	68	1	Thus	thus	RB
cord-340028-6oicmeam	68	2	,	,	,
cord-340028-6oicmeam	68	3	an	an	DT
cord-340028-6oicmeam	68	4	ongoing	ongoing	JJ
cord-340028-6oicmeam	68	5	additive	additive	NN
cord-340028-6oicmeam	68	6	geroprotective	geroprotective	NNP
cord-340028-6oicmeam	68	7	therapy	therapy	NN
cord-340028-6oicmeam	68	8	is	be	VBZ
cord-340028-6oicmeam	68	9	of	of	IN
cord-340028-6oicmeam	68	10	high	high	JJ
cord-340028-6oicmeam	68	11	importance	importance	NN
cord-340028-6oicmeam	68	12	[	[	-LRB-
cord-340028-6oicmeam	68	13	33	33	CD
cord-340028-6oicmeam	68	14	,	,	,
cord-340028-6oicmeam	68	15	34	34	CD
cord-340028-6oicmeam	68	16	]	]	-RRB-
cord-340028-6oicmeam	68	17	and	and	CC
cord-340028-6oicmeam	68	18	is	be	VBZ
cord-340028-6oicmeam	68	19	applicable	applicable	JJ
cord-340028-6oicmeam	68	20	beyond	beyond	IN
cord-340028-6oicmeam	68	21	the	the	DT
cord-340028-6oicmeam	68	22	current	current	JJ
cord-340028-6oicmeam	68	23	pandemic	pandemic	NN
cord-340028-6oicmeam	68	24	.	.	.
cord-340028-6oicmeam	69	1	While	while	IN
cord-340028-6oicmeam	69	2	vaccines	vaccine	NNS
cord-340028-6oicmeam	69	3	may	may	MD
cord-340028-6oicmeam	69	4	be	be	VB
cord-340028-6oicmeam	69	5	the	the	DT
cord-340028-6oicmeam	69	6	best	good	JJS
cord-340028-6oicmeam	69	7	preventative	preventative	JJ
cord-340028-6oicmeam	69	8	strategy	strategy	NN
cord-340028-6oicmeam	69	9	for	for	IN
cord-340028-6oicmeam	69	10	reducing	reduce	VBG
cord-340028-6oicmeam	69	11	the	the	DT
cord-340028-6oicmeam	69	12	infection	infection	NN
cord-340028-6oicmeam	69	13	rates	rate	NNS
cord-340028-6oicmeam	69	14	,	,	,
cord-340028-6oicmeam	69	15	severity	severity	NN
cord-340028-6oicmeam	69	16	,	,	,
cord-340028-6oicmeam	69	17	and	and	CC
cord-340028-6oicmeam	69	18	lethality	lethality	NN
cord-340028-6oicmeam	69	19	of	of	IN
cord-340028-6oicmeam	69	20	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	69	21	,	,	,
cord-340028-6oicmeam	69	22	the	the	DT
cord-340028-6oicmeam	69	23	rates	rate	NNS
cord-340028-6oicmeam	69	24	to	to	IN
cord-340028-6oicmeam	69	25	vaccines	vaccine	NNS
cord-340028-6oicmeam	69	26	in	in	IN
cord-340028-6oicmeam	69	27	the	the	DT
cord-340028-6oicmeam	69	28	elderly	elderly	JJ
cord-340028-6oicmeam	69	29	will	will	MD
cord-340028-6oicmeam	69	30	likely	likely	RB
cord-340028-6oicmeam	69	31	be	be	VB
cord-340028-6oicmeam	69	32	lower	low	JJR
cord-340028-6oicmeam	69	33	[	[	-LRB-
cord-340028-6oicmeam	69	34	35	35	CD
cord-340028-6oicmeam	69	35	]	]	-RRB-
cord-340028-6oicmeam	69	36	and	and	CC
cord-340028-6oicmeam	69	37	vaccine	vaccine	NN
cord-340028-6oicmeam	69	38	potentiation	potentiation	NN
cord-340028-6oicmeam	69	39	strategies	strategy	NNS
cord-340028-6oicmeam	69	40	[	[	-LRB-
cord-340028-6oicmeam	69	41	36	36	CD
cord-340028-6oicmeam	69	42	]	]	-RRB-
cord-340028-6oicmeam	69	43	may	may	MD
cord-340028-6oicmeam	69	44	be	be	VB
cord-340028-6oicmeam	69	45	explored	explore	VBN
cord-340028-6oicmeam	69	46	and	and	CC
cord-340028-6oicmeam	69	47	evaluated	evaluate	VBN
cord-340028-6oicmeam	69	48	in	in	IN
cord-340028-6oicmeam	69	49	clinical	clinical	JJ
cord-340028-6oicmeam	69	50	trials	trial	NNS
cord-340028-6oicmeam	69	51	.	.	.
cord-340028-6oicmeam	70	1	While	while	IN
cord-340028-6oicmeam	70	2	chemoprophylaxis	chemoprophylaxis	NNP
cord-340028-6oicmeam	70	3	is	be	VBZ
cord-340028-6oicmeam	70	4	not	not	RB
cord-340028-6oicmeam	70	5	routinely	routinely	RB
cord-340028-6oicmeam	70	6	indicated	indicate	VBN
cord-340028-6oicmeam	70	7	and	and	CC
cord-340028-6oicmeam	70	8	is	be	VBZ
cord-340028-6oicmeam	70	9	not	not	RB
cord-340028-6oicmeam	70	10	considered	consider	VBN
cord-340028-6oicmeam	70	11	a	a	DT
cord-340028-6oicmeam	70	12	replacement	replacement	NN
cord-340028-6oicmeam	70	13	for	for	IN
cord-340028-6oicmeam	70	14	vaccination	vaccination	NN
cord-340028-6oicmeam	70	15	,	,	,
cord-340028-6oicmeam	70	16	using	use	VBG
cord-340028-6oicmeam	70	17	influenza	influenza	NN
cord-340028-6oicmeam	70	18	as	as	IN
cord-340028-6oicmeam	70	19	an	an	DT
cord-340028-6oicmeam	70	20	example	example	NN
cord-340028-6oicmeam	70	21	,	,	,
cord-340028-6oicmeam	70	22	prophylactic	prophylactic	JJ
cord-340028-6oicmeam	70	23	treatment	treatment	NN
cord-340028-6oicmeam	70	24	prior	prior	RB
cord-340028-6oicmeam	70	25	to	to	IN
cord-340028-6oicmeam	70	26	symptom	symptom	NN
cord-340028-6oicmeam	70	27	onset	onset	NN
cord-340028-6oicmeam	70	28	in	in	IN
cord-340028-6oicmeam	70	29	high	high	JJ
cord-340028-6oicmeam	70	30	-	-	HYPH
cord-340028-6oicmeam	70	31	risk	risk	NN
cord-340028-6oicmeam	70	32	groups	group	NNS
cord-340028-6oicmeam	70	33	or	or	CC
cord-340028-6oicmeam	70	34	after	after	IN
cord-340028-6oicmeam	70	35	close	close	JJ
cord-340028-6oicmeam	70	36	contact	contact	NN
cord-340028-6oicmeam	70	37	exposure	exposure	NN
cord-340028-6oicmeam	70	38	to	to	IN
cord-340028-6oicmeam	70	39	the	the	DT
cord-340028-6oicmeam	70	40	virus	virus	NN
cord-340028-6oicmeam	70	41	is	be	VBZ
cord-340028-6oicmeam	70	42	an	an	DT
cord-340028-6oicmeam	70	43	alternative	alternative	JJ
cord-340028-6oicmeam	70	44	preventative	preventative	JJ
cord-340028-6oicmeam	70	45	strategy	strategy	NN
cord-340028-6oicmeam	70	46	against	against	IN
cord-340028-6oicmeam	70	47	viral	viral	JJ
cord-340028-6oicmeam	70	48	disease	disease	NN
cord-340028-6oicmeam	70	49	[	[	-LRB-
cord-340028-6oicmeam	70	50	31	31	CD
cord-340028-6oicmeam	70	51	]	]	-RRB-
cord-340028-6oicmeam	70	52	.	.	.
cord-340028-6oicmeam	71	1	For	for	IN
cord-340028-6oicmeam	71	2	influenza	influenza	NN
cord-340028-6oicmeam	71	3	,	,	,
cord-340028-6oicmeam	71	4	the	the	DT
cord-340028-6oicmeam	71	5	neuraminidase	neuraminidase	NN
cord-340028-6oicmeam	71	6	inhibitors	inhibitor	NNS
cord-340028-6oicmeam	71	7	oseltamivir	oseltamivir	NNP
cord-340028-6oicmeam	71	8	and	and	CC
cord-340028-6oicmeam	71	9	zanamivir	zanamivir	NNP
cord-340028-6oicmeam	71	10	are	be	VBP
cord-340028-6oicmeam	71	11	occasionally	occasionally	RB
cord-340028-6oicmeam	71	12	given	give	VBN
cord-340028-6oicmeam	71	13	prophylactically	prophylactically	RB
cord-340028-6oicmeam	71	14	to	to	IN
cord-340028-6oicmeam	71	15	high	high	JJ
cord-340028-6oicmeam	71	16	-	-	HYPH
cord-340028-6oicmeam	71	17	risk	risk	NN
cord-340028-6oicmeam	71	18	individuals	individual	NNS
cord-340028-6oicmeam	71	19	in	in	IN
cord-340028-6oicmeam	71	20	long	long	JJ
cord-340028-6oicmeam	71	21	-	-	HYPH
cord-340028-6oicmeam	71	22	term	term	NN
cord-340028-6oicmeam	71	23	care	care	NN
cord-340028-6oicmeam	71	24	facilities	facility	NNS
cord-340028-6oicmeam	71	25	during	during	IN
cord-340028-6oicmeam	71	26	outbreaks	outbreak	NNS
cord-340028-6oicmeam	71	27	[	[	-LRB-
cord-340028-6oicmeam	71	28	37	37	CD
cord-340028-6oicmeam	71	29	]	]	-RRB-
cord-340028-6oicmeam	71	30	.	.	.
cord-340028-6oicmeam	72	1	Nevertheless	nevertheless	RB
cord-340028-6oicmeam	72	2	,	,	,
cord-340028-6oicmeam	72	3	there	there	EX
cord-340028-6oicmeam	72	4	is	be	VBZ
cord-340028-6oicmeam	72	5	currently	currently	RB
cord-340028-6oicmeam	72	6	no	no	DT
cord-340028-6oicmeam	72	7	definitive	definitive	JJ
cord-340028-6oicmeam	72	8	benefit	benefit	NN
cord-340028-6oicmeam	72	9	proven	prove	VBN
cord-340028-6oicmeam	72	10	for	for	IN
cord-340028-6oicmeam	72	11	antiviral	antiviral	JJ
cord-340028-6oicmeam	72	12	treatment	treatment	NN
cord-340028-6oicmeam	72	13	outside	outside	IN
cord-340028-6oicmeam	72	14	of	of	IN
cord-340028-6oicmeam	72	15	these	these	DT
cord-340028-6oicmeam	72	16	specific	specific	JJ
cord-340028-6oicmeam	72	17	circumstances	circumstance	NNS
cord-340028-6oicmeam	72	18	,	,	,
cord-340028-6oicmeam	72	19	as	as	IN
cord-340028-6oicmeam	72	20	it	-PRON-	PRP
cord-340028-6oicmeam	72	21	comes	come	VBZ
cord-340028-6oicmeam	72	22	at	at	IN
cord-340028-6oicmeam	72	23	a	a	DT
cord-340028-6oicmeam	72	24	cost	cost	NN
cord-340028-6oicmeam	72	25	and	and	CC
cord-340028-6oicmeam	72	26	may	may	MD
cord-340028-6oicmeam	72	27	be	be	VB
cord-340028-6oicmeam	72	28	associated	associate	VBN
cord-340028-6oicmeam	72	29	with	with	IN
cord-340028-6oicmeam	72	30	side	side	JJ
cord-340028-6oicmeam	72	31	effects	effect	NNS
cord-340028-6oicmeam	72	32	;	;	:
cord-340028-6oicmeam	72	33	for	for	IN
cord-340028-6oicmeam	72	34	example	example	NN
cord-340028-6oicmeam	72	35	,	,	,
cord-340028-6oicmeam	72	36	zanamivir	zanamivir	NNP
cord-340028-6oicmeam	72	37	can	can	MD
cord-340028-6oicmeam	72	38	induce	induce	VB
cord-340028-6oicmeam	72	39	bronchospasms	bronchospasm	NNS
cord-340028-6oicmeam	72	40	in	in	IN
cord-340028-6oicmeam	72	41	patients	patient	NNS
cord-340028-6oicmeam	72	42	with	with	IN
cord-340028-6oicmeam	72	43	chronic	chronic	JJ
cord-340028-6oicmeam	72	44	respiratory	respiratory	JJ
cord-340028-6oicmeam	72	45	disease	disease	NN
cord-340028-6oicmeam	72	46	and	and	CC
cord-340028-6oicmeam	72	47	asthma	asthma	NN
cord-340028-6oicmeam	72	48	.	.	.
cord-340028-6oicmeam	73	1	Pharmacotherapy	pharmacotherapy	NN
cord-340028-6oicmeam	73	2	for	for	IN
cord-340028-6oicmeam	73	3	individuals	individual	NNS
cord-340028-6oicmeam	73	4	with	with	IN
cord-340028-6oicmeam	73	5	infection	infection	NN
cord-340028-6oicmeam	73	6	remains	remain	VBZ
cord-340028-6oicmeam	73	7	the	the	DT
cord-340028-6oicmeam	73	8	cornerstone	cornerstone	NN
cord-340028-6oicmeam	73	9	of	of	IN
cord-340028-6oicmeam	73	10	clinical	clinical	JJ
cord-340028-6oicmeam	73	11	practice	practice	NN
cord-340028-6oicmeam	73	12	.	.	.
cord-340028-6oicmeam	74	1	The	the	DT
cord-340028-6oicmeam	74	2	success	success	NN
cord-340028-6oicmeam	74	3	of	of	IN
cord-340028-6oicmeam	74	4	antiviral	antiviral	JJ
cord-340028-6oicmeam	74	5	treatment	treatment	NN
cord-340028-6oicmeam	74	6	is	be	VBZ
cord-340028-6oicmeam	74	7	condition	condition	NN
cord-340028-6oicmeam	74	8	-	-	HYPH
cord-340028-6oicmeam	74	9	specific	specific	JJ
cord-340028-6oicmeam	74	10	,	,	,
cord-340028-6oicmeam	74	11	ranging	range	VBG
cord-340028-6oicmeam	74	12	from	from	IN
cord-340028-6oicmeam	74	13	new	new	JJ
cord-340028-6oicmeam	74	14	,	,	,
cord-340028-6oicmeam	74	15	direct	direct	JJ
cord-340028-6oicmeam	74	16	-	-	HYPH
cord-340028-6oicmeam	74	17	acting	act	VBG
cord-340028-6oicmeam	74	18	antiviral	antiviral	JJ
cord-340028-6oicmeam	74	19	drugs	drug	NNS
cord-340028-6oicmeam	74	20	that	that	WDT
cord-340028-6oicmeam	74	21	offer	offer	VBP
cord-340028-6oicmeam	74	22	a	a	DT
cord-340028-6oicmeam	74	23	potential	potential	JJ
cord-340028-6oicmeam	74	24	cure	cure	NN
cord-340028-6oicmeam	74	25	for	for	IN
cord-340028-6oicmeam	74	26	hepatitis	hepatitis	NN
cord-340028-6oicmeam	74	27	C	C	NNP
cord-340028-6oicmeam	74	28	[	[	-LRB-
cord-340028-6oicmeam	74	29	38	38	CD
cord-340028-6oicmeam	74	30	]	]	-RRB-
cord-340028-6oicmeam	74	31	;	;	:
cord-340028-6oicmeam	74	32	to	to	IN
cord-340028-6oicmeam	74	33	the	the	DT
cord-340028-6oicmeam	74	34	highly	highly	RB
cord-340028-6oicmeam	74	35	active	active	JJ
cord-340028-6oicmeam	74	36	antiretroviral	antiretroviral	JJ
cord-340028-6oicmeam	74	37	drugs	drug	NNS
cord-340028-6oicmeam	74	38	that	that	WDT
cord-340028-6oicmeam	74	39	enable	enable	VBP
cord-340028-6oicmeam	74	40	HIV	HIV	NNP
cord-340028-6oicmeam	74	41	positive	positive	JJ
cord-340028-6oicmeam	74	42	individuals	individual	NNS
cord-340028-6oicmeam	74	43	the	the	DT
cord-340028-6oicmeam	74	44	prospect	prospect	NN
cord-340028-6oicmeam	74	45	of	of	IN
cord-340028-6oicmeam	74	46	a	a	DT
cord-340028-6oicmeam	74	47	healthy	healthy	JJ
cord-340028-6oicmeam	74	48	life	life	NN
cord-340028-6oicmeam	74	49	expectancy	expectancy	NN
cord-340028-6oicmeam	74	50	while	while	IN
cord-340028-6oicmeam	74	51	on	on	IN
cord-340028-6oicmeam	74	52	treatment	treatment	NN
cord-340028-6oicmeam	74	53	;	;	:
cord-340028-6oicmeam	74	54	to	to	IN
cord-340028-6oicmeam	74	55	antiviral	antiviral	JJ
cord-340028-6oicmeam	74	56	drugs	drug	NNS
cord-340028-6oicmeam	74	57	for	for	IN
cord-340028-6oicmeam	74	58	herpes	herpes	NN
cord-340028-6oicmeam	74	59	simplex	simplex	NNP
cord-340028-6oicmeam	74	60	types	type	NNS
cord-340028-6oicmeam	74	61	1	1	CD
cord-340028-6oicmeam	74	62	and	and	CC
cord-340028-6oicmeam	74	63	2	2	CD
cord-340028-6oicmeam	74	64	that	that	WDT
cord-340028-6oicmeam	74	65	lead	lead	VBP
cord-340028-6oicmeam	74	66	to	to	IN
cord-340028-6oicmeam	74	67	symptom	symptom	NN
cord-340028-6oicmeam	74	68	alleviation	alleviation	NN
cord-340028-6oicmeam	74	69	but	but	CC
cord-340028-6oicmeam	74	70	do	do	VBP
cord-340028-6oicmeam	74	71	not	not	RB
cord-340028-6oicmeam	74	72	eradicate	eradicate	VB
cord-340028-6oicmeam	74	73	the	the	DT
cord-340028-6oicmeam	74	74	latent	latent	JJ
cord-340028-6oicmeam	74	75	infection	infection	NN
cord-340028-6oicmeam	74	76	;	;	:
cord-340028-6oicmeam	74	77	to	to	IN
cord-340028-6oicmeam	74	78	antivirals	antiviral	NNS
cord-340028-6oicmeam	74	79	for	for	IN
cord-340028-6oicmeam	74	80	seasonal	seasonal	JJ
cord-340028-6oicmeam	74	81	influenza	influenza	NN
cord-340028-6oicmeam	74	82	that	that	WDT
cord-340028-6oicmeam	74	83	are	be	VBP
cord-340028-6oicmeam	74	84	believed	believe	VBN
cord-340028-6oicmeam	74	85	to	to	TO
cord-340028-6oicmeam	74	86	reduce	reduce	VB
cord-340028-6oicmeam	74	87	symptom	symptom	NN
cord-340028-6oicmeam	74	88	duration	duration	NN
cord-340028-6oicmeam	74	89	,	,	,
cord-340028-6oicmeam	74	90	and	and	CC
cord-340028-6oicmeam	74	91	reduce	reduce	VB
cord-340028-6oicmeam	74	92	complications	complication	NNS
cord-340028-6oicmeam	74	93	and	and	CC
cord-340028-6oicmeam	74	94	transmission	transmission	NN
cord-340028-6oicmeam	74	95	risk	risk	NN
cord-340028-6oicmeam	74	96	.	.	.
cord-340028-6oicmeam	75	1	Other	other	JJ
cord-340028-6oicmeam	75	2	anti	anti	JJ
cord-340028-6oicmeam	75	3	-	-	JJ
cord-340028-6oicmeam	75	4	influenza	influenza	JJ
cord-340028-6oicmeam	75	5	medications	medication	NNS
cord-340028-6oicmeam	75	6	licensed	license	VBN
cord-340028-6oicmeam	75	7	for	for	IN
cord-340028-6oicmeam	75	8	treatment	treatment	NN
cord-340028-6oicmeam	75	9	,	,	,
cord-340028-6oicmeam	75	10	aside	aside	RB
cord-340028-6oicmeam	75	11	from	from	IN
cord-340028-6oicmeam	75	12	oseltamivir	oseltamivir	NNP
cord-340028-6oicmeam	75	13	and	and	CC
cord-340028-6oicmeam	75	14	zanamivir	zanamivir	NNP
cord-340028-6oicmeam	75	15	,	,	,
cord-340028-6oicmeam	75	16	consist	consist	VBP
cord-340028-6oicmeam	75	17	of	of	IN
cord-340028-6oicmeam	75	18	an	an	DT
cord-340028-6oicmeam	75	19	intravenous	intravenous	JJ
cord-340028-6oicmeam	75	20	neuraminidase	neuraminidase	NN
cord-340028-6oicmeam	75	21	inhibitor	inhibitor	NN
cord-340028-6oicmeam	75	22	,	,	,
cord-340028-6oicmeam	75	23	peravamir	peravamir	NNP
cord-340028-6oicmeam	75	24	,	,	,
cord-340028-6oicmeam	75	25	and	and	CC
cord-340028-6oicmeam	75	26	a	a	DT
cord-340028-6oicmeam	75	27	novel	novel	JJ
cord-340028-6oicmeam	75	28	oral	oral	JJ
cord-340028-6oicmeam	75	29	inhibitor	inhibitor	NN
cord-340028-6oicmeam	75	30	of	of	IN
cord-340028-6oicmeam	75	31	cap	cap	NN
cord-340028-6oicmeam	75	32	-	-	HYPH
cord-340028-6oicmeam	75	33	dependent	dependent	JJ
cord-340028-6oicmeam	75	34	endonuclease	endonuclease	NN
cord-340028-6oicmeam	75	35	,	,	,
cord-340028-6oicmeam	75	36	baloxavir	baloxavir	NNP
cord-340028-6oicmeam	75	37	.	.	.
cord-340028-6oicmeam	76	1	Neuraminidase	Neuraminidase	NNP
cord-340028-6oicmeam	76	2	inhibitors	inhibitor	NNS
cord-340028-6oicmeam	76	3	are	be	VBP
cord-340028-6oicmeam	76	4	effective	effective	JJ
cord-340028-6oicmeam	76	5	against	against	IN
cord-340028-6oicmeam	76	6	both	both	DT
cord-340028-6oicmeam	76	7	influenza	influenza	NN
cord-340028-6oicmeam	76	8	A	a	NN
cord-340028-6oicmeam	76	9	and	and	CC
cord-340028-6oicmeam	76	10	B	b	NN
cord-340028-6oicmeam	76	11	,	,	,
cord-340028-6oicmeam	76	12	while	while	IN
cord-340028-6oicmeam	76	13	an	an	DT
cord-340028-6oicmeam	76	14	additional	additional	JJ
cord-340028-6oicmeam	76	15	class	class	NN
cord-340028-6oicmeam	76	16	of	of	IN
cord-340028-6oicmeam	76	17	antivirals	antiviral	NNS
cord-340028-6oicmeam	76	18	that	that	WDT
cord-340028-6oicmeam	76	19	are	be	VBP
cord-340028-6oicmeam	76	20	no	no	RB
cord-340028-6oicmeam	76	21	longer	long	RBR
cord-340028-6oicmeam	76	22	recommended	recommend	VBN
cord-340028-6oicmeam	76	23	for	for	IN
cord-340028-6oicmeam	76	24	treatment	treatment	NN
cord-340028-6oicmeam	76	25	of	of	IN
cord-340028-6oicmeam	76	26	influenza	influenza	NN
cord-340028-6oicmeam	76	27	due	due	IN
cord-340028-6oicmeam	76	28	to	to	IN
cord-340028-6oicmeam	76	29	reduced	reduce	VBN
cord-340028-6oicmeam	76	30	efficacy	efficacy	NN
cord-340028-6oicmeam	76	31	,	,	,
cord-340028-6oicmeam	76	32	neurological	neurological	JJ
cord-340028-6oicmeam	76	33	side	side	NN
cord-340028-6oicmeam	76	34	effects	effect	NNS
cord-340028-6oicmeam	76	35	,	,	,
cord-340028-6oicmeam	76	36	and	and	CC
cord-340028-6oicmeam	76	37	widespread	widespread	JJ
cord-340028-6oicmeam	76	38	resistance	resistance	NN
cord-340028-6oicmeam	76	39	,	,	,
cord-340028-6oicmeam	76	40	adamantanes	adamantanes	NNP
cord-340028-6oicmeam	76	41	(	(	-LRB-
cord-340028-6oicmeam	76	42	M2	M2	NNP
cord-340028-6oicmeam	76	43	inhibitors	inhibitor	NNS
cord-340028-6oicmeam	76	44	,	,	,
cord-340028-6oicmeam	76	45	amantadine	amantadine	NNP
cord-340028-6oicmeam	76	46	and	and	CC
cord-340028-6oicmeam	76	47	rimantadine	rimantadine	NNP
cord-340028-6oicmeam	76	48	)	)	-RRB-
cord-340028-6oicmeam	76	49	,	,	,
cord-340028-6oicmeam	76	50	are	be	VBP
cord-340028-6oicmeam	76	51	only	only	RB
cord-340028-6oicmeam	76	52	active	active	JJ
cord-340028-6oicmeam	76	53	against	against	IN
cord-340028-6oicmeam	76	54	influenza	influenza	NN
cord-340028-6oicmeam	76	55	A	a	DT
cord-340028-6oicmeam	76	56	[	[	-LRB-
cord-340028-6oicmeam	76	57	31	31	CD
cord-340028-6oicmeam	76	58	]	]	-RRB-
cord-340028-6oicmeam	76	59	.	.	.
cord-340028-6oicmeam	77	1	Although	although	IN
cord-340028-6oicmeam	77	2	many	many	JJ
cord-340028-6oicmeam	77	3	patients	patient	NNS
cord-340028-6oicmeam	77	4	with	with	IN
cord-340028-6oicmeam	77	5	influenza	influenza	NN
cord-340028-6oicmeam	77	6	exhibit	exhibit	VB
cord-340028-6oicmeam	77	7	minimal	minimal	JJ
cord-340028-6oicmeam	77	8	clinical	clinical	JJ
cord-340028-6oicmeam	77	9	improvement	improvement	NN
cord-340028-6oicmeam	77	10	upon	upon	IN
cord-340028-6oicmeam	77	11	treatment	treatment	NN
cord-340028-6oicmeam	77	12	with	with	IN
cord-340028-6oicmeam	77	13	these	these	DT
cord-340028-6oicmeam	77	14	medications	medication	NNS
cord-340028-6oicmeam	77	15	,	,	,
cord-340028-6oicmeam	77	16	they	-PRON-	PRP
cord-340028-6oicmeam	77	17	are	be	VBP
cord-340028-6oicmeam	77	18	currently	currently	RB
cord-340028-6oicmeam	77	19	recommended	recommend	VBN
cord-340028-6oicmeam	77	20	for	for	IN
cord-340028-6oicmeam	77	21	treatment	treatment	NN
cord-340028-6oicmeam	77	22	of	of	IN
cord-340028-6oicmeam	77	23	all	all	DT
cord-340028-6oicmeam	77	24	hospitalised	hospitalise	VBN
cord-340028-6oicmeam	77	25	patients	patient	NNS
cord-340028-6oicmeam	77	26	,	,	,
cord-340028-6oicmeam	77	27	even	even	RB
cord-340028-6oicmeam	77	28	prior	prior	RB
cord-340028-6oicmeam	77	29	to	to	IN
cord-340028-6oicmeam	77	30	laboratory	laboratory	NN
cord-340028-6oicmeam	77	31	confirmation	confirmation	NN
cord-340028-6oicmeam	77	32	of	of	IN
cord-340028-6oicmeam	77	33	influenza	influenza	NN
cord-340028-6oicmeam	77	34	infection	infection	NN
cord-340028-6oicmeam	77	35	.	.	.
cord-340028-6oicmeam	78	1	Evidence	evidence	NN
cord-340028-6oicmeam	78	2	shows	show	VBZ
cord-340028-6oicmeam	78	3	that	that	IN
cord-340028-6oicmeam	78	4	the	the	DT
cord-340028-6oicmeam	78	5	greatest	great	JJS
cord-340028-6oicmeam	78	6	benefit	benefit	NN
cord-340028-6oicmeam	78	7	is	be	VBZ
cord-340028-6oicmeam	78	8	seen	see	VBN
cord-340028-6oicmeam	78	9	when	when	WRB
cord-340028-6oicmeam	78	10	these	these	DT
cord-340028-6oicmeam	78	11	drugs	drug	NNS
cord-340028-6oicmeam	78	12	are	be	VBP
cord-340028-6oicmeam	78	13	administered	administer	VBN
cord-340028-6oicmeam	78	14	24	24	CD
cord-340028-6oicmeam	78	15	-	-	SYM
cord-340028-6oicmeam	78	16	30	30	CD
cord-340028-6oicmeam	78	17	hours	hour	NNS
cord-340028-6oicmeam	78	18	prior	prior	RB
cord-340028-6oicmeam	78	19	to	to	IN
cord-340028-6oicmeam	78	20	symptom	symptom	NN
cord-340028-6oicmeam	78	21	onset	onset	NN
cord-340028-6oicmeam	78	22	,	,	,
cord-340028-6oicmeam	78	23	in	in	IN
cord-340028-6oicmeam	78	24	which	which	WDT
cord-340028-6oicmeam	78	25	case	case	NN
cord-340028-6oicmeam	78	26	they	-PRON-	PRP
cord-340028-6oicmeam	78	27	reduce	reduce	VBP
cord-340028-6oicmeam	78	28	symptom	symptom	NN
cord-340028-6oicmeam	78	29	duration	duration	NN
cord-340028-6oicmeam	78	30	by	by	IN
cord-340028-6oicmeam	78	31	0.5	0.5	CD
cord-340028-6oicmeam	78	32	-	-	SYM
cord-340028-6oicmeam	78	33	3	3	CD
cord-340028-6oicmeam	78	34	days	day	NNS
cord-340028-6oicmeam	78	35	and	and	CC
cord-340028-6oicmeam	78	36	reduce	reduce	VB
cord-340028-6oicmeam	78	37	transmission	transmission	NN
cord-340028-6oicmeam	78	38	risk	risk	NN
cord-340028-6oicmeam	78	39	[	[	-LRB-
cord-340028-6oicmeam	78	40	39	39	CD
cord-340028-6oicmeam	78	41	]	]	-RRB-
cord-340028-6oicmeam	78	42	[	[	-LRB-
cord-340028-6oicmeam	78	43	40	40	CD
cord-340028-6oicmeam	78	44	]	]	-RRB-
cord-340028-6oicmeam	78	45	[	[	-LRB-
cord-340028-6oicmeam	78	46	41	41	CD
cord-340028-6oicmeam	78	47	]	]	-RRB-
cord-340028-6oicmeam	78	48	[	[	-LRB-
cord-340028-6oicmeam	78	49	42	42	CD
cord-340028-6oicmeam	78	50	]	]	-RRB-
cord-340028-6oicmeam	78	51	.	.	.
cord-340028-6oicmeam	79	1	According	accord	VBG
cord-340028-6oicmeam	79	2	to	to	IN
cord-340028-6oicmeam	79	3	the	the	DT
cord-340028-6oicmeam	79	4	recent	recent	JJ
cord-340028-6oicmeam	79	5	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	79	6	treatment	treatment	NN
cord-340028-6oicmeam	79	7	guidelines	guideline	NNS
cord-340028-6oicmeam	79	8	in	in	IN
cord-340028-6oicmeam	79	9	China	China	NNP
cord-340028-6oicmeam	79	10	[	[	-LRB-
cord-340028-6oicmeam	79	11	43	43	CD
cord-340028-6oicmeam	79	12	]	]	-RRB-
cord-340028-6oicmeam	79	13	,	,	,
cord-340028-6oicmeam	79	14	symptomatic	symptomatic	JJ
cord-340028-6oicmeam	79	15	treatment	treatment	NN
cord-340028-6oicmeam	79	16	for	for	IN
cord-340028-6oicmeam	79	17	COVID-19	covid-19	JJ
cord-340028-6oicmeam	79	18	patients	patient	NNS
cord-340028-6oicmeam	79	19	is	be	VBZ
cord-340028-6oicmeam	79	20	recommended	recommend	VBN
cord-340028-6oicmeam	79	21	for	for	IN
cord-340028-6oicmeam	79	22	mild	mild	JJ
cord-340028-6oicmeam	79	23	cases	case	NNS
cord-340028-6oicmeam	79	24	and	and	CC
cord-340028-6oicmeam	79	25	consists	consist	VBZ
cord-340028-6oicmeam	79	26	of	of	IN
cord-340028-6oicmeam	79	27	AGING	age	VBG
cord-340028-6oicmeam	79	28	rest	rest	NN
cord-340028-6oicmeam	79	29	,	,	,
cord-340028-6oicmeam	79	30	isolation	isolation	NN
cord-340028-6oicmeam	79	31	,	,	,
cord-340028-6oicmeam	79	32	adequate	adequate	JJ
cord-340028-6oicmeam	79	33	hydration	hydration	NN
cord-340028-6oicmeam	79	34	,	,	,
cord-340028-6oicmeam	79	35	analgesia	analgesia	NN
cord-340028-6oicmeam	79	36	,	,	,
cord-340028-6oicmeam	79	37	and	and	CC
cord-340028-6oicmeam	79	38	antipyretic	antipyretic	JJ
cord-340028-6oicmeam	79	39	medication	medication	NN
cord-340028-6oicmeam	79	40	.	.	.
cord-340028-6oicmeam	80	1	Moderate	moderate	JJ
cord-340028-6oicmeam	80	2	and	and	CC
cord-340028-6oicmeam	80	3	severe	severe	JJ
cord-340028-6oicmeam	80	4	cases	case	NNS
cord-340028-6oicmeam	80	5	(	(	-LRB-
cord-340028-6oicmeam	80	6	mostly	mostly	RB
cord-340028-6oicmeam	80	7	hospitalized	hospitalize	VBN
cord-340028-6oicmeam	80	8	)	)	-RRB-
cord-340028-6oicmeam	80	9	require	require	VBP
cord-340028-6oicmeam	80	10	additional	additional	JJ
cord-340028-6oicmeam	80	11	measures	measure	NNS
cord-340028-6oicmeam	80	12	,	,	,
cord-340028-6oicmeam	80	13	such	such	JJ
cord-340028-6oicmeam	80	14	as	as	IN
cord-340028-6oicmeam	80	15	careful	careful	JJ
cord-340028-6oicmeam	80	16	fluid	fluid	NN
cord-340028-6oicmeam	80	17	balance	balance	NN
cord-340028-6oicmeam	80	18	,	,	,
cord-340028-6oicmeam	80	19	intravenous	intravenous	JJ
cord-340028-6oicmeam	80	20	antibiotics	antibiotic	NNS
cord-340028-6oicmeam	80	21	for	for	IN
cord-340028-6oicmeam	80	22	superinfections	superinfection	NNS
cord-340028-6oicmeam	80	23	,	,	,
cord-340028-6oicmeam	80	24	oxygen	oxygen	NN
cord-340028-6oicmeam	80	25	supplementation	supplementation	NN
cord-340028-6oicmeam	80	26	,	,	,
cord-340028-6oicmeam	80	27	non	non	JJ
cord-340028-6oicmeam	80	28	-	-	JJ
cord-340028-6oicmeam	80	29	invasive	invasive	JJ
cord-340028-6oicmeam	80	30	ventilation	ventilation	NN
cord-340028-6oicmeam	80	31	with	with	IN
cord-340028-6oicmeam	80	32	or	or	CC
cord-340028-6oicmeam	80	33	without	without	IN
cord-340028-6oicmeam	80	34	positive	positive	JJ
cord-340028-6oicmeam	80	35	pulmonary	pulmonary	JJ
cord-340028-6oicmeam	80	36	pressure	pressure	NN
cord-340028-6oicmeam	80	37	,	,	,
cord-340028-6oicmeam	80	38	and	and	CC
cord-340028-6oicmeam	80	39	in	in	IN
cord-340028-6oicmeam	80	40	some	some	DT
cord-340028-6oicmeam	80	41	cases	case	NNS
cord-340028-6oicmeam	80	42	intubation	intubation	NN
cord-340028-6oicmeam	80	43	and	and	CC
cord-340028-6oicmeam	80	44	mechanical	mechanical	JJ
cord-340028-6oicmeam	80	45	ventilation	ventilation	NN
cord-340028-6oicmeam	80	46	.	.	.
cord-340028-6oicmeam	81	1	Although	although	IN
cord-340028-6oicmeam	81	2	the	the	DT
cord-340028-6oicmeam	81	3	projected	project	VBN
cord-340028-6oicmeam	81	4	global	global	JJ
cord-340028-6oicmeam	81	5	infection	infection	NN
cord-340028-6oicmeam	81	6	rates	rate	NNS
cord-340028-6oicmeam	81	7	are	be	VBP
cord-340028-6oicmeam	81	8	variable	variable	JJ
cord-340028-6oicmeam	81	9	,	,	,
cord-340028-6oicmeam	81	10	we	-PRON-	PRP
cord-340028-6oicmeam	81	11	share	share	VBP
cord-340028-6oicmeam	81	12	a	a	DT
cord-340028-6oicmeam	81	13	common	common	JJ
cord-340028-6oicmeam	81	14	concern	concern	NN
cord-340028-6oicmeam	81	15	that	that	IN
cord-340028-6oicmeam	81	16	outside	outside	NN
cord-340028-6oicmeam	81	17	of	of	IN
cord-340028-6oicmeam	81	18	China	China	NNP
cord-340028-6oicmeam	81	19	there	there	EX
cord-340028-6oicmeam	81	20	may	may	MD
cord-340028-6oicmeam	81	21	be	be	VB
cord-340028-6oicmeam	81	22	an	an	DT
cord-340028-6oicmeam	81	23	insufficient	insufficient	JJ
cord-340028-6oicmeam	81	24	number	number	NN
cord-340028-6oicmeam	81	25	of	of	IN
cord-340028-6oicmeam	81	26	beds	bed	NNS
cord-340028-6oicmeam	81	27	for	for	IN
cord-340028-6oicmeam	81	28	hospitalization	hospitalization	NN
cord-340028-6oicmeam	81	29	and	and	CC
cord-340028-6oicmeam	81	30	ventilation	ventilation	NN
cord-340028-6oicmeam	81	31	units	unit	NNS
cord-340028-6oicmeam	81	32	if	if	IN
cord-340028-6oicmeam	81	33	the	the	DT
cord-340028-6oicmeam	81	34	disease	disease	NN
cord-340028-6oicmeam	81	35	spread	spread	VBD
cord-340028-6oicmeam	81	36	does	do	VBZ
cord-340028-6oicmeam	81	37	not	not	RB
cord-340028-6oicmeam	81	38	slow	slow	VB
cord-340028-6oicmeam	81	39	down	down	RP
cord-340028-6oicmeam	81	40	.	.	.
cord-340028-6oicmeam	82	1	Even	even	RB
cord-340028-6oicmeam	82	2	asymptomatic	asymptomatic	JJ
cord-340028-6oicmeam	82	3	COVID-19	covid-19	JJ
cord-340028-6oicmeam	82	4	infections	infection	NNS
cord-340028-6oicmeam	82	5	can	can	MD
cord-340028-6oicmeam	82	6	induce	induce	VB
cord-340028-6oicmeam	82	7	lung	lung	NN
cord-340028-6oicmeam	82	8	fibrosis	fibrosis	NN
cord-340028-6oicmeam	82	9	,	,	,
cord-340028-6oicmeam	82	10	which	which	WDT
cord-340028-6oicmeam	82	11	may	may	MD
cord-340028-6oicmeam	82	12	lead	lead	VB
cord-340028-6oicmeam	82	13	to	to	IN
cord-340028-6oicmeam	82	14	reduced	reduced	JJ
cord-340028-6oicmeam	82	15	function	function	NN
cord-340028-6oicmeam	82	16	of	of	IN
cord-340028-6oicmeam	82	17	the	the	DT
cord-340028-6oicmeam	82	18	respiratory	respiratory	JJ
cord-340028-6oicmeam	82	19	system	system	NN
cord-340028-6oicmeam	82	20	.	.	.
cord-340028-6oicmeam	83	1	Further	further	RB
cord-340028-6oicmeam	83	2	,	,	,
cord-340028-6oicmeam	83	3	severe	severe	JJ
cord-340028-6oicmeam	83	4	cases	case	NNS
cord-340028-6oicmeam	83	5	are	be	VBP
cord-340028-6oicmeam	83	6	often	often	RB
cord-340028-6oicmeam	83	7	complicated	complicate	VBN
cord-340028-6oicmeam	83	8	by	by	IN
cord-340028-6oicmeam	83	9	bacterial	bacterial	JJ
cord-340028-6oicmeam	83	10	infections	infection	NNS
cord-340028-6oicmeam	83	11	and	and	CC
cord-340028-6oicmeam	83	12	pneumonia	pneumonia	NN
cord-340028-6oicmeam	83	13	,	,	,
cord-340028-6oicmeam	83	14	leading	lead	VBG
cord-340028-6oicmeam	83	15	to	to	IN
cord-340028-6oicmeam	83	16	fibrosis	fibrosis	NN
cord-340028-6oicmeam	83	17	.	.	.
cord-340028-6oicmeam	84	1	Therefore	therefore	RB
cord-340028-6oicmeam	84	2	,	,	,
cord-340028-6oicmeam	84	3	COVID-19	covid-19	JJ
cord-340028-6oicmeam	84	4	rehabilitation	rehabilitation	NN
cord-340028-6oicmeam	84	5	may	may	MD
cord-340028-6oicmeam	84	6	include	include	VB
cord-340028-6oicmeam	84	7	antifibrotic	antifibrotic	JJ
cord-340028-6oicmeam	84	8	compounds	compound	NNS
cord-340028-6oicmeam	84	9	,	,	,
cord-340028-6oicmeam	84	10	anti	anti	NNP
cord-340028-6oicmeam	84	11	-	-	NNP
cord-340028-6oicmeam	84	12	COPD	COPD	NNP
cord-340028-6oicmeam	84	13	,	,	,
cord-340028-6oicmeam	84	14	and	and	CC
cord-340028-6oicmeam	84	15	regenerative	regenerative	JJ
cord-340028-6oicmeam	84	16	medicine	medicine	NN
cord-340028-6oicmeam	84	17	therapies	therapy	NNS
cord-340028-6oicmeam	84	18	.	.	.
cord-340028-6oicmeam	85	1	There	there	EX
cord-340028-6oicmeam	85	2	are	be	VBP
cord-340028-6oicmeam	85	3	multiple	multiple	JJ
cord-340028-6oicmeam	85	4	interventions	intervention	NNS
cord-340028-6oicmeam	85	5	proposed	propose	VBN
cord-340028-6oicmeam	85	6	in	in	IN
cord-340028-6oicmeam	85	7	the	the	DT
cord-340028-6oicmeam	85	8	academic	academic	JJ
cord-340028-6oicmeam	85	9	literature	literature	NN
cord-340028-6oicmeam	85	10	to	to	TO
cord-340028-6oicmeam	85	11	remedy	remedy	NN
cord-340028-6oicmeam	85	12	age	age	NN
cord-340028-6oicmeam	85	13	-	-	HYPH
cord-340028-6oicmeam	85	14	associated	associate	VBN
cord-340028-6oicmeam	85	15	increases	increase	NNS
cord-340028-6oicmeam	85	16	in	in	IN
cord-340028-6oicmeam	85	17	infection	infection	NN
cord-340028-6oicmeam	85	18	rates	rate	NNS
cord-340028-6oicmeam	85	19	,	,	,
cord-340028-6oicmeam	85	20	severity	severity	NN
cord-340028-6oicmeam	85	21	,	,	,
cord-340028-6oicmeam	85	22	and	and	CC
cord-340028-6oicmeam	85	23	lethality	lethality	NN
cord-340028-6oicmeam	85	24	for	for	IN
cord-340028-6oicmeam	85	25	a	a	DT
cord-340028-6oicmeam	85	26	variety	variety	NN
cord-340028-6oicmeam	85	27	of	of	IN
cord-340028-6oicmeam	85	28	infections	infection	NNS
cord-340028-6oicmeam	85	29	.	.	.
cord-340028-6oicmeam	86	1	For	for	IN
cord-340028-6oicmeam	86	2	example	example	NN
cord-340028-6oicmeam	86	3	,	,	,
cord-340028-6oicmeam	86	4	regular	regular	JJ
cord-340028-6oicmeam	86	5	increased	increase	VBN
cord-340028-6oicmeam	86	6	physical	physical	JJ
cord-340028-6oicmeam	86	7	activity	activity	NN
cord-340028-6oicmeam	86	8	has	have	VBZ
cord-340028-6oicmeam	86	9	been	be	VBN
cord-340028-6oicmeam	86	10	proposed	propose	VBN
cord-340028-6oicmeam	86	11	to	to	TO
cord-340028-6oicmeam	86	12	reduce	reduce	VB
cord-340028-6oicmeam	86	13	immunosenescence	immunosenescence	RB
cord-340028-6oicmeam	86	14	[	[	-LRB-
cord-340028-6oicmeam	86	15	44	44	CD
cord-340028-6oicmeam	86	16	]	]	-RRB-
cord-340028-6oicmeam	86	17	.	.	.
cord-340028-6oicmeam	87	1	Fahy	Fahy	NNP
cord-340028-6oicmeam	87	2	et	et	NNP
cord-340028-6oicmeam	87	3	al	al	NNP
cord-340028-6oicmeam	87	4	.	.	.
cord-340028-6oicmeam	88	1	[	[	-LRB-
cord-340028-6oicmeam	88	2	45	45	CD
cord-340028-6oicmeam	88	3	]	]	-RRB-
cord-340028-6oicmeam	88	4	and	and	CC
cord-340028-6oicmeam	88	5	Horvath	Horvath	NNP
cord-340028-6oicmeam	88	6	[	[	-LRB-
cord-340028-6oicmeam	88	7	46	46	CD
cord-340028-6oicmeam	88	8	]	]	-RRB-
cord-340028-6oicmeam	88	9	have	have	VBP
cord-340028-6oicmeam	88	10	suggested	suggest	VBN
cord-340028-6oicmeam	88	11	that	that	IN
cord-340028-6oicmeam	88	12	a	a	DT
cord-340028-6oicmeam	88	13	combination	combination	NN
cord-340028-6oicmeam	88	14	of	of	IN
cord-340028-6oicmeam	88	15	the	the	DT
cord-340028-6oicmeam	88	16	potentially	potentially	RB
cord-340028-6oicmeam	88	17	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	88	18	compound	compound	NN
cord-340028-6oicmeam	88	19	metformin	metformin	NNP
cord-340028-6oicmeam	88	20	,	,	,
cord-340028-6oicmeam	88	21	recombinant	recombinant	JJ
cord-340028-6oicmeam	88	22	human	human	JJ
cord-340028-6oicmeam	88	23	Growth	Growth	NNP
cord-340028-6oicmeam	88	24	Hormone	Hormone	NNP
cord-340028-6oicmeam	88	25	(	(	-LRB-
cord-340028-6oicmeam	88	26	rhGH	rhGH	NNP
cord-340028-6oicmeam	88	27	)	)	-RRB-
cord-340028-6oicmeam	88	28	,	,	,
cord-340028-6oicmeam	88	29	and	and	CC
cord-340028-6oicmeam	88	30	dehydroepiandrosterone	dehydroepiandrosterone	NNP
cord-340028-6oicmeam	88	31	(	(	-LRB-
cord-340028-6oicmeam	88	32	DHEA	DHEA	NNP
cord-340028-6oicmeam	88	33	)	)	-RRB-
cord-340028-6oicmeam	88	34	may	may	MD
cord-340028-6oicmeam	88	35	reverse	reverse	VB
cord-340028-6oicmeam	88	36	biological	biological	JJ
cord-340028-6oicmeam	88	37	age	age	NN
cord-340028-6oicmeam	88	38	,	,	,
cord-340028-6oicmeam	88	39	as	as	IN
cord-340028-6oicmeam	88	40	measured	measure	VBN
cord-340028-6oicmeam	88	41	using	use	VBG
cord-340028-6oicmeam	88	42	the	the	DT
cord-340028-6oicmeam	88	43	methylation	methylation	NN
cord-340028-6oicmeam	88	44	aging	age	VBG
cord-340028-6oicmeam	88	45	clock	clock	NN
cord-340028-6oicmeam	88	46	,	,	,
cord-340028-6oicmeam	88	47	and	and	CC
cord-340028-6oicmeam	88	48	immunosenescence	immunosenescence	NNP
cord-340028-6oicmeam	88	49	[	[	-LRB-
cord-340028-6oicmeam	88	50	45	45	CD
cord-340028-6oicmeam	88	51	]	]	-RRB-
cord-340028-6oicmeam	88	52	.	.	.
cord-340028-6oicmeam	89	1	Geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	89	2	were	be	VBD
cord-340028-6oicmeam	89	3	previously	previously	RB
cord-340028-6oicmeam	89	4	proposed	propose	VBN
cord-340028-6oicmeam	89	5	to	to	TO
cord-340028-6oicmeam	89	6	enhance	enhance	VB
cord-340028-6oicmeam	89	7	human	human	JJ
cord-340028-6oicmeam	89	8	radioresistance	radioresistance	NN
cord-340028-6oicmeam	89	9	in	in	IN
cord-340028-6oicmeam	89	10	extreme	extreme	JJ
cord-340028-6oicmeam	89	11	conditions	condition	NNS
cord-340028-6oicmeam	89	12	[	[	-LRB-
cord-340028-6oicmeam	89	13	47	47	CD
cord-340028-6oicmeam	89	14	]	]	-RRB-
cord-340028-6oicmeam	89	15	.	.	.
cord-340028-6oicmeam	90	1	While	while	IN
cord-340028-6oicmeam	90	2	there	there	EX
cord-340028-6oicmeam	90	3	is	be	VBZ
cord-340028-6oicmeam	90	4	no	no	DT
cord-340028-6oicmeam	90	5	clinical	clinical	JJ
cord-340028-6oicmeam	90	6	evidence	evidence	NN
cord-340028-6oicmeam	90	7	yet	yet	CC
cord-340028-6oicmeam	90	8	suggesting	suggest	VBG
cord-340028-6oicmeam	90	9	age	age	NN
cord-340028-6oicmeam	90	10	reversal	reversal	NN
cord-340028-6oicmeam	90	11	or	or	CC
cord-340028-6oicmeam	90	12	improved	improved	JJ
cord-340028-6oicmeam	90	13	immune	immune	JJ
cord-340028-6oicmeam	90	14	function	function	NN
cord-340028-6oicmeam	90	15	in	in	IN
cord-340028-6oicmeam	90	16	the	the	DT
cord-340028-6oicmeam	90	17	elderly	elderly	JJ
cord-340028-6oicmeam	90	18	,	,	,
cord-340028-6oicmeam	90	19	efforts	effort	NNS
cord-340028-6oicmeam	90	20	are	be	VBP
cord-340028-6oicmeam	90	21	being	be	VBG
cord-340028-6oicmeam	90	22	made	make	VBN
cord-340028-6oicmeam	90	23	to	to	TO
cord-340028-6oicmeam	90	24	identify	identify	VB
cord-340028-6oicmeam	90	25	new	new	JJ
cord-340028-6oicmeam	90	26	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	90	27	using	use	VBG
cord-340028-6oicmeam	90	28	human	human	JJ
cord-340028-6oicmeam	90	29	data	datum	NNS
cord-340028-6oicmeam	90	30	and	and	CC
cord-340028-6oicmeam	90	31	artificial	artificial	JJ
cord-340028-6oicmeam	90	32	intelligence	intelligence	NN
cord-340028-6oicmeam	90	33	[	[	-LRB-
cord-340028-6oicmeam	90	34	48	48	CD
cord-340028-6oicmeam	90	35	]	]	-RRB-
cord-340028-6oicmeam	91	1	[	[	-LRB-
cord-340028-6oicmeam	91	2	49	49	CD
cord-340028-6oicmeam	91	3	]	]	-RRB-
cord-340028-6oicmeam	91	4	[	[	-LRB-
cord-340028-6oicmeam	91	5	50	50	CD
cord-340028-6oicmeam	91	6	]	]	-RRB-
cord-340028-6oicmeam	91	7	.	.	.
cord-340028-6oicmeam	92	1	Further	further	RB
cord-340028-6oicmeam	92	2	,	,	,
cord-340028-6oicmeam	92	3	the	the	DT
cord-340028-6oicmeam	92	4	use	use	NN
cord-340028-6oicmeam	92	5	of	of	IN
cord-340028-6oicmeam	92	6	natural	natural	JJ
cord-340028-6oicmeam	92	7	compounds	compound	NNS
cord-340028-6oicmeam	92	8	that	that	WDT
cord-340028-6oicmeam	92	9	mimic	mimic	VBP
cord-340028-6oicmeam	92	10	the	the	DT
cord-340028-6oicmeam	92	11	effects	effect	NNS
cord-340028-6oicmeam	92	12	of	of	IN
cord-340028-6oicmeam	92	13	known	know	VBN
cord-340028-6oicmeam	92	14	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	92	15	is	be	VBZ
cord-340028-6oicmeam	92	16	generally	generally	RB
cord-340028-6oicmeam	92	17	recognized	recognize	VBN
cord-340028-6oicmeam	92	18	as	as	RB
cord-340028-6oicmeam	92	19	safe	safe	JJ
cord-340028-6oicmeam	92	20	[	[	-LRB-
cord-340028-6oicmeam	92	21	51	51	CD
cord-340028-6oicmeam	92	22	]	]	-RRB-
cord-340028-6oicmeam	92	23	.	.	.
cord-340028-6oicmeam	93	1	However	however	RB
cord-340028-6oicmeam	93	2	,	,	,
cord-340028-6oicmeam	93	3	attempts	attempt	NNS
cord-340028-6oicmeam	93	4	have	have	VBP
cord-340028-6oicmeam	93	5	been	be	VBN
cord-340028-6oicmeam	93	6	made	make	VBN
cord-340028-6oicmeam	93	7	to	to	TO
cord-340028-6oicmeam	93	8	develop	develop	VB
cord-340028-6oicmeam	93	9	criteria	criterion	NNS
cord-340028-6oicmeam	93	10	for	for	IN
cord-340028-6oicmeam	93	11	the	the	DT
cord-340028-6oicmeam	93	12	evaluation	evaluation	NN
cord-340028-6oicmeam	93	13	of	of	IN
cord-340028-6oicmeam	93	14	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	93	15	for	for	IN
cord-340028-6oicmeam	93	16	clinical	clinical	JJ
cord-340028-6oicmeam	93	17	validation	validation	NN
cord-340028-6oicmeam	93	18	.	.	.
cord-340028-6oicmeam	94	1	There	there	EX
cord-340028-6oicmeam	94	2	are	be	VBP
cord-340028-6oicmeam	94	3	multiple	multiple	JJ
cord-340028-6oicmeam	94	4	strategies	strategy	NNS
cord-340028-6oicmeam	94	5	proposed	propose	VBN
cord-340028-6oicmeam	94	6	to	to	TO
cord-340028-6oicmeam	94	7	restore	restore	VB
cord-340028-6oicmeam	94	8	immune	immune	JJ
cord-340028-6oicmeam	94	9	function	function	NN
cord-340028-6oicmeam	94	10	in	in	IN
cord-340028-6oicmeam	94	11	the	the	DT
cord-340028-6oicmeam	94	12	elderly	elderly	JJ
cord-340028-6oicmeam	94	13	[	[	-LRB-
cord-340028-6oicmeam	94	14	52	52	CD
cord-340028-6oicmeam	94	15	]	]	-RRB-
cord-340028-6oicmeam	94	16	,	,	,
cord-340028-6oicmeam	94	17	and	and	CC
cord-340028-6oicmeam	94	18	multiple	multiple	JJ
cord-340028-6oicmeam	94	19	databases	database	NNS
cord-340028-6oicmeam	94	20	of	of	IN
cord-340028-6oicmeam	94	21	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	94	22	exist	exist	VBP
cord-340028-6oicmeam	94	23	[	[	-LRB-
cord-340028-6oicmeam	94	24	53	53	CD
cord-340028-6oicmeam	94	25	,	,	,
cord-340028-6oicmeam	94	26	54	54	CD
cord-340028-6oicmeam	94	27	]	]	-RRB-
cord-340028-6oicmeam	94	28	.	.	.
cord-340028-6oicmeam	95	1	However	however	RB
cord-340028-6oicmeam	95	2	,	,	,
cord-340028-6oicmeam	95	3	to	to	IN
cord-340028-6oicmeam	95	4	date	date	NN
cord-340028-6oicmeam	95	5	the	the	DT
cord-340028-6oicmeam	95	6	only	only	RB
cord-340028-6oicmeam	95	7	known	know	VBN
cord-340028-6oicmeam	95	8	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	95	9	backed	back	VBN
cord-340028-6oicmeam	95	10	by	by	IN
cord-340028-6oicmeam	95	11	promising	promise	VBG
cord-340028-6oicmeam	95	12	clinical	clinical	JJ
cord-340028-6oicmeam	95	13	evidence	evidence	NN
cord-340028-6oicmeam	95	14	of	of	IN
cord-340028-6oicmeam	95	15	improved	improved	JJ
cord-340028-6oicmeam	95	16	immune	immune	JJ
cord-340028-6oicmeam	95	17	response	response	NN
cord-340028-6oicmeam	95	18	to	to	IN
cord-340028-6oicmeam	95	19	viral	viral	JJ
cord-340028-6oicmeam	95	20	infection	infection	NN
cord-340028-6oicmeam	95	21	in	in	IN
cord-340028-6oicmeam	95	22	the	the	DT
cord-340028-6oicmeam	95	23	elderly	elderly	JJ
cord-340028-6oicmeam	95	24	,	,	,
cord-340028-6oicmeam	95	25	although	although	IN
cord-340028-6oicmeam	95	26	still	still	RB
cord-340028-6oicmeam	95	27	limited	limit	VBN
cord-340028-6oicmeam	95	28	by	by	IN
cord-340028-6oicmeam	95	29	a	a	DT
cord-340028-6oicmeam	95	30	lack	lack	NN
cord-340028-6oicmeam	95	31	of	of	IN
cord-340028-6oicmeam	95	32	large	large	JJ
cord-340028-6oicmeam	95	33	clinical	clinical	JJ
cord-340028-6oicmeam	95	34	trials	trial	NNS
cord-340028-6oicmeam	95	35	,	,	,
cord-340028-6oicmeam	95	36	are	be	VBP
cord-340028-6oicmeam	95	37	sirolimus	sirolimus	NNP
cord-340028-6oicmeam	95	38	(	(	-LRB-
cord-340028-6oicmeam	95	39	rapamycin	rapamycin	NNP
cord-340028-6oicmeam	95	40	)	)	-RRB-
cord-340028-6oicmeam	95	41	and	and	CC
cord-340028-6oicmeam	95	42	everolimus	everolimus	NNP
cord-340028-6oicmeam	95	43	.	.	.
cord-340028-6oicmeam	96	1	These	these	DT
cord-340028-6oicmeam	96	2	may	may	MD
cord-340028-6oicmeam	96	3	be	be	VB
cord-340028-6oicmeam	96	4	used	use	VBN
cord-340028-6oicmeam	96	5	as	as	IN
cord-340028-6oicmeam	96	6	single	single	JJ
cord-340028-6oicmeam	96	7	agents	agent	NNS
cord-340028-6oicmeam	96	8	in	in	IN
cord-340028-6oicmeam	96	9	combination	combination	NN
cord-340028-6oicmeam	96	10	with	with	IN
cord-340028-6oicmeam	96	11	other	other	JJ
cord-340028-6oicmeam	96	12	treatments	treatment	NNS
cord-340028-6oicmeam	96	13	(	(	-LRB-
cord-340028-6oicmeam	96	14	Figure	figure	NN
cord-340028-6oicmeam	96	15	3	3	CD
cord-340028-6oicmeam	96	16	)	)	-RRB-
cord-340028-6oicmeam	96	17	.	.	.
cord-340028-6oicmeam	96	18	 	 	_SP
cord-340028-6oicmeam	97	1	Sirolimus	Sirolimus	NNP
cord-340028-6oicmeam	97	2	(	(	-LRB-
cord-340028-6oicmeam	97	3	rapamycin	rapamycin	NNP
cord-340028-6oicmeam	97	4	)	)	-RRB-
cord-340028-6oicmeam	97	5	is	be	VBZ
cord-340028-6oicmeam	97	6	a	a	DT
cord-340028-6oicmeam	97	7	well	well	RB
cord-340028-6oicmeam	97	8	-	-	HYPH
cord-340028-6oicmeam	97	9	known	know	VBN
cord-340028-6oicmeam	97	10	geroprotector	geroprotector	NN
cord-340028-6oicmeam	97	11	,	,	,
cord-340028-6oicmeam	97	12	known	know	VBN
cord-340028-6oicmeam	97	13	to	to	TO
cord-340028-6oicmeam	97	14	effectively	effectively	RB
cord-340028-6oicmeam	97	15	increase	increase	VB
cord-340028-6oicmeam	97	16	lifespan	lifespan	NN
cord-340028-6oicmeam	97	17	and	and	CC
cord-340028-6oicmeam	97	18	slow	slow	JJ
cord-340028-6oicmeam	97	19	aging	aging	NN
cord-340028-6oicmeam	97	20	in	in	IN
cord-340028-6oicmeam	97	21	many	many	JJ
cord-340028-6oicmeam	97	22	species	specie	NNS
cord-340028-6oicmeam	97	23	,	,	,
cord-340028-6oicmeam	97	24	including	include	VBG
cord-340028-6oicmeam	97	25	yeast	yeast	NN
cord-340028-6oicmeam	97	26	[	[	-LRB-
cord-340028-6oicmeam	97	27	55	55	CD
cord-340028-6oicmeam	97	28	,	,	,
cord-340028-6oicmeam	97	29	56	56	CD
cord-340028-6oicmeam	97	30	]	]	-RRB-
cord-340028-6oicmeam	97	31	,	,	,
cord-340028-6oicmeam	97	32	Drosophila	Drosophila	NNP
cord-340028-6oicmeam	97	33	[	[	-LRB-
cord-340028-6oicmeam	97	34	57	57	CD
cord-340028-6oicmeam	97	35	,	,	,
cord-340028-6oicmeam	97	36	58	58	CD
cord-340028-6oicmeam	97	37	]	]	-RRB-
cord-340028-6oicmeam	97	38	,	,	,
cord-340028-6oicmeam	97	39	C.	C.	NNP
cord-340028-6oicmeam	97	40	elegans	elegan	NNS
cord-340028-6oicmeam	97	41	[	[	-LRB-
cord-340028-6oicmeam	97	42	59	59	CD
cord-340028-6oicmeam	97	43	]	]	-RRB-
cord-340028-6oicmeam	97	44	,	,	,
cord-340028-6oicmeam	97	45	and	and	CC
cord-340028-6oicmeam	97	46	mice	mouse	NNS
cord-340028-6oicmeam	97	47	[	[	-LRB-
cord-340028-6oicmeam	97	48	60	60	CD
cord-340028-6oicmeam	97	49	]	]	-RRB-
cord-340028-6oicmeam	97	50	[	[	-LRB-
cord-340028-6oicmeam	97	51	61	61	CD
cord-340028-6oicmeam	97	52	]	]	-RRB-
cord-340028-6oicmeam	97	53	[	[	-LRB-
cord-340028-6oicmeam	97	54	62	62	CD
cord-340028-6oicmeam	97	55	]	]	-RRB-
cord-340028-6oicmeam	97	56	[	[	-LRB-
cord-340028-6oicmeam	97	57	63	63	CD
cord-340028-6oicmeam	97	58	]	]	-RRB-
cord-340028-6oicmeam	97	59	[	[	-LRB-
cord-340028-6oicmeam	97	60	64	64	CD
cord-340028-6oicmeam	97	61	]	]	-RRB-
cord-340028-6oicmeam	97	62	.	.	.
cord-340028-6oicmeam	98	1	It	-PRON-	PRP
cord-340028-6oicmeam	98	2	also	also	RB
cord-340028-6oicmeam	98	3	delays	delay	VBZ
cord-340028-6oicmeam	98	4	age	age	NN
cord-340028-6oicmeam	98	5	-	-	HYPH
cord-340028-6oicmeam	98	6	related	relate	VBN
cord-340028-6oicmeam	98	7	diseases	disease	NNS
cord-340028-6oicmeam	98	8	in	in	IN
cord-340028-6oicmeam	98	9	humans	human	NNS
cord-340028-6oicmeam	98	10	[	[	-LRB-
cord-340028-6oicmeam	98	11	65	65	CD
cord-340028-6oicmeam	98	12	]	]	-RRB-
cord-340028-6oicmeam	98	13	[	[	-LRB-
cord-340028-6oicmeam	98	14	66	66	CD
cord-340028-6oicmeam	98	15	]	]	-RRB-
cord-340028-6oicmeam	98	16	[	[	-LRB-
cord-340028-6oicmeam	98	17	67	67	CD
cord-340028-6oicmeam	98	18	]	]	-RRB-
cord-340028-6oicmeam	98	19	[	[	-LRB-
cord-340028-6oicmeam	98	20	68	68	CD
cord-340028-6oicmeam	98	21	]	]	-RRB-
cord-340028-6oicmeam	98	22	,	,	,
cord-340028-6oicmeam	98	23	and	and	CC
cord-340028-6oicmeam	98	24	Blagosklonny	Blagosklonny	NNP
cord-340028-6oicmeam	98	25	proposed	propose	VBD
cord-340028-6oicmeam	98	26	rapamycin	rapamycin	NNS
cord-340028-6oicmeam	98	27	for	for	IN
cord-340028-6oicmeam	98	28	the	the	DT
cord-340028-6oicmeam	98	29	prevention	prevention	NN
cord-340028-6oicmeam	98	30	of	of	IN
cord-340028-6oicmeam	98	31	multiple	multiple	JJ
cord-340028-6oicmeam	98	32	age	age	NN
cord-340028-6oicmeam	98	33	-	-	HYPH
cord-340028-6oicmeam	98	34	related	relate	VBN
cord-340028-6oicmeam	98	35	diseases	disease	NNS
cord-340028-6oicmeam	98	36	in	in	IN
cord-340028-6oicmeam	98	37	humans	human	NNS
cord-340028-6oicmeam	98	38	[	[	-LRB-
cord-340028-6oicmeam	98	39	69	69	CD
cord-340028-6oicmeam	98	40	]	]	-RRB-
cord-340028-6oicmeam	98	41	[	[	-LRB-
cord-340028-6oicmeam	98	42	70	70	CD
cord-340028-6oicmeam	98	43	]	]	-RRB-
cord-340028-6oicmeam	98	44	[	[	-LRB-
cord-340028-6oicmeam	98	45	71	71	CD
cord-340028-6oicmeam	98	46	]	]	-RRB-
cord-340028-6oicmeam	98	47	[	[	-LRB-
cord-340028-6oicmeam	98	48	72	72	CD
cord-340028-6oicmeam	98	49	]	]	-RRB-
cord-340028-6oicmeam	98	50	.	.	.
cord-340028-6oicmeam	99	1	Sirolimus	Sirolimus	NNP
cord-340028-6oicmeam	99	2	and	and	CC
cord-340028-6oicmeam	99	3	rapalogs	rapalogs	NNP
cord-340028-6oicmeam	99	4	are	be	VBP
cord-340028-6oicmeam	99	5	commonly	commonly	RB
cord-340028-6oicmeam	99	6	used	use	VBN
cord-340028-6oicmeam	99	7	as	as	IN
cord-340028-6oicmeam	99	8	immunosuppressants	immunosuppressant	NNS
cord-340028-6oicmeam	99	9	.	.	.
cord-340028-6oicmeam	100	1	Rapalogs	Rapalogs	NNP
cord-340028-6oicmeam	100	2	,	,	,
cord-340028-6oicmeam	100	3	the	the	DT
cord-340028-6oicmeam	100	4	derivatives	derivative	NNS
cord-340028-6oicmeam	100	5	and	and	CC
cord-340028-6oicmeam	100	6	mimetics	mimetic	NNS
cord-340028-6oicmeam	100	7	of	of	IN
cord-340028-6oicmeam	100	8	rapamycin	rapamycin	NNS
cord-340028-6oicmeam	100	9	,	,	,
cord-340028-6oicmeam	100	10	target	target	VB
cord-340028-6oicmeam	100	11	critical	critical	JJ
cord-340028-6oicmeam	100	12	factors	factor	NNS
cord-340028-6oicmeam	100	13	in	in	IN
cord-340028-6oicmeam	100	14	the	the	DT
cord-340028-6oicmeam	100	15	rapamycin	rapamycin	NN
cord-340028-6oicmeam	100	16	(	(	-LRB-
cord-340028-6oicmeam	100	17	TOR	TOR	NNP
cord-340028-6oicmeam	100	18	)	)	-RRB-
cord-340028-6oicmeam	100	19	pathway	pathway	NN
cord-340028-6oicmeam	100	20	.	.	.
cord-340028-6oicmeam	101	1	Everolimus	Everolimus	NNP
cord-340028-6oicmeam	101	2	(	(	-LRB-
cord-340028-6oicmeam	101	3	RAD001	RAD001	NNP
cord-340028-6oicmeam	101	4	)	)	-RRB-
cord-340028-6oicmeam	101	5	,	,	,
cord-340028-6oicmeam	101	6	another	another	DT
cord-340028-6oicmeam	101	7	close	close	JJ
cord-340028-6oicmeam	101	8	structural	structural	JJ
cord-340028-6oicmeam	101	9	derivative	derivative	NN
cord-340028-6oicmeam	101	10	of	of	IN
cord-340028-6oicmeam	101	11	sirolimus	sirolimus	NN
cord-340028-6oicmeam	101	12	developed	develop	VBN
cord-340028-6oicmeam	101	13	by	by	IN
cord-340028-6oicmeam	101	14	Novartis	Novartis	NNP
cord-340028-6oicmeam	101	15	,	,	,
cord-340028-6oicmeam	101	16	acts	act	VBZ
cord-340028-6oicmeam	101	17	as	as	IN
cord-340028-6oicmeam	101	18	an	an	DT
cord-340028-6oicmeam	101	19	immunosuppressant	immunosuppressant	NN
cord-340028-6oicmeam	101	20	;	;	:
cord-340028-6oicmeam	101	21	but	but	CC
cord-340028-6oicmeam	101	22	like	like	IN
cord-340028-6oicmeam	101	23	sirolimus	sirolimus	NNP
cord-340028-6oicmeam	101	24	,	,	,
cord-340028-6oicmeam	101	25	it	-PRON-	PRP
cord-340028-6oicmeam	101	26	has	have	VBZ
cord-340028-6oicmeam	101	27	many	many	JJ
cord-340028-6oicmeam	101	28	other	other	JJ
cord-340028-6oicmeam	101	29	properties	property	NNS
cord-340028-6oicmeam	101	30	beyond	beyond	IN
cord-340028-6oicmeam	101	31	immunosuppression	immunosuppression	NN
cord-340028-6oicmeam	101	32	[	[	-LRB-
cord-340028-6oicmeam	101	33	73	73	CD
cord-340028-6oicmeam	101	34	]	]	-RRB-
cord-340028-6oicmeam	101	35	.	.	.
cord-340028-6oicmeam	102	1	Paradoxically	paradoxically	RB
cord-340028-6oicmeam	102	2	,	,	,
cord-340028-6oicmeam	102	3	these	these	DT
cord-340028-6oicmeam	102	4	compounds	compound	NNS
cord-340028-6oicmeam	102	5	also	also	RB
cord-340028-6oicmeam	102	6	exert	exert	VBP
cord-340028-6oicmeam	102	7	immunostimulatory	immunostimulatory	JJ
cord-340028-6oicmeam	102	8	effects	effect	NNS
cord-340028-6oicmeam	102	9	,	,	,
cord-340028-6oicmeam	102	10	such	such	JJ
cord-340028-6oicmeam	102	11	as	as	IN
cord-340028-6oicmeam	102	12	boosting	boost	VBG
cord-340028-6oicmeam	102	13	T	t	NN
cord-340028-6oicmeam	102	14	cell	cell	NN
cord-340028-6oicmeam	102	15	responses	response	NNS
cord-340028-6oicmeam	102	16	in	in	IN
cord-340028-6oicmeam	102	17	reaction	reaction	NN
cord-340028-6oicmeam	102	18	to	to	IN
cord-340028-6oicmeam	102	19	pathogen	pathogen	NN
cord-340028-6oicmeam	102	20	infection	infection	NN
cord-340028-6oicmeam	102	21	and	and	CC
cord-340028-6oicmeam	102	22	vaccination	vaccination	NN
cord-340028-6oicmeam	102	23	[	[	-LRB-
cord-340028-6oicmeam	102	24	74	74	CD
cord-340028-6oicmeam	102	25	]	]	-RRB-
cord-340028-6oicmeam	102	26	.	.	.
cord-340028-6oicmeam	103	1	Nevertheless	nevertheless	RB
cord-340028-6oicmeam	103	2	,	,	,
cord-340028-6oicmeam	103	3	this	this	DT
cord-340028-6oicmeam	103	4	would	would	MD
cord-340028-6oicmeam	103	5	not	not	RB
cord-340028-6oicmeam	103	6	be	be	VB
cord-340028-6oicmeam	103	7	the	the	DT
cord-340028-6oicmeam	103	8	first	first	JJ
cord-340028-6oicmeam	103	9	case	case	NN
cord-340028-6oicmeam	103	10	of	of	IN
cord-340028-6oicmeam	103	11	a	a	DT
cord-340028-6oicmeam	103	12	physiological	physiological	JJ
cord-340028-6oicmeam	103	13	paradox	paradox	NN
cord-340028-6oicmeam	103	14	in	in	IN
cord-340028-6oicmeam	103	15	clinical	clinical	JJ
cord-340028-6oicmeam	103	16	medicine	medicine	NN
cord-340028-6oicmeam	103	17	.	.	.
cord-340028-6oicmeam	104	1	The	the	DT
cord-340028-6oicmeam	104	2	administration	administration	NN
cord-340028-6oicmeam	104	3	of	of	IN
cord-340028-6oicmeam	104	4	beta	beta	NN
cord-340028-6oicmeam	104	5	-	-	HYPH
cord-340028-6oicmeam	104	6	blockers	blocker	NNS
cord-340028-6oicmeam	104	7	to	to	IN
cord-340028-6oicmeam	104	8	heart	heart	NN
cord-340028-6oicmeam	104	9	failure	failure	NN
cord-340028-6oicmeam	104	10	patients	patient	NNS
cord-340028-6oicmeam	104	11	at	at	IN
cord-340028-6oicmeam	104	12	first	first	RB
cord-340028-6oicmeam	104	13	seemed	seem	VBD
cord-340028-6oicmeam	104	14	contradictory	contradictory	JJ
cord-340028-6oicmeam	104	15	,	,	,
cord-340028-6oicmeam	104	16	as	as	IN
cord-340028-6oicmeam	104	17	these	these	DT
cord-340028-6oicmeam	104	18	compounds	compound	NNS
cord-340028-6oicmeam	104	19	slow	slow	VBP
cord-340028-6oicmeam	104	20	down	down	RP
cord-340028-6oicmeam	104	21	an	an	DT
cord-340028-6oicmeam	104	22	already	already	RB
cord-340028-6oicmeam	104	23	failing	fail	VBG
cord-340028-6oicmeam	104	24	heart	heart	NN
cord-340028-6oicmeam	104	25	,	,	,
cord-340028-6oicmeam	104	26	but	but	CC
cord-340028-6oicmeam	104	27	proved	prove	VBD
cord-340028-6oicmeam	104	28	to	to	TO
cord-340028-6oicmeam	104	29	provide	provide	VB
cord-340028-6oicmeam	104	30	the	the	DT
cord-340028-6oicmeam	104	31	most	most	JJS
cord-340028-6oicmeam	104	32	benefit	benefit	NN
cord-340028-6oicmeam	104	33	for	for	IN
cord-340028-6oicmeam	104	34	the	the	DT
cord-340028-6oicmeam	104	35	treatment	treatment	NN
cord-340028-6oicmeam	104	36	of	of	IN
cord-340028-6oicmeam	104	37	heart	heart	NN
cord-340028-6oicmeam	104	38	failure	failure	NN
cord-340028-6oicmeam	104	39	patients	patient	NNS
cord-340028-6oicmeam	104	40	.	.	.
cord-340028-6oicmeam	105	1	Likewise	likewise	RB
cord-340028-6oicmeam	105	2	,	,	,
cord-340028-6oicmeam	105	3	hormonal	hormonal	JJ
cord-340028-6oicmeam	105	4	treatment	treatment	NN
cord-340028-6oicmeam	105	5	of	of	IN
cord-340028-6oicmeam	105	6	hormone	hormone	NN
cord-340028-6oicmeam	105	7	-	-	HYPH
cord-340028-6oicmeam	105	8	dependent	dependent	JJ
cord-340028-6oicmeam	105	9	cancers	cancer	NNS
cord-340028-6oicmeam	105	10	,	,	,
cord-340028-6oicmeam	105	11	such	such	JJ
cord-340028-6oicmeam	105	12	as	as	IN
cord-340028-6oicmeam	105	13	testosteronedependent	testosteronedependent	JJ
cord-340028-6oicmeam	105	14	prostate	prostate	NN
cord-340028-6oicmeam	105	15	cancer	cancer	NN
cord-340028-6oicmeam	105	16	,	,	,
cord-340028-6oicmeam	105	17	seems	seem	VBZ
cord-340028-6oicmeam	105	18	incongruous	incongruous	JJ
cord-340028-6oicmeam	105	19	.	.	.
cord-340028-6oicmeam	106	1	However	however	RB
cord-340028-6oicmeam	106	2	,	,	,
cord-340028-6oicmeam	106	3	administration	administration	NN
cord-340028-6oicmeam	106	4	of	of	IN
cord-340028-6oicmeam	106	5	a	a	DT
cord-340028-6oicmeam	106	6	synthetic	synthetic	JJ
cord-340028-6oicmeam	106	7	version	version	NN
cord-340028-6oicmeam	106	8	of	of	IN
cord-340028-6oicmeam	106	9	gonadotropin	gonadotropin	NN
cord-340028-6oicmeam	106	10	-	-	HYPH
cord-340028-6oicmeam	106	11	releasing	release	VBG
cord-340028-6oicmeam	106	12	hormone	hormone	NN
cord-340028-6oicmeam	106	13	(	(	-LRB-
cord-340028-6oicmeam	106	14	GnRH	GnRH	NNP
cord-340028-6oicmeam	106	15	)	)	-RRB-
cord-340028-6oicmeam	106	16	in	in	IN
cord-340028-6oicmeam	106	17	a	a	DT
cord-340028-6oicmeam	106	18	different	different	JJ
cord-340028-6oicmeam	106	19	dosing	dosing	NN
cord-340028-6oicmeam	106	20	regime	regime	NN
cord-340028-6oicmeam	106	21	from	from	IN
cord-340028-6oicmeam	106	22	the	the	DT
cord-340028-6oicmeam	106	23	cyclical	cyclical	JJ
cord-340028-6oicmeam	106	24	secretion	secretion	NN
cord-340028-6oicmeam	106	25	that	that	WDT
cord-340028-6oicmeam	106	26	occurs	occur	VBZ
cord-340028-6oicmeam	106	27	physiologically	physiologically	RB
cord-340028-6oicmeam	106	28	,	,	,
cord-340028-6oicmeam	106	29	which	which	WDT
cord-340028-6oicmeam	106	30	normally	normally	RB
cord-340028-6oicmeam	106	31	indirectly	indirectly	RB
cord-340028-6oicmeam	106	32	increases	increase	VBZ
cord-340028-6oicmeam	106	33	testosterone	testosterone	NN
cord-340028-6oicmeam	106	34	levels	level	NNS
cord-340028-6oicmeam	106	35	,	,	,
cord-340028-6oicmeam	106	36	actually	actually	RB
cord-340028-6oicmeam	106	37	reduces	reduce	VBZ
cord-340028-6oicmeam	106	38	hormone	hormone	NN
cord-340028-6oicmeam	106	39	levels	level	NNS
cord-340028-6oicmeam	106	40	.	.	.
cord-340028-6oicmeam	107	1	Therefore	therefore	RB
cord-340028-6oicmeam	107	2	,	,	,
cord-340028-6oicmeam	107	3	it	-PRON-	PRP
cord-340028-6oicmeam	107	4	might	may	MD
cord-340028-6oicmeam	107	5	be	be	VB
cord-340028-6oicmeam	107	6	possible	possible	JJ
cord-340028-6oicmeam	107	7	that	that	IN
cord-340028-6oicmeam	107	8	a	a	DT
cord-340028-6oicmeam	107	9	drug	drug	NN
cord-340028-6oicmeam	107	10	that	that	WDT
cord-340028-6oicmeam	107	11	is	be	VBZ
cord-340028-6oicmeam	107	12	known	know	VBN
cord-340028-6oicmeam	107	13	to	to	TO
cord-340028-6oicmeam	107	14	be	be	VB
cord-340028-6oicmeam	107	15	an	an	DT
cord-340028-6oicmeam	107	16	immunosuppressant	immunosuppressant	JJ
cord-340028-6oicmeam	107	17	might	might	NN
cord-340028-6oicmeam	107	18	in	in	IN
cord-340028-6oicmeam	107	19	a	a	DT
cord-340028-6oicmeam	107	20	different	different	JJ
cord-340028-6oicmeam	107	21	dosing	dosing	NN
cord-340028-6oicmeam	107	22	regimen	regimen	NN
cord-340028-6oicmeam	107	23	prove	prove	VB
cord-340028-6oicmeam	107	24	to	to	TO
cord-340028-6oicmeam	107	25	be	be	VB
cord-340028-6oicmeam	107	26	an	an	DT
cord-340028-6oicmeam	107	27	immunostimulant	immunostimulant	NN
cord-340028-6oicmeam	107	28	.	.	.
cord-340028-6oicmeam	108	1	However	however	RB
cord-340028-6oicmeam	108	2	,	,	,
cord-340028-6oicmeam	108	3	extremely	extremely	RB
cord-340028-6oicmeam	108	4	cautious	cautious	JJ
cord-340028-6oicmeam	108	5	clinical	clinical	JJ
cord-340028-6oicmeam	108	6	validation	validation	NN
cord-340028-6oicmeam	108	7	is	be	VBZ
cord-340028-6oicmeam	108	8	required	require	VBN
cord-340028-6oicmeam	108	9	as	as	IN
cord-340028-6oicmeam	108	10	this	this	DT
cord-340028-6oicmeam	108	11	treatment	treatment	NN
cord-340028-6oicmeam	108	12	might	may	MD
cord-340028-6oicmeam	108	13	carry	carry	VB
cord-340028-6oicmeam	108	14	significant	significant	JJ
cord-340028-6oicmeam	108	15	risks	risk	NNS
cord-340028-6oicmeam	108	16	;	;	:
cord-340028-6oicmeam	108	17	indeed	indeed	RB
cord-340028-6oicmeam	108	18	,	,	,
cord-340028-6oicmeam	108	19	there	there	EX
cord-340028-6oicmeam	108	20	is	be	VBZ
cord-340028-6oicmeam	108	21	some	some	DT
cord-340028-6oicmeam	108	22	indication	indication	NN
cord-340028-6oicmeam	108	23	that	that	IN
cord-340028-6oicmeam	108	24	morbidity	morbidity	NN
cord-340028-6oicmeam	108	25	from	from	IN
cord-340028-6oicmeam	108	26	coronavirus	coronavirus	NN
cord-340028-6oicmeam	108	27	infections	infection	NNS
cord-340028-6oicmeam	108	28	occurs	occur	VBZ
cord-340028-6oicmeam	108	29	from	from	IN
cord-340028-6oicmeam	108	30	secondary	secondary	JJ
cord-340028-6oicmeam	108	31	overactive	overactive	JJ
cord-340028-6oicmeam	108	32	immune	immune	JJ
cord-340028-6oicmeam	108	33	responses	response	NNS
cord-340028-6oicmeam	108	34	[	[	-LRB-
cord-340028-6oicmeam	108	35	75	75	CD
cord-340028-6oicmeam	108	36	,	,	,
cord-340028-6oicmeam	108	37	76	76	CD
cord-340028-6oicmeam	108	38	]	]	-RRB-
cord-340028-6oicmeam	108	39	.	.	.
cord-340028-6oicmeam	109	1	In	in	IN
cord-340028-6oicmeam	109	2	addition	addition	NN
cord-340028-6oicmeam	109	3	to	to	IN
cord-340028-6oicmeam	109	4	rapamycin	rapamycin	NN
cord-340028-6oicmeam	109	5	,	,	,
cord-340028-6oicmeam	109	6	other	other	JJ
cord-340028-6oicmeam	109	7	agents	agent	NNS
cord-340028-6oicmeam	109	8	that	that	WDT
cord-340028-6oicmeam	109	9	inhibit	inhibit	VBP
cord-340028-6oicmeam	109	10	mTOR	mTOR	NNP
cord-340028-6oicmeam	109	11	,	,	,
cord-340028-6oicmeam	109	12	such	such	JJ
cord-340028-6oicmeam	109	13	as	as	IN
cord-340028-6oicmeam	109	14	Torin1	Torin1	NNP
cord-340028-6oicmeam	109	15	,	,	,
cord-340028-6oicmeam	109	16	Torin2	Torin2	NNP
cord-340028-6oicmeam	109	17	,	,	,
cord-340028-6oicmeam	109	18	AZD8055	AZD8055	NNP
cord-340028-6oicmeam	109	19	,	,	,
cord-340028-6oicmeam	109	20	PP242	PP242	NNP
cord-340028-6oicmeam	109	21	,	,	,
cord-340028-6oicmeam	109	22	KU-006379	ku-006379	NN
cord-340028-6oicmeam	109	23	and	and	CC
cord-340028-6oicmeam	109	24	GSK1059615	GSK1059615	NNP
cord-340028-6oicmeam	109	25	,	,	,
cord-340028-6oicmeam	109	26	may	may	MD
cord-340028-6oicmeam	109	27	act	act	VB
cord-340028-6oicmeam	109	28	similarly	similarly	RB
cord-340028-6oicmeam	109	29	to	to	IN
cord-340028-6oicmeam	109	30	rapamycin	rapamycin	VB
cord-340028-6oicmeam	109	31	in	in	IN
cord-340028-6oicmeam	109	32	low	low	JJ
cord-340028-6oicmeam	109	33	-	-	HYPH
cord-340028-6oicmeam	109	34	doses	dose	NNS
cord-340028-6oicmeam	109	35	and	and	CC
cord-340028-6oicmeam	109	36	may	may	MD
cord-340028-6oicmeam	109	37	have	have	VB
cord-340028-6oicmeam	109	38	a	a	DT
cord-340028-6oicmeam	109	39	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	109	40	effect	effect	NN
cord-340028-6oicmeam	109	41	[	[	-LRB-
cord-340028-6oicmeam	109	42	77	77	CD
cord-340028-6oicmeam	109	43	]	]	-RRB-
cord-340028-6oicmeam	110	1	[	[	-LRB-
cord-340028-6oicmeam	110	2	78	78	CD
cord-340028-6oicmeam	110	3	]	]	-RRB-
cord-340028-6oicmeam	110	4	[	[	-LRB-
cord-340028-6oicmeam	110	5	79	79	CD
cord-340028-6oicmeam	110	6	]	]	-RRB-
cord-340028-6oicmeam	110	7	.	.	.
cord-340028-6oicmeam	111	1	Substantial	substantial	JJ
cord-340028-6oicmeam	111	2	pre	pre	JJ
cord-340028-6oicmeam	111	3	-	-	JJ
cord-340028-6oicmeam	111	4	clinical	clinical	JJ
cord-340028-6oicmeam	111	5	validation	validation	NN
cord-340028-6oicmeam	111	6	would	would	MD
cord-340028-6oicmeam	111	7	be	be	VB
cord-340028-6oicmeam	111	8	required	require	VBN
cord-340028-6oicmeam	111	9	to	to	TO
cord-340028-6oicmeam	111	10	apply	apply	VB
cord-340028-6oicmeam	111	11	these	these	DT
cord-340028-6oicmeam	111	12	compounds	compound	NNS
cord-340028-6oicmeam	111	13	to	to	IN
cord-340028-6oicmeam	111	14	specific	specific	JJ
cord-340028-6oicmeam	111	15	age	age	NN
cord-340028-6oicmeam	111	16	-	-	HYPH
cord-340028-6oicmeam	111	17	associated	associate	VBN
cord-340028-6oicmeam	111	18	diseases	disease	NNS
cord-340028-6oicmeam	111	19	and	and	CC
cord-340028-6oicmeam	111	20	to	to	TO
cord-340028-6oicmeam	111	21	explore	explore	VB
cord-340028-6oicmeam	111	22	clinical	clinical	JJ
cord-340028-6oicmeam	111	23	applications	application	NNS
cord-340028-6oicmeam	111	24	of	of	IN
cord-340028-6oicmeam	111	25	these	these	DT
cord-340028-6oicmeam	111	26	compounds	compound	NNS
cord-340028-6oicmeam	111	27	in	in	IN
cord-340028-6oicmeam	111	28	human	human	JJ
cord-340028-6oicmeam	111	29	clinical	clinical	JJ
cord-340028-6oicmeam	111	30	trials	trial	NNS
cord-340028-6oicmeam	111	31	.	.	.
cord-340028-6oicmeam	112	1	Multiple	multiple	JJ
cord-340028-6oicmeam	112	2	clinical	clinical	JJ
cord-340028-6oicmeam	112	3	observations	observation	NNS
cord-340028-6oicmeam	112	4	suggested	suggest	VBD
cord-340028-6oicmeam	112	5	that	that	IN
cord-340028-6oicmeam	112	6	patients	patient	NNS
cord-340028-6oicmeam	112	7	with	with	IN
cord-340028-6oicmeam	112	8	cytomegalovirus	cytomegalovirus	NNP
cord-340028-6oicmeam	112	9	(	(	-LRB-
cord-340028-6oicmeam	112	10	CMV	CMV	NNP
cord-340028-6oicmeam	112	11	)	)	-RRB-
cord-340028-6oicmeam	112	12	disease	disease	NN
cord-340028-6oicmeam	112	13	who	who	WP
cord-340028-6oicmeam	112	14	were	be	VBD
cord-340028-6oicmeam	112	15	treated	treat	VBN
cord-340028-6oicmeam	112	16	with	with	IN
cord-340028-6oicmeam	112	17	rapamycin	rapamycin	NNS
cord-340028-6oicmeam	112	18	demonstrated	demonstrate	VBD
cord-340028-6oicmeam	112	19	better	well	JJR
cord-340028-6oicmeam	112	20	outcomes	outcome	NNS
cord-340028-6oicmeam	112	21	and	and	CC
cord-340028-6oicmeam	112	22	were	be	VBD
cord-340028-6oicmeam	112	23	better	well	RBR
cord-340028-6oicmeam	112	24	able	able	JJ
cord-340028-6oicmeam	112	25	to	to	TO
cord-340028-6oicmeam	112	26	control	control	VB
cord-340028-6oicmeam	112	27	CMV	CMV	NNP
cord-340028-6oicmeam	112	28	viremia	viremia	NN
cord-340028-6oicmeam	112	29	than	than	IN
cord-340028-6oicmeam	112	30	patients	patient	NNS
cord-340028-6oicmeam	112	31	treated	treat	VBN
cord-340028-6oicmeam	112	32	with	with	IN
cord-340028-6oicmeam	112	33	standard	standard	JJ
cord-340028-6oicmeam	112	34	calcineurin	calcineurin	JJ
cord-340028-6oicmeam	112	35	inhibitor	inhibitor	NN
cord-340028-6oicmeam	112	36	-	-	HYPH
cord-340028-6oicmeam	112	37	based	base	VBN
cord-340028-6oicmeam	112	38	immunosuppression	immunosuppression	NN
cord-340028-6oicmeam	112	39	following	follow	VBG
cord-340028-6oicmeam	112	40	transplantation	transplantation	NN
cord-340028-6oicmeam	112	41	[	[	-LRB-
cord-340028-6oicmeam	112	42	74	74	CD
cord-340028-6oicmeam	112	43	,	,	,
cord-340028-6oicmeam	112	44	80	80	CD
cord-340028-6oicmeam	112	45	]	]	-RRB-
cord-340028-6oicmeam	112	46	.	.	.
cord-340028-6oicmeam	113	1	In	in	IN
cord-340028-6oicmeam	113	2	2009	2009	CD
cord-340028-6oicmeam	113	3	,	,	,
cord-340028-6oicmeam	113	4	two	two	CD
cord-340028-6oicmeam	113	5	seminal	seminal	JJ
cord-340028-6oicmeam	113	6	studies	study	NNS
cord-340028-6oicmeam	113	7	of	of	IN
cord-340028-6oicmeam	113	8	sirolimus	sirolimus	NNP
cord-340028-6oicmeam	113	9	demonstrated	demonstrate	VBD
cord-340028-6oicmeam	113	10	the	the	DT
cord-340028-6oicmeam	113	11	immunostimulatory	immunostimulatory	JJ
cord-340028-6oicmeam	113	12	effects	effect	NNS
cord-340028-6oicmeam	113	13	of	of	IN
cord-340028-6oicmeam	113	14	rapamycin	rapamycin	NNS
cord-340028-6oicmeam	113	15	on	on	IN
cord-340028-6oicmeam	113	16	the	the	DT
cord-340028-6oicmeam	113	17	CD8	CD8	NNP
cord-340028-6oicmeam	113	18	+	+	SYM
cord-340028-6oicmeam	113	19	memory	memory	NN
cord-340028-6oicmeam	113	20	T	T	NNP
cord-340028-6oicmeam	113	21	cell	cell	NN
cord-340028-6oicmeam	113	22	response	response	NN
cord-340028-6oicmeam	113	23	following	follow	VBG
cord-340028-6oicmeam	113	24	pathogen	pathogen	NN
cord-340028-6oicmeam	113	25	infection	infection	NN
cord-340028-6oicmeam	113	26	[	[	-LRB-
cord-340028-6oicmeam	113	27	74	74	CD
cord-340028-6oicmeam	113	28	,	,	,
cord-340028-6oicmeam	113	29	80	80	CD
cord-340028-6oicmeam	113	30	]	]	-RRB-
cord-340028-6oicmeam	113	31	.	.	.
cord-340028-6oicmeam	114	1	Later	later	JJ
cord-340028-6oicmeam	114	2	studies	study	NNS
cord-340028-6oicmeam	114	3	also	also	RB
cord-340028-6oicmeam	114	4	showed	show	VBD
cord-340028-6oicmeam	114	5	that	that	IN
cord-340028-6oicmeam	114	6	monkeys	monkey	NNS
cord-340028-6oicmeam	114	7	treated	treat	VBN
cord-340028-6oicmeam	114	8	with	with	IN
cord-340028-6oicmeam	114	9	sirolimus	sirolimus	NNP
cord-340028-6oicmeam	114	10	exhibited	exhibit	VBD
cord-340028-6oicmeam	114	11	increased	increase	VBN
cord-340028-6oicmeam	114	12	recall	recall	NN
cord-340028-6oicmeam	114	13	responses	response	NNS
cord-340028-6oicmeam	114	14	and	and	CC
cord-340028-6oicmeam	114	15	enhanced	enhanced	JJ
cord-340028-6oicmeam	114	16	differentiation	differentiation	NN
cord-340028-6oicmeam	114	17	of	of	IN
cord-340028-6oicmeam	114	18	memory	memory	NN
cord-340028-6oicmeam	114	19	T	T	NNP
cord-340028-6oicmeam	114	20	cells	cell	NNS
cord-340028-6oicmeam	114	21	following	follow	VBG
cord-340028-6oicmeam	114	22	vaccination	vaccination	NN
cord-340028-6oicmeam	114	23	with	with	IN
cord-340028-6oicmeam	114	24	Modified	Modified	NNP
cord-340028-6oicmeam	114	25	Vaccinia	Vaccinia	NNP
cord-340028-6oicmeam	114	26	Ankara	Ankara	NNP
cord-340028-6oicmeam	114	27	[	[	-LRB-
cord-340028-6oicmeam	114	28	81	81	CD
cord-340028-6oicmeam	114	29	]	]	-RRB-
cord-340028-6oicmeam	114	30	.	.	.
cord-340028-6oicmeam	115	1	Additional	additional	JJ
cord-340028-6oicmeam	115	2	clinical	clinical	JJ
cord-340028-6oicmeam	115	3	studies	study	NNS
cord-340028-6oicmeam	115	4	by	by	IN
cord-340028-6oicmeam	115	5	Mannick	Mannick	NNP
cord-340028-6oicmeam	115	6	et	et	NNP
cord-340028-6oicmeam	115	7	al	al	NNP
cord-340028-6oicmeam	115	8	.	.	.
cord-340028-6oicmeam	116	1	[	[	-LRB-
cord-340028-6oicmeam	116	2	82	82	CD
cord-340028-6oicmeam	116	3	,	,	,
cord-340028-6oicmeam	116	4	83	83	CD
cord-340028-6oicmeam	116	5	]	]	-RRB-
cord-340028-6oicmeam	116	6	demonstrated	demonstrate	VBD
cord-340028-6oicmeam	116	7	the	the	DT
cord-340028-6oicmeam	116	8	immunostimulatory	immunostimulatory	JJ
cord-340028-6oicmeam	116	9	role	role	NN
cord-340028-6oicmeam	116	10	of	of	IN
cord-340028-6oicmeam	116	11	rapalogs	rapalogs	NNP
cord-340028-6oicmeam	116	12	in	in	IN
cord-340028-6oicmeam	116	13	the	the	DT
cord-340028-6oicmeam	116	14	elderly	elderly	JJ
cord-340028-6oicmeam	116	15	using	use	VBG
cord-340028-6oicmeam	116	16	the	the	DT
cord-340028-6oicmeam	116	17	Novartis	Novartis	NNP
cord-340028-6oicmeam	116	18	rapalog	rapalog	NN
cord-340028-6oicmeam	116	19	everolimus	everolimus	NNP
cord-340028-6oicmeam	116	20	(	(	-LRB-
cord-340028-6oicmeam	116	21	RAD001	RAD001	NNP
cord-340028-6oicmeam	116	22	)	)	-RRB-
cord-340028-6oicmeam	116	23	,	,	,
cord-340028-6oicmeam	116	24	a	a	DT
cord-340028-6oicmeam	116	25	close	close	JJ
cord-340028-6oicmeam	116	26	structural	structural	JJ
cord-340028-6oicmeam	116	27	analog	analog	NN
cord-340028-6oicmeam	116	28	of	of	IN
cord-340028-6oicmeam	116	29	sirolimus	sirolimus	NNP
cord-340028-6oicmeam	116	30	(	(	-LRB-
cord-340028-6oicmeam	116	31	rapamycin	rapamycin	NNP
cord-340028-6oicmeam	116	32	)	)	-RRB-
cord-340028-6oicmeam	116	33	.	.	.
cord-340028-6oicmeam	117	1	Administration	Administration	NNP
cord-340028-6oicmeam	117	2	of	of	IN
cord-340028-6oicmeam	117	3	everolimus	everolimus	NNP
cord-340028-6oicmeam	117	4	ameliorated	ameliorate	VBD
cord-340028-6oicmeam	117	5	immunosenescence	immunosenescence	RB
cord-340028-6oicmeam	117	6	in	in	IN
cord-340028-6oicmeam	117	7	healthy	healthy	JJ
cord-340028-6oicmeam	117	8	elderly	elderly	JJ
cord-340028-6oicmeam	117	9	volunteers	volunteer	NNS
cord-340028-6oicmeam	117	10	and	and	CC
cord-340028-6oicmeam	117	11	enhanced	enhance	VBD
cord-340028-6oicmeam	117	12	the	the	DT
cord-340028-6oicmeam	117	13	response	response	NN
cord-340028-6oicmeam	117	14	to	to	IN
cord-340028-6oicmeam	117	15	the	the	DT
cord-340028-6oicmeam	117	16	influenza	influenza	NN
cord-340028-6oicmeam	117	17	vaccine	vaccine	NN
cord-340028-6oicmeam	117	18	by	by	IN
cord-340028-6oicmeam	117	19	around	around	IN
cord-340028-6oicmeam	117	20	20	20	CD
cord-340028-6oicmeam	117	21	%	%	NN
cord-340028-6oicmeam	117	22	at	at	IN
cord-340028-6oicmeam	117	23	doses	dose	NNS
cord-340028-6oicmeam	117	24	that	that	WDT
cord-340028-6oicmeam	117	25	were	be	VBD
cord-340028-6oicmeam	117	26	well	well	RB
cord-340028-6oicmeam	117	27	tolerated	tolerate	VBN
cord-340028-6oicmeam	117	28	[	[	-LRB-
cord-340028-6oicmeam	117	29	82	82	CD
cord-340028-6oicmeam	117	30	]	]	-RRB-
cord-340028-6oicmeam	117	31	.	.	.
cord-340028-6oicmeam	118	1	Further	further	JJ
cord-340028-6oicmeam	118	2	studies	study	NNS
cord-340028-6oicmeam	118	3	demonstrated	demonstrate	VBD
cord-340028-6oicmeam	118	4	enhanced	enhanced	JJ
cord-340028-6oicmeam	118	5	immune	immune	JJ
cord-340028-6oicmeam	118	6	function	function	NN
cord-340028-6oicmeam	118	7	and	and	CC
cord-340028-6oicmeam	118	8	reduced	reduce	VBN
cord-340028-6oicmeam	118	9	infection	infection	NN
cord-340028-6oicmeam	118	10	in	in	IN
cord-340028-6oicmeam	118	11	elderly	elderly	JJ
cord-340028-6oicmeam	118	12	patients	patient	NNS
cord-340028-6oicmeam	118	13	receiving	receive	VBG
cord-340028-6oicmeam	118	14	tolerable	tolerable	JJ
cord-340028-6oicmeam	118	15	doses	dose	NNS
cord-340028-6oicmeam	118	16	of	of	IN
cord-340028-6oicmeam	118	17	everolimus	everolimus	NNP
cord-340028-6oicmeam	118	18	.	.	.
cord-340028-6oicmeam	119	1	Mannick	Mannick	NNP
cord-340028-6oicmeam	119	2	et	et	NNP
cord-340028-6oicmeam	119	3	al	al	NNP
cord-340028-6oicmeam	119	4	.	.	.
cord-340028-6oicmeam	120	1	also	also	RB
cord-340028-6oicmeam	120	2	conducted	conduct	VBD
cord-340028-6oicmeam	120	3	a	a	DT
cord-340028-6oicmeam	120	4	phase	phase	NN
cord-340028-6oicmeam	120	5	2a	2a	CD
cord-340028-6oicmeam	120	6	randomized	randomize	VBN
cord-340028-6oicmeam	120	7	,	,	,
cord-340028-6oicmeam	120	8	placebo	placebo	NN
cord-340028-6oicmeam	120	9	-	-	HYPH
cord-340028-6oicmeam	120	10	controlled	control	VBN
cord-340028-6oicmeam	120	11	clinical	clinical	JJ
cord-340028-6oicmeam	120	12	trial	trial	NN
cord-340028-6oicmeam	120	13	which	which	WDT
cord-340028-6oicmeam	120	14	demonstrated	demonstrate	VBD
cord-340028-6oicmeam	120	15	that	that	IN
cord-340028-6oicmeam	120	16	a	a	DT
cord-340028-6oicmeam	120	17	low	low	JJ
cord-340028-6oicmeam	120	18	-	-	HYPH
cord-340028-6oicmeam	120	19	dose	dose	NN
cord-340028-6oicmeam	120	20	combination	combination	NN
cord-340028-6oicmeam	120	21	of	of	IN
cord-340028-6oicmeam	120	22	dactolisib	dactolisib	NNP
cord-340028-6oicmeam	120	23	(	(	-LRB-
cord-340028-6oicmeam	120	24	BEZ235	BEZ235	NNP
cord-340028-6oicmeam	120	25	)	)	-RRB-
cord-340028-6oicmeam	120	26	and	and	CC
cord-340028-6oicmeam	120	27	everolimus	everolimus	VB
cord-340028-6oicmeam	120	28	in	in	IN
cord-340028-6oicmeam	120	29	an	an	DT
cord-340028-6oicmeam	120	30	elderly	elderly	JJ
cord-340028-6oicmeam	120	31	population	population	NN
cord-340028-6oicmeam	120	32	was	be	VBD
cord-340028-6oicmeam	120	33	safe	safe	JJ
cord-340028-6oicmeam	120	34	and	and	CC
cord-340028-6oicmeam	120	35	associated	associate	VBN
cord-340028-6oicmeam	120	36	with	with	IN
cord-340028-6oicmeam	120	37	a	a	DT
cord-340028-6oicmeam	120	38	significant	significant	JJ
cord-340028-6oicmeam	120	39	(	(	-LRB-
cord-340028-6oicmeam	120	40	P=0.001	P=0.001	NNP
cord-340028-6oicmeam	120	41	)	)	-RRB-
cord-340028-6oicmeam	120	42	decrease	decrease	NN
cord-340028-6oicmeam	120	43	in	in	IN
cord-340028-6oicmeam	120	44	the	the	DT
cord-340028-6oicmeam	120	45	rate	rate	NN
cord-340028-6oicmeam	120	46	of	of	IN
cord-340028-6oicmeam	120	47	reported	report	VBN
cord-340028-6oicmeam	120	48	infections	infection	NNS
cord-340028-6oicmeam	120	49	[	[	-LRB-
cord-340028-6oicmeam	120	50	83	83	CD
cord-340028-6oicmeam	120	51	]	]	-RRB-
cord-340028-6oicmeam	120	52	.	.	.
cord-340028-6oicmeam	121	1	Mannick	mannick	NN
cord-340028-6oicmeam	121	2	and	and	CC
cord-340028-6oicmeam	121	3	colleagues	colleague	NNS
cord-340028-6oicmeam	121	4	further	further	RB
cord-340028-6oicmeam	121	5	conducted	conduct	VBD
cord-340028-6oicmeam	121	6	a	a	DT
cord-340028-6oicmeam	121	7	phase	phase	NN
cord-340028-6oicmeam	121	8	2a	2a	CD
cord-340028-6oicmeam	121	9	randomized	randomize	VBN
cord-340028-6oicmeam	121	10	,	,	,
cord-340028-6oicmeam	121	11	placebo	placebo	NN
cord-340028-6oicmeam	121	12	-	-	HYPH
cord-340028-6oicmeam	121	13	controlled	control	VBN
cord-340028-6oicmeam	121	14	clinical	clinical	JJ
cord-340028-6oicmeam	121	15	trial	trial	NN
cord-340028-6oicmeam	121	16	that	that	WDT
cord-340028-6oicmeam	121	17	demonstrated	demonstrate	VBD
cord-340028-6oicmeam	121	18	that	that	IN
cord-340028-6oicmeam	121	19	a	a	DT
cord-340028-6oicmeam	121	20	low	low	JJ
cord-340028-6oicmeam	121	21	-	-	HYPH
cord-340028-6oicmeam	121	22	dose	dose	NN
cord-340028-6oicmeam	121	23	combination	combination	NN
cord-340028-6oicmeam	121	24	of	of	IN
cord-340028-6oicmeam	121	25	dactolisib	dactolisib	NNP
cord-340028-6oicmeam	121	26	(	(	-LRB-
cord-340028-6oicmeam	121	27	BEZ235	BEZ235	NNP
cord-340028-6oicmeam	121	28	)	)	-RRB-
cord-340028-6oicmeam	121	29	,	,	,
cord-340028-6oicmeam	121	30	a	a	DT
cord-340028-6oicmeam	121	31	PI3	pi3	NN
cord-340028-6oicmeam	121	32	K	K	NNP
cord-340028-6oicmeam	121	33	inhibitor	inhibitor	NN
cord-340028-6oicmeam	121	34	[	[	-LRB-
cord-340028-6oicmeam	121	35	84	84	CD
cord-340028-6oicmeam	121	36	]	]	-RRB-
cord-340028-6oicmeam	121	37	and	and	CC
cord-340028-6oicmeam	121	38	catalytic	catalytic	JJ
cord-340028-6oicmeam	121	39	mTOR	mTOR	NNP
cord-340028-6oicmeam	121	40	inhibitor	inhibitor	NN
cord-340028-6oicmeam	121	41	,	,	,
cord-340028-6oicmeam	121	42	and	and	CC
cord-340028-6oicmeam	121	43	everolimus	everolimus	NN
cord-340028-6oicmeam	121	44	in	in	IN
cord-340028-6oicmeam	121	45	an	an	DT
cord-340028-6oicmeam	121	46	elderly	elderly	JJ
cord-340028-6oicmeam	121	47	population	population	NN
cord-340028-6oicmeam	121	48	was	be	VBD
cord-340028-6oicmeam	121	49	safe	safe	JJ
cord-340028-6oicmeam	121	50	and	and	CC
cord-340028-6oicmeam	121	51	associated	associate	VBN
cord-340028-6oicmeam	121	52	with	with	IN
cord-340028-6oicmeam	121	53	a	a	DT
cord-340028-6oicmeam	121	54	significant	significant	JJ
cord-340028-6oicmeam	121	55	(	(	-LRB-
cord-340028-6oicmeam	121	56	P=0.001	P=0.001	NNP
cord-340028-6oicmeam	121	57	)	)	-RRB-
cord-340028-6oicmeam	121	58	decrease	decrease	NN
cord-340028-6oicmeam	121	59	in	in	IN
cord-340028-6oicmeam	121	60	the	the	DT
cord-340028-6oicmeam	121	61	rate	rate	NN
cord-340028-6oicmeam	121	62	of	of	IN
cord-340028-6oicmeam	121	63	reported	report	VBN
cord-340028-6oicmeam	121	64	infections	infection	NNS
cord-340028-6oicmeam	121	65	[	[	-LRB-
cord-340028-6oicmeam	121	66	83	83	CD
cord-340028-6oicmeam	121	67	]	]	-RRB-
cord-340028-6oicmeam	121	68	.	.	.
cord-340028-6oicmeam	122	1	A	a	DT
cord-340028-6oicmeam	122	2	follow	follow	VB
cord-340028-6oicmeam	122	3	-	-	HYPH
cord-340028-6oicmeam	122	4	up	up	NN
cord-340028-6oicmeam	122	5	trial	trial	NN
cord-340028-6oicmeam	122	6	of	of	IN
cord-340028-6oicmeam	122	7	dactolisib	dactolisib	NNP
cord-340028-6oicmeam	122	8	alone	alone	JJ
cord-340028-6oicmeam	122	9	(	(	-LRB-
cord-340028-6oicmeam	122	10	BEZ235	BEZ235	NNP
cord-340028-6oicmeam	122	11	rebranded	rebrande	VBN
cord-340028-6oicmeam	122	12	as	as	IN
cord-340028-6oicmeam	122	13	RTB101	RTB101	NNP
cord-340028-6oicmeam	122	14	)	)	-RRB-
cord-340028-6oicmeam	122	15	for	for	IN
cord-340028-6oicmeam	122	16	prevention	prevention	NN
cord-340028-6oicmeam	122	17	of	of	IN
cord-340028-6oicmeam	122	18	respiratory	respiratory	JJ
cord-340028-6oicmeam	122	19	tract	tract	NN
cord-340028-6oicmeam	122	20	infections	infection	NNS
cord-340028-6oicmeam	122	21	in	in	IN
cord-340028-6oicmeam	122	22	the	the	DT
cord-340028-6oicmeam	122	23	elderly	elderly	JJ
cord-340028-6oicmeam	122	24	did	do	VBD
cord-340028-6oicmeam	122	25	not	not	RB
cord-340028-6oicmeam	122	26	meet	meet	VB
cord-340028-6oicmeam	122	27	the	the	DT
cord-340028-6oicmeam	122	28	primary	primary	JJ
cord-340028-6oicmeam	122	29	endpoint	endpoint	NN
cord-340028-6oicmeam	122	30	and	and	CC
cord-340028-6oicmeam	122	31	further	further	JJ
cord-340028-6oicmeam	122	32	trials	trial	NNS
cord-340028-6oicmeam	122	33	were	be	VBD
cord-340028-6oicmeam	122	34	withdrawn	withdraw	VBN
cord-340028-6oicmeam	122	35	[	[	-LRB-
cord-340028-6oicmeam	122	36	85	85	CD
cord-340028-6oicmeam	122	37	]	]	-RRB-
cord-340028-6oicmeam	122	38	.	.	.
cord-340028-6oicmeam	123	1	In	in	IN
cord-340028-6oicmeam	123	2	prior	prior	JJ
cord-340028-6oicmeam	123	3	studies	study	NNS
cord-340028-6oicmeam	123	4	,	,	,
cord-340028-6oicmeam	123	5	everolimus	everolimus	NNP
cord-340028-6oicmeam	123	6	(	(	-LRB-
cord-340028-6oicmeam	123	7	RAD001	RAD001	NNP
cord-340028-6oicmeam	123	8	)	)	-RRB-
cord-340028-6oicmeam	123	9	was	be	VBD
cord-340028-6oicmeam	123	10	used	use	VBN
cord-340028-6oicmeam	123	11	as	as	IN
cord-340028-6oicmeam	123	12	a	a	DT
cord-340028-6oicmeam	123	13	standalone	standalone	JJ
cord-340028-6oicmeam	123	14	agent	agent	NN
cord-340028-6oicmeam	123	15	or	or	CC
cord-340028-6oicmeam	123	16	in	in	IN
cord-340028-6oicmeam	123	17	combination	combination	NN
cord-340028-6oicmeam	123	18	with	with	IN
cord-340028-6oicmeam	123	19	dactolisib	dactolisib	NNP
cord-340028-6oicmeam	123	20	,	,	,
cord-340028-6oicmeam	123	21	which	which	WDT
cord-340028-6oicmeam	123	22	may	may	MD
cord-340028-6oicmeam	123	23	explain	explain	VB
cord-340028-6oicmeam	123	24	the	the	DT
cord-340028-6oicmeam	123	25	phase	phase	NN
cord-340028-6oicmeam	123	26	3	3	CD
cord-340028-6oicmeam	123	27	failure	failure	NN
cord-340028-6oicmeam	123	28	of	of	IN
cord-340028-6oicmeam	123	29	BEZ235/	bez235/	NN
cord-340028-6oicmeam	124	1	RTB101	RTB101	NNP
cord-340028-6oicmeam	124	2	.	.	.
cord-340028-6oicmeam	125	1	There	there	EX
cord-340028-6oicmeam	125	2	are	be	VBP
cord-340028-6oicmeam	125	3	over	over	IN
cord-340028-6oicmeam	125	4	95	95	CD
cord-340028-6oicmeam	125	5	phase	phase	NN
cord-340028-6oicmeam	125	6	3	3	CD
cord-340028-6oicmeam	125	7	and	and	CC
cord-340028-6oicmeam	125	8	phase	phase	VB
cord-340028-6oicmeam	125	9	4	4	CD
cord-340028-6oicmeam	125	10	studies	study	NNS
cord-340028-6oicmeam	125	11	for	for	IN
cord-340028-6oicmeam	125	12	these	these	DT
cord-340028-6oicmeam	125	13	agents	agent	NNS
cord-340028-6oicmeam	125	14	[	[	-LRB-
cord-340028-6oicmeam	125	15	86	86	CD
cord-340028-6oicmeam	125	16	]	]	-RRB-
cord-340028-6oicmeam	125	17	,	,	,
cord-340028-6oicmeam	125	18	and	and	CC
cord-340028-6oicmeam	125	19	they	-PRON-	PRP
cord-340028-6oicmeam	125	20	are	be	VBP
cord-340028-6oicmeam	125	21	generally	generally	RB
cord-340028-6oicmeam	125	22	well	well	RB
cord-340028-6oicmeam	125	23	tolerated	tolerate	VBN
cord-340028-6oicmeam	125	24	even	even	RB
cord-340028-6oicmeam	125	25	in	in	IN
cord-340028-6oicmeam	125	26	high	high	JJ
cord-340028-6oicmeam	125	27	doses	dose	NNS
cord-340028-6oicmeam	125	28	.	.	.
cord-340028-6oicmeam	126	1	Even	even	RB
cord-340028-6oicmeam	126	2	though	though	IN
cord-340028-6oicmeam	126	3	it	-PRON-	PRP
cord-340028-6oicmeam	126	4	may	may	MD
cord-340028-6oicmeam	126	5	not	not	RB
cord-340028-6oicmeam	126	6	be	be	VB
cord-340028-6oicmeam	126	7	commercially	commercially	RB
cord-340028-6oicmeam	126	8	viable	viable	JJ
cord-340028-6oicmeam	126	9	due	due	IN
cord-340028-6oicmeam	126	10	to	to	IN
cord-340028-6oicmeam	126	11	the	the	DT
cord-340028-6oicmeam	126	12	patent	patent	NN
cord-340028-6oicmeam	126	13	expirations	expiration	NNS
cord-340028-6oicmeam	126	14	,	,	,
cord-340028-6oicmeam	126	15	clinical	clinical	JJ
cord-340028-6oicmeam	126	16	trials	trial	NNS
cord-340028-6oicmeam	126	17	should	should	MD
cord-340028-6oicmeam	126	18	be	be	VB
cord-340028-6oicmeam	126	19	conducted	conduct	VBN
cord-340028-6oicmeam	126	20	to	to	TO
cord-340028-6oicmeam	126	21	evaluate	evaluate	VB
cord-340028-6oicmeam	126	22	the	the	DT
cord-340028-6oicmeam	126	23	effectiveness	effectiveness	NN
cord-340028-6oicmeam	126	24	of	of	IN
cord-340028-6oicmeam	126	25	these	these	DT
cord-340028-6oicmeam	126	26	agents	agent	NNS
cord-340028-6oicmeam	126	27	for	for	IN
cord-340028-6oicmeam	126	28	protection	protection	NN
cord-340028-6oicmeam	126	29	against	against	IN
cord-340028-6oicmeam	126	30	SARS	SARS	NNP
cord-340028-6oicmeam	126	31	-	-	HYPH
cord-340028-6oicmeam	126	32	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	126	33	(	(	-LRB-
cord-340028-6oicmeam	126	34	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	126	35	)	)	-RRB-
cord-340028-6oicmeam	126	36	and	and	CC
cord-340028-6oicmeam	126	37	other	other	JJ
cord-340028-6oicmeam	126	38	gerophilic	gerophilic	JJ
cord-340028-6oicmeam	126	39	and	and	CC
cord-340028-6oicmeam	126	40	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	126	41	infections	infection	NNS
cord-340028-6oicmeam	126	42	.	.	.
cord-340028-6oicmeam	127	1	Metformin	Metformin	NNP
cord-340028-6oicmeam	127	2	is	be	VBZ
cord-340028-6oicmeam	127	3	a	a	DT
cord-340028-6oicmeam	127	4	drug	drug	NN
cord-340028-6oicmeam	127	5	approved	approve	VBN
cord-340028-6oicmeam	127	6	to	to	TO
cord-340028-6oicmeam	127	7	treat	treat	VB
cord-340028-6oicmeam	127	8	type	type	NN
cord-340028-6oicmeam	127	9	2	2	CD
cord-340028-6oicmeam	127	10	diabetes	diabete	NNS
cord-340028-6oicmeam	127	11	but	but	CC
cord-340028-6oicmeam	127	12	appears	appear	VBZ
cord-340028-6oicmeam	127	13	to	to	TO
cord-340028-6oicmeam	127	14	target	target	VB
cord-340028-6oicmeam	127	15	a	a	DT
cord-340028-6oicmeam	127	16	number	number	NN
cord-340028-6oicmeam	127	17	of	of	IN
cord-340028-6oicmeam	127	18	aging	age	VBG
cord-340028-6oicmeam	127	19	-	-	HYPH
cord-340028-6oicmeam	127	20	related	relate	VBN
cord-340028-6oicmeam	127	21	mechanisms	mechanism	NNS
cord-340028-6oicmeam	127	22	,	,	,
cord-340028-6oicmeam	127	23	including	include	VBG
cord-340028-6oicmeam	127	24	decreasing	decrease	VBG
cord-340028-6oicmeam	127	25	IGF-1	IGF-1	NNP
cord-340028-6oicmeam	127	26	levels	level	NNS
cord-340028-6oicmeam	127	27	,	,	,
cord-340028-6oicmeam	127	28	inhibiting	inhibit	VBG
cord-340028-6oicmeam	127	29	mTOR	mTOR	NNP
cord-340028-6oicmeam	127	30	,	,	,
cord-340028-6oicmeam	127	31	and	and	CC
cord-340028-6oicmeam	127	32	inhibiting	inhibit	VBG
cord-340028-6oicmeam	127	33	mitochondrial	mitochondrial	JJ
cord-340028-6oicmeam	127	34	complex	complex	JJ
cord-340028-6oicmeam	127	35	1	1	CD
cord-340028-6oicmeam	127	36	.	.	.
cord-340028-6oicmeam	128	1	Metformin	Metformin	NNP
cord-340028-6oicmeam	128	2	is	be	VBZ
cord-340028-6oicmeam	128	3	currently	currently	RB
cord-340028-6oicmeam	128	4	in	in	IN
cord-340028-6oicmeam	128	5	the	the	DT
cord-340028-6oicmeam	128	6	first	first	JJ
cord-340028-6oicmeam	128	7	large	large	JJ
cord-340028-6oicmeam	128	8	-	-	HYPH
cord-340028-6oicmeam	128	9	scale	scale	NN
cord-340028-6oicmeam	128	10	human	human	NN
cord-340028-6oicmeam	128	11	AGING	age	VBG
cord-340028-6oicmeam	128	12	clinical	clinical	JJ
cord-340028-6oicmeam	128	13	trial	trial	NN
cord-340028-6oicmeam	128	14	of	of	IN
cord-340028-6oicmeam	128	15	aging	age	VBG
cord-340028-6oicmeam	128	16	,	,	,
cord-340028-6oicmeam	128	17	the	the	DT
cord-340028-6oicmeam	128	18	Targeting	targeting	NN
cord-340028-6oicmeam	128	19	Aging	age	VBG
cord-340028-6oicmeam	128	20	with	with	IN
cord-340028-6oicmeam	128	21	Metformin	Metformin	NNP
cord-340028-6oicmeam	128	22	(	(	-LRB-
cord-340028-6oicmeam	128	23	TAME	TAME	NNP
cord-340028-6oicmeam	128	24	)	)	-RRB-
cord-340028-6oicmeam	128	25	study	study	NN
cord-340028-6oicmeam	128	26	,	,	,
cord-340028-6oicmeam	128	27	which	which	WDT
cord-340028-6oicmeam	128	28	is	be	VBZ
cord-340028-6oicmeam	128	29	investigating	investigate	VBG
cord-340028-6oicmeam	128	30	its	-PRON-	PRP$
cord-340028-6oicmeam	128	31	effect	effect	NN
cord-340028-6oicmeam	128	32	on	on	IN
cord-340028-6oicmeam	128	33	time	time	NN
cord-340028-6oicmeam	128	34	to	to	IN
cord-340028-6oicmeam	128	35	a	a	DT
cord-340028-6oicmeam	128	36	new	new	JJ
cord-340028-6oicmeam	128	37	occurrence	occurrence	NN
cord-340028-6oicmeam	128	38	of	of	IN
cord-340028-6oicmeam	128	39	a	a	DT
cord-340028-6oicmeam	128	40	composite	composite	JJ
cord-340028-6oicmeam	128	41	outcome	outcome	NN
cord-340028-6oicmeam	128	42	that	that	WDT
cord-340028-6oicmeam	128	43	includes	include	VBZ
cord-340028-6oicmeam	128	44	cardiovascular	cardiovascular	JJ
cord-340028-6oicmeam	128	45	events	event	NNS
cord-340028-6oicmeam	128	46	,	,	,
cord-340028-6oicmeam	128	47	cancer	cancer	NN
cord-340028-6oicmeam	128	48	,	,	,
cord-340028-6oicmeam	128	49	dementia	dementia	NN
cord-340028-6oicmeam	128	50	,	,	,
cord-340028-6oicmeam	128	51	and	and	CC
cord-340028-6oicmeam	128	52	mortality	mortality	NN
cord-340028-6oicmeam	128	53	[	[	-LRB-
cord-340028-6oicmeam	128	54	87	87	CD
cord-340028-6oicmeam	128	55	]	]	-RRB-
cord-340028-6oicmeam	128	56	.	.	.
cord-340028-6oicmeam	129	1	Metformin	Metformin	NNP
cord-340028-6oicmeam	129	2	would	would	MD
cord-340028-6oicmeam	129	3	likely	likely	RB
cord-340028-6oicmeam	129	4	still	still	RB
cord-340028-6oicmeam	129	5	be	be	VB
cord-340028-6oicmeam	129	6	contraindicated	contraindicated	JJ
cord-340028-6oicmeam	129	7	in	in	IN
cord-340028-6oicmeam	129	8	elderly	elderly	JJ
cord-340028-6oicmeam	129	9	patients	patient	NNS
cord-340028-6oicmeam	129	10	with	with	IN
cord-340028-6oicmeam	129	11	advanced	advanced	JJ
cord-340028-6oicmeam	129	12	chronic	chronic	JJ
cord-340028-6oicmeam	129	13	kidney	kidney	NN
cord-340028-6oicmeam	129	14	disease	disease	NN
cord-340028-6oicmeam	129	15	and	and	CC
cord-340028-6oicmeam	129	16	eGFR<15	egfr<15	NN
cord-340028-6oicmeam	129	17	.	.	.
cord-340028-6oicmeam	130	1	A	a	DT
cord-340028-6oicmeam	130	2	reduced	reduced	JJ
cord-340028-6oicmeam	130	3	dose	dose	NN
cord-340028-6oicmeam	130	4	would	would	MD
cord-340028-6oicmeam	130	5	potentially	potentially	RB
cord-340028-6oicmeam	130	6	be	be	VB
cord-340028-6oicmeam	130	7	required	require	VBN
cord-340028-6oicmeam	130	8	for	for	IN
cord-340028-6oicmeam	130	9	eGFR<30	eGFR<30	NNP
cord-340028-6oicmeam	130	10	due	due	IN
cord-340028-6oicmeam	130	11	to	to	IN
cord-340028-6oicmeam	130	12	a	a	DT
cord-340028-6oicmeam	130	13	risk	risk	NN
cord-340028-6oicmeam	130	14	of	of	IN
cord-340028-6oicmeam	130	15	lactic	lactic	JJ
cord-340028-6oicmeam	130	16	acidosis	acidosis	NN
cord-340028-6oicmeam	130	17	.	.	.
cord-340028-6oicmeam	131	1	The	the	DT
cord-340028-6oicmeam	131	2	effects	effect	NNS
cord-340028-6oicmeam	131	3	on	on	IN
cord-340028-6oicmeam	131	4	gerophilic	gerophilic	JJ
cord-340028-6oicmeam	131	5	and	and	CC
cord-340028-6oicmeam	131	6	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	131	7	infections	infection	NNS
cord-340028-6oicmeam	131	8	should	should	MD
cord-340028-6oicmeam	131	9	be	be	VB
cord-340028-6oicmeam	131	10	carefully	carefully	RB
cord-340028-6oicmeam	131	11	examined	examine	VBN
cord-340028-6oicmeam	131	12	in	in	IN
cord-340028-6oicmeam	131	13	the	the	DT
cord-340028-6oicmeam	131	14	context	context	NN
cord-340028-6oicmeam	131	15	of	of	IN
cord-340028-6oicmeam	131	16	the	the	DT
cord-340028-6oicmeam	131	17	TAME	tame	JJ
cord-340028-6oicmeam	131	18	study	study	NN
cord-340028-6oicmeam	131	19	,	,	,
cord-340028-6oicmeam	131	20	and	and	CC
cord-340028-6oicmeam	131	21	other	other	JJ
cord-340028-6oicmeam	131	22	clinical	clinical	JJ
cord-340028-6oicmeam	131	23	trials	trial	NNS
cord-340028-6oicmeam	131	24	involving	involve	VBG
cord-340028-6oicmeam	131	25	metformin	metformin	NNP
cord-340028-6oicmeam	131	26	.	.	.
cord-340028-6oicmeam	132	1	Nicotine	nicotine	NN
cord-340028-6oicmeam	132	2	adenine	adenine	NN
cord-340028-6oicmeam	132	3	dinucleotide	dinucleotide	NN
cord-340028-6oicmeam	132	4	(	(	-LRB-
cord-340028-6oicmeam	132	5	NAD	NAD	NNP
cord-340028-6oicmeam	132	6	)	)	-RRB-
cord-340028-6oicmeam	132	7	is	be	VBZ
cord-340028-6oicmeam	132	8	a	a	DT
cord-340028-6oicmeam	132	9	cofactor	cofactor	NN
cord-340028-6oicmeam	132	10	of	of	IN
cord-340028-6oicmeam	132	11	multiple	multiple	JJ
cord-340028-6oicmeam	132	12	fundamental	fundamental	JJ
cord-340028-6oicmeam	132	13	enzymes	enzyme	NNS
cord-340028-6oicmeam	132	14	.	.	.
cord-340028-6oicmeam	133	1	It	-PRON-	PRP
cord-340028-6oicmeam	133	2	is	be	VBZ
cord-340028-6oicmeam	133	3	involved	involve	VBN
cord-340028-6oicmeam	133	4	in	in	IN
cord-340028-6oicmeam	133	5	metabolic	metabolic	JJ
cord-340028-6oicmeam	133	6	regulation	regulation	NN
cord-340028-6oicmeam	133	7	through	through	IN
cord-340028-6oicmeam	133	8	the	the	DT
cord-340028-6oicmeam	133	9	Krebs	Krebs	NNP
cord-340028-6oicmeam	133	10	(	(	-LRB-
cord-340028-6oicmeam	133	11	citric	citric	JJ
cord-340028-6oicmeam	133	12	acid	acid	NN
cord-340028-6oicmeam	133	13	)	)	-RRB-
cord-340028-6oicmeam	133	14	cycle	cycle	NN
cord-340028-6oicmeam	133	15	,	,	,
cord-340028-6oicmeam	133	16	oxidative	oxidative	JJ
cord-340028-6oicmeam	133	17	phosphorylation	phosphorylation	NN
cord-340028-6oicmeam	133	18	,	,	,
cord-340028-6oicmeam	133	19	and	and	CC
cord-340028-6oicmeam	133	20	cellular	cellular	JJ
cord-340028-6oicmeam	133	21	signaling	signaling	NN
cord-340028-6oicmeam	133	22	,	,	,
cord-340028-6oicmeam	133	23	as	as	RB
cord-340028-6oicmeam	133	24	well	well	RB
cord-340028-6oicmeam	133	25	as	as	IN
cord-340028-6oicmeam	133	26	cellular	cellular	JJ
cord-340028-6oicmeam	133	27	senescence	senescence	NN
cord-340028-6oicmeam	133	28	and	and	CC
cord-340028-6oicmeam	133	29	DNA	dna	NN
cord-340028-6oicmeam	133	30	repair	repair	NN
cord-340028-6oicmeam	133	31	through	through	IN
cord-340028-6oicmeam	133	32	the	the	DT
cord-340028-6oicmeam	133	33	poly	poly	JJ
cord-340028-6oicmeam	133	34	-	-	HYPH
cord-340028-6oicmeam	133	35	ADP	adp	NN
cord-340028-6oicmeam	133	36	-	-	HYPH
cord-340028-6oicmeam	133	37	ribose	ribose	NN
cord-340028-6oicmeam	133	38	polymerases	polymerase	NNS
cord-340028-6oicmeam	133	39	(	(	-LRB-
cord-340028-6oicmeam	133	40	PARPs	PARPs	NNPS
cord-340028-6oicmeam	133	41	)	)	-RRB-
cord-340028-6oicmeam	133	42	,	,	,
cord-340028-6oicmeam	133	43	sirtuins	sirtuin	NNS
cord-340028-6oicmeam	133	44	,	,	,
cord-340028-6oicmeam	133	45	and	and	CC
cord-340028-6oicmeam	133	46	CD38	CD38	NNP
cord-340028-6oicmeam	133	47	.	.	.
cord-340028-6oicmeam	134	1	NAD	NAD	NNP
cord-340028-6oicmeam	134	2	levels	level	NNS
cord-340028-6oicmeam	134	3	decrease	decrease	VBP
cord-340028-6oicmeam	134	4	with	with	IN
cord-340028-6oicmeam	134	5	aging	age	VBG
cord-340028-6oicmeam	134	6	,	,	,
cord-340028-6oicmeam	134	7	and	and	CC
cord-340028-6oicmeam	134	8	benefits	benefit	NNS
cord-340028-6oicmeam	134	9	of	of	IN
cord-340028-6oicmeam	134	10	NAD	NAD	NNP
cord-340028-6oicmeam	134	11	supplementation	supplementation	NN
cord-340028-6oicmeam	134	12	have	have	VBP
cord-340028-6oicmeam	134	13	been	be	VBN
cord-340028-6oicmeam	134	14	reported	report	VBN
cord-340028-6oicmeam	134	15	in	in	IN
cord-340028-6oicmeam	134	16	multiple	multiple	JJ
cord-340028-6oicmeam	134	17	animal	animal	NN
cord-340028-6oicmeam	134	18	studies	study	NNS
cord-340028-6oicmeam	134	19	.	.	.
cord-340028-6oicmeam	135	1	Although	although	IN
cord-340028-6oicmeam	135	2	no	no	DT
cord-340028-6oicmeam	135	3	proof	proof	NN
cord-340028-6oicmeam	135	4	of	of	IN
cord-340028-6oicmeam	135	5	a	a	DT
cord-340028-6oicmeam	135	6	similar	similar	JJ
cord-340028-6oicmeam	135	7	effect	effect	NN
cord-340028-6oicmeam	135	8	in	in	IN
cord-340028-6oicmeam	135	9	humans	human	NNS
cord-340028-6oicmeam	135	10	has	have	VBZ
cord-340028-6oicmeam	135	11	been	be	VBN
cord-340028-6oicmeam	135	12	shown	show	VBN
cord-340028-6oicmeam	135	13	,	,	,
cord-340028-6oicmeam	135	14	several	several	JJ
cord-340028-6oicmeam	135	15	clinical	clinical	JJ
cord-340028-6oicmeam	135	16	trials	trial	NNS
cord-340028-6oicmeam	135	17	are	be	VBP
cord-340028-6oicmeam	135	18	in	in	IN
cord-340028-6oicmeam	135	19	progress	progress	NN
cord-340028-6oicmeam	135	20	[	[	-LRB-
cord-340028-6oicmeam	135	21	88	88	CD
cord-340028-6oicmeam	135	22	]	]	-RRB-
cord-340028-6oicmeam	135	23	[	[	-LRB-
cord-340028-6oicmeam	135	24	89	89	CD
cord-340028-6oicmeam	135	25	]	]	-RRB-
cord-340028-6oicmeam	135	26	[	[	-LRB-
cord-340028-6oicmeam	135	27	90	90	CD
cord-340028-6oicmeam	135	28	]	]	-RRB-
cord-340028-6oicmeam	135	29	[	[	-LRB-
cord-340028-6oicmeam	135	30	91	91	CD
cord-340028-6oicmeam	135	31	]	]	-RRB-
cord-340028-6oicmeam	135	32	.	.	.
cord-340028-6oicmeam	136	1	Supplementation	supplementation	NN
cord-340028-6oicmeam	136	2	with	with	IN
cord-340028-6oicmeam	136	3	nicotinamide	nicotinamide	NN
cord-340028-6oicmeam	136	4	riboside	riboside	NN
cord-340028-6oicmeam	136	5	(	(	-LRB-
cord-340028-6oicmeam	136	6	NR	NR	NNP
cord-340028-6oicmeam	136	7	)	)	-RRB-
cord-340028-6oicmeam	136	8	in	in	IN
cord-340028-6oicmeam	136	9	one	one	CD
cord-340028-6oicmeam	136	10	human	human	JJ
cord-340028-6oicmeam	136	11	study	study	NN
cord-340028-6oicmeam	136	12	produced	produce	VBD
cord-340028-6oicmeam	136	13	an	an	DT
cord-340028-6oicmeam	136	14	improvement	improvement	NN
cord-340028-6oicmeam	136	15	in	in	IN
cord-340028-6oicmeam	136	16	exercise	exercise	NN
cord-340028-6oicmeam	136	17	capacity	capacity	NN
cord-340028-6oicmeam	136	18	in	in	IN
cord-340028-6oicmeam	136	19	a	a	DT
cord-340028-6oicmeam	136	20	population	population	NN
cord-340028-6oicmeam	136	21	with	with	IN
cord-340028-6oicmeam	136	22	a	a	DT
cord-340028-6oicmeam	136	23	mean	mean	JJ
cord-340028-6oicmeam	136	24	age	age	NN
cord-340028-6oicmeam	136	25	of	of	IN
cord-340028-6oicmeam	136	26	71	71	CD
cord-340028-6oicmeam	136	27	[	[	-LRB-
cord-340028-6oicmeam	136	28	92	92	CD
cord-340028-6oicmeam	136	29	]	]	-RRB-
cord-340028-6oicmeam	136	30	.	.	.
cord-340028-6oicmeam	137	1	This	this	DT
cord-340028-6oicmeam	137	2	compound	compound	NN
cord-340028-6oicmeam	137	3	was	be	VBD
cord-340028-6oicmeam	137	4	also	also	RB
cord-340028-6oicmeam	137	5	shown	show	VBN
cord-340028-6oicmeam	137	6	to	to	TO
cord-340028-6oicmeam	137	7	reduce	reduce	VB
cord-340028-6oicmeam	137	8	blood	blood	NN
cord-340028-6oicmeam	137	9	pressure	pressure	NN
cord-340028-6oicmeam	137	10	in	in	IN
cord-340028-6oicmeam	137	11	hypertensive	hypertensive	JJ
cord-340028-6oicmeam	137	12	patients	patient	NNS
cord-340028-6oicmeam	137	13	[	[	-LRB-
cord-340028-6oicmeam	137	14	93	93	CD
cord-340028-6oicmeam	137	15	]	]	-RRB-
cord-340028-6oicmeam	137	16	.	.	.
cord-340028-6oicmeam	138	1	Nicotinic	nicotinic	JJ
cord-340028-6oicmeam	138	2	acid	acid	NN
cord-340028-6oicmeam	138	3	is	be	VBZ
cord-340028-6oicmeam	138	4	another	another	DT
cord-340028-6oicmeam	138	5	NAD	NAD	NNP
cord-340028-6oicmeam	138	6	precursor	precursor	NN
cord-340028-6oicmeam	138	7	that	that	WDT
cord-340028-6oicmeam	138	8	is	be	VBZ
cord-340028-6oicmeam	138	9	converted	convert	VBN
cord-340028-6oicmeam	138	10	in	in	IN
cord-340028-6oicmeam	138	11	the	the	DT
cord-340028-6oicmeam	138	12	body	body	NN
cord-340028-6oicmeam	138	13	to	to	IN
cord-340028-6oicmeam	138	14	NAD	NAD	NNP
cord-340028-6oicmeam	138	15	by	by	IN
cord-340028-6oicmeam	138	16	the	the	DT
cord-340028-6oicmeam	138	17	enzymes	enzyme	NNS
cord-340028-6oicmeam	138	18	NAPRT	NAPRT	NNP
cord-340028-6oicmeam	138	19	,	,	,
cord-340028-6oicmeam	138	20	NMNAT	NMNAT	NNP
cord-340028-6oicmeam	138	21	,	,	,
cord-340028-6oicmeam	138	22	and	and	CC
cord-340028-6oicmeam	138	23	NADS	nads	NN
cord-340028-6oicmeam	138	24	.	.	.
cord-340028-6oicmeam	139	1	Large	large	JJ
cord-340028-6oicmeam	139	2	-	-	HYPH
cord-340028-6oicmeam	139	3	scale	scale	NN
cord-340028-6oicmeam	139	4	trials	trial	NNS
cord-340028-6oicmeam	139	5	of	of	IN
cord-340028-6oicmeam	139	6	nicotinic	nicotinic	JJ
cord-340028-6oicmeam	139	7	acid	acid	NN
cord-340028-6oicmeam	139	8	for	for	IN
cord-340028-6oicmeam	139	9	cardiovascular	cardiovascular	JJ
cord-340028-6oicmeam	139	10	disease	disease	NN
cord-340028-6oicmeam	139	11	[	[	-LRB-
cord-340028-6oicmeam	139	12	94	94	CD
cord-340028-6oicmeam	139	13	,	,	,
cord-340028-6oicmeam	139	14	95	95	CD
cord-340028-6oicmeam	139	15	]	]	-RRB-
cord-340028-6oicmeam	139	16	showed	show	VBD
cord-340028-6oicmeam	139	17	some	some	DT
cord-340028-6oicmeam	139	18	efficacy	efficacy	NN
cord-340028-6oicmeam	139	19	,	,	,
cord-340028-6oicmeam	139	20	but	but	CC
cord-340028-6oicmeam	139	21	produced	produce	VBD
cord-340028-6oicmeam	139	22	adverse	adverse	JJ
cord-340028-6oicmeam	139	23	side	side	NN
cord-340028-6oicmeam	139	24	effects	effect	NNS
cord-340028-6oicmeam	139	25	,	,	,
cord-340028-6oicmeam	139	26	such	such	JJ
cord-340028-6oicmeam	139	27	as	as	IN
cord-340028-6oicmeam	139	28	headache	headache	NN
cord-340028-6oicmeam	139	29	,	,	,
cord-340028-6oicmeam	139	30	skin	skin	NN
cord-340028-6oicmeam	139	31	flushing	flushing	NN
cord-340028-6oicmeam	139	32	,	,	,
cord-340028-6oicmeam	139	33	and	and	CC
cord-340028-6oicmeam	139	34	dizziness	dizziness	NN
cord-340028-6oicmeam	139	35	[	[	-LRB-
cord-340028-6oicmeam	139	36	96	96	CD
cord-340028-6oicmeam	139	37	]	]	-RRB-
cord-340028-6oicmeam	139	38	.	.	.
cord-340028-6oicmeam	140	1	NAD	NAD	NNP
cord-340028-6oicmeam	140	2	acts	act	VBZ
cord-340028-6oicmeam	140	3	at	at	IN
cord-340028-6oicmeam	140	4	a	a	DT
cord-340028-6oicmeam	140	5	cellular	cellular	JJ
cord-340028-6oicmeam	140	6	level	level	NN
cord-340028-6oicmeam	140	7	and	and	CC
cord-340028-6oicmeam	140	8	it	-PRON-	PRP
cord-340028-6oicmeam	140	9	is	be	VBZ
cord-340028-6oicmeam	140	10	still	still	RB
cord-340028-6oicmeam	140	11	unclear	unclear	JJ
cord-340028-6oicmeam	140	12	whether	whether	IN
cord-340028-6oicmeam	140	13	oral	oral	JJ
cord-340028-6oicmeam	140	14	or	or	CC
cord-340028-6oicmeam	140	15	intravenous	intravenous	JJ
cord-340028-6oicmeam	140	16	supplementation	supplementation	NN
cord-340028-6oicmeam	140	17	with	with	IN
cord-340028-6oicmeam	140	18	NAD	NAD	NNP
cord-340028-6oicmeam	140	19	donors	donor	NNS
cord-340028-6oicmeam	140	20	,	,	,
cord-340028-6oicmeam	140	21	such	such	JJ
cord-340028-6oicmeam	140	22	as	as	IN
cord-340028-6oicmeam	140	23	NR	NR	NNP
cord-340028-6oicmeam	140	24	and	and	CC
cord-340028-6oicmeam	140	25	nicotinic	nicotinic	JJ
cord-340028-6oicmeam	140	26	acid	acid	NN
cord-340028-6oicmeam	140	27	,	,	,
cord-340028-6oicmeam	140	28	will	will	MD
cord-340028-6oicmeam	140	29	increase	increase	VB
cord-340028-6oicmeam	140	30	NAD	NAD	NNP
cord-340028-6oicmeam	140	31	levels	level	NNS
cord-340028-6oicmeam	140	32	and	and	CC
cord-340028-6oicmeam	140	33	exert	exert	VB
cord-340028-6oicmeam	140	34	a	a	DT
cord-340028-6oicmeam	140	35	clinical	clinical	JJ
cord-340028-6oicmeam	140	36	benefit	benefit	NN
cord-340028-6oicmeam	140	37	in	in	IN
cord-340028-6oicmeam	140	38	humans	human	NNS
cord-340028-6oicmeam	140	39	.	.	.
cord-340028-6oicmeam	141	1	However	however	RB
cord-340028-6oicmeam	141	2	,	,	,
cord-340028-6oicmeam	141	3	COVID-19	covid-19	JJ
cord-340028-6oicmeam	141	4	patients	patient	NNS
cord-340028-6oicmeam	141	5	may	may	MD
cord-340028-6oicmeam	141	6	benefit	benefit	VB
cord-340028-6oicmeam	141	7	tremendously	tremendously	RB
cord-340028-6oicmeam	141	8	from	from	IN
cord-340028-6oicmeam	141	9	these	these	DT
cord-340028-6oicmeam	141	10	compounds	compound	NNS
cord-340028-6oicmeam	141	11	,	,	,
cord-340028-6oicmeam	141	12	as	as	IN
cord-340028-6oicmeam	141	13	SARS	SARS	NNP
cord-340028-6oicmeam	141	14	-	-	HYPH
cord-340028-6oicmeam	141	15	CoV-2infected	cov-2infecte	VBN
cord-340028-6oicmeam	141	16	patients	patient	NNS
cord-340028-6oicmeam	141	17	have	have	VBP
cord-340028-6oicmeam	141	18	increased	increase	VBN
cord-340028-6oicmeam	141	19	levels	level	NNS
cord-340028-6oicmeam	141	20	of	of	IN
cord-340028-6oicmeam	141	21	CD38	CD38	NNP
cord-340028-6oicmeam	141	22	+	+	SYM
cord-340028-6oicmeam	141	23	,	,	,
cord-340028-6oicmeam	141	24	and	and	CC
cord-340028-6oicmeam	141	25	NAD	NAD	NNP
cord-340028-6oicmeam	141	26	has	have	VBZ
cord-340028-6oicmeam	141	27	been	be	VBN
cord-340028-6oicmeam	141	28	shown	show	VBN
cord-340028-6oicmeam	141	29	to	to	TO
cord-340028-6oicmeam	141	30	enhance	enhance	VB
cord-340028-6oicmeam	141	31	DNA	dna	NN
cord-340028-6oicmeam	141	32	repair	repair	NN
cord-340028-6oicmeam	141	33	via	via	IN
cord-340028-6oicmeam	141	34	PARP	PARP	NNP
cord-340028-6oicmeam	141	35	pathways	pathway	NNS
cord-340028-6oicmeam	141	36	[	[	-LRB-
cord-340028-6oicmeam	141	37	97	97	CD
cord-340028-6oicmeam	141	38	]	]	-RRB-
cord-340028-6oicmeam	141	39	.	.	.
cord-340028-6oicmeam	142	1	Caution	caution	NN
cord-340028-6oicmeam	142	2	should	should	MD
cord-340028-6oicmeam	142	3	be	be	VB
cord-340028-6oicmeam	142	4	exercised	exercise	VBN
cord-340028-6oicmeam	142	5	when	when	WRB
cord-340028-6oicmeam	142	6	conducting	conduct	VBG
cord-340028-6oicmeam	142	7	any	any	DT
cord-340028-6oicmeam	142	8	clinical	clinical	JJ
cord-340028-6oicmeam	142	9	trials	trial	NNS
cord-340028-6oicmeam	142	10	for	for	IN
cord-340028-6oicmeam	142	11	NAD	NAD	NNP
cord-340028-6oicmeam	142	12	boosters	booster	NNS
cord-340028-6oicmeam	142	13	against	against	IN
cord-340028-6oicmeam	142	14	gerophilic	gerophilic	NNP
cord-340028-6oicmeam	142	15	and	and	CC
cord-340028-6oicmeam	142	16	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	142	17	infections	infection	NNS
cord-340028-6oicmeam	142	18	,	,	,
cord-340028-6oicmeam	142	19	as	as	IN
cord-340028-6oicmeam	142	20	the	the	DT
cord-340028-6oicmeam	142	21	underlying	underlie	VBG
cord-340028-6oicmeam	142	22	biology	biology	NN
cord-340028-6oicmeam	142	23	of	of	IN
cord-340028-6oicmeam	142	24	NAS	NAS	NNP
cord-340028-6oicmeam	142	25	metabolism	metabolism	NN
cord-340028-6oicmeam	142	26	and	and	CC
cord-340028-6oicmeam	142	27	viral	viral	JJ
cord-340028-6oicmeam	142	28	infections	infection	NNS
cord-340028-6oicmeam	142	29	is	be	VBZ
cord-340028-6oicmeam	142	30	still	still	RB
cord-340028-6oicmeam	142	31	poorly	poorly	RB
cord-340028-6oicmeam	142	32	understood	understand	VBN
cord-340028-6oicmeam	142	33	.	.	.
cord-340028-6oicmeam	143	1	Recent	recent	JJ
cord-340028-6oicmeam	143	2	studies	study	NNS
cord-340028-6oicmeam	143	3	in	in	IN
cord-340028-6oicmeam	143	4	humans	human	NNS
cord-340028-6oicmeam	143	5	demonstrate	demonstrate	VBP
cord-340028-6oicmeam	143	6	that	that	IN
cord-340028-6oicmeam	143	7	NR	NR	NNP
cord-340028-6oicmeam	143	8	supplementation	supplementation	NN
cord-340028-6oicmeam	143	9	reduces	reduce	VBZ
cord-340028-6oicmeam	143	10	the	the	DT
cord-340028-6oicmeam	143	11	levels	level	NNS
cord-340028-6oicmeam	143	12	of	of	IN
cord-340028-6oicmeam	143	13	circulating	circulate	VBG
cord-340028-6oicmeam	143	14	inflammatory	inflammatory	JJ
cord-340028-6oicmeam	143	15	cytokines	cytokine	NNS
cord-340028-6oicmeam	143	16	[	[	-LRB-
cord-340028-6oicmeam	143	17	98	98	CD
cord-340028-6oicmeam	143	18	]	]	-RRB-
cord-340028-6oicmeam	143	19	,	,	,
cord-340028-6oicmeam	143	20	while	while	IN
cord-340028-6oicmeam	143	21	Nicotinamide	Nicotinamide	NNP
cord-340028-6oicmeam	143	22	Mononucleotide	Mononucleotide	NNP
cord-340028-6oicmeam	143	23	(	(	-LRB-
cord-340028-6oicmeam	143	24	NMN	NMN	NNP
cord-340028-6oicmeam	143	25	)	)	-RRB-
cord-340028-6oicmeam	143	26	may	may	MD
cord-340028-6oicmeam	143	27	reduce	reduce	VB
cord-340028-6oicmeam	143	28	the	the	DT
cord-340028-6oicmeam	143	29	expression	expression	NN
cord-340028-6oicmeam	143	30	of	of	IN
cord-340028-6oicmeam	143	31	these	these	DT
cord-340028-6oicmeam	143	32	cytokines	cytokine	NNS
cord-340028-6oicmeam	143	33	[	[	-LRB-
cord-340028-6oicmeam	143	34	99	99	CD
cord-340028-6oicmeam	143	35	]	]	-RRB-
cord-340028-6oicmeam	143	36	.	.	.
cord-340028-6oicmeam	144	1	Other	other	JJ
cord-340028-6oicmeam	144	2	studies	study	NNS
cord-340028-6oicmeam	144	3	implicate	implicate	VBP
cord-340028-6oicmeam	144	4	NAD	NAD	NNP
cord-340028-6oicmeam	144	5	in	in	IN
cord-340028-6oicmeam	144	6	increased	increase	VBN
cord-340028-6oicmeam	144	7	cytokine	cytokine	NN
cord-340028-6oicmeam	144	8	production	production	NN
cord-340028-6oicmeam	144	9	[	[	-LRB-
cord-340028-6oicmeam	144	10	100	100	CD
cord-340028-6oicmeam	144	11	]	]	-RRB-
cord-340028-6oicmeam	144	12	and	and	CC
cord-340028-6oicmeam	144	13	the	the	DT
cord-340028-6oicmeam	144	14	NAD+consuming	nad+consume	VBG
cord-340028-6oicmeam	144	15	enzyme	enzyme	NN
cord-340028-6oicmeam	144	16	CD38	CD38	NNP
cord-340028-6oicmeam	144	17	in	in	IN
cord-340028-6oicmeam	144	18	increased	increase	VBN
cord-340028-6oicmeam	144	19	inflammation	inflammation	NN
cord-340028-6oicmeam	144	20	[	[	-LRB-
cord-340028-6oicmeam	144	21	101	101	CD
cord-340028-6oicmeam	144	22	]	]	-RRB-
cord-340028-6oicmeam	144	23	.	.	.
cord-340028-6oicmeam	145	1	Additional	additional	JJ
cord-340028-6oicmeam	145	2	immunological	immunological	JJ
cord-340028-6oicmeam	145	3	studies	study	NNS
cord-340028-6oicmeam	145	4	of	of	IN
cord-340028-6oicmeam	145	5	NAD	NAD	NNP
cord-340028-6oicmeam	145	6	boosters	booster	NNS
cord-340028-6oicmeam	145	7	must	must	MD
cord-340028-6oicmeam	145	8	be	be	VB
cord-340028-6oicmeam	145	9	performed	perform	VBN
cord-340028-6oicmeam	145	10	before	before	IN
cord-340028-6oicmeam	145	11	clinical	clinical	JJ
cord-340028-6oicmeam	145	12	trials	trial	NNS
cord-340028-6oicmeam	145	13	may	may	MD
cord-340028-6oicmeam	145	14	be	be	VB
cord-340028-6oicmeam	145	15	conducted	conduct	VBN
cord-340028-6oicmeam	145	16	.	.	.
cord-340028-6oicmeam	146	1	However	however	RB
cord-340028-6oicmeam	146	2	,	,	,
cord-340028-6oicmeam	146	3	considering	consider	VBG
cord-340028-6oicmeam	146	4	the	the	DT
cord-340028-6oicmeam	146	5	large	large	JJ
cord-340028-6oicmeam	146	6	consumer	consumer	NN
cord-340028-6oicmeam	146	7	base	base	NN
cord-340028-6oicmeam	146	8	of	of	IN
cord-340028-6oicmeam	146	9	NR	NR	NNP
cord-340028-6oicmeam	146	10	and	and	CC
cord-340028-6oicmeam	146	11	NMN	NMN	NNP
cord-340028-6oicmeam	146	12	supplements	supplement	NNS
cord-340028-6oicmeam	146	13	,	,	,
cord-340028-6oicmeam	146	14	it	-PRON-	PRP
cord-340028-6oicmeam	146	15	may	may	MD
cord-340028-6oicmeam	146	16	be	be	VB
cord-340028-6oicmeam	146	17	possible	possible	JJ
cord-340028-6oicmeam	146	18	to	to	TO
cord-340028-6oicmeam	146	19	conduct	conduct	VB
cord-340028-6oicmeam	146	20	metastudies	metastudie	NNS
cord-340028-6oicmeam	146	21	on	on	IN
cord-340028-6oicmeam	146	22	influenza	influenza	NN
cord-340028-6oicmeam	146	23	and	and	CC
cord-340028-6oicmeam	146	24	SARS	SARS	NNP
cord-340028-6oicmeam	146	25	-	-	HYPH
cord-340028-6oicmeam	146	26	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	146	27	infectivity	infectivity	NN
cord-340028-6oicmeam	146	28	,	,	,
cord-340028-6oicmeam	146	29	severity	severity	NN
cord-340028-6oicmeam	146	30	,	,	,
cord-340028-6oicmeam	146	31	and	and	CC
cord-340028-6oicmeam	146	32	lethality	lethality	NN
cord-340028-6oicmeam	146	33	.	.	.
cord-340028-6oicmeam	147	1	Senolytics	senolytic	NNS
cord-340028-6oicmeam	147	2	are	be	VBP
cord-340028-6oicmeam	147	3	drugs	drug	NNS
cord-340028-6oicmeam	147	4	that	that	WDT
cord-340028-6oicmeam	147	5	are	be	VBP
cord-340028-6oicmeam	147	6	postulated	postulate	VBN
cord-340028-6oicmeam	147	7	to	to	TO
cord-340028-6oicmeam	147	8	selectively	selectively	RB
cord-340028-6oicmeam	147	9	destroy	destroy	VB
cord-340028-6oicmeam	147	10	senescent	senescent	JJ
cord-340028-6oicmeam	147	11	cells	cell	NNS
cord-340028-6oicmeam	147	12	,	,	,
cord-340028-6oicmeam	147	13	which	which	WDT
cord-340028-6oicmeam	147	14	accumulate	accumulate	VBP
cord-340028-6oicmeam	147	15	with	with	IN
cord-340028-6oicmeam	147	16	aging	age	VBG
cord-340028-6oicmeam	147	17	and	and	CC
cord-340028-6oicmeam	147	18	exhibit	exhibit	NN
cord-340028-6oicmeam	147	19	senescence	senescence	NN
cord-340028-6oicmeam	147	20	-	-	HYPH
cord-340028-6oicmeam	147	21	associated	associate	VBN
cord-340028-6oicmeam	147	22	secretory	secretory	JJ
cord-340028-6oicmeam	147	23	phenotype	phenotype	NN
cord-340028-6oicmeam	147	24	(	(	-LRB-
cord-340028-6oicmeam	147	25	SASP	SASP	NNP
cord-340028-6oicmeam	147	26	)	)	-RRB-
cord-340028-6oicmeam	147	27	,	,	,
cord-340028-6oicmeam	147	28	through	through	IN
cord-340028-6oicmeam	147	29	senolysis	senolysis	NNP
cord-340028-6oicmeam	147	30	,	,	,
cord-340028-6oicmeam	147	31	apoptosis	apoptosis	NN
cord-340028-6oicmeam	147	32	,	,	,
cord-340028-6oicmeam	147	33	immunosurveillance	immunosurveillance	NN
cord-340028-6oicmeam	147	34	,	,	,
cord-340028-6oicmeam	147	35	or	or	CC
cord-340028-6oicmeam	147	36	other	other	JJ
cord-340028-6oicmeam	147	37	mechanisms	mechanism	NNS
cord-340028-6oicmeam	147	38	of	of	IN
cord-340028-6oicmeam	147	39	action	action	NN
cord-340028-6oicmeam	147	40	[	[	-LRB-
cord-340028-6oicmeam	147	41	102	102	CD
cord-340028-6oicmeam	147	42	]	]	-RRB-
cord-340028-6oicmeam	147	43	.	.	.
cord-340028-6oicmeam	148	1	SASP	SASP	NNP
cord-340028-6oicmeam	148	2	is	be	VBZ
cord-340028-6oicmeam	148	3	now	now	RB
cord-340028-6oicmeam	148	4	hypothesised	hypothesise	VBN
cord-340028-6oicmeam	148	5	to	to	TO
cord-340028-6oicmeam	148	6	lead	lead	VB
cord-340028-6oicmeam	148	7	to	to	IN
cord-340028-6oicmeam	148	8	NAD	NAD	NNP
cord-340028-6oicmeam	148	9	depletion	depletion	NN
cord-340028-6oicmeam	148	10	and	and	CC
cord-340028-6oicmeam	148	11	thus	thus	RB
cord-340028-6oicmeam	148	12	initiate	initiate	VB
cord-340028-6oicmeam	148	13	or	or	CC
cord-340028-6oicmeam	148	14	perpetuate	perpetuate	VB
cord-340028-6oicmeam	148	15	an	an	DT
cord-340028-6oicmeam	148	16	increase	increase	NN
cord-340028-6oicmeam	148	17	in	in	IN
cord-340028-6oicmeam	148	18	sterile	sterile	JJ
cord-340028-6oicmeam	148	19	chronic	chronic	JJ
cord-340028-6oicmeam	148	20	inflammation	inflammation	NN
cord-340028-6oicmeam	148	21	.	.	.
cord-340028-6oicmeam	149	1	Many	many	JJ
cord-340028-6oicmeam	149	2	drug	drug	NN
cord-340028-6oicmeam	149	3	classes	class	NNS
cord-340028-6oicmeam	149	4	,	,	,
cord-340028-6oicmeam	149	5	ranging	range	VBG
cord-340028-6oicmeam	149	6	from	from	IN
cord-340028-6oicmeam	149	7	fibrates	fibrate	NNS
cord-340028-6oicmeam	149	8	to	to	IN
cord-340028-6oicmeam	149	9	cardiac	cardiac	JJ
cord-340028-6oicmeam	149	10	glycosides	glycoside	NNS
cord-340028-6oicmeam	149	11	,	,	,
cord-340028-6oicmeam	149	12	have	have	VBP
cord-340028-6oicmeam	149	13	been	be	VBN
cord-340028-6oicmeam	149	14	reported	report	VBN
cord-340028-6oicmeam	149	15	to	to	TO
cord-340028-6oicmeam	149	16	have	have	VB
cord-340028-6oicmeam	149	17	senolytic	senolytic	JJ
cord-340028-6oicmeam	149	18	properties	property	NNS
cord-340028-6oicmeam	149	19	in	in	IN
cord-340028-6oicmeam	149	20	animal	animal	NN
cord-340028-6oicmeam	149	21	models	model	NNS
cord-340028-6oicmeam	149	22	[	[	-LRB-
cord-340028-6oicmeam	149	23	103	103	CD
cord-340028-6oicmeam	149	24	]	]	-RRB-
cord-340028-6oicmeam	149	25	.	.	.
cord-340028-6oicmeam	150	1	However	however	RB
cord-340028-6oicmeam	150	2	,	,	,
cord-340028-6oicmeam	150	3	recent	recent	JJ
cord-340028-6oicmeam	150	4	promising	promising	JJ
cord-340028-6oicmeam	150	5	human	human	JJ
cord-340028-6oicmeam	150	6	data	datum	NNS
cord-340028-6oicmeam	150	7	have	have	VBP
cord-340028-6oicmeam	150	8	been	be	VBN
cord-340028-6oicmeam	150	9	reported	report	VBN
cord-340028-6oicmeam	150	10	with	with	IN
cord-340028-6oicmeam	150	11	the	the	DT
cord-340028-6oicmeam	150	12	tyrosine	tyrosine	NN
cord-340028-6oicmeam	150	13	kinase	kinase	NN
cord-340028-6oicmeam	150	14	inhibitor	inhibitor	NN
cord-340028-6oicmeam	150	15	dasatinib	dasatinib	NN
cord-340028-6oicmeam	150	16	in	in	IN
cord-340028-6oicmeam	150	17	combination	combination	NN
cord-340028-6oicmeam	150	18	with	with	IN
cord-340028-6oicmeam	150	19	the	the	DT
cord-340028-6oicmeam	150	20	plant	plant	NN
cord-340028-6oicmeam	150	21	flavonol	flavonol	NN
cord-340028-6oicmeam	150	22	quercetin	quercetin	NN
cord-340028-6oicmeam	150	23	in	in	IN
cord-340028-6oicmeam	150	24	a	a	DT
cord-340028-6oicmeam	150	25	trial	trial	NN
cord-340028-6oicmeam	150	26	by	by	IN
cord-340028-6oicmeam	150	27	the	the	DT
cord-340028-6oicmeam	150	28	Mayo	Mayo	NNP
cord-340028-6oicmeam	150	29	Clinic	Clinic	NNP
cord-340028-6oicmeam	150	30	[	[	-LRB-
cord-340028-6oicmeam	150	31	104	104	CD
cord-340028-6oicmeam	150	32	]	]	-RRB-
cord-340028-6oicmeam	150	33	;	;	:
cord-340028-6oicmeam	150	34	flavonoid	flavonoid	NN
cord-340028-6oicmeam	150	35	polyphenols	polyphenol	NNS
cord-340028-6oicmeam	150	36	have	have	VBP
cord-340028-6oicmeam	150	37	also	also	RB
cord-340028-6oicmeam	150	38	proven	prove	VBN
cord-340028-6oicmeam	150	39	beneficial	beneficial	JJ
cord-340028-6oicmeam	150	40	.	.	.
cord-340028-6oicmeam	151	1	In	in	IN
cord-340028-6oicmeam	151	2	addition	addition	NN
cord-340028-6oicmeam	151	3	,	,	,
cord-340028-6oicmeam	151	4	pre	pre	JJ
cord-340028-6oicmeam	151	5	-	-	JJ
cord-340028-6oicmeam	151	6	clinical	clinical	JJ
cord-340028-6oicmeam	151	7	and	and	CC
cord-340028-6oicmeam	151	8	clinical	clinical	JJ
cord-340028-6oicmeam	151	9	data	datum	NNS
cord-340028-6oicmeam	151	10	suggest	suggest	VBP
cord-340028-6oicmeam	151	11	that	that	IN
cord-340028-6oicmeam	151	12	flavonoids	flavonoid	NNS
cord-340028-6oicmeam	151	13	may	may	MD
cord-340028-6oicmeam	151	14	be	be	VB
cord-340028-6oicmeam	151	15	used	use	VBN
cord-340028-6oicmeam	151	16	for	for	IN
cord-340028-6oicmeam	151	17	prophylaxis	prophylaxis	NN
cord-340028-6oicmeam	151	18	in	in	IN
cord-340028-6oicmeam	151	19	upper	upper	JJ
cord-340028-6oicmeam	151	20	respiratory	respiratory	JJ
cord-340028-6oicmeam	151	21	tract	tract	NN
cord-340028-6oicmeam	151	22	infections	infection	NNS
cord-340028-6oicmeam	151	23	[	[	-LRB-
cord-340028-6oicmeam	151	24	105	105	CD
cord-340028-6oicmeam	151	25	]	]	-RRB-
cord-340028-6oicmeam	151	26	.	.	.
cord-340028-6oicmeam	152	1	Although	although	IN
cord-340028-6oicmeam	152	2	senolytic	senolytic	JJ
cord-340028-6oicmeam	152	3	drugs	drug	NNS
cord-340028-6oicmeam	152	4	would	would	MD
cord-340028-6oicmeam	152	5	have	have	VB
cord-340028-6oicmeam	152	6	a	a	DT
cord-340028-6oicmeam	152	7	scientifically	scientifically	RB
cord-340028-6oicmeam	152	8	plausible	plausible	JJ
cord-340028-6oicmeam	152	9	role	role	NN
cord-340028-6oicmeam	152	10	in	in	IN
cord-340028-6oicmeam	152	11	biological	biological	JJ
cord-340028-6oicmeam	152	12	age	age	NN
cord-340028-6oicmeam	152	13	reversal	reversal	NN
cord-340028-6oicmeam	152	14	and	and	CC
cord-340028-6oicmeam	152	15	thus	thus	RB
cord-340028-6oicmeam	152	16	reduction	reduction	NN
cord-340028-6oicmeam	152	17	of	of	IN
cord-340028-6oicmeam	152	18	mortality	mortality	NN
cord-340028-6oicmeam	152	19	from	from	IN
cord-340028-6oicmeam	152	20	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	152	21	viruses	virus	NNS
cord-340028-6oicmeam	152	22	like	like	IN
cord-340028-6oicmeam	152	23	SARS	SARS	NNP
cord-340028-6oicmeam	152	24	-	-	HYPH
cord-340028-6oicmeam	152	25	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	152	26	,	,	,
cord-340028-6oicmeam	152	27	it	-PRON-	PRP
cord-340028-6oicmeam	152	28	has	have	VBZ
cord-340028-6oicmeam	152	29	not	not	RB
cord-340028-6oicmeam	152	30	been	be	VBN
cord-340028-6oicmeam	152	31	shown	show	VBN
cord-340028-6oicmeam	152	32	that	that	IN
cord-340028-6oicmeam	152	33	these	these	DT
cord-340028-6oicmeam	152	34	classes	class	NNS
cord-340028-6oicmeam	152	35	of	of	IN
cord-340028-6oicmeam	152	36	drugs	drug	NNS
cord-340028-6oicmeam	152	37	would	would	MD
cord-340028-6oicmeam	152	38	protect	protect	VB
cord-340028-6oicmeam	152	39	against	against	IN
cord-340028-6oicmeam	152	40	infection	infection	NN
cord-340028-6oicmeam	152	41	or	or	CC
cord-340028-6oicmeam	152	42	could	could	MD
cord-340028-6oicmeam	152	43	be	be	VB
cord-340028-6oicmeam	152	44	used	use	VBN
cord-340028-6oicmeam	152	45	as	as	IN
cord-340028-6oicmeam	152	46	adjuncts	adjunct	NNS
cord-340028-6oicmeam	152	47	to	to	IN
cord-340028-6oicmeam	152	48	vaccination	vaccination	NN
cord-340028-6oicmeam	152	49	.	.	.
cord-340028-6oicmeam	153	1	In	in	IN
cord-340028-6oicmeam	153	2	addition	addition	NN
cord-340028-6oicmeam	153	3	,	,	,
cord-340028-6oicmeam	153	4	there	there	EX
cord-340028-6oicmeam	153	5	remains	remain	VBZ
cord-340028-6oicmeam	153	6	the	the	DT
cord-340028-6oicmeam	153	7	risk	risk	NN
cord-340028-6oicmeam	153	8	that	that	IN
cord-340028-6oicmeam	153	9	senolytics	senolytic	NNS
cord-340028-6oicmeam	153	10	would	would	MD
cord-340028-6oicmeam	153	11	not	not	RB
cord-340028-6oicmeam	153	12	be	be	VB
cord-340028-6oicmeam	153	13	sufficiently	sufficiently	RB
cord-340028-6oicmeam	153	14	specific	specific	JJ
cord-340028-6oicmeam	153	15	to	to	TO
cord-340028-6oicmeam	153	16	discriminate	discriminate	VB
cord-340028-6oicmeam	153	17	between	between	IN
cord-340028-6oicmeam	153	18	deleterious	deleterious	JJ
cord-340028-6oicmeam	153	19	senescent	senescent	JJ
cord-340028-6oicmeam	153	20	cells	cell	NNS
cord-340028-6oicmeam	153	21	and	and	CC
cord-340028-6oicmeam	153	22	quiescent	quiescent	JJ
cord-340028-6oicmeam	153	23	(	(	-LRB-
cord-340028-6oicmeam	153	24	dormant	dormant	JJ
cord-340028-6oicmeam	153	25	)	)	-RRB-
cord-340028-6oicmeam	153	26	cells	cell	NNS
cord-340028-6oicmeam	153	27	,	,	,
cord-340028-6oicmeam	153	28	which	which	WDT
cord-340028-6oicmeam	153	29	might	may	MD
cord-340028-6oicmeam	153	30	still	still	RB
cord-340028-6oicmeam	153	31	differentiate	differentiate	VB
cord-340028-6oicmeam	153	32	into	into	IN
cord-340028-6oicmeam	153	33	the	the	DT
cord-340028-6oicmeam	153	34	mature	mature	JJ
cord-340028-6oicmeam	153	35	cell	cell	NN
cord-340028-6oicmeam	153	36	types	type	NNS
cord-340028-6oicmeam	153	37	of	of	IN
cord-340028-6oicmeam	153	38	a	a	DT
cord-340028-6oicmeam	153	39	given	give	VBN
cord-340028-6oicmeam	153	40	tissue	tissue	NN
cord-340028-6oicmeam	153	41	,	,	,
cord-340028-6oicmeam	153	42	and	and	CC
cord-340028-6oicmeam	153	43	could	could	MD
cord-340028-6oicmeam	153	44	thus	thus	RB
cord-340028-6oicmeam	153	45	deplete	deplete	VB
cord-340028-6oicmeam	153	46	beneficial	beneficial	JJ
cord-340028-6oicmeam	153	47	protective	protective	JJ
cord-340028-6oicmeam	153	48	stem	stem	NN
cord-340028-6oicmeam	153	49	cell	cell	NN
cord-340028-6oicmeam	153	50	reserves	reserve	NNS
cord-340028-6oicmeam	153	51	.	.	.
cord-340028-6oicmeam	154	1	It	-PRON-	PRP
cord-340028-6oicmeam	154	2	has	have	VBZ
cord-340028-6oicmeam	154	3	been	be	VBN
cord-340028-6oicmeam	154	4	shown	show	VBN
cord-340028-6oicmeam	154	5	in	in	IN
cord-340028-6oicmeam	154	6	multiple	multiple	JJ
cord-340028-6oicmeam	154	7	studies	study	NNS
cord-340028-6oicmeam	154	8	that	that	WDT
cord-340028-6oicmeam	154	9	calorie	calorie	NN
cord-340028-6oicmeam	154	10	restriction	restriction	NN
cord-340028-6oicmeam	154	11	leads	lead	VBZ
cord-340028-6oicmeam	154	12	to	to	IN
cord-340028-6oicmeam	154	13	increased	increase	VBN
cord-340028-6oicmeam	154	14	lifespan	lifespan	NN
cord-340028-6oicmeam	154	15	and	and	CC
cord-340028-6oicmeam	154	16	improved	improve	VBN
cord-340028-6oicmeam	154	17	cardiometabolic	cardiometabolic	JJ
cord-340028-6oicmeam	154	18	markers	marker	NNS
cord-340028-6oicmeam	154	19	,	,	,
cord-340028-6oicmeam	154	20	even	even	RB
cord-340028-6oicmeam	154	21	when	when	WRB
cord-340028-6oicmeam	154	22	initiated	initiate	VBN
cord-340028-6oicmeam	154	23	in	in	IN
cord-340028-6oicmeam	154	24	middle	middle	JJ
cord-340028-6oicmeam	154	25	age	age	NN
cord-340028-6oicmeam	154	26	[	[	-LRB-
cord-340028-6oicmeam	154	27	106	106	CD
cord-340028-6oicmeam	154	28	]	]	-RRB-
cord-340028-6oicmeam	154	29	.	.	.
cord-340028-6oicmeam	155	1	Caloric	caloric	JJ
cord-340028-6oicmeam	155	2	restriction	restriction	NN
cord-340028-6oicmeam	155	3	should	should	MD
cord-340028-6oicmeam	155	4	be	be	VB
cord-340028-6oicmeam	155	5	considered	consider	VBN
cord-340028-6oicmeam	155	6	as	as	IN
cord-340028-6oicmeam	155	7	a	a	DT
cord-340028-6oicmeam	155	8	preventive	preventive	JJ
cord-340028-6oicmeam	155	9	measure	measure	NN
cord-340028-6oicmeam	155	10	on	on	IN
cord-340028-6oicmeam	155	11	a	a	DT
cord-340028-6oicmeam	155	12	long	long	JJ
cord-340028-6oicmeam	155	13	-	-	HYPH
cord-340028-6oicmeam	155	14	term	term	NN
cord-340028-6oicmeam	155	15	basis	basis	NN
cord-340028-6oicmeam	155	16	and	and	CC
cord-340028-6oicmeam	155	17	is	be	VBZ
cord-340028-6oicmeam	155	18	indicated	indicate	VBN
cord-340028-6oicmeam	155	19	for	for	IN
cord-340028-6oicmeam	155	20	younger	young	JJR
cord-340028-6oicmeam	155	21	individuals	individual	NNS
cord-340028-6oicmeam	155	22	.	.	.
cord-340028-6oicmeam	156	1	Some	some	DT
cord-340028-6oicmeam	156	2	elderly	elderly	JJ
cord-340028-6oicmeam	156	3	patients	patient	NNS
cord-340028-6oicmeam	156	4	already	already	RB
cord-340028-6oicmeam	156	5	have	have	VBP
cord-340028-6oicmeam	156	6	frailty	frailty	NN
cord-340028-6oicmeam	156	7	syndromes	syndrome	NNS
cord-340028-6oicmeam	156	8	and	and	CC
cord-340028-6oicmeam	156	9	evident	evident	JJ
cord-340028-6oicmeam	156	10	sarcopenia/	sarcopenia/	CD
cord-340028-6oicmeam	156	11	osteopenia	osteopenia	NN
cord-340028-6oicmeam	156	12	,	,	,
cord-340028-6oicmeam	156	13	which	which	WDT
cord-340028-6oicmeam	156	14	limits	limit	VBZ
cord-340028-6oicmeam	156	15	the	the	DT
cord-340028-6oicmeam	156	16	suitability	suitability	NN
cord-340028-6oicmeam	156	17	of	of	IN
cord-340028-6oicmeam	156	18	intermittent	intermittent	JJ
cord-340028-6oicmeam	156	19	caloric	caloric	JJ
cord-340028-6oicmeam	156	20	restriction	restriction	NN
cord-340028-6oicmeam	156	21	.	.	.
cord-340028-6oicmeam	157	1	Nevertheless	nevertheless	RB
cord-340028-6oicmeam	157	2	,	,	,
cord-340028-6oicmeam	157	3	the	the	DT
cord-340028-6oicmeam	157	4	AGING	age	VBG
cord-340028-6oicmeam	157	5	benefits	benefit	NNS
cord-340028-6oicmeam	157	6	of	of	IN
cord-340028-6oicmeam	157	7	time	time	NN
cord-340028-6oicmeam	157	8	-	-	HYPH
cord-340028-6oicmeam	157	9	restricted	restrict	VBN
cord-340028-6oicmeam	157	10	feeding	feeding	NN
cord-340028-6oicmeam	157	11	and	and	CC
cord-340028-6oicmeam	157	12	intermittent	intermittent	JJ
cord-340028-6oicmeam	157	13	fasting	fasting	NN
cord-340028-6oicmeam	157	14	go	go	VBP
cord-340028-6oicmeam	157	15	beyond	beyond	IN
cord-340028-6oicmeam	157	16	simple	simple	JJ
cord-340028-6oicmeam	157	17	caloric	caloric	JJ
cord-340028-6oicmeam	157	18	restriction	restriction	NN
cord-340028-6oicmeam	157	19	due	due	IN
cord-340028-6oicmeam	157	20	to	to	IN
cord-340028-6oicmeam	157	21	the	the	DT
cord-340028-6oicmeam	157	22	production	production	NN
cord-340028-6oicmeam	157	23	of	of	IN
cord-340028-6oicmeam	157	24	ketones	ketone	NNS
cord-340028-6oicmeam	157	25	.	.	.
cord-340028-6oicmeam	158	1	Ketones	ketone	NNS
cord-340028-6oicmeam	158	2	are	be	VBP
cord-340028-6oicmeam	158	3	active	active	JJ
cord-340028-6oicmeam	158	4	signaling	signal	VBG
cord-340028-6oicmeam	158	5	molecules	molecule	NNS
cord-340028-6oicmeam	158	6	that	that	WDT
cord-340028-6oicmeam	158	7	play	play	VBP
cord-340028-6oicmeam	158	8	a	a	DT
cord-340028-6oicmeam	158	9	major	major	JJ
cord-340028-6oicmeam	158	10	role	role	NN
cord-340028-6oicmeam	158	11	in	in	IN
cord-340028-6oicmeam	158	12	the	the	DT
cord-340028-6oicmeam	158	13	PPAR	PPAR	NNP
cord-340028-6oicmeam	158	14	,	,	,
cord-340028-6oicmeam	158	15	sirtuin	sirtuin	NNP
cord-340028-6oicmeam	158	16	,	,	,
cord-340028-6oicmeam	158	17	NAD	NAD	NNP
cord-340028-6oicmeam	158	18	and	and	CC
cord-340028-6oicmeam	158	19	CD38	CD38	NNP
cord-340028-6oicmeam	158	20	pathways	pathway	NNS
cord-340028-6oicmeam	158	21	,	,	,
cord-340028-6oicmeam	158	22	encourage	encourage	VB
cord-340028-6oicmeam	158	23	autophagy	autophagy	NN
cord-340028-6oicmeam	158	24	(	(	-LRB-
cord-340028-6oicmeam	158	25	the	the	DT
cord-340028-6oicmeam	158	26	removal	removal	NN
cord-340028-6oicmeam	158	27	of	of	IN
cord-340028-6oicmeam	158	28	damaged	damaged	JJ
cord-340028-6oicmeam	158	29	cellular	cellular	JJ
cord-340028-6oicmeam	158	30	materials	material	NNS
cord-340028-6oicmeam	158	31	)	)	-RRB-
cord-340028-6oicmeam	158	32	,	,	,
cord-340028-6oicmeam	158	33	modulate	modulate	VB
cord-340028-6oicmeam	158	34	the	the	DT
cord-340028-6oicmeam	158	35	immune	immune	JJ
cord-340028-6oicmeam	158	36	response	response	NN
cord-340028-6oicmeam	158	37	,	,	,
cord-340028-6oicmeam	158	38	and	and	CC
cord-340028-6oicmeam	158	39	have	have	VBP
cord-340028-6oicmeam	158	40	been	be	VBN
cord-340028-6oicmeam	158	41	explored	explore	VBN
cord-340028-6oicmeam	158	42	in	in	IN
cord-340028-6oicmeam	158	43	clinical	clinical	JJ
cord-340028-6oicmeam	158	44	trials	trial	NNS
cord-340028-6oicmeam	158	45	as	as	IN
cord-340028-6oicmeam	158	46	an	an	DT
cord-340028-6oicmeam	158	47	adjuvant	adjuvant	NN
cord-340028-6oicmeam	158	48	therapy	therapy	NN
cord-340028-6oicmeam	158	49	for	for	IN
cord-340028-6oicmeam	158	50	cancer	cancer	NN
cord-340028-6oicmeam	158	51	treatments	treatment	NNS
cord-340028-6oicmeam	158	52	[	[	-LRB-
cord-340028-6oicmeam	158	53	107	107	CD
cord-340028-6oicmeam	158	54	]	]	-RRB-
cord-340028-6oicmeam	158	55	.	.	.
cord-340028-6oicmeam	159	1	Within	within	IN
cord-340028-6oicmeam	159	2	8	8	CD
cord-340028-6oicmeam	159	3	-	-	SYM
cord-340028-6oicmeam	159	4	12	12	CD
cord-340028-6oicmeam	159	5	hours	hour	NNS
cord-340028-6oicmeam	159	6	of	of	IN
cord-340028-6oicmeam	159	7	food	food	NN
cord-340028-6oicmeam	159	8	restriction	restriction	NN
cord-340028-6oicmeam	159	9	,	,	,
cord-340028-6oicmeam	159	10	ketones	ketone	NNS
cord-340028-6oicmeam	159	11	are	be	VBP
cord-340028-6oicmeam	159	12	believed	believe	VBN
cord-340028-6oicmeam	159	13	to	to	TO
cord-340028-6oicmeam	159	14	rise	rise	VB
cord-340028-6oicmeam	159	15	to	to	IN
cord-340028-6oicmeam	159	16	0.2	0.2	CD
cord-340028-6oicmeam	159	17	to	to	IN
cord-340028-6oicmeam	159	18	0.5mM	0.5mm	CD
cord-340028-6oicmeam	159	19	and	and	CC
cord-340028-6oicmeam	159	20	continue	continue	VB
cord-340028-6oicmeam	159	21	to	to	TO
cord-340028-6oicmeam	159	22	increase	increase	VB
cord-340028-6oicmeam	159	23	within	within	IN
cord-340028-6oicmeam	159	24	the	the	DT
cord-340028-6oicmeam	159	25	first	first	JJ
cord-340028-6oicmeam	159	26	48	48	CD
cord-340028-6oicmeam	159	27	hours	hour	NNS
cord-340028-6oicmeam	159	28	to	to	IN
cord-340028-6oicmeam	159	29	1	1	CD
cord-340028-6oicmeam	159	30	to	to	IN
cord-340028-6oicmeam	159	31	2mM	2mm	CD
cord-340028-6oicmeam	159	32	[	[	-LRB-
cord-340028-6oicmeam	159	33	108	108	CD
cord-340028-6oicmeam	159	34	]	]	-RRB-
cord-340028-6oicmeam	159	35	.	.	.
cord-340028-6oicmeam	160	1	Under	under	IN
cord-340028-6oicmeam	160	2	fasting	fast	VBG
cord-340028-6oicmeam	160	3	conditions	condition	NNS
cord-340028-6oicmeam	160	4	the	the	DT
cord-340028-6oicmeam	160	5	major	major	JJ
cord-340028-6oicmeam	160	6	body	body	NN
cord-340028-6oicmeam	160	7	ketone	ketone	NN
cord-340028-6oicmeam	160	8	in	in	IN
cord-340028-6oicmeam	160	9	the	the	DT
cord-340028-6oicmeam	160	10	plasma	plasma	NN
cord-340028-6oicmeam	160	11	,	,	,
cord-340028-6oicmeam	160	12	beta	beta	NN
cord-340028-6oicmeam	160	13	-	-	HYPH
cord-340028-6oicmeam	160	14	hydroxybutyrate	hydroxybutyrate	NN
cord-340028-6oicmeam	160	15	(	(	-LRB-
cord-340028-6oicmeam	160	16	BHB	BHB	NNP
cord-340028-6oicmeam	160	17	)	)	-RRB-
cord-340028-6oicmeam	160	18	,	,	,
cord-340028-6oicmeam	160	19	increases	increase	NNS
cord-340028-6oicmeam	160	20	.	.	.
cord-340028-6oicmeam	161	1	BHB	BHB	NNP
cord-340028-6oicmeam	161	2	is	be	VBZ
cord-340028-6oicmeam	161	3	believed	believe	VBN
cord-340028-6oicmeam	161	4	to	to	TO
cord-340028-6oicmeam	161	5	confer	confer	VB
cord-340028-6oicmeam	161	6	the	the	DT
cord-340028-6oicmeam	161	7	major	major	JJ
cord-340028-6oicmeam	161	8	metabolic	metabolic	JJ
cord-340028-6oicmeam	161	9	benefit	benefit	NN
cord-340028-6oicmeam	161	10	of	of	IN
cord-340028-6oicmeam	161	11	fasting	fasting	NN
cord-340028-6oicmeam	161	12	and	and	CC
cord-340028-6oicmeam	161	13	is	be	VBZ
cord-340028-6oicmeam	161	14	in	in	IN
cord-340028-6oicmeam	161	15	development	development	NN
cord-340028-6oicmeam	161	16	as	as	IN
cord-340028-6oicmeam	161	17	an	an	DT
cord-340028-6oicmeam	161	18	independent	independent	JJ
cord-340028-6oicmeam	161	19	therapeutic	therapeutic	JJ
cord-340028-6oicmeam	161	20	supplement	supplement	NN
cord-340028-6oicmeam	161	21	.	.	.
cord-340028-6oicmeam	162	1	An	an	DT
cord-340028-6oicmeam	162	2	age	age	NN
cord-340028-6oicmeam	162	3	-	-	HYPH
cord-340028-6oicmeam	162	4	related	relate	VBN
cord-340028-6oicmeam	162	5	decrease	decrease	NN
cord-340028-6oicmeam	162	6	of	of	IN
cord-340028-6oicmeam	162	7	thymic	thymic	JJ
cord-340028-6oicmeam	162	8	function	function	NN
cord-340028-6oicmeam	162	9	consequently	consequently	RB
cord-340028-6oicmeam	162	10	reduces	reduce	VBZ
cord-340028-6oicmeam	162	11	the	the	DT
cord-340028-6oicmeam	162	12	levels	level	NNS
cord-340028-6oicmeam	162	13	of	of	IN
cord-340028-6oicmeam	162	14	specific	specific	JJ
cord-340028-6oicmeam	162	15	T	t	NN
cord-340028-6oicmeam	162	16	cell	cell	NN
cord-340028-6oicmeam	162	17	subsets	subset	NNS
cord-340028-6oicmeam	162	18	[	[	-LRB-
cord-340028-6oicmeam	162	19	109	109	CD
cord-340028-6oicmeam	162	20	]	]	-RRB-
cord-340028-6oicmeam	162	21	.	.	.
cord-340028-6oicmeam	163	1	FOXP3	FOXP3	NNS
cord-340028-6oicmeam	163	2	+	+	CC
cord-340028-6oicmeam	164	1	regulatory	regulatory	JJ
cord-340028-6oicmeam	164	2	T	T	NNP
cord-340028-6oicmeam	164	3	(	(	-LRB-
cord-340028-6oicmeam	164	4	Treg	Treg	NNP
cord-340028-6oicmeam	164	5	)	)	-RRB-
cord-340028-6oicmeam	164	6	cells	cell	NNS
cord-340028-6oicmeam	164	7	are	be	VBP
cord-340028-6oicmeam	164	8	critical	critical	JJ
cord-340028-6oicmeam	164	9	in	in	IN
cord-340028-6oicmeam	164	10	homeostasis	homeostasis	NN
cord-340028-6oicmeam	164	11	of	of	IN
cord-340028-6oicmeam	164	12	the	the	DT
cord-340028-6oicmeam	164	13	immune	immune	JJ
cord-340028-6oicmeam	164	14	system	system	NN
cord-340028-6oicmeam	164	15	and	and	CC
cord-340028-6oicmeam	164	16	are	be	VBP
cord-340028-6oicmeam	164	17	believed	believe	VBN
cord-340028-6oicmeam	164	18	to	to	TO
cord-340028-6oicmeam	164	19	start	start	VB
cord-340028-6oicmeam	164	20	declining	decline	VBG
cord-340028-6oicmeam	164	21	in	in	IN
cord-340028-6oicmeam	164	22	numbers	number	NNS
cord-340028-6oicmeam	164	23	at	at	IN
cord-340028-6oicmeam	164	24	around	around	RB
cord-340028-6oicmeam	164	25	50	50	CD
cord-340028-6oicmeam	164	26	-	-	SYM
cord-340028-6oicmeam	164	27	60	60	CD
cord-340028-6oicmeam	164	28	years	year	NNS
cord-340028-6oicmeam	164	29	of	of	IN
cord-340028-6oicmeam	164	30	age	age	NN
cord-340028-6oicmeam	164	31	;	;	:
cord-340028-6oicmeam	164	32	this	this	DT
cord-340028-6oicmeam	164	33	remains	remain	VBZ
cord-340028-6oicmeam	164	34	one	one	CD
cord-340028-6oicmeam	164	35	of	of	IN
cord-340028-6oicmeam	164	36	the	the	DT
cord-340028-6oicmeam	164	37	fundamental	fundamental	JJ
cord-340028-6oicmeam	164	38	drivers	driver	NNS
cord-340028-6oicmeam	164	39	of	of	IN
cord-340028-6oicmeam	164	40	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	164	41	.	.	.
cord-340028-6oicmeam	165	1	There	there	EX
cord-340028-6oicmeam	165	2	are	be	VBP
cord-340028-6oicmeam	165	3	two	two	CD
cord-340028-6oicmeam	165	4	known	know	VBN
cord-340028-6oicmeam	165	5	origins	origin	NNS
cord-340028-6oicmeam	165	6	for	for	IN
cord-340028-6oicmeam	165	7	Treg	Treg	NNP
cord-340028-6oicmeam	165	8	cells	cell	NNS
cord-340028-6oicmeam	165	9	:	:	:
cord-340028-6oicmeam	165	10	thymus	thymus	NN
cord-340028-6oicmeam	165	11	-	-	HYPH
cord-340028-6oicmeam	165	12	derived	derive	VBN
cord-340028-6oicmeam	165	13	Treg	Treg	NNP
cord-340028-6oicmeam	165	14	cells	cell	NNS
cord-340028-6oicmeam	165	15	and	and	CC
cord-340028-6oicmeam	165	16	peripherally	peripherally	RB
cord-340028-6oicmeam	165	17	-	-	HYPH
cord-340028-6oicmeam	165	18	derived	derive	VBN
cord-340028-6oicmeam	165	19	Treg	Treg	NNP
cord-340028-6oicmeam	165	20	(	(	-LRB-
cord-340028-6oicmeam	165	21	pTreg	pTreg	NNP
cord-340028-6oicmeam	165	22	)	)	-RRB-
cord-340028-6oicmeam	165	23	cells	cell	NNS
cord-340028-6oicmeam	165	24	.	.	.
cord-340028-6oicmeam	166	1	Thus	thus	RB
cord-340028-6oicmeam	166	2	,	,	,
cord-340028-6oicmeam	166	3	inducing	induce	VBG
cord-340028-6oicmeam	166	4	a	a	DT
cord-340028-6oicmeam	166	5	peripheral	peripheral	JJ
cord-340028-6oicmeam	166	6	Treg	Treg	NNP
cord-340028-6oicmeam	166	7	response	response	NN
cord-340028-6oicmeam	166	8	in	in	IN
cord-340028-6oicmeam	166	9	older	old	JJR
cord-340028-6oicmeam	166	10	individuals	individual	NNS
cord-340028-6oicmeam	166	11	might	may	MD
cord-340028-6oicmeam	166	12	be	be	VB
cord-340028-6oicmeam	166	13	a	a	DT
cord-340028-6oicmeam	166	14	feasible	feasible	JJ
cord-340028-6oicmeam	166	15	strategy	strategy	NN
cord-340028-6oicmeam	166	16	for	for	IN
cord-340028-6oicmeam	166	17	increasing	increase	VBG
cord-340028-6oicmeam	166	18	Treg	Treg	NNP
cord-340028-6oicmeam	166	19	cell	cell	NN
cord-340028-6oicmeam	166	20	levels	level	NNS
cord-340028-6oicmeam	166	21	until	until	IN
cord-340028-6oicmeam	166	22	we	-PRON-	PRP
cord-340028-6oicmeam	166	23	have	have	VBP
cord-340028-6oicmeam	166	24	more	more	RBR
cord-340028-6oicmeam	166	25	plausible	plausible	JJ
cord-340028-6oicmeam	166	26	options	option	NNS
cord-340028-6oicmeam	166	27	for	for	IN
cord-340028-6oicmeam	166	28	thymic	thymic	JJ
cord-340028-6oicmeam	166	29	rejuvenation	rejuvenation	NN
cord-340028-6oicmeam	166	30	.	.	.
cord-340028-6oicmeam	167	1	FOXP3	foxp3	NN
cord-340028-6oicmeam	167	2	transcription	transcription	NN
cord-340028-6oicmeam	167	3	factor	factor	NN
cord-340028-6oicmeam	167	4	(	(	-LRB-
cord-340028-6oicmeam	167	5	TF	TF	NNP
cord-340028-6oicmeam	167	6	)	)	-RRB-
cord-340028-6oicmeam	167	7	is	be	VBZ
cord-340028-6oicmeam	167	8	the	the	DT
cord-340028-6oicmeam	167	9	most	most	RBS
cord-340028-6oicmeam	167	10	important	important	JJ
cord-340028-6oicmeam	167	11	regulator	regulator	NN
cord-340028-6oicmeam	167	12	of	of	IN
cord-340028-6oicmeam	167	13	Tregs	Tregs	NNP
cord-340028-6oicmeam	167	14	and	and	CC
cord-340028-6oicmeam	167	15	ageassociated	ageassociate	VBD
cord-340028-6oicmeam	167	16	immunosenescence	immunosenescence	RB
cord-340028-6oicmeam	167	17	.	.	.
cord-340028-6oicmeam	168	1	FOXP3	FOXP3	NNP
cord-340028-6oicmeam	169	1	TF	TF	NNP
cord-340028-6oicmeam	169	2	expression	expression	NN
cord-340028-6oicmeam	169	3	is	be	VBZ
cord-340028-6oicmeam	169	4	regulated	regulate	VBN
cord-340028-6oicmeam	169	5	by	by	IN
cord-340028-6oicmeam	169	6	chemical	chemical	JJ
cord-340028-6oicmeam	169	7	modification	modification	NN
cord-340028-6oicmeam	169	8	by	by	IN
cord-340028-6oicmeam	169	9	sirtuin	sirtuin	NNP
cord-340028-6oicmeam	169	10	(	(	-LRB-
cord-340028-6oicmeam	169	11	sirt	sirt	NNP
cord-340028-6oicmeam	169	12	)	)	-RRB-
cord-340028-6oicmeam	169	13	and	and	CC
cord-340028-6oicmeam	169	14	histone	histone	NNP
cord-340028-6oicmeam	169	15	deacetylases	deacetylase	NNS
cord-340028-6oicmeam	169	16	,	,	,
cord-340028-6oicmeam	169	17	in	in	IN
cord-340028-6oicmeam	169	18	particular	particular	JJ
cord-340028-6oicmeam	169	19	Sirt1	Sirt1	NNS
cord-340028-6oicmeam	170	1	and	and	CC
cord-340028-6oicmeam	170	2	HDAC9	hdac9	XX
cord-340028-6oicmeam	170	3	[	[	-LRB-
cord-340028-6oicmeam	170	4	110	110	CD
cord-340028-6oicmeam	170	5	,	,	,
cord-340028-6oicmeam	170	6	111	111	CD
cord-340028-6oicmeam	170	7	]	]	-RRB-
cord-340028-6oicmeam	170	8	.	.	.
cord-340028-6oicmeam	171	1	Interestingly	interestingly	RB
cord-340028-6oicmeam	171	2	,	,	,
cord-340028-6oicmeam	171	3	NAD	NAD	NNP
cord-340028-6oicmeam	171	4	is	be	VBZ
cord-340028-6oicmeam	171	5	essential	essential	JJ
cord-340028-6oicmeam	171	6	for	for	IN
cord-340028-6oicmeam	171	7	sirtuin	sirtuin	NNP
cord-340028-6oicmeam	171	8	action	action	NN
cord-340028-6oicmeam	171	9	.	.	.
cord-340028-6oicmeam	172	1	Therefore	therefore	RB
cord-340028-6oicmeam	172	2	,	,	,
cord-340028-6oicmeam	172	3	it	-PRON-	PRP
cord-340028-6oicmeam	172	4	is	be	VBZ
cord-340028-6oicmeam	172	5	plausible	plausible	JJ
cord-340028-6oicmeam	172	6	that	that	IN
cord-340028-6oicmeam	172	7	NAD	NAD	NNP
cord-340028-6oicmeam	172	8	and	and	CC
cord-340028-6oicmeam	172	9	NAD	NAD	NNP
cord-340028-6oicmeam	172	10	-	-	HYPH
cord-340028-6oicmeam	172	11	related	relate	VBN
cord-340028-6oicmeam	172	12	compounds	compound	NNS
cord-340028-6oicmeam	172	13	such	such	JJ
cord-340028-6oicmeam	172	14	as	as	IN
cord-340028-6oicmeam	172	15	NR	NR	NNP
cord-340028-6oicmeam	172	16	and	and	CC
cord-340028-6oicmeam	172	17	NMN	NMN	NNP
cord-340028-6oicmeam	172	18	,	,	,
cord-340028-6oicmeam	172	19	which	which	WDT
cord-340028-6oicmeam	172	20	are	be	VBP
cord-340028-6oicmeam	172	21	under	under	IN
cord-340028-6oicmeam	172	22	investigation	investigation	NN
cord-340028-6oicmeam	172	23	as	as	IN
cord-340028-6oicmeam	172	24	therapeutic	therapeutic	JJ
cord-340028-6oicmeam	172	25	interventions	intervention	NNS
cord-340028-6oicmeam	172	26	that	that	WDT
cord-340028-6oicmeam	172	27	increase	increase	VBP
cord-340028-6oicmeam	172	28	serum	serum	NN
cord-340028-6oicmeam	172	29	and	and	CC
cord-340028-6oicmeam	172	30	cellular	cellular	JJ
cord-340028-6oicmeam	172	31	NAD	NAD	NNP
cord-340028-6oicmeam	172	32	levels	level	NNS
cord-340028-6oicmeam	172	33	,	,	,
cord-340028-6oicmeam	172	34	also	also	RB
cord-340028-6oicmeam	172	35	act	act	VB
cord-340028-6oicmeam	172	36	via	via	IN
cord-340028-6oicmeam	173	1	Sirt1	Sirt1	NNS
cord-340028-6oicmeam	173	2	along	along	IN
cord-340028-6oicmeam	173	3	the	the	DT
cord-340028-6oicmeam	173	4	FOXP3	FOXP3	NNP
cord-340028-6oicmeam	173	5	and	and	CC
cord-340028-6oicmeam	173	6	Treg	Treg	NNP
cord-340028-6oicmeam	173	7	axis	axis	NN
cord-340028-6oicmeam	173	8	,	,	,
cord-340028-6oicmeam	173	9	and	and	CC
cord-340028-6oicmeam	173	10	play	play	VB
cord-340028-6oicmeam	173	11	a	a	DT
cord-340028-6oicmeam	173	12	role	role	NN
cord-340028-6oicmeam	173	13	in	in	IN
cord-340028-6oicmeam	173	14	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	173	15	and	and	CC
cord-340028-6oicmeam	173	16	"	"	``
cord-340028-6oicmeam	173	17	inflammaging	inflammage	VBG
cord-340028-6oicmeam	173	18	"	"	''
cord-340028-6oicmeam	173	19	.	.	.
cord-340028-6oicmeam	174	1	A	a	DT
cord-340028-6oicmeam	174	2	brief	brief	JJ
cord-340028-6oicmeam	174	3	summary	summary	NN
cord-340028-6oicmeam	174	4	of	of	IN
cord-340028-6oicmeam	174	5	the	the	DT
cord-340028-6oicmeam	174	6	conventional	conventional	JJ
cord-340028-6oicmeam	174	7	and	and	CC
cord-340028-6oicmeam	174	8	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	174	9	and	and	CC
cord-340028-6oicmeam	174	10	senoremediative	senoremediative	JJ
cord-340028-6oicmeam	174	11	strategies	strategy	NNS
cord-340028-6oicmeam	174	12	for	for	IN
cord-340028-6oicmeam	174	13	patients	patient	NNS
cord-340028-6oicmeam	174	14	60	60	CD
cord-340028-6oicmeam	174	15	or	or	CC
cord-340028-6oicmeam	174	16	older	old	JJR
cord-340028-6oicmeam	174	17	is	be	VBZ
cord-340028-6oicmeam	174	18	provided	provide	VBN
cord-340028-6oicmeam	174	19	in	in	IN
cord-340028-6oicmeam	174	20	Table	Table	NNP
cord-340028-6oicmeam	174	21	1	1	CD
cord-340028-6oicmeam	174	22	.	.	.
cord-340028-6oicmeam	175	1	While	while	IN
cord-340028-6oicmeam	175	2	there	there	EX
cord-340028-6oicmeam	175	3	are	be	VBP
cord-340028-6oicmeam	175	4	decades	decade	NNS
cord-340028-6oicmeam	175	5	of	of	IN
cord-340028-6oicmeam	175	6	clinical	clinical	JJ
cord-340028-6oicmeam	175	7	evidence	evidence	NN
cord-340028-6oicmeam	175	8	supporting	support	VBG
cord-340028-6oicmeam	175	9	the	the	DT
cord-340028-6oicmeam	175	10	use	use	NN
cord-340028-6oicmeam	175	11	of	of	IN
cord-340028-6oicmeam	175	12	rapalogs	rapalog	NNS
cord-340028-6oicmeam	175	13	,	,	,
cord-340028-6oicmeam	175	14	such	such	JJ
cord-340028-6oicmeam	175	15	as	as	IN
cord-340028-6oicmeam	175	16	sirolimus	sirolimus	NNP
cord-340028-6oicmeam	175	17	,	,	,
cord-340028-6oicmeam	175	18	everolimus	everolimus	NNP
cord-340028-6oicmeam	175	19	,	,	,
cord-340028-6oicmeam	175	20	and	and	CC
cord-340028-6oicmeam	175	21	metformin	metformin	NNP
cord-340028-6oicmeam	175	22	,	,	,
cord-340028-6oicmeam	175	23	substantial	substantial	JJ
cord-340028-6oicmeam	175	24	meta	meta	NNP
cord-340028-6oicmeam	175	25	-	-	HYPH
cord-340028-6oicmeam	175	26	analysis	analysis	NN
cord-340028-6oicmeam	175	27	and	and	CC
cord-340028-6oicmeam	175	28	additional	additional	JJ
cord-340028-6oicmeam	175	29	clinical	clinical	JJ
cord-340028-6oicmeam	175	30	trials	trial	NNS
cord-340028-6oicmeam	175	31	must	must	MD
cord-340028-6oicmeam	175	32	be	be	VB
cord-340028-6oicmeam	175	33	conducted	conduct	VBN
cord-340028-6oicmeam	175	34	to	to	TO
cord-340028-6oicmeam	175	35	understand	understand	VB
cord-340028-6oicmeam	175	36	the	the	DT
cord-340028-6oicmeam	175	37	population	population	NN
cord-340028-6oicmeam	175	38	-	-	HYPH
cord-340028-6oicmeam	175	39	level	level	NN
cord-340028-6oicmeam	175	40	and	and	CC
cord-340028-6oicmeam	175	41	individual	individual	JJ
cord-340028-6oicmeam	175	42	effects	effect	NNS
cord-340028-6oicmeam	175	43	of	of	IN
cord-340028-6oicmeam	175	44	these	these	DT
cord-340028-6oicmeam	175	45	drugs	drug	NNS
cord-340028-6oicmeam	175	46	taken	take	VBN
cord-340028-6oicmeam	175	47	as	as	IN
cord-340028-6oicmeam	175	48	single	single	JJ
cord-340028-6oicmeam	175	49	agents	agent	NNS
cord-340028-6oicmeam	175	50	and	and	CC
cord-340028-6oicmeam	175	51	in	in	IN
cord-340028-6oicmeam	175	52	combination	combination	NN
cord-340028-6oicmeam	175	53	in	in	IN
cord-340028-6oicmeam	175	54	the	the	DT
cord-340028-6oicmeam	175	55	context	context	NN
cord-340028-6oicmeam	175	56	of	of	IN
cord-340028-6oicmeam	175	57	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	175	58	diseases	disease	NNS
cord-340028-6oicmeam	175	59	.	.	.
cord-340028-6oicmeam	176	1	In	in	IN
cord-340028-6oicmeam	176	2	this	this	DT
cord-340028-6oicmeam	176	3	paper	paper	NN
cord-340028-6oicmeam	176	4	I	-PRON-	PRP
cord-340028-6oicmeam	176	5	propose	propose	VBP
cord-340028-6oicmeam	176	6	conducting	conduct	VBG
cord-340028-6oicmeam	176	7	clinical	clinical	JJ
cord-340028-6oicmeam	176	8	trials	trial	NNS
cord-340028-6oicmeam	176	9	on	on	IN
cord-340028-6oicmeam	176	10	these	these	DT
cord-340028-6oicmeam	176	11	known	know	VBN
cord-340028-6oicmeam	176	12	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	176	13	as	as	IN
cord-340028-6oicmeam	176	14	a	a	DT
cord-340028-6oicmeam	176	15	preventative	preventative	JJ
cord-340028-6oicmeam	176	16	measure	measure	NN
cord-340028-6oicmeam	176	17	before	before	IN
cord-340028-6oicmeam	176	18	patients	patient	NNS
cord-340028-6oicmeam	176	19	are	be	VBP
cord-340028-6oicmeam	176	20	exposed	expose	VBN
cord-340028-6oicmeam	176	21	to	to	IN
cord-340028-6oicmeam	176	22	disease	disease	NN
cord-340028-6oicmeam	176	23	(	(	-LRB-
cord-340028-6oicmeam	176	24	Figure	figure	NN
cord-340028-6oicmeam	176	25	4	4	CD
cord-340028-6oicmeam	176	26	)	)	-RRB-
cord-340028-6oicmeam	176	27	.	.	.
cord-340028-6oicmeam	177	1	In	in	IN
cord-340028-6oicmeam	177	2	the	the	DT
cord-340028-6oicmeam	177	3	case	case	NN
cord-340028-6oicmeam	177	4	of	of	IN
cord-340028-6oicmeam	177	5	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	177	6	as	as	IN
cord-340028-6oicmeam	177	7	the	the	DT
cord-340028-6oicmeam	177	8	number	number	NN
cord-340028-6oicmeam	177	9	of	of	IN
cord-340028-6oicmeam	177	10	cases	case	NNS
cord-340028-6oicmeam	177	11	worldwide	worldwide	RB
cord-340028-6oicmeam	177	12	increases	increase	NNS
cord-340028-6oicmeam	177	13	,	,	,
cord-340028-6oicmeam	177	14	meta	meta	NN
cord-340028-6oicmeam	177	15	-	-	HYPH
cord-340028-6oicmeam	177	16	analysis	analysis	NN
cord-340028-6oicmeam	177	17	of	of	IN
cord-340028-6oicmeam	177	18	infection	infection	NN
cord-340028-6oicmeam	177	19	rates	rate	NNS
cord-340028-6oicmeam	177	20	,	,	,
cord-340028-6oicmeam	177	21	severity	severity	NN
cord-340028-6oicmeam	177	22	,	,	,
cord-340028-6oicmeam	177	23	and	and	CC
cord-340028-6oicmeam	177	24	lethality	lethality	NN
cord-340028-6oicmeam	177	25	should	should	MD
cord-340028-6oicmeam	177	26	be	be	VB
cord-340028-6oicmeam	177	27	performed	perform	VBN
cord-340028-6oicmeam	177	28	rapidly	rapidly	RB
cord-340028-6oicmeam	177	29	to	to	TO
cord-340028-6oicmeam	177	30	evaluate	evaluate	VB
cord-340028-6oicmeam	177	31	the	the	DT
cord-340028-6oicmeam	177	32	effects	effect	NNS
cord-340028-6oicmeam	177	33	of	of	IN
cord-340028-6oicmeam	177	34	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	177	35	,	,	,
cord-340028-6oicmeam	177	36	with	with	IN
cord-340028-6oicmeam	177	37	particular	particular	JJ
cord-340028-6oicmeam	177	38	focus	focus	NN
cord-340028-6oicmeam	177	39	on	on	IN
cord-340028-6oicmeam	177	40	rapamycin	rapamycin	NNS
cord-340028-6oicmeam	177	41	.	.	.
cord-340028-6oicmeam	178	1	Since	since	IN
cord-340028-6oicmeam	178	2	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	178	3	engages	engage	VBZ
cord-340028-6oicmeam	178	4	the	the	DT
cord-340028-6oicmeam	178	5	immune	immune	JJ
cord-340028-6oicmeam	178	6	system	system	NN
cord-340028-6oicmeam	178	7	to	to	TO
cord-340028-6oicmeam	178	8	damage	damage	VB
cord-340028-6oicmeam	178	9	the	the	DT
cord-340028-6oicmeam	178	10	lungs	lung	NNS
cord-340028-6oicmeam	178	11	,	,	,
cord-340028-6oicmeam	178	12	it	-PRON-	PRP
cord-340028-6oicmeam	178	13	may	may	MD
cord-340028-6oicmeam	178	14	be	be	VB
cord-340028-6oicmeam	178	15	entirely	entirely	RB
cord-340028-6oicmeam	178	16	plausible	plausible	JJ
cord-340028-6oicmeam	178	17	that	that	IN
cord-340028-6oicmeam	178	18	the	the	DT
cord-340028-6oicmeam	178	19	immunomodulatory	immunomodulatory	JJ
cord-340028-6oicmeam	178	20	properties	property	NNS
cord-340028-6oicmeam	178	21	of	of	IN
cord-340028-6oicmeam	178	22	rapamycin	rapamycin	NNS
cord-340028-6oicmeam	178	23	may	may	MD
cord-340028-6oicmeam	178	24	go	go	VB
cord-340028-6oicmeam	178	25	beyond	beyond	IN
cord-340028-6oicmeam	178	26	prevention	prevention	NN
cord-340028-6oicmeam	178	27	and	and	CC
cord-340028-6oicmeam	178	28	may	may	MD
cord-340028-6oicmeam	178	29	provide	provide	VB
cord-340028-6oicmeam	178	30	an	an	DT
cord-340028-6oicmeam	178	31	effective	effective	JJ
cord-340028-6oicmeam	178	32	treatment	treatment	NN
cord-340028-6oicmeam	178	33	option	option	NN
cord-340028-6oicmeam	178	34	.	.	.
cord-340028-6oicmeam	179	1	However	however	RB
cord-340028-6oicmeam	179	2	,	,	,
cord-340028-6oicmeam	179	3	this	this	DT
cord-340028-6oicmeam	179	4	hypothesis	hypothesis	NN
cord-340028-6oicmeam	179	5	must	must	MD
cord-340028-6oicmeam	179	6	be	be	VB
cord-340028-6oicmeam	179	7	validated	validate	VBN
cord-340028-6oicmeam	179	8	using	use	VBG
cord-340028-6oicmeam	179	9	meta	meta	NNP
cord-340028-6oicmeam	179	10	-	-	HYPH
cord-340028-6oicmeam	179	11	analysis	analysis	NN
cord-340028-6oicmeam	179	12	before	before	IN
cord-340028-6oicmeam	179	13	being	be	VBG
cord-340028-6oicmeam	179	14	proposed	propose	VBN
cord-340028-6oicmeam	179	15	for	for	IN
cord-340028-6oicmeam	179	16	a	a	DT
cord-340028-6oicmeam	179	17	clinical	clinical	JJ
cord-340028-6oicmeam	179	18	trial	trial	NN
cord-340028-6oicmeam	179	19	.	.	.
cord-340028-6oicmeam	180	1	As	as	IN
cord-340028-6oicmeam	180	2	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	180	3	causes	cause	VBZ
cord-340028-6oicmeam	180	4	substantial	substantial	JJ
cord-340028-6oicmeam	180	5	lung	lung	NN
cord-340028-6oicmeam	180	6	damage	damage	NN
cord-340028-6oicmeam	180	7	,	,	,
cord-340028-6oicmeam	180	8	antifibrotics	antifibrotic	NNS
cord-340028-6oicmeam	180	9	,	,	,
cord-340028-6oicmeam	180	10	senolytics	senolytic	NNS
cord-340028-6oicmeam	180	11	and	and	CC
cord-340028-6oicmeam	180	12	other	other	JJ
cord-340028-6oicmeam	180	13	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	180	14	may	may	MD
cord-340028-6oicmeam	180	15	be	be	VB
cord-340028-6oicmeam	180	16	explored	explore	VBN
cord-340028-6oicmeam	180	17	in	in	IN
cord-340028-6oicmeam	180	18	clinical	clinical	JJ
cord-340028-6oicmeam	180	19	trials	trial	NNS
cord-340028-6oicmeam	180	20	to	to	TO
cord-340028-6oicmeam	180	21	assist	assist	VB
cord-340028-6oicmeam	180	22	in	in	IN
cord-340028-6oicmeam	180	23	patient	patient	JJ
cord-340028-6oicmeam	180	24	recovery	recovery	NN
cord-340028-6oicmeam	180	25	to	to	TO
cord-340028-6oicmeam	180	26	prevent	prevent	VB
cord-340028-6oicmeam	180	27	a	a	DT
cord-340028-6oicmeam	180	28	reduction	reduction	NN
cord-340028-6oicmeam	180	29	in	in	IN
cord-340028-6oicmeam	180	30	respiratory	respiratory	JJ
cord-340028-6oicmeam	180	31	function	function	NN
cord-340028-6oicmeam	180	32	.	.	.
cord-340028-6oicmeam	181	1	Since	since	IN
cord-340028-6oicmeam	181	2	senescence	senescence	NN
cord-340028-6oicmeam	181	3	varies	vary	VBZ
cord-340028-6oicmeam	181	4	among	among	IN
cord-340028-6oicmeam	181	5	individuals	individual	NNS
cord-340028-6oicmeam	181	6	,	,	,
cord-340028-6oicmeam	181	7	a	a	DT
cord-340028-6oicmeam	181	8	person	person	NN
cord-340028-6oicmeam	181	9	's	's	POS
cord-340028-6oicmeam	181	10	chronological	chronological	JJ
cord-340028-6oicmeam	181	11	age	age	NN
cord-340028-6oicmeam	181	12	is	be	VBZ
cord-340028-6oicmeam	181	13	not	not	RB
cord-340028-6oicmeam	181	14	as	as	RB
cord-340028-6oicmeam	181	15	important	important	JJ
cord-340028-6oicmeam	181	16	as	as	IN
cord-340028-6oicmeam	181	17	their	-PRON-	PRP$
cord-340028-6oicmeam	181	18	biological	biological	JJ
cord-340028-6oicmeam	181	19	age	age	NN
cord-340028-6oicmeam	181	20	.	.	.
cord-340028-6oicmeam	182	1	For	for	IN
cord-340028-6oicmeam	182	2	several	several	JJ
cord-340028-6oicmeam	182	3	years	year	NNS
cord-340028-6oicmeam	182	4	,	,	,
cord-340028-6oicmeam	182	5	scientists	scientist	NNS
cord-340028-6oicmeam	182	6	have	have	VBP
cord-340028-6oicmeam	182	7	sought	seek	VBN
cord-340028-6oicmeam	182	8	accurate	accurate	JJ
cord-340028-6oicmeam	182	9	aging	age	VBG
cord-340028-6oicmeam	182	10	biomarkers	biomarker	NNS
cord-340028-6oicmeam	182	11	that	that	WDT
cord-340028-6oicmeam	182	12	may	may	MD
cord-340028-6oicmeam	182	13	predict	predict	VB
cord-340028-6oicmeam	182	14	an	an	DT
cord-340028-6oicmeam	182	15	individuals	individual	NNS
cord-340028-6oicmeam	182	16	'	'	POS
cord-340028-6oicmeam	182	17	biological	biological	JJ
cord-340028-6oicmeam	182	18	age	age	NN
cord-340028-6oicmeam	182	19	and	and	CC
cord-340028-6oicmeam	182	20	,	,	,
cord-340028-6oicmeam	182	21	independently	independently	RB
cord-340028-6oicmeam	182	22	of	of	IN
cord-340028-6oicmeam	182	23	immunosenescence	immunosenescence	NNP
cord-340028-6oicmeam	182	24	,	,	,
cord-340028-6oicmeam	182	25	their	-PRON-	PRP$
cord-340028-6oicmeam	182	26	risk	risk	NN
cord-340028-6oicmeam	182	27	of	of	IN
cord-340028-6oicmeam	182	28	morbidity	morbidity	NN
cord-340028-6oicmeam	182	29	and	and	CC
cord-340028-6oicmeam	182	30	mortality	mortality	NN
cord-340028-6oicmeam	182	31	.	.	.
cord-340028-6oicmeam	183	1	These	these	DT
cord-340028-6oicmeam	183	2	biomarkers	biomarker	NNS
cord-340028-6oicmeam	183	3	,	,	,
cord-340028-6oicmeam	183	4	or	or	CC
cord-340028-6oicmeam	183	5	"	"	``
cord-340028-6oicmeam	183	6	clocks	clock	NNS
cord-340028-6oicmeam	183	7	"	"	''
cord-340028-6oicmeam	183	8	,	,	,
cord-340028-6oicmeam	183	9	could	could	MD
cord-340028-6oicmeam	183	10	then	then	RB
cord-340028-6oicmeam	183	11	be	be	VB
cord-340028-6oicmeam	183	12	used	use	VBN
cord-340028-6oicmeam	183	13	to	to	TO
cord-340028-6oicmeam	183	14	test	test	VB
cord-340028-6oicmeam	183	15	for	for	IN
cord-340028-6oicmeam	183	16	the	the	DT
cord-340028-6oicmeam	183	17	effectiveness	effectiveness	NN
cord-340028-6oicmeam	183	18	of	of	IN
cord-340028-6oicmeam	183	19	proposed	propose	VBN
cord-340028-6oicmeam	183	20	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	183	21	treatments	treatment	NNS
cord-340028-6oicmeam	183	22	and	and	CC
cord-340028-6oicmeam	183	23	as	as	IN
cord-340028-6oicmeam	183	24	surrogate	surrogate	JJ
cord-340028-6oicmeam	183	25	markers	marker	NNS
cord-340028-6oicmeam	183	26	in	in	IN
cord-340028-6oicmeam	183	27	anti	anti	JJ
cord-340028-6oicmeam	183	28	-	-	JJ
cord-340028-6oicmeam	183	29	aging	aging	JJ
cord-340028-6oicmeam	183	30	clinical	clinical	JJ
cord-340028-6oicmeam	183	31	trials	trial	NNS
cord-340028-6oicmeam	183	32	.	.	.
cord-340028-6oicmeam	184	1	While	while	IN
cord-340028-6oicmeam	184	2	there	there	EX
cord-340028-6oicmeam	184	3	are	be	VBP
cord-340028-6oicmeam	184	4	no	no	DT
cord-340028-6oicmeam	184	5	reliable	reliable	JJ
cord-340028-6oicmeam	184	6	aging	age	VBG
cord-340028-6oicmeam	184	7	clocks	clock	NNS
cord-340028-6oicmeam	184	8	to	to	TO
cord-340028-6oicmeam	184	9	evaluate	evaluate	VB
cord-340028-6oicmeam	184	10	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	184	11	and	and	CC
cord-340028-6oicmeam	184	12	inflamaging	inflamage	VBG
cord-340028-6oicmeam	184	13	[	[	-LRB-
cord-340028-6oicmeam	184	14	112	112	CD
cord-340028-6oicmeam	184	15	]	]	-RRB-
cord-340028-6oicmeam	184	16	,	,	,
cord-340028-6oicmeam	184	17	these	these	DT
cord-340028-6oicmeam	184	18	biomarkers	biomarker	NNS
cord-340028-6oicmeam	184	19	may	may	MD
cord-340028-6oicmeam	184	20	be	be	VB
cord-340028-6oicmeam	184	21	rapidly	rapidly	RB
cord-340028-6oicmeam	184	22	developed	develop	VBN
cord-340028-6oicmeam	184	23	using	use	VBG
cord-340028-6oicmeam	184	24	historical	historical	JJ
cord-340028-6oicmeam	184	25	data	datum	NNS
cord-340028-6oicmeam	184	26	.	.	.
cord-340028-6oicmeam	185	1	At	at	IN
cord-340028-6oicmeam	185	2	present	present	JJ
cord-340028-6oicmeam	185	3	,	,	,
cord-340028-6oicmeam	185	4	age	age	NN
cord-340028-6oicmeam	185	5	clocks	clock	NNS
cord-340028-6oicmeam	185	6	trained	train	VBN
cord-340028-6oicmeam	185	7	on	on	IN
cord-340028-6oicmeam	185	8	clinical	clinical	JJ
cord-340028-6oicmeam	185	9	blood	blood	NN
cord-340028-6oicmeam	185	10	tests	test	NNS
cord-340028-6oicmeam	185	11	[	[	-LRB-
cord-340028-6oicmeam	185	12	113	113	CD
cord-340028-6oicmeam	185	13	]	]	-RRB-
cord-340028-6oicmeam	185	14	,	,	,
cord-340028-6oicmeam	185	15	transcriptomic	transcriptomic	NNP
cord-340028-6oicmeam	185	16	[	[	-LRB-
cord-340028-6oicmeam	185	17	114	114	CD
cord-340028-6oicmeam	185	18	]	]	-RRB-
cord-340028-6oicmeam	185	19	and	and	CC
cord-340028-6oicmeam	185	20	proteomic	proteomic	JJ
cord-340028-6oicmeam	185	21	data	datum	NNS
cord-340028-6oicmeam	185	22	[	[	-LRB-
cord-340028-6oicmeam	185	23	115	115	CD
cord-340028-6oicmeam	185	24	]	]	-RRB-
cord-340028-6oicmeam	185	25	,	,	,
cord-340028-6oicmeam	185	26	methylation	methylation	NN
cord-340028-6oicmeam	185	27	clocks	clock	NNS
cord-340028-6oicmeam	185	28	[	[	-LRB-
cord-340028-6oicmeam	185	29	46	46	CD
cord-340028-6oicmeam	185	30	,	,	,
cord-340028-6oicmeam	185	31	116	116	CD
cord-340028-6oicmeam	185	32	]	]	-RRB-
cord-340028-6oicmeam	185	33	,	,	,
cord-340028-6oicmeam	185	34	microbiomic	microbiomic	NNP
cord-340028-6oicmeam	185	35	clocks	clock	NNS
cord-340028-6oicmeam	185	36	[	[	-LRB-
cord-340028-6oicmeam	185	37	117	117	CD
cord-340028-6oicmeam	185	38	]	]	-RRB-
cord-340028-6oicmeam	185	39	and	and	CC
cord-340028-6oicmeam	185	40	other	other	JJ
cord-340028-6oicmeam	185	41	clocks	clock	NNS
cord-340028-6oicmeam	185	42	have	have	VBP
cord-340028-6oicmeam	185	43	been	be	VBN
cord-340028-6oicmeam	185	44	described	describe	VBN
cord-340028-6oicmeam	185	45	.	.	.
cord-340028-6oicmeam	186	1	Recent	recent	JJ
cord-340028-6oicmeam	186	2	advances	advance	NNS
cord-340028-6oicmeam	186	3	in	in	IN
cord-340028-6oicmeam	186	4	artificial	artificial	JJ
cord-340028-6oicmeam	186	5	intelligence	intelligence	NN
cord-340028-6oicmeam	186	6	have	have	VBP
cord-340028-6oicmeam	186	7	enabled	enable	VBN
cord-340028-6oicmeam	186	8	the	the	DT
cord-340028-6oicmeam	186	9	development	development	NN
cord-340028-6oicmeam	186	10	of	of	IN
cord-340028-6oicmeam	186	11	multimodal	multimodal	JJ
cord-340028-6oicmeam	186	12	multi	multi	JJ
cord-340028-6oicmeam	186	13	-	-	HYPH
cord-340028-6oicmeam	186	14	omics	omic	NNS
cord-340028-6oicmeam	186	15	age	age	NN
cord-340028-6oicmeam	186	16	-	-	HYPH
cord-340028-6oicmeam	186	17	predictors	predictor	NNS
cord-340028-6oicmeam	186	18	,	,	,
cord-340028-6oicmeam	186	19	able	able	JJ
cord-340028-6oicmeam	186	20	to	to	TO
cord-340028-6oicmeam	186	21	learn	learn	VB
cord-340028-6oicmeam	186	22	complex	complex	JJ
cord-340028-6oicmeam	186	23	non	non	JJ
cord-340028-6oicmeam	186	24	-	-	JJ
cord-340028-6oicmeam	186	25	linear	linear	JJ
cord-340028-6oicmeam	186	26	patterns	pattern	NNS
cord-340028-6oicmeam	186	27	and	and	CC
cord-340028-6oicmeam	186	28	extract	extract	VB
cord-340028-6oicmeam	186	29	the	the	DT
cord-340028-6oicmeam	186	30	most	most	RBS
cord-340028-6oicmeam	186	31	important	important	JJ
cord-340028-6oicmeam	186	32	features	feature	NNS
cord-340028-6oicmeam	186	33	[	[	-LRB-
cord-340028-6oicmeam	186	34	113	113	CD
cord-340028-6oicmeam	186	35	,	,	,
cord-340028-6oicmeam	186	36	118	118	CD
cord-340028-6oicmeam	186	37	]	]	-RRB-
cord-340028-6oicmeam	186	38	.	.	.
cord-340028-6oicmeam	187	1	None	none	NN
cord-340028-6oicmeam	187	2	of	of	IN
cord-340028-6oicmeam	187	3	these	these	DT
cord-340028-6oicmeam	187	4	currently	currently	RB
cord-340028-6oicmeam	187	5	have	have	VBP
cord-340028-6oicmeam	187	6	robust	robust	JJ
cord-340028-6oicmeam	187	7	clinical	clinical	JJ
cord-340028-6oicmeam	187	8	validation	validation	NN
cord-340028-6oicmeam	187	9	and	and	CC
cord-340028-6oicmeam	187	10	can	can	MD
cord-340028-6oicmeam	187	11	not	not	RB
cord-340028-6oicmeam	187	12	yet	yet	RB
cord-340028-6oicmeam	187	13	serve	serve	VB
cord-340028-6oicmeam	187	14	as	as	IN
cord-340028-6oicmeam	187	15	companion	companion	NN
cord-340028-6oicmeam	187	16	biomarkers	biomarker	NNS
cord-340028-6oicmeam	187	17	for	for	IN
cord-340028-6oicmeam	187	18	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	187	19	and	and	CC
cord-340028-6oicmeam	187	20	antiaging	antiaging	NN
cord-340028-6oicmeam	187	21	interventions	intervention	NNS
cord-340028-6oicmeam	187	22	intended	intend	VBN
cord-340028-6oicmeam	187	23	to	to	TO
cord-340028-6oicmeam	187	24	ameliorate	ameliorate	VB
cord-340028-6oicmeam	187	25	the	the	DT
cord-340028-6oicmeam	187	26	population	population	NN
cord-340028-6oicmeam	187	27	-	-	HYPH
cord-340028-6oicmeam	187	28	level	level	NN
cord-340028-6oicmeam	187	29	effects	effect	NNS
cord-340028-6oicmeam	187	30	of	of	IN
cord-340028-6oicmeam	187	31	infectious	infectious	JJ
cord-340028-6oicmeam	187	32	diseases	disease	NNS
cord-340028-6oicmeam	187	33	during	during	IN
cord-340028-6oicmeam	187	34	flu	flu	NN
cord-340028-6oicmeam	187	35	seasons	season	NNS
cord-340028-6oicmeam	187	36	and	and	CC
cord-340028-6oicmeam	187	37	pandemics	pandemic	NNS
cord-340028-6oicmeam	187	38	.	.	.
cord-340028-6oicmeam	188	1	We	-PRON-	PRP
cord-340028-6oicmeam	188	2	call	call	VBP
cord-340028-6oicmeam	188	3	for	for	IN
cord-340028-6oicmeam	188	4	rigorous	rigorous	JJ
cord-340028-6oicmeam	188	5	clinical	clinical	JJ
cord-340028-6oicmeam	188	6	validation	validation	NN
cord-340028-6oicmeam	188	7	and	and	CC
cord-340028-6oicmeam	188	8	further	further	JJ
cord-340028-6oicmeam	188	9	development	development	NN
cord-340028-6oicmeam	188	10	of	of	IN
cord-340028-6oicmeam	188	11	biological	biological	JJ
cord-340028-6oicmeam	188	12	aging	age	VBG
cord-340028-6oicmeam	188	13	clocks	clock	NNS
cord-340028-6oicmeam	188	14	that	that	WDT
cord-340028-6oicmeam	188	15	could	could	MD
cord-340028-6oicmeam	188	16	,	,	,
cord-340028-6oicmeam	188	17	in	in	IN
cord-340028-6oicmeam	188	18	the	the	DT
cord-340028-6oicmeam	188	19	future	future	NN
cord-340028-6oicmeam	188	20	,	,	,
cord-340028-6oicmeam	188	21	allow	allow	VB
cord-340028-6oicmeam	188	22	us	-PRON-	PRP
cord-340028-6oicmeam	188	23	to	to	TO
cord-340028-6oicmeam	188	24	measure	measure	VB
cord-340028-6oicmeam	188	25	the	the	DT
cord-340028-6oicmeam	188	26	effectiveness	effectiveness	NN
cord-340028-6oicmeam	188	27	of	of	IN
cord-340028-6oicmeam	188	28	the	the	DT
cord-340028-6oicmeam	188	29	numerous	numerous	JJ
cord-340028-6oicmeam	188	30	speculative	speculative	JJ
cord-340028-6oicmeam	188	31	geroprotective	geroprotective	NN
cord-340028-6oicmeam	188	32	and	and	CC
cord-340028-6oicmeam	188	33	senoremediative	senoremediative	JJ
cord-340028-6oicmeam	188	34	interventions	intervention	NNS
cord-340028-6oicmeam	188	35	described	describe	VBN
cord-340028-6oicmeam	188	36	herein	herein	RB
cord-340028-6oicmeam	188	37	.	.	.
cord-340028-6oicmeam	189	1	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	189	2	is	be	VBZ
cord-340028-6oicmeam	189	3	a	a	DT
cord-340028-6oicmeam	189	4	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	189	5	infection	infection	NN
cord-340028-6oicmeam	189	6	.	.	.
cord-340028-6oicmeam	190	1	Efficacy	efficacy	NN
cord-340028-6oicmeam	190	2	of	of	IN
cord-340028-6oicmeam	190	3	the	the	DT
cord-340028-6oicmeam	190	4	vaccine	vaccine	NN
cord-340028-6oicmeam	190	5	will	will	MD
cord-340028-6oicmeam	190	6	likely	likely	RB
cord-340028-6oicmeam	190	7	be	be	VB
cord-340028-6oicmeam	190	8	significantly	significantly	RB
cord-340028-6oicmeam	190	9	reduced	reduce	VBN
cord-340028-6oicmeam	190	10	due	due	IN
cord-340028-6oicmeam	190	11	to	to	IN
cord-340028-6oicmeam	190	12	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	190	13	and	and	CC
cord-340028-6oicmeam	190	14	multimorbidity	multimorbidity	NN
cord-340028-6oicmeam	190	15	.	.	.
cord-340028-6oicmeam	191	1	Possible	possible	JJ
cord-340028-6oicmeam	191	2	immunogenicity	immunogenicity	NN
cord-340028-6oicmeam	191	3	and	and	CC
cord-340028-6oicmeam	191	4	mild	mild	JJ
cord-340028-6oicmeam	191	5	viral	viral	JJ
cord-340028-6oicmeam	191	6	prodrome	prodrome	NN
cord-340028-6oicmeam	191	7	symptoms	symptom	NNS
cord-340028-6oicmeam	191	8	as	as	IN
cord-340028-6oicmeam	191	9	a	a	DT
cord-340028-6oicmeam	191	10	result	result	NN
cord-340028-6oicmeam	191	11	of	of	IN
cord-340028-6oicmeam	191	12	vaccination	vaccination	NN
cord-340028-6oicmeam	191	13	.	.	.
cord-340028-6oicmeam	192	1	Antibodies	antibody	NNS
cord-340028-6oicmeam	192	2	for	for	IN
cord-340028-6oicmeam	192	3	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	192	4	Antibodies	Antibodies	NNPS
cord-340028-6oicmeam	192	5	of	of	IN
cord-340028-6oicmeam	192	6	serum	serum	NN
cord-340028-6oicmeam	192	7	of	of	IN
cord-340028-6oicmeam	192	8	recovered	recover	VBN
cord-340028-6oicmeam	192	9	individuals	individual	NNS
cord-340028-6oicmeam	192	10	.	.	.
cord-340028-6oicmeam	193	1	Antibodies	antibody	NNS
cord-340028-6oicmeam	193	2	targeting	target	VBG
cord-340028-6oicmeam	193	3	specific	specific	JJ
cord-340028-6oicmeam	193	4	SARS	SARS	NNP
cord-340028-6oicmeam	193	5	-	-	HYPH
cord-340028-6oicmeam	193	6	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	193	7	proteins	protein	NNS
cord-340028-6oicmeam	193	8	.	.	.
cord-340028-6oicmeam	194	1	Successfully	successfully	RB
cord-340028-6oicmeam	194	2	trialed	triale	VBN
cord-340028-6oicmeam	194	3	in	in	IN
cord-340028-6oicmeam	194	4	other	other	JJ
cord-340028-6oicmeam	194	5	viral	viral	JJ
cord-340028-6oicmeam	194	6	diseases	disease	NNS
cord-340028-6oicmeam	194	7	including	include	VBG
cord-340028-6oicmeam	194	8	Ebola	Ebola	NNP
cord-340028-6oicmeam	194	9	.	.	.
cord-340028-6oicmeam	195	1	Reduction	reduction	NN
cord-340028-6oicmeam	195	2	in	in	IN
cord-340028-6oicmeam	195	3	disease	disease	NN
cord-340028-6oicmeam	195	4	severity	severity	NN
cord-340028-6oicmeam	195	5	and	and	CC
cord-340028-6oicmeam	195	6	lethality	lethality	NN
cord-340028-6oicmeam	195	7	in	in	IN
cord-340028-6oicmeam	195	8	exposed	expose	VBN
cord-340028-6oicmeam	195	9	individuals	individual	NNS
cord-340028-6oicmeam	195	10	.	.	.
cord-340028-6oicmeam	196	1	Risk	risk	NN
cord-340028-6oicmeam	196	2	of	of	IN
cord-340028-6oicmeam	196	3	systemic	systemic	JJ
cord-340028-6oicmeam	196	4	immune	immune	JJ
cord-340028-6oicmeam	196	5	reactions	reaction	NNS
cord-340028-6oicmeam	196	6	and	and	CC
cord-340028-6oicmeam	196	7	certain	certain	JJ
cord-340028-6oicmeam	196	8	blood	blood	NN
cord-340028-6oicmeam	196	9	borne	bear	VBN
cord-340028-6oicmeam	196	10	infections	infection	NNS
cord-340028-6oicmeam	196	11	.	.	.
cord-340028-6oicmeam	197	1	Selective	selective	JJ
cord-340028-6oicmeam	197	2	small	small	JJ
cord-340028-6oicmeam	197	3	molecule	molecule	NN
cord-340028-6oicmeam	197	4	inhibitors	inhibitor	NNS
cord-340028-6oicmeam	197	5	targeting	target	VBG
cord-340028-6oicmeam	197	6	SARS	SARS	NNP
cord-340028-6oicmeam	197	7	-	-	HYPH
cord-340028-6oicmeam	197	8	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	197	9	proteins	protein	NNS
cord-340028-6oicmeam	197	10	such	such	JJ
cord-340028-6oicmeam	197	11	as	as	IN
cord-340028-6oicmeam	197	12	3C	3c	NN
cord-340028-6oicmeam	197	13	-	-	HYPH
cord-340028-6oicmeam	197	14	like	like	JJ
cord-340028-6oicmeam	197	15	protease	protease	NN
cord-340028-6oicmeam	197	16	.	.	.
cord-340028-6oicmeam	198	1	Multiple	multiple	JJ
cord-340028-6oicmeam	198	2	examples	example	NNS
cord-340028-6oicmeam	198	3	from	from	IN
cord-340028-6oicmeam	198	4	Influenza	Influenza	NNP
cord-340028-6oicmeam	198	5	.	.	.
cord-340028-6oicmeam	199	1	Neuraminidase	neuraminidase	NN
cord-340028-6oicmeam	199	2	and	and	CC
cord-340028-6oicmeam	199	3	endonuclease	endonuclease	NN
cord-340028-6oicmeam	199	4	inhibitors	inhibitor	NNS
cord-340028-6oicmeam	199	5	.	.	.
cord-340028-6oicmeam	200	1	Reduction	reduction	NN
cord-340028-6oicmeam	200	2	in	in	IN
cord-340028-6oicmeam	200	3	disease	disease	NN
cord-340028-6oicmeam	200	4	duration	duration	NN
cord-340028-6oicmeam	200	5	,	,	,
cord-340028-6oicmeam	200	6	severity	severity	NN
cord-340028-6oicmeam	200	7	,	,	,
cord-340028-6oicmeam	200	8	and	and	CC
cord-340028-6oicmeam	200	9	lethality	lethality	NN
cord-340028-6oicmeam	200	10	in	in	IN
cord-340028-6oicmeam	200	11	exposed	expose	VBN
cord-340028-6oicmeam	200	12	individuals	individual	NNS
cord-340028-6oicmeam	200	13	.	.	.
cord-340028-6oicmeam	201	1	Mild	mild	JJ
cord-340028-6oicmeam	201	2	side	side	NN
cord-340028-6oicmeam	201	3	effects	effect	NNS
cord-340028-6oicmeam	201	4	such	such	JJ
cord-340028-6oicmeam	201	5	as	as	IN
cord-340028-6oicmeam	201	6	nausea	nausea	NN
cord-340028-6oicmeam	201	7	,	,	,
cord-340028-6oicmeam	201	8	vomiting	vomiting	NN
cord-340028-6oicmeam	201	9	,	,	,
cord-340028-6oicmeam	201	10	diarrhea	diarrhea	NN
cord-340028-6oicmeam	201	11	,	,	,
cord-340028-6oicmeam	201	12	etc	etc	FW
cord-340028-6oicmeam	201	13	.	.	.
cord-340028-6oicmeam	202	1	Non	non	JJ
cord-340028-6oicmeam	202	2	-	-	JJ
cord-340028-6oicmeam	202	3	steroidal	steroidal	JJ
cord-340028-6oicmeam	202	4	antiinflammatory	antiinflammatory	JJ
cord-340028-6oicmeam	202	5	drugs	drug	NNS
cord-340028-6oicmeam	202	6	(	(	-LRB-
cord-340028-6oicmeam	202	7	NSAIDs	NSAIDs	NNP
cord-340028-6oicmeam	202	8	)	)	-RRB-
cord-340028-6oicmeam	202	9	,	,	,
cord-340028-6oicmeam	202	10	antibacterials	antibacterial	NNS
cord-340028-6oicmeam	202	11	,	,	,
cord-340028-6oicmeam	202	12	pain	pain	NN
cord-340028-6oicmeam	202	13	management	management	NN
cord-340028-6oicmeam	202	14	.	.	.
cord-340028-6oicmeam	203	1	Multiple	multiple	JJ
cord-340028-6oicmeam	203	2	clinical	clinical	JJ
cord-340028-6oicmeam	203	3	trials	trial	NNS
cord-340028-6oicmeam	203	4	,	,	,
cord-340028-6oicmeam	203	5	common	common	JJ
cord-340028-6oicmeam	203	6	use	use	NN
cord-340028-6oicmeam	203	7	.	.	.
cord-340028-6oicmeam	204	1	Reduction	reduction	NN
cord-340028-6oicmeam	204	2	in	in	IN
cord-340028-6oicmeam	204	3	severity	severity	NN
cord-340028-6oicmeam	204	4	of	of	IN
cord-340028-6oicmeam	204	5	disease	disease	NN
cord-340028-6oicmeam	204	6	.	.	.
cord-340028-6oicmeam	205	1	Mild	mild	JJ
cord-340028-6oicmeam	205	2	side	side	NN
cord-340028-6oicmeam	205	3	effects	effect	NNS
cord-340028-6oicmeam	205	4	such	such	JJ
cord-340028-6oicmeam	205	5	as	as	IN
cord-340028-6oicmeam	205	6	nausea	nausea	NN
cord-340028-6oicmeam	205	7	,	,	,
cord-340028-6oicmeam	205	8	vomiting	vomiting	NN
cord-340028-6oicmeam	205	9	,	,	,
cord-340028-6oicmeam	205	10	diarrhea	diarrhea	NN
cord-340028-6oicmeam	205	11	,	,	,
cord-340028-6oicmeam	205	12	etc	etc	FW
cord-340028-6oicmeam	205	13	.	.	.
cord-340028-6oicmeam	206	1	[	[	-LRB-
cord-340028-6oicmeam	206	2	24	24	CD
cord-340028-6oicmeam	206	3	]	]	-RRB-
cord-340028-6oicmeam	206	4	.	.	.
cord-340028-6oicmeam	207	1	Theoretically	theoretically	RB
cord-340028-6oicmeam	207	2	,	,	,
cord-340028-6oicmeam	207	3	treatments	treatment	NNS
cord-340028-6oicmeam	207	4	found	find	VBD
cord-340028-6oicmeam	207	5	to	to	TO
cord-340028-6oicmeam	207	6	be	be	VB
cord-340028-6oicmeam	207	7	effective	effective	JJ
cord-340028-6oicmeam	207	8	against	against	IN
cord-340028-6oicmeam	207	9	SARS	SARS	NNP
cord-340028-6oicmeam	207	10	and	and	CC
cord-340028-6oicmeam	207	11	MERS	MERS	NNP
cord-340028-6oicmeam	208	1	are	be	VBP
cord-340028-6oicmeam	208	2	the	the	DT
cord-340028-6oicmeam	208	3	most	most	RBS
cord-340028-6oicmeam	208	4	promising	promising	JJ
cord-340028-6oicmeam	208	5	starting	starting	NN
cord-340028-6oicmeam	208	6	points	point	NNS
cord-340028-6oicmeam	208	7	for	for	IN
cord-340028-6oicmeam	208	8	treatments	treatment	NNS
cord-340028-6oicmeam	208	9	likely	likely	JJ
cord-340028-6oicmeam	208	10	to	to	TO
cord-340028-6oicmeam	208	11	be	be	VB
cord-340028-6oicmeam	208	12	effective	effective	JJ
cord-340028-6oicmeam	208	13	against	against	IN
cord-340028-6oicmeam	208	14	SARS	SARS	NNP
cord-340028-6oicmeam	208	15	-	-	HYPH
cord-340028-6oicmeam	208	16	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	208	17	.	.	.
cord-340028-6oicmeam	209	1	The	the	DT
cord-340028-6oicmeam	209	2	SARS	SARS	NNP
cord-340028-6oicmeam	209	3	outbreak	outbreak	NN
cord-340028-6oicmeam	209	4	of	of	IN
cord-340028-6oicmeam	209	5	2002	2002	CD
cord-340028-6oicmeam	209	6	was	be	VBD
cord-340028-6oicmeam	209	7	rapidly	rapidly	RB
cord-340028-6oicmeam	209	8	contained	contain	VBN
cord-340028-6oicmeam	209	9	,	,	,
cord-340028-6oicmeam	209	10	and	and	CC
cord-340028-6oicmeam	209	11	no	no	DT
cord-340028-6oicmeam	209	12	new	new	JJ
cord-340028-6oicmeam	209	13	cases	case	NNS
cord-340028-6oicmeam	209	14	have	have	VBP
cord-340028-6oicmeam	209	15	been	be	VBN
cord-340028-6oicmeam	209	16	reported	report	VBN
cord-340028-6oicmeam	209	17	since	since	IN
cord-340028-6oicmeam	209	18	2004	2004	CD
cord-340028-6oicmeam	209	19	[	[	-LRB-
cord-340028-6oicmeam	209	20	119	119	CD
cord-340028-6oicmeam	209	21	]	]	-RRB-
cord-340028-6oicmeam	209	22	.	.	.
cord-340028-6oicmeam	210	1	Since	since	IN
cord-340028-6oicmeam	210	2	the	the	DT
cord-340028-6oicmeam	210	3	scale	scale	NN
cord-340028-6oicmeam	210	4	of	of	IN
cord-340028-6oicmeam	210	5	the	the	DT
cord-340028-6oicmeam	210	6	outbreak	outbreak	NN
cord-340028-6oicmeam	210	7	did	do	VBD
cord-340028-6oicmeam	210	8	not	not	RB
cord-340028-6oicmeam	210	9	provide	provide	VB
cord-340028-6oicmeam	210	10	any	any	DT
cord-340028-6oicmeam	210	11	commercial	commercial	JJ
cord-340028-6oicmeam	210	12	benefit	benefit	NN
cord-340028-6oicmeam	210	13	for	for	IN
cord-340028-6oicmeam	210	14	the	the	DT
cord-340028-6oicmeam	210	15	pharmaceutical	pharmaceutical	JJ
cord-340028-6oicmeam	210	16	industry	industry	NN
cord-340028-6oicmeam	210	17	to	to	TO
cord-340028-6oicmeam	210	18	develop	develop	VB
cord-340028-6oicmeam	210	19	effective	effective	JJ
cord-340028-6oicmeam	210	20	drugs	drug	NNS
cord-340028-6oicmeam	210	21	for	for	IN
cord-340028-6oicmeam	210	22	SARS	SARS	NNP
cord-340028-6oicmeam	210	23	,	,	,
cord-340028-6oicmeam	210	24	much	much	JJ
cord-340028-6oicmeam	210	25	of	of	IN
cord-340028-6oicmeam	210	26	the	the	DT
cord-340028-6oicmeam	210	27	discovery	discovery	NN
cord-340028-6oicmeam	210	28	efforts	effort	NNS
cord-340028-6oicmeam	210	29	stopped	stop	VBD
cord-340028-6oicmeam	210	30	after	after	IN
cord-340028-6oicmeam	210	31	the	the	DT
cord-340028-6oicmeam	210	32	epidemic	epidemic	NN
cord-340028-6oicmeam	210	33	.	.	.
cord-340028-6oicmeam	211	1	When	when	WRB
cord-340028-6oicmeam	211	2	the	the	DT
cord-340028-6oicmeam	211	3	news	news	NN
cord-340028-6oicmeam	211	4	of	of	IN
cord-340028-6oicmeam	211	5	SARS	SARS	NNP
cord-340028-6oicmeam	211	6	-	-	HYPH
cord-340028-6oicmeam	211	7	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	211	8	/	/	SYM
cord-340028-6oicmeam	211	9	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	211	10	emerged	emerge	VBD
cord-340028-6oicmeam	211	11	in	in	IN
cord-340028-6oicmeam	211	12	early	early	JJ
cord-340028-6oicmeam	211	13	January	January	NNP
cord-340028-6oicmeam	211	14	2020	2020	CD
cord-340028-6oicmeam	211	15	,	,	,
cord-340028-6oicmeam	211	16	it	-PRON-	PRP
cord-340028-6oicmeam	211	17	was	be	VBD
cord-340028-6oicmeam	211	18	difficult	difficult	JJ
cord-340028-6oicmeam	211	19	to	to	TO
cord-340028-6oicmeam	211	20	justify	justify	VB
cord-340028-6oicmeam	211	21	a	a	DT
cord-340028-6oicmeam	211	22	business	business	NN
cord-340028-6oicmeam	211	23	case	case	NN
cord-340028-6oicmeam	211	24	for	for	IN
cord-340028-6oicmeam	211	25	small	small	JJ
cord-340028-6oicmeam	211	26	biotechnology	biotechnology	NN
cord-340028-6oicmeam	211	27	companies	company	NNS
cord-340028-6oicmeam	211	28	to	to	TO
cord-340028-6oicmeam	211	29	allocate	allocate	VB
cord-340028-6oicmeam	211	30	resources	resource	NNS
cord-340028-6oicmeam	211	31	to	to	IN
cord-340028-6oicmeam	211	32	the	the	DT
cord-340028-6oicmeam	211	33	effort	effort	NN
cord-340028-6oicmeam	211	34	.	.	.
cord-340028-6oicmeam	212	1	By	by	IN
cord-340028-6oicmeam	212	2	January	January	NNP
cord-340028-6oicmeam	212	3	28	28	CD
cord-340028-6oicmeam	212	4	th	th	XX
cord-340028-6oicmeam	212	5	,	,	,
cord-340028-6oicmeam	212	6	however	however	RB
cord-340028-6oicmeam	212	7	,	,	,
cord-340028-6oicmeam	212	8	Insilico	Insilico	NNP
cord-340028-6oicmeam	212	9	Medicine	Medicine	NNP
cord-340028-6oicmeam	212	10	allocated	allocate	VBD
cord-340028-6oicmeam	212	11	resources	resource	NNS
cord-340028-6oicmeam	212	12	to	to	TO
cord-340028-6oicmeam	212	13	generate	generate	VB
cord-340028-6oicmeam	212	14	and	and	CC
cord-340028-6oicmeam	212	15	test	test	VB
cord-340028-6oicmeam	212	16	small	small	JJ
cord-340028-6oicmeam	212	17	molecules	molecule	NNS
cord-340028-6oicmeam	212	18	against	against	IN
cord-340028-6oicmeam	212	19	the	the	DT
cord-340028-6oicmeam	212	20	SARS	SARS	NNP
cord-340028-6oicmeam	212	21	-	-	HYPH
cord-340028-6oicmeam	212	22	CoV-2	CoV-2	NNP
cord-340028-6oicmeam	212	23	3C	3c	NN
cord-340028-6oicmeam	212	24	-	-	HYPH
cord-340028-6oicmeam	212	25	like	like	JJ
cord-340028-6oicmeam	212	26	protease	protease	NN
cord-340028-6oicmeam	212	27	[	[	-LRB-
cord-340028-6oicmeam	212	28	120	120	CD
cord-340028-6oicmeam	212	29	,	,	,
cord-340028-6oicmeam	212	30	121	121	CD
cord-340028-6oicmeam	212	31	]	]	-RRB-
cord-340028-6oicmeam	212	32	.	.	.
cord-340028-6oicmeam	213	1	As	as	IN
cord-340028-6oicmeam	213	2	the	the	DT
cord-340028-6oicmeam	213	3	scale	scale	NN
cord-340028-6oicmeam	213	4	of	of	IN
cord-340028-6oicmeam	213	5	the	the	DT
cord-340028-6oicmeam	213	6	current	current	JJ
cord-340028-6oicmeam	213	7	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	213	8	pandemic	pandemic	NN
cord-340028-6oicmeam	213	9	remains	remain	VBZ
cord-340028-6oicmeam	213	10	uncertain	uncertain	JJ
cord-340028-6oicmeam	213	11	,	,	,
cord-340028-6oicmeam	213	12	it	-PRON-	PRP
cord-340028-6oicmeam	213	13	is	be	VBZ
cord-340028-6oicmeam	213	14	still	still	RB
cord-340028-6oicmeam	213	15	difficult	difficult	JJ
cord-340028-6oicmeam	213	16	to	to	TO
cord-340028-6oicmeam	213	17	justify	justify	VB
cord-340028-6oicmeam	213	18	allocating	allocate	VBG
cord-340028-6oicmeam	213	19	scarce	scarce	JJ
cord-340028-6oicmeam	213	20	company	company	NN
cord-340028-6oicmeam	213	21	resources	resource	NNS
cord-340028-6oicmeam	213	22	to	to	IN
cord-340028-6oicmeam	213	23	full	full	JJ
cord-340028-6oicmeam	213	24	-	-	HYPH
cord-340028-6oicmeam	213	25	scale	scale	NN
cord-340028-6oicmeam	213	26	drug	drug	NN
cord-340028-6oicmeam	213	27	discovery	discovery	NN
cord-340028-6oicmeam	213	28	and	and	CC
cord-340028-6oicmeam	213	29	drug	drug	NN
cord-340028-6oicmeam	213	30	development	development	NN
cord-340028-6oicmeam	213	31	programs	program	NNS
cord-340028-6oicmeam	213	32	,	,	,
cord-340028-6oicmeam	213	33	which	which	WDT
cord-340028-6oicmeam	213	34	may	may	MD
cord-340028-6oicmeam	213	35	cost	cost	VB
cord-340028-6oicmeam	213	36	tens	ten	NNS
cord-340028-6oicmeam	213	37	or	or	CC
cord-340028-6oicmeam	213	38	even	even	RB
cord-340028-6oicmeam	213	39	hundreds	hundred	NNS
cord-340028-6oicmeam	213	40	of	of	IN
cord-340028-6oicmeam	213	41	millions	million	NNS
cord-340028-6oicmeam	213	42	of	of	IN
cord-340028-6oicmeam	213	43	dollars	dollar	NNS
cord-340028-6oicmeam	213	44	[	[	-LRB-
cord-340028-6oicmeam	213	45	122	122	CD
cord-340028-6oicmeam	213	46	]	]	-RRB-
cord-340028-6oicmeam	213	47	.	.	.
cord-340028-6oicmeam	214	1	Multiple	multiple	JJ
cord-340028-6oicmeam	214	2	biotechnology	biotechnology	NN
cord-340028-6oicmeam	214	3	companies	company	NNS
cord-340028-6oicmeam	214	4	are	be	VBP
cord-340028-6oicmeam	214	5	in	in	IN
cord-340028-6oicmeam	214	6	the	the	DT
cord-340028-6oicmeam	214	7	same	same	JJ
cord-340028-6oicmeam	214	8	situation	situation	NN
cord-340028-6oicmeam	214	9	and	and	CC
cord-340028-6oicmeam	214	10	will	will	MD
cord-340028-6oicmeam	214	11	not	not	RB
cord-340028-6oicmeam	214	12	be	be	VB
cord-340028-6oicmeam	214	13	able	able	JJ
cord-340028-6oicmeam	214	14	to	to	TO
cord-340028-6oicmeam	214	15	proceed	proceed	VB
cord-340028-6oicmeam	214	16	without	without	IN
cord-340028-6oicmeam	214	17	substantial	substantial	JJ
cord-340028-6oicmeam	214	18	backing	backing	NN
cord-340028-6oicmeam	214	19	from	from	IN
cord-340028-6oicmeam	214	20	government	government	NN
cord-340028-6oicmeam	214	21	agencies	agency	NNS
cord-340028-6oicmeam	214	22	,	,	,
cord-340028-6oicmeam	214	23	nonprofit	nonprofit	JJ
cord-340028-6oicmeam	214	24	organizations	organization	NNS
cord-340028-6oicmeam	214	25	,	,	,
cord-340028-6oicmeam	214	26	or	or	CC
cord-340028-6oicmeam	214	27	bigger	big	JJR
cord-340028-6oicmeam	214	28	pharmaceutical	pharmaceutical	JJ
cord-340028-6oicmeam	214	29	companies	company	NNS
cord-340028-6oicmeam	214	30	.	.	.
cord-340028-6oicmeam	215	1	However	however	RB
cord-340028-6oicmeam	215	2	,	,	,
cord-340028-6oicmeam	215	3	given	give	VBN
cord-340028-6oicmeam	215	4	the	the	DT
cord-340028-6oicmeam	215	5	gerophilic	gerophilic	JJ
cord-340028-6oicmeam	215	6	and	and	CC
cord-340028-6oicmeam	215	7	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	215	8	nature	nature	NN
cord-340028-6oicmeam	215	9	of	of	IN
cord-340028-6oicmeam	215	10	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	215	11	,	,	,
cord-340028-6oicmeam	215	12	strategies	strategy	NNS
cord-340028-6oicmeam	215	13	targeting	target	VBG
cord-340028-6oicmeam	215	14	age	age	NN
cord-340028-6oicmeam	215	15	-	-	HYPH
cord-340028-6oicmeam	215	16	associated	associate	VBN
cord-340028-6oicmeam	215	17	pathologies	pathology	NNS
cord-340028-6oicmeam	215	18	and	and	CC
cord-340028-6oicmeam	215	19	immunosenescence	immunosenescence	NNP
cord-340028-6oicmeam	215	20	,	,	,
cord-340028-6oicmeam	215	21	which	which	WDT
cord-340028-6oicmeam	215	22	could	could	MD
cord-340028-6oicmeam	215	23	decrease	decrease	VB
cord-340028-6oicmeam	215	24	the	the	DT
cord-340028-6oicmeam	215	25	comorbidity	comorbidity	NN
cord-340028-6oicmeam	215	26	,	,	,
cord-340028-6oicmeam	215	27	infection	infection	NN
cord-340028-6oicmeam	215	28	rates	rate	NNS
cord-340028-6oicmeam	215	29	,	,	,
cord-340028-6oicmeam	215	30	severity	severity	NN
cord-340028-6oicmeam	215	31	,	,	,
cord-340028-6oicmeam	215	32	and	and	CC
cord-340028-6oicmeam	215	33	lethality	lethality	NN
cord-340028-6oicmeam	215	34	of	of	IN
cord-340028-6oicmeam	215	35	the	the	DT
cord-340028-6oicmeam	215	36	disease	disease	NN
cord-340028-6oicmeam	215	37	,	,	,
cord-340028-6oicmeam	215	38	will	will	MD
cord-340028-6oicmeam	215	39	remain	remain	VB
cord-340028-6oicmeam	215	40	commercially	commercially	RB
cord-340028-6oicmeam	215	41	-	-	HYPH
cord-340028-6oicmeam	215	42	viable	viable	JJ
cord-340028-6oicmeam	215	43	even	even	RB
cord-340028-6oicmeam	215	44	when	when	WRB
cord-340028-6oicmeam	215	45	the	the	DT
cord-340028-6oicmeam	215	46	pandemic	pandemic	NN
cord-340028-6oicmeam	215	47	subsides	subside	VBZ
cord-340028-6oicmeam	215	48	.	.	.
cord-340028-6oicmeam	216	1	In	in	IN
cord-340028-6oicmeam	216	2	addition	addition	NN
cord-340028-6oicmeam	216	3	,	,	,
cord-340028-6oicmeam	216	4	respiratory	respiratory	JJ
cord-340028-6oicmeam	216	5	infections	infection	NNS
cord-340028-6oicmeam	216	6	are	be	VBP
cord-340028-6oicmeam	216	7	now	now	RB
cord-340028-6oicmeam	216	8	the	the	DT
cord-340028-6oicmeam	216	9	third	third	JJ
cord-340028-6oicmeam	216	10	leading	leading	JJ
cord-340028-6oicmeam	216	11	cause	cause	NN
cord-340028-6oicmeam	216	12	of	of	IN
cord-340028-6oicmeam	216	13	death	death	NN
cord-340028-6oicmeam	216	14	in	in	IN
cord-340028-6oicmeam	216	15	the	the	DT
cord-340028-6oicmeam	216	16	world	world	NN
cord-340028-6oicmeam	216	17	,	,	,
cord-340028-6oicmeam	216	18	following	follow	VBG
cord-340028-6oicmeam	216	19	cardiac	cardiac	JJ
cord-340028-6oicmeam	216	20	disease	disease	NN
cord-340028-6oicmeam	216	21	and	and	CC
cord-340028-6oicmeam	216	22	stroke	stroke	NN
cord-340028-6oicmeam	216	23	[	[	-LRB-
cord-340028-6oicmeam	216	24	123	123	CD
cord-340028-6oicmeam	216	25	]	]	-RRB-
cord-340028-6oicmeam	216	26	,	,	,
cord-340028-6oicmeam	216	27	further	further	RB
cord-340028-6oicmeam	216	28	justifying	justify	VBG
cord-340028-6oicmeam	216	29	the	the	DT
cord-340028-6oicmeam	216	30	need	need	NN
cord-340028-6oicmeam	216	31	for	for	IN
cord-340028-6oicmeam	216	32	these	these	DT
cord-340028-6oicmeam	216	33	interventions	intervention	NNS
cord-340028-6oicmeam	216	34	.	.	.
cord-340028-6oicmeam	217	1	Considering	consider	VBG
cord-340028-6oicmeam	217	2	the	the	DT
cord-340028-6oicmeam	217	3	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	217	4	nature	nature	NN
cord-340028-6oicmeam	217	5	of	of	IN
cord-340028-6oicmeam	217	6	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	217	7	,	,	,
cord-340028-6oicmeam	217	8	where	where	WRB
cord-340028-6oicmeam	217	9	the	the	DT
cord-340028-6oicmeam	217	10	majority	majority	NN
cord-340028-6oicmeam	217	11	of	of	IN
cord-340028-6oicmeam	217	12	the	the	DT
cord-340028-6oicmeam	217	13	seriously	seriously	RB
cord-340028-6oicmeam	217	14	affected	affect	VBN
cord-340028-6oicmeam	217	15	population	population	NN
cord-340028-6oicmeam	217	16	is	be	VBZ
cord-340028-6oicmeam	217	17	older	old	JJR
cord-340028-6oicmeam	217	18	than	than	IN
cord-340028-6oicmeam	217	19	60	60	CD
cord-340028-6oicmeam	217	20	,	,	,
cord-340028-6oicmeam	217	21	classical	classical	JJ
cord-340028-6oicmeam	217	22	prevention	prevention	NN
cord-340028-6oicmeam	217	23	and	and	CC
cord-340028-6oicmeam	217	24	treatment	treatment	NN
cord-340028-6oicmeam	217	25	strategies	strategy	NNS
cord-340028-6oicmeam	217	26	may	may	MD
cord-340028-6oicmeam	217	27	not	not	RB
cord-340028-6oicmeam	217	28	be	be	VB
cord-340028-6oicmeam	217	29	effective	effective	JJ
cord-340028-6oicmeam	217	30	.	.	.
cord-340028-6oicmeam	218	1	Given	give	VBN
cord-340028-6oicmeam	218	2	the	the	DT
cord-340028-6oicmeam	218	3	severity	severity	NN
cord-340028-6oicmeam	218	4	and	and	CC
cord-340028-6oicmeam	218	5	lethality	lethality	NN
cord-340028-6oicmeam	218	6	of	of	IN
cord-340028-6oicmeam	218	7	the	the	DT
cord-340028-6oicmeam	218	8	pandemic	pandemic	NN
cord-340028-6oicmeam	218	9	,	,	,
cord-340028-6oicmeam	218	10	even	even	RB
cord-340028-6oicmeam	218	11	healthcare	healthcare	NN
cord-340028-6oicmeam	218	12	systems	system	NNS
cord-340028-6oicmeam	218	13	in	in	IN
cord-340028-6oicmeam	218	14	developed	develop	VBN
cord-340028-6oicmeam	218	15	countries	country	NNS
cord-340028-6oicmeam	218	16	will	will	MD
cord-340028-6oicmeam	218	17	find	find	VB
cord-340028-6oicmeam	218	18	it	-PRON-	PRP
cord-340028-6oicmeam	218	19	challenging	challenging	JJ
cord-340028-6oicmeam	218	20	to	to	TO
cord-340028-6oicmeam	218	21	cope	cope	VB
cord-340028-6oicmeam	218	22	with	with	IN
cord-340028-6oicmeam	218	23	the	the	DT
cord-340028-6oicmeam	218	24	increased	increase	VBN
cord-340028-6oicmeam	218	25	disease	disease	NN
cord-340028-6oicmeam	218	26	burden	burden	NN
cord-340028-6oicmeam	218	27	and	and	CC
cord-340028-6oicmeam	218	28	hospital	hospital	NN
cord-340028-6oicmeam	218	29	needs	need	NNS
cord-340028-6oicmeam	218	30	.	.	.
cord-340028-6oicmeam	219	1	Conventional	conventional	JJ
cord-340028-6oicmeam	219	2	approaches	approach	NNS
cord-340028-6oicmeam	219	3	to	to	IN
cord-340028-6oicmeam	219	4	prevention	prevention	NN
cord-340028-6oicmeam	219	5	such	such	JJ
cord-340028-6oicmeam	219	6	as	as	IN
cord-340028-6oicmeam	219	7	vaccines	vaccine	NNS
cord-340028-6oicmeam	219	8	are	be	VBP
cord-340028-6oicmeam	219	9	much	much	RB
cord-340028-6oicmeam	219	10	needed	need	VBN
cord-340028-6oicmeam	219	11	,	,	,
cord-340028-6oicmeam	219	12	but	but	CC
cord-340028-6oicmeam	219	13	even	even	RB
cord-340028-6oicmeam	219	14	these	these	DT
cord-340028-6oicmeam	219	15	do	do	VBP
cord-340028-6oicmeam	219	16	not	not	RB
cord-340028-6oicmeam	219	17	offer	offer	VB
cord-340028-6oicmeam	219	18	complete	complete	JJ
cord-340028-6oicmeam	219	19	protection	protection	NN
cord-340028-6oicmeam	219	20	in	in	IN
cord-340028-6oicmeam	219	21	the	the	DT
cord-340028-6oicmeam	219	22	elderly	elderly	JJ
cord-340028-6oicmeam	219	23	due	due	IN
cord-340028-6oicmeam	219	24	to	to	IN
cord-340028-6oicmeam	219	25	multi	multi	JJ
cord-340028-6oicmeam	219	26	-	-	JJ
cord-340028-6oicmeam	219	27	morbidity	morbidity	JJ
cord-340028-6oicmeam	219	28	and	and	CC
cord-340028-6oicmeam	219	29	agerelated	agerelate	VBN
cord-340028-6oicmeam	219	30	immune	immune	JJ
cord-340028-6oicmeam	219	31	declines	decline	NNS
cord-340028-6oicmeam	219	32	.	.	.
cord-340028-6oicmeam	220	1	Therefore	therefore	RB
cord-340028-6oicmeam	220	2	,	,	,
cord-340028-6oicmeam	220	3	interventions	intervention	NNS
cord-340028-6oicmeam	220	4	that	that	WDT
cord-340028-6oicmeam	220	5	enable	enable	VBP
cord-340028-6oicmeam	220	6	immunocompromised	immunocompromised	JJ
cord-340028-6oicmeam	220	7	elderly	elderly	JJ
cord-340028-6oicmeam	220	8	to	to	TO
cord-340028-6oicmeam	220	9	mount	mount	VB
cord-340028-6oicmeam	220	10	an	an	DT
cord-340028-6oicmeam	220	11	immune	immune	JJ
cord-340028-6oicmeam	220	12	response	response	NN
cord-340028-6oicmeam	220	13	to	to	IN
cord-340028-6oicmeam	220	14	newly	newly	RB
cord-340028-6oicmeam	220	15	developed	develop	VBN
cord-340028-6oicmeam	220	16	vaccines	vaccine	NNS
cord-340028-6oicmeam	220	17	are	be	VBP
cord-340028-6oicmeam	220	18	necessary	necessary	JJ
cord-340028-6oicmeam	220	19	to	to	TO
cord-340028-6oicmeam	220	20	help	help	VB
cord-340028-6oicmeam	220	21	eradicate	eradicate	VB
cord-340028-6oicmeam	220	22	the	the	DT
cord-340028-6oicmeam	220	23	disease	disease	NN
cord-340028-6oicmeam	220	24	and	and	CC
cord-340028-6oicmeam	220	25	reduce	reduce	VB
cord-340028-6oicmeam	220	26	the	the	DT
cord-340028-6oicmeam	220	27	associated	associated	JJ
cord-340028-6oicmeam	220	28	mortality	mortality	NN
cord-340028-6oicmeam	220	29	.	.	.
cord-340028-6oicmeam	221	1	To	to	TO
cord-340028-6oicmeam	221	2	avoid	avoid	VB
cord-340028-6oicmeam	221	3	substantial	substantial	JJ
cord-340028-6oicmeam	221	4	loss	loss	NN
cord-340028-6oicmeam	221	5	of	of	IN
cord-340028-6oicmeam	221	6	life	life	NN
cord-340028-6oicmeam	221	7	and	and	CC
cord-340028-6oicmeam	221	8	quality	quality	NN
cord-340028-6oicmeam	221	9	of	of	IN
cord-340028-6oicmeam	221	10	life	life	NN
cord-340028-6oicmeam	221	11	,	,	,
cord-340028-6oicmeam	221	12	primarily	primarily	RB
cord-340028-6oicmeam	221	13	among	among	IN
cord-340028-6oicmeam	221	14	the	the	DT
cord-340028-6oicmeam	221	15	elderly	elderly	JJ
cord-340028-6oicmeam	221	16	and	and	CC
cord-340028-6oicmeam	221	17	vulnerable	vulnerable	JJ
cord-340028-6oicmeam	221	18	populations	population	NNS
cord-340028-6oicmeam	221	19	,	,	,
cord-340028-6oicmeam	221	20	governments	government	NNS
cord-340028-6oicmeam	221	21	and	and	CC
cord-340028-6oicmeam	221	22	healthcare	healthcare	NN
cord-340028-6oicmeam	221	23	systems	system	NNS
cord-340028-6oicmeam	221	24	should	should	MD
cord-340028-6oicmeam	221	25	investigate	investigate	VB
cord-340028-6oicmeam	221	26	preventative	preventative	JJ
cord-340028-6oicmeam	221	27	and	and	CC
cord-340028-6oicmeam	221	28	intervention	intervention	NN
cord-340028-6oicmeam	221	29	strategies	strategy	NNS
cord-340028-6oicmeam	221	30	stemming	stem	VBG
cord-340028-6oicmeam	221	31	from	from	IN
cord-340028-6oicmeam	221	32	recent	recent	JJ
cord-340028-6oicmeam	221	33	advances	advance	NNS
cord-340028-6oicmeam	221	34	in	in	IN
cord-340028-6oicmeam	221	35	aging	age	VBG
cord-340028-6oicmeam	221	36	research	research	NN
cord-340028-6oicmeam	221	37	.	.	.
cord-340028-6oicmeam	222	1	As	as	IN
cord-340028-6oicmeam	222	2	discussed	discuss	VBN
cord-340028-6oicmeam	222	3	in	in	IN
cord-340028-6oicmeam	222	4	this	this	DT
cord-340028-6oicmeam	222	5	paper	paper	NN
cord-340028-6oicmeam	222	6	,	,	,
cord-340028-6oicmeam	222	7	small	small	JJ
cord-340028-6oicmeam	222	8	clinical	clinical	JJ
cord-340028-6oicmeam	222	9	studies	study	NNS
cord-340028-6oicmeam	222	10	have	have	VBP
cord-340028-6oicmeam	222	11	shown	show	VBN
cord-340028-6oicmeam	222	12	that	that	IN
cord-340028-6oicmeam	222	13	several	several	JJ
cord-340028-6oicmeam	222	14	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	222	15	and	and	CC
cord-340028-6oicmeam	222	16	senoremediative	senoremediative	JJ
cord-340028-6oicmeam	222	17	interventions	intervention	NNS
cord-340028-6oicmeam	222	18	,	,	,
cord-340028-6oicmeam	222	19	such	such	JJ
cord-340028-6oicmeam	222	20	as	as	IN
cord-340028-6oicmeam	222	21	treatment	treatment	NN
cord-340028-6oicmeam	222	22	with	with	IN
cord-340028-6oicmeam	222	23	AGING	AGING	NNP
cord-340028-6oicmeam	222	24	sirolimus	sirolimus	NN
cord-340028-6oicmeam	222	25	and	and	CC
cord-340028-6oicmeam	222	26	rapalogs	rapalogs	NNP
cord-340028-6oicmeam	222	27	,	,	,
cord-340028-6oicmeam	222	28	can	can	MD
cord-340028-6oicmeam	222	29	induce	induce	VB
cord-340028-6oicmeam	222	30	immunopotentiation	immunopotentiation	NN
cord-340028-6oicmeam	222	31	,	,	,
cord-340028-6oicmeam	222	32	increase	increase	VB
cord-340028-6oicmeam	222	33	resistance	resistance	NN
cord-340028-6oicmeam	222	34	to	to	IN
cord-340028-6oicmeam	222	35	infection	infection	NN
cord-340028-6oicmeam	222	36	,	,	,
cord-340028-6oicmeam	222	37	and	and	CC
cord-340028-6oicmeam	222	38	reduce	reduce	VB
cord-340028-6oicmeam	222	39	disease	disease	NN
cord-340028-6oicmeam	222	40	severity	severity	NN
cord-340028-6oicmeam	222	41	in	in	IN
cord-340028-6oicmeam	222	42	the	the	DT
cord-340028-6oicmeam	222	43	elderly	elderly	JJ
cord-340028-6oicmeam	222	44	,	,	,
cord-340028-6oicmeam	222	45	without	without	IN
cord-340028-6oicmeam	222	46	severe	severe	JJ
cord-340028-6oicmeam	222	47	side	side	NN
cord-340028-6oicmeam	222	48	effects	effect	NNS
cord-340028-6oicmeam	222	49	.	.	.
cord-340028-6oicmeam	223	1	Serendipitously	serendipitously	RB
cord-340028-6oicmeam	223	2	,	,	,
cord-340028-6oicmeam	223	3	during	during	IN
cord-340028-6oicmeam	223	4	the	the	DT
cord-340028-6oicmeam	223	5	revision	revision	NN
cord-340028-6oicmeam	223	6	of	of	IN
cord-340028-6oicmeam	223	7	this	this	DT
cord-340028-6oicmeam	223	8	article	article	NN
cord-340028-6oicmeam	223	9	,	,	,
cord-340028-6oicmeam	223	10	another	another	DT
cord-340028-6oicmeam	223	11	group	group	NN
cord-340028-6oicmeam	223	12	utilizing	utilize	VBG
cord-340028-6oicmeam	223	13	computational	computational	JJ
cord-340028-6oicmeam	223	14	approaches	approach	NNS
cord-340028-6oicmeam	223	15	proposed	propose	VBN
cord-340028-6oicmeam	223	16	using	use	VBG
cord-340028-6oicmeam	223	17	melatonin	melatonin	NN
cord-340028-6oicmeam	223	18	and	and	CC
cord-340028-6oicmeam	223	19	sirolimus	sirolimus	NN
cord-340028-6oicmeam	223	20	(	(	-LRB-
cord-340028-6oicmeam	223	21	rapamycin	rapamycin	NN
cord-340028-6oicmeam	223	22	)	)	-RRB-
cord-340028-6oicmeam	223	23	in	in	IN
cord-340028-6oicmeam	223	24	combination	combination	NN
cord-340028-6oicmeam	223	25	to	to	TO
cord-340028-6oicmeam	223	26	treat	treat	VB
cord-340028-6oicmeam	223	27	the	the	DT
cord-340028-6oicmeam	223	28	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	223	29	infection	infection	NN
cord-340028-6oicmeam	223	30	outside	outside	IN
cord-340028-6oicmeam	223	31	the	the	DT
cord-340028-6oicmeam	223	32	context	context	NN
cord-340028-6oicmeam	223	33	of	of	IN
cord-340028-6oicmeam	223	34	geroprotection	geroprotection	NN
cord-340028-6oicmeam	223	35	[	[	-LRB-
cord-340028-6oicmeam	223	36	124	124	CD
cord-340028-6oicmeam	223	37	]	]	-RRB-
cord-340028-6oicmeam	223	38	.	.	.
cord-340028-6oicmeam	224	1	Many	many	JJ
cord-340028-6oicmeam	224	2	of	of	IN
cord-340028-6oicmeam	224	3	these	these	DT
cord-340028-6oicmeam	224	4	predicted	predict	VBN
cord-340028-6oicmeam	224	5	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	224	6	are	be	VBP
cord-340028-6oicmeam	224	7	available	available	JJ
cord-340028-6oicmeam	224	8	as	as	IN
cord-340028-6oicmeam	224	9	supplements	supplement	NNS
cord-340028-6oicmeam	224	10	;	;	:
cord-340028-6oicmeam	224	11	however	however	RB
cord-340028-6oicmeam	224	12	,	,	,
cord-340028-6oicmeam	224	13	no	no	DT
cord-340028-6oicmeam	224	14	meta	meta	NN
cord-340028-6oicmeam	224	15	-	-	HYPH
cord-340028-6oicmeam	224	16	analysis	analysis	NN
cord-340028-6oicmeam	224	17	or	or	CC
cord-340028-6oicmeam	224	18	metaclinical	metaclinical	JJ
cord-340028-6oicmeam	224	19	trials	trial	NNS
cord-340028-6oicmeam	224	20	have	have	VBP
cord-340028-6oicmeam	224	21	been	be	VBN
cord-340028-6oicmeam	224	22	performed	perform	VBN
cord-340028-6oicmeam	224	23	at	at	IN
cord-340028-6oicmeam	224	24	scale	scale	NN
cord-340028-6oicmeam	224	25	to	to	TO
cord-340028-6oicmeam	224	26	evaluate	evaluate	VB
cord-340028-6oicmeam	224	27	their	-PRON-	PRP$
cord-340028-6oicmeam	224	28	effectiveness	effectiveness	NN
cord-340028-6oicmeam	224	29	.	.	.
cord-340028-6oicmeam	225	1	The	the	DT
cord-340028-6oicmeam	225	2	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	225	3	pandemic	pandemic	NN
cord-340028-6oicmeam	225	4	highlights	highlight	VBZ
cord-340028-6oicmeam	225	5	the	the	DT
cord-340028-6oicmeam	225	6	paucity	paucity	NN
cord-340028-6oicmeam	225	7	of	of	IN
cord-340028-6oicmeam	225	8	clinical	clinical	JJ
cord-340028-6oicmeam	225	9	trials	trial	NNS
cord-340028-6oicmeam	225	10	on	on	IN
cord-340028-6oicmeam	225	11	the	the	DT
cord-340028-6oicmeam	225	12	effects	effect	NNS
cord-340028-6oicmeam	225	13	of	of	IN
cord-340028-6oicmeam	225	14	dietary	dietary	JJ
cord-340028-6oicmeam	225	15	supplements	supplement	NNS
cord-340028-6oicmeam	225	16	and	and	CC
cord-340028-6oicmeam	225	17	drugs	drug	NNS
cord-340028-6oicmeam	225	18	on	on	IN
cord-340028-6oicmeam	225	19	aging	age	VBG
cord-340028-6oicmeam	225	20	and	and	CC
cord-340028-6oicmeam	225	21	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	225	22	.	.	.
cord-340028-6oicmeam	226	1	The	the	DT
cord-340028-6oicmeam	226	2	existence	existence	NN
cord-340028-6oicmeam	226	3	of	of	IN
cord-340028-6oicmeam	226	4	pseudoscience	pseudoscience	NN
cord-340028-6oicmeam	226	5	and	and	CC
cord-340028-6oicmeam	226	6	anecdotal	anecdotal	JJ
cord-340028-6oicmeam	226	7	promotion	promotion	NN
cord-340028-6oicmeam	226	8	in	in	IN
cord-340028-6oicmeam	226	9	the	the	DT
cord-340028-6oicmeam	226	10	supplement	supplement	NN
cord-340028-6oicmeam	226	11	industry	industry	NN
cord-340028-6oicmeam	226	12	does	do	VBZ
cord-340028-6oicmeam	226	13	not	not	RB
cord-340028-6oicmeam	226	14	mean	mean	VB
cord-340028-6oicmeam	226	15	that	that	IN
cord-340028-6oicmeam	226	16	protective	protective	JJ
cord-340028-6oicmeam	226	17	compounds	compound	NNS
cord-340028-6oicmeam	226	18	do	do	VBP
cord-340028-6oicmeam	226	19	not	not	RB
cord-340028-6oicmeam	226	20	exist	exist	VB
cord-340028-6oicmeam	226	21	.	.	.
cord-340028-6oicmeam	227	1	Dietary	dietary	JJ
cord-340028-6oicmeam	227	2	supplement	supplement	NN
cord-340028-6oicmeam	227	3	vendors	vendor	NNS
cord-340028-6oicmeam	227	4	and	and	CC
cord-340028-6oicmeam	227	5	pharmaceutical	pharmaceutical	NN
cord-340028-6oicmeam	227	6	companies	company	NNS
cord-340028-6oicmeam	227	7	need	need	VBP
cord-340028-6oicmeam	227	8	to	to	TO
cord-340028-6oicmeam	227	9	actively	actively	RB
cord-340028-6oicmeam	227	10	engage	engage	VB
cord-340028-6oicmeam	227	11	in	in	IN
cord-340028-6oicmeam	227	12	preclinical	preclinical	JJ
cord-340028-6oicmeam	227	13	and	and	CC
cord-340028-6oicmeam	227	14	clinical	clinical	JJ
cord-340028-6oicmeam	227	15	research	research	NN
cord-340028-6oicmeam	227	16	to	to	TO
cord-340028-6oicmeam	227	17	evaluate	evaluate	VB
cord-340028-6oicmeam	227	18	the	the	DT
cord-340028-6oicmeam	227	19	effectiveness	effectiveness	NN
cord-340028-6oicmeam	227	20	of	of	IN
cord-340028-6oicmeam	227	21	the	the	DT
cord-340028-6oicmeam	227	22	currently	currently	RB
cord-340028-6oicmeam	227	23	available	available	JJ
cord-340028-6oicmeam	227	24	products	product	NNS
cord-340028-6oicmeam	227	25	on	on	IN
cord-340028-6oicmeam	227	26	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	227	27	and	and	CC
cord-340028-6oicmeam	227	28	aging	age	VBG
cord-340028-6oicmeam	227	29	.	.	.
cord-340028-6oicmeam	228	1	This	this	DT
cord-340028-6oicmeam	228	2	paper	paper	NN
cord-340028-6oicmeam	228	3	is	be	VBZ
cord-340028-6oicmeam	228	4	not	not	RB
cord-340028-6oicmeam	228	5	intended	intend	VBN
cord-340028-6oicmeam	228	6	to	to	TO
cord-340028-6oicmeam	228	7	encourage	encourage	VB
cord-340028-6oicmeam	228	8	the	the	DT
cord-340028-6oicmeam	228	9	use	use	NN
cord-340028-6oicmeam	228	10	of	of	IN
cord-340028-6oicmeam	228	11	rapalogs	rapalog	NNS
cord-340028-6oicmeam	228	12	or	or	CC
cord-340028-6oicmeam	228	13	other	other	JJ
cord-340028-6oicmeam	228	14	potential	potential	JJ
cord-340028-6oicmeam	228	15	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	228	16	during	during	IN
cord-340028-6oicmeam	228	17	the	the	DT
cord-340028-6oicmeam	228	18	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	228	19	pandemic	pandemic	NN
cord-340028-6oicmeam	228	20	.	.	.
cord-340028-6oicmeam	229	1	It	-PRON-	PRP
cord-340028-6oicmeam	229	2	may	may	MD
cord-340028-6oicmeam	229	3	be	be	VB
cord-340028-6oicmeam	229	4	possible	possible	JJ
cord-340028-6oicmeam	229	5	that	that	IN
cord-340028-6oicmeam	229	6	some	some	DT
cord-340028-6oicmeam	229	7	of	of	IN
cord-340028-6oicmeam	229	8	the	the	DT
cord-340028-6oicmeam	229	9	potential	potential	JJ
cord-340028-6oicmeam	229	10	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	229	11	described	describe	VBN
cord-340028-6oicmeam	229	12	in	in	IN
cord-340028-6oicmeam	229	13	this	this	DT
cord-340028-6oicmeam	229	14	paper	paper	NN
cord-340028-6oicmeam	229	15	are	be	VBP
cord-340028-6oicmeam	229	16	harmful	harmful	JJ
cord-340028-6oicmeam	229	17	to	to	IN
cord-340028-6oicmeam	229	18	the	the	DT
cord-340028-6oicmeam	229	19	elderly	elderly	JJ
cord-340028-6oicmeam	229	20	after	after	IN
cord-340028-6oicmeam	229	21	infection	infection	NN
cord-340028-6oicmeam	229	22	,	,	,
cord-340028-6oicmeam	229	23	and	and	CC
cord-340028-6oicmeam	229	24	may	may	MD
cord-340028-6oicmeam	229	25	actually	actually	RB
cord-340028-6oicmeam	229	26	increase	increase	VB
cord-340028-6oicmeam	229	27	disease	disease	NN
cord-340028-6oicmeam	229	28	severity	severity	NN
cord-340028-6oicmeam	229	29	and	and	CC
cord-340028-6oicmeam	229	30	lethality	lethality	NN
cord-340028-6oicmeam	229	31	.	.	.
cord-340028-6oicmeam	230	1	However	however	RB
cord-340028-6oicmeam	230	2	,	,	,
cord-340028-6oicmeam	230	3	it	-PRON-	PRP
cord-340028-6oicmeam	230	4	may	may	MD
cord-340028-6oicmeam	230	5	be	be	VB
cord-340028-6oicmeam	230	6	possible	possible	JJ
cord-340028-6oicmeam	230	7	to	to	TO
cord-340028-6oicmeam	230	8	conduct	conduct	VB
cord-340028-6oicmeam	230	9	clinical	clinical	JJ
cord-340028-6oicmeam	230	10	trials	trial	NNS
cord-340028-6oicmeam	230	11	on	on	IN
cord-340028-6oicmeam	230	12	the	the	DT
cord-340028-6oicmeam	230	13	efficacy	efficacy	NN
cord-340028-6oicmeam	230	14	of	of	IN
cord-340028-6oicmeam	230	15	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	230	16	previously	previously	RB
cord-340028-6oicmeam	230	17	tested	test	VBN
cord-340028-6oicmeam	230	18	in	in	IN
cord-340028-6oicmeam	230	19	human	human	JJ
cord-340028-6oicmeam	230	20	clinical	clinical	JJ
cord-340028-6oicmeam	230	21	trials	trial	NNS
cord-340028-6oicmeam	230	22	in	in	IN
cord-340028-6oicmeam	230	23	treating	treat	VBG
cord-340028-6oicmeam	230	24	COVID-19	covid-19	CD
cord-340028-6oicmeam	230	25	and	and	CC
cord-340028-6oicmeam	230	26	other	other	JJ
cord-340028-6oicmeam	230	27	gerophilic	gerophilic	NN
cord-340028-6oicmeam	230	28	and	and	CC
cord-340028-6oicmeam	230	29	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	230	30	infections	infection	NNS
cord-340028-6oicmeam	230	31	.	.	.
cord-340028-6oicmeam	231	1	To	to	TO
cord-340028-6oicmeam	231	2	combat	combat	VB
cord-340028-6oicmeam	231	3	the	the	DT
cord-340028-6oicmeam	231	4	growing	grow	VBG
cord-340028-6oicmeam	231	5	COVID-19	covid-19	JJ
cord-340028-6oicmeam	231	6	pandemic	pandemic	NN
cord-340028-6oicmeam	231	7	,	,	,
cord-340028-6oicmeam	231	8	researchers	researcher	NNS
cord-340028-6oicmeam	231	9	have	have	VBP
cord-340028-6oicmeam	231	10	united	unite	VBN
cord-340028-6oicmeam	231	11	globally	globally	RB
cord-340028-6oicmeam	231	12	to	to	TO
cord-340028-6oicmeam	231	13	tackle	tackle	VB
cord-340028-6oicmeam	231	14	a	a	DT
cord-340028-6oicmeam	231	15	disease	disease	NN
cord-340028-6oicmeam	231	16	that	that	WDT
cord-340028-6oicmeam	231	17	is	be	VBZ
cord-340028-6oicmeam	231	18	impacting	impact	VBG
cord-340028-6oicmeam	231	19	lives	life	NNS
cord-340028-6oicmeam	231	20	and	and	CC
cord-340028-6oicmeam	231	21	healthcare	healthcare	NN
cord-340028-6oicmeam	231	22	systems	system	NNS
cord-340028-6oicmeam	231	23	around	around	IN
cord-340028-6oicmeam	231	24	the	the	DT
cord-340028-6oicmeam	231	25	world	world	NN
cord-340028-6oicmeam	231	26	.	.	.
cord-340028-6oicmeam	232	1	After	after	IN
cord-340028-6oicmeam	232	2	carefully	carefully	RB
cord-340028-6oicmeam	232	3	analysing	analyse	VBG
cord-340028-6oicmeam	232	4	preliminary	preliminary	JJ
cord-340028-6oicmeam	232	5	data	datum	NNS
cord-340028-6oicmeam	232	6	,	,	,
cord-340028-6oicmeam	232	7	we	-PRON-	PRP
cord-340028-6oicmeam	232	8	suggest	suggest	VBP
cord-340028-6oicmeam	232	9	that	that	IN
cord-340028-6oicmeam	232	10	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	232	11	has	have	VBZ
cord-340028-6oicmeam	232	12	a	a	DT
cord-340028-6oicmeam	232	13	gerophilic	gerophilic	JJ
cord-340028-6oicmeam	232	14	and	and	CC
cord-340028-6oicmeam	232	15	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	232	16	profile	profile	NN
cord-340028-6oicmeam	232	17	,	,	,
cord-340028-6oicmeam	232	18	being	be	VBG
cord-340028-6oicmeam	232	19	more	more	RBR
cord-340028-6oicmeam	232	20	infectious	infectious	JJ
cord-340028-6oicmeam	232	21	and	and	CC
cord-340028-6oicmeam	232	22	more	more	RBR
cord-340028-6oicmeam	232	23	severe	severe	JJ
cord-340028-6oicmeam	232	24	in	in	IN
cord-340028-6oicmeam	232	25	the	the	DT
cord-340028-6oicmeam	232	26	elderly	elderly	JJ
cord-340028-6oicmeam	232	27	.	.	.
cord-340028-6oicmeam	233	1	In	in	IN
cord-340028-6oicmeam	233	2	this	this	DT
cord-340028-6oicmeam	233	3	paper	paper	NN
cord-340028-6oicmeam	233	4	,	,	,
cord-340028-6oicmeam	233	5	we	-PRON-	PRP
cord-340028-6oicmeam	233	6	review	review	VBP
cord-340028-6oicmeam	233	7	the	the	DT
cord-340028-6oicmeam	233	8	current	current	JJ
cord-340028-6oicmeam	233	9	literature	literature	NN
cord-340028-6oicmeam	233	10	on	on	IN
cord-340028-6oicmeam	233	11	speculative	speculative	JJ
cord-340028-6oicmeam	233	12	aging	aging	NN
cord-340028-6oicmeam	233	13	reversal	reversal	NN
cord-340028-6oicmeam	233	14	treatments	treatment	NNS
cord-340028-6oicmeam	233	15	,	,	,
cord-340028-6oicmeam	233	16	such	such	JJ
cord-340028-6oicmeam	233	17	as	as	IN
cord-340028-6oicmeam	233	18	experimental	experimental	JJ
cord-340028-6oicmeam	233	19	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	233	20	strategies	strategy	NNS
cord-340028-6oicmeam	233	21	using	use	VBG
cord-340028-6oicmeam	233	22	everolimus	everolimus	NNP
cord-340028-6oicmeam	233	23	(	(	-LRB-
cord-340028-6oicmeam	233	24	RAD001	RAD001	NNP
cord-340028-6oicmeam	233	25	)	)	-RRB-
cord-340028-6oicmeam	233	26	and	and	CC
cord-340028-6oicmeam	233	27	sirolimus	sirolimus	NNP
cord-340028-6oicmeam	233	28	(	(	-LRB-
cord-340028-6oicmeam	233	29	rapamycin	rapamycin	NN
cord-340028-6oicmeam	233	30	)	)	-RRB-
cord-340028-6oicmeam	233	31	.	.	.
cord-340028-6oicmeam	234	1	We	-PRON-	PRP
cord-340028-6oicmeam	234	2	summarize	summarize	VBP
cord-340028-6oicmeam	234	3	the	the	DT
cord-340028-6oicmeam	234	4	current	current	JJ
cord-340028-6oicmeam	234	5	possible	possible	JJ
cord-340028-6oicmeam	234	6	interventions	intervention	NNS
cord-340028-6oicmeam	234	7	and	and	CC
cord-340028-6oicmeam	234	8	identify	identify	VB
cord-340028-6oicmeam	234	9	the	the	DT
cord-340028-6oicmeam	234	10	lack	lack	NN
cord-340028-6oicmeam	234	11	of	of	IN
cord-340028-6oicmeam	234	12	clinical	clinical	JJ
cord-340028-6oicmeam	234	13	evidence	evidence	NN
cord-340028-6oicmeam	234	14	to	to	TO
cord-340028-6oicmeam	234	15	support	support	VB
cord-340028-6oicmeam	234	16	their	-PRON-	PRP$
cord-340028-6oicmeam	234	17	immediate	immediate	JJ
cord-340028-6oicmeam	234	18	use	use	NN
cord-340028-6oicmeam	234	19	with	with	IN
cord-340028-6oicmeam	234	20	the	the	DT
cord-340028-6oicmeam	234	21	aim	aim	NN
cord-340028-6oicmeam	234	22	of	of	IN
cord-340028-6oicmeam	234	23	encouraging	encourage	VBG
cord-340028-6oicmeam	234	24	further	far	RBR
cord-340028-6oicmeam	234	25	,	,	,
cord-340028-6oicmeam	234	26	more	more	RBR
cord-340028-6oicmeam	234	27	rigorous	rigorous	JJ
cord-340028-6oicmeam	234	28	reviews	review	NNS
cord-340028-6oicmeam	234	29	of	of	IN
cord-340028-6oicmeam	234	30	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	234	31	compounds	compound	NNS
cord-340028-6oicmeam	234	32	such	such	JJ
cord-340028-6oicmeam	234	33	as	as	IN
cord-340028-6oicmeam	234	34	rapalogs	rapalogs	NNP
cord-340028-6oicmeam	234	35	,	,	,
cord-340028-6oicmeam	234	36	metformin	metformin	NNP
cord-340028-6oicmeam	234	37	,	,	,
cord-340028-6oicmeam	234	38	senolytics	senolytic	NNS
cord-340028-6oicmeam	234	39	,	,	,
cord-340028-6oicmeam	234	40	and	and	CC
cord-340028-6oicmeam	234	41	conventional	conventional	JJ
cord-340028-6oicmeam	234	42	and	and	CC
cord-340028-6oicmeam	234	43	investigational	investigational	JJ
cord-340028-6oicmeam	234	44	NAD+	NAD+	NNP
cord-340028-6oicmeam	234	45	boosters	booster	NNS
cord-340028-6oicmeam	234	46	.	.	.
cord-340028-6oicmeam	235	1	We	-PRON-	PRP
cord-340028-6oicmeam	235	2	also	also	RB
cord-340028-6oicmeam	235	3	suggest	suggest	VBP
cord-340028-6oicmeam	235	4	that	that	IN
cord-340028-6oicmeam	235	5	further	further	JJ
cord-340028-6oicmeam	235	6	clinical	clinical	JJ
cord-340028-6oicmeam	235	7	studies	study	NNS
cord-340028-6oicmeam	235	8	should	should	MD
cord-340028-6oicmeam	235	9	be	be	VB
cord-340028-6oicmeam	235	10	carefully	carefully	RB
cord-340028-6oicmeam	235	11	designed	design	VBN
cord-340028-6oicmeam	235	12	and	and	CC
cord-340028-6oicmeam	235	13	adequately	adequately	RB
cord-340028-6oicmeam	235	14	powered	powered	JJ
cord-340028-6oicmeam	235	15	to	to	TO
cord-340028-6oicmeam	235	16	determine	determine	VB
cord-340028-6oicmeam	235	17	if	if	IN
cord-340028-6oicmeam	235	18	these	these	DT
cord-340028-6oicmeam	235	19	interventions	intervention	NNS
cord-340028-6oicmeam	235	20	might	may	MD
cord-340028-6oicmeam	235	21	provide	provide	VB
cord-340028-6oicmeam	235	22	clinical	clinical	JJ
cord-340028-6oicmeam	235	23	benefit	benefit	NN
cord-340028-6oicmeam	235	24	as	as	IN
cord-340028-6oicmeam	235	25	adjuncts	adjunct	NNS
cord-340028-6oicmeam	235	26	to	to	IN
cord-340028-6oicmeam	235	27	vaccines	vaccine	NNS
cord-340028-6oicmeam	235	28	and	and	CC
cord-340028-6oicmeam	235	29	antiviral	antiviral	JJ
cord-340028-6oicmeam	235	30	treatments	treatment	NNS
cord-340028-6oicmeam	235	31	by	by	IN
cord-340028-6oicmeam	235	32	acting	act	VBG
cord-340028-6oicmeam	235	33	as	as	IN
cord-340028-6oicmeam	235	34	immune	immune	JJ
cord-340028-6oicmeam	235	35	response	response	NN
cord-340028-6oicmeam	235	36	potentiators	potentiator	NNS
cord-340028-6oicmeam	235	37	.	.	.
cord-340028-6oicmeam	236	1	Lastly	lastly	RB
cord-340028-6oicmeam	236	2	,	,	,
cord-340028-6oicmeam	236	3	as	as	IN
cord-340028-6oicmeam	236	4	with	with	IN
cord-340028-6oicmeam	236	5	many	many	JJ
cord-340028-6oicmeam	236	6	other	other	JJ
cord-340028-6oicmeam	236	7	diseases	disease	NNS
cord-340028-6oicmeam	236	8	,	,	,
cord-340028-6oicmeam	236	9	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	236	10	is	be	VBZ
cord-340028-6oicmeam	236	11	more	more	RBR
cord-340028-6oicmeam	236	12	common	common	JJ
cord-340028-6oicmeam	236	13	and	and	CC
cord-340028-6oicmeam	236	14	severe	severe	JJ
cord-340028-6oicmeam	236	15	in	in	IN
cord-340028-6oicmeam	236	16	elderly	elderly	JJ
cord-340028-6oicmeam	236	17	populations	population	NNS
cord-340028-6oicmeam	236	18	,	,	,
cord-340028-6oicmeam	236	19	and	and	CC
cord-340028-6oicmeam	236	20	we	-PRON-	PRP
cord-340028-6oicmeam	236	21	thus	thus	RB
cord-340028-6oicmeam	236	22	invite	invite	VBP
cord-340028-6oicmeam	236	23	further	further	JJ
cord-340028-6oicmeam	236	24	research	research	NN
cord-340028-6oicmeam	236	25	and	and	CC
cord-340028-6oicmeam	236	26	clinical	clinical	JJ
cord-340028-6oicmeam	236	27	validation	validation	NN
cord-340028-6oicmeam	236	28	in	in	IN
cord-340028-6oicmeam	236	29	the	the	DT
cord-340028-6oicmeam	236	30	field	field	NN
cord-340028-6oicmeam	236	31	of	of	IN
cord-340028-6oicmeam	236	32	biological	biological	JJ
cord-340028-6oicmeam	236	33	aging	age	VBG
cord-340028-6oicmeam	236	34	clocks	clock	NNS
cord-340028-6oicmeam	236	35	.	.	.
cord-340028-6oicmeam	237	1	These	these	DT
cord-340028-6oicmeam	237	2	markers	marker	NNS
cord-340028-6oicmeam	237	3	could	could	MD
cord-340028-6oicmeam	237	4	potentially	potentially	RB
cord-340028-6oicmeam	237	5	be	be	VB
cord-340028-6oicmeam	237	6	used	use	VBN
cord-340028-6oicmeam	237	7	in	in	IN
cord-340028-6oicmeam	237	8	the	the	DT
cord-340028-6oicmeam	237	9	future	future	NN
cord-340028-6oicmeam	237	10	to	to	TO
cord-340028-6oicmeam	237	11	measure	measure	VB
cord-340028-6oicmeam	237	12	and	and	CC
cord-340028-6oicmeam	237	13	analyze	analyze	VB
cord-340028-6oicmeam	237	14	immunosenescence	immunosenescence	NN
cord-340028-6oicmeam	237	15	and	and	CC
cord-340028-6oicmeam	237	16	the	the	DT
cord-340028-6oicmeam	237	17	efficacy	efficacy	NN
cord-340028-6oicmeam	237	18	of	of	IN
cord-340028-6oicmeam	237	19	interventions	intervention	NNS
cord-340028-6oicmeam	237	20	claimed	claim	VBN
cord-340028-6oicmeam	237	21	to	to	TO
cord-340028-6oicmeam	237	22	slow	slow	VB
cord-340028-6oicmeam	237	23	down	down	RP
cord-340028-6oicmeam	237	24	or	or	CC
cord-340028-6oicmeam	237	25	reverse	reverse	VB
cord-340028-6oicmeam	237	26	age	age	NN
cord-340028-6oicmeam	237	27	-	-	HYPH
cord-340028-6oicmeam	237	28	related	relate	VBN
cord-340028-6oicmeam	237	29	immune	immune	JJ
cord-340028-6oicmeam	237	30	decline	decline	NN
cord-340028-6oicmeam	237	31	.	.	.
cord-340028-6oicmeam	238	1	This	this	DT
cord-340028-6oicmeam	238	2	perspective	perspective	NN
cord-340028-6oicmeam	238	3	is	be	VBZ
cord-340028-6oicmeam	238	4	of	of	IN
cord-340028-6oicmeam	238	5	a	a	DT
cord-340028-6oicmeam	238	6	highly	highly	RB
cord-340028-6oicmeam	238	7	speculative	speculative	JJ
cord-340028-6oicmeam	238	8	nature	nature	NN
cord-340028-6oicmeam	238	9	presented	present	VBN
cord-340028-6oicmeam	238	10	during	during	IN
cord-340028-6oicmeam	238	11	the	the	DT
cord-340028-6oicmeam	238	12	time	time	NN
cord-340028-6oicmeam	238	13	of	of	IN
cord-340028-6oicmeam	238	14	a	a	DT
cord-340028-6oicmeam	238	15	global	global	JJ
cord-340028-6oicmeam	238	16	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	238	17	pandemic	pandemic	NN
cord-340028-6oicmeam	238	18	.	.	.
cord-340028-6oicmeam	239	1	It	-PRON-	PRP
cord-340028-6oicmeam	239	2	is	be	VBZ
cord-340028-6oicmeam	239	3	intended	intend	VBN
cord-340028-6oicmeam	239	4	for	for	IN
cord-340028-6oicmeam	239	5	a	a	DT
cord-340028-6oicmeam	239	6	professional	professional	JJ
cord-340028-6oicmeam	239	7	audience	audience	NN
cord-340028-6oicmeam	239	8	to	to	TO
cord-340028-6oicmeam	239	9	stimulate	stimulate	VB
cord-340028-6oicmeam	239	10	ideas	idea	NNS
cord-340028-6oicmeam	239	11	and	and	CC
cord-340028-6oicmeam	239	12	aid	aid	VB
cord-340028-6oicmeam	239	13	the	the	DT
cord-340028-6oicmeam	239	14	global	global	JJ
cord-340028-6oicmeam	239	15	efforts	effort	NNS
cord-340028-6oicmeam	239	16	of	of	IN
cord-340028-6oicmeam	239	17	the	the	DT
cord-340028-6oicmeam	239	18	scientific	scientific	JJ
cord-340028-6oicmeam	239	19	community	community	NN
cord-340028-6oicmeam	239	20	to	to	TO
cord-340028-6oicmeam	239	21	develop	develop	VB
cord-340028-6oicmeam	239	22	effective	effective	JJ
cord-340028-6oicmeam	239	23	new	new	JJ
cord-340028-6oicmeam	239	24	treatments	treatment	NNS
cord-340028-6oicmeam	239	25	for	for	IN
cord-340028-6oicmeam	239	26	this	this	DT
cord-340028-6oicmeam	239	27	disease	disease	NN
cord-340028-6oicmeam	239	28	.	.	.
cord-340028-6oicmeam	240	1	This	this	DT
cord-340028-6oicmeam	240	2	article	article	NN
cord-340028-6oicmeam	240	3	does	do	VBZ
cord-340028-6oicmeam	240	4	not	not	RB
cord-340028-6oicmeam	240	5	represent	represent	VB
cord-340028-6oicmeam	240	6	medical	medical	JJ
cord-340028-6oicmeam	240	7	advice	advice	NN
cord-340028-6oicmeam	240	8	or	or	CC
cord-340028-6oicmeam	240	9	recommendations	recommendation	NNS
cord-340028-6oicmeam	240	10	to	to	IN
cord-340028-6oicmeam	240	11	patients	patient	NNS
cord-340028-6oicmeam	240	12	.	.	.
cord-340028-6oicmeam	241	1	There	there	EX
cord-340028-6oicmeam	241	2	is	be	VBZ
cord-340028-6oicmeam	241	3	no	no	DT
cord-340028-6oicmeam	241	4	clinical	clinical	JJ
cord-340028-6oicmeam	241	5	evidence	evidence	NN
cord-340028-6oicmeam	241	6	to	to	TO
cord-340028-6oicmeam	241	7	support	support	VB
cord-340028-6oicmeam	241	8	the	the	DT
cord-340028-6oicmeam	241	9	use	use	NN
cord-340028-6oicmeam	241	10	of	of	IN
cord-340028-6oicmeam	241	11	the	the	DT
cord-340028-6oicmeam	241	12	treatments	treatment	NNS
cord-340028-6oicmeam	241	13	described	describe	VBN
cord-340028-6oicmeam	241	14	in	in	IN
cord-340028-6oicmeam	241	15	this	this	DT
cord-340028-6oicmeam	241	16	article	article	NN
cord-340028-6oicmeam	241	17	for	for	IN
cord-340028-6oicmeam	241	18	this	this	DT
cord-340028-6oicmeam	241	19	indication	indication	NN
cord-340028-6oicmeam	241	20	and	and	CC
cord-340028-6oicmeam	241	21	the	the	DT
cord-340028-6oicmeam	241	22	authors	author	NNS
cord-340028-6oicmeam	241	23	do	do	VBP
cord-340028-6oicmeam	241	24	not	not	RB
cord-340028-6oicmeam	241	25	advise	advise	VB
cord-340028-6oicmeam	241	26	anyone	anyone	NN
cord-340028-6oicmeam	241	27	to	to	IN
cord-340028-6oicmeam	241	28	self	self	NN
cord-340028-6oicmeam	241	29	-	-	:
cord-340028-6oicmeam	241	30	administer	administer	VB
cord-340028-6oicmeam	241	31	these	these	DT
cord-340028-6oicmeam	241	32	drugs	drug	NNS
cord-340028-6oicmeam	241	33	as	as	IN
cord-340028-6oicmeam	241	34	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	241	35	prevention	prevention	NN
cord-340028-6oicmeam	241	36	or	or	CC
cord-340028-6oicmeam	241	37	treatment	treatment	NN
cord-340028-6oicmeam	241	38	.	.	.
cord-340028-6oicmeam	242	1	Furthermore	furthermore	RB
cord-340028-6oicmeam	242	2	,	,	,
cord-340028-6oicmeam	242	3	this	this	DT
cord-340028-6oicmeam	242	4	perspective	perspective	NN
cord-340028-6oicmeam	242	5	is	be	VBZ
cord-340028-6oicmeam	242	6	based	base	VBN
cord-340028-6oicmeam	242	7	on	on	IN
cord-340028-6oicmeam	242	8	the	the	DT
cord-340028-6oicmeam	242	9	limited	limited	JJ
cord-340028-6oicmeam	242	10	data	datum	NNS
cord-340028-6oicmeam	242	11	from	from	IN
cord-340028-6oicmeam	242	12	the	the	DT
cord-340028-6oicmeam	242	13	first	first	JJ
cord-340028-6oicmeam	242	14	weeks	week	NNS
cord-340028-6oicmeam	242	15	of	of	IN
cord-340028-6oicmeam	242	16	the	the	DT
cord-340028-6oicmeam	242	17	COVID-19	covid-19	JJ
cord-340028-6oicmeam	242	18	outbreak	outbreak	NN
cord-340028-6oicmeam	242	19	.	.	.
cord-340028-6oicmeam	243	1	The	the	DT
cord-340028-6oicmeam	243	2	demographic	demographic	JJ
cord-340028-6oicmeam	243	3	distribution	distribution	NN
cord-340028-6oicmeam	243	4	of	of	IN
cord-340028-6oicmeam	243	5	the	the	DT
cord-340028-6oicmeam	243	6	infected	infected	JJ
cord-340028-6oicmeam	243	7	and	and	CC
cord-340028-6oicmeam	243	8	diseased	disease	VBN
cord-340028-6oicmeam	243	9	may	may	MD
cord-340028-6oicmeam	243	10	change	change	VB
cord-340028-6oicmeam	243	11	and	and	CC
cord-340028-6oicmeam	243	12	differ	differ	VB
cord-340028-6oicmeam	243	13	in	in	IN
cord-340028-6oicmeam	243	14	different	different	JJ
cord-340028-6oicmeam	243	15	countries	country	NNS
cord-340028-6oicmeam	243	16	with	with	IN
cord-340028-6oicmeam	243	17	different	different	JJ
cord-340028-6oicmeam	243	18	social	social	JJ
cord-340028-6oicmeam	243	19	customs	custom	NNS
cord-340028-6oicmeam	243	20	and	and	CC
cord-340028-6oicmeam	243	21	different	different	JJ
cord-340028-6oicmeam	243	22	ethnicities	ethnicity	NNS
cord-340028-6oicmeam	243	23	.	.	.
cord-340028-6oicmeam	244	1	The	the	DT
cord-340028-6oicmeam	244	2	media	medium	NNS
cord-340028-6oicmeam	244	3	should	should	MD
cord-340028-6oicmeam	244	4	exercise	exercise	VB
cord-340028-6oicmeam	244	5	caution	caution	NN
cord-340028-6oicmeam	244	6	and	and	CC
cord-340028-6oicmeam	244	7	seek	seek	VB
cord-340028-6oicmeam	244	8	expert	expert	JJ
cord-340028-6oicmeam	244	9	medical	medical	JJ
cord-340028-6oicmeam	244	10	advice	advice	NN
cord-340028-6oicmeam	244	11	for	for	IN
cord-340028-6oicmeam	244	12	interpretation	interpretation	NN
cord-340028-6oicmeam	244	13	when	when	WRB
cord-340028-6oicmeam	244	14	referring	refer	VBG
cord-340028-6oicmeam	244	15	to	to	IN
cord-340028-6oicmeam	244	16	this	this	DT
cord-340028-6oicmeam	244	17	article	article	NN
cord-340028-6oicmeam	244	18	to	to	TO
cord-340028-6oicmeam	244	19	avoid	avoid	VB
cord-340028-6oicmeam	244	20	misinterpretation	misinterpretation	NN
cord-340028-6oicmeam	244	21	or	or	CC
cord-340028-6oicmeam	244	22	unsafe	unsafe	JJ
cord-340028-6oicmeam	244	23	messages	message	NNS
cord-340028-6oicmeam	244	24	being	be	VBG
cord-340028-6oicmeam	244	25	delivered	deliver	VBN
cord-340028-6oicmeam	244	26	to	to	IN
cord-340028-6oicmeam	244	27	the	the	DT
cord-340028-6oicmeam	244	28	community	community	NN
cord-340028-6oicmeam	244	29	amidst	amidst	IN
cord-340028-6oicmeam	244	30	exceptional	exceptional	JJ
cord-340028-6oicmeam	244	31	coverage	coverage	NN
cord-340028-6oicmeam	244	32	of	of	IN
cord-340028-6oicmeam	244	33	this	this	DT
cord-340028-6oicmeam	244	34	disease	disease	NN
cord-340028-6oicmeam	244	35	in	in	IN
cord-340028-6oicmeam	244	36	the	the	DT
cord-340028-6oicmeam	244	37	media	medium	NNS
cord-340028-6oicmeam	244	38	at	at	IN
cord-340028-6oicmeam	244	39	present	present	NN
cord-340028-6oicmeam	244	40	.	.	.
cord-340028-6oicmeam	245	1	The	the	DT
cord-340028-6oicmeam	245	2	author	author	NN
cord-340028-6oicmeam	245	3	would	would	MD
cord-340028-6oicmeam	245	4	like	like	VB
cord-340028-6oicmeam	245	5	to	to	TO
cord-340028-6oicmeam	245	6	thank	thank	VB
cord-340028-6oicmeam	245	7	Dr.	Dr.	NNP
cord-340028-6oicmeam	245	8	Quentin	Quentin	NNP
cord-340028-6oicmeam	245	9	Vahaelen	Vahaelen	NNP
cord-340028-6oicmeam	245	10	of	of	IN
cord-340028-6oicmeam	245	11	Insilico	Insilico	NNP
cord-340028-6oicmeam	245	12	Medicine	Medicine	NNP
cord-340028-6oicmeam	245	13	,	,	,
cord-340028-6oicmeam	245	14	Dr.	Dr.	NNP
cord-340028-6oicmeam	245	15	Evelyne	Evelyne	NNP
cord-340028-6oicmeam	245	16	Bischof	Bischof	NNP
cord-340028-6oicmeam	245	17	of	of	IN
cord-340028-6oicmeam	245	18	the	the	DT
cord-340028-6oicmeam	245	19	Jiaotong	Jiaotong	NNP
cord-340028-6oicmeam	245	20	and	and	CC
cord-340028-6oicmeam	245	21	Shanghai	Shanghai	NNP
cord-340028-6oicmeam	245	22	University	University	NNP
cord-340028-6oicmeam	245	23	of	of	IN
cord-340028-6oicmeam	245	24	Medicine	Medicine	NNP
cord-340028-6oicmeam	245	25	and	and	CC
cord-340028-6oicmeam	245	26	the	the	DT
cord-340028-6oicmeam	245	27	University	University	NNP
cord-340028-6oicmeam	245	28	of	of	IN
cord-340028-6oicmeam	245	29	Basel	Basel	NNP
cord-340028-6oicmeam	245	30	,	,	,
cord-340028-6oicmeam	245	31	and	and	CC
cord-340028-6oicmeam	245	32	Mr.	Mr.	NNP
cord-340028-6oicmeam	245	33	Dara	Dara	NNP
cord-340028-6oicmeam	245	34	Vakili	Vakili	NNP
cord-340028-6oicmeam	245	35	of	of	IN
cord-340028-6oicmeam	245	36	Imperial	Imperial	NNP
cord-340028-6oicmeam	245	37	College	College	NNP
cord-340028-6oicmeam	245	38	London	London	NNP
cord-340028-6oicmeam	245	39	for	for	IN
cord-340028-6oicmeam	245	40	advice	advice	NN
cord-340028-6oicmeam	245	41	and	and	CC
cord-340028-6oicmeam	245	42	valuable	valuable	JJ
cord-340028-6oicmeam	245	43	contributions	contribution	NNS
cord-340028-6oicmeam	245	44	.	.	.
cord-340028-6oicmeam	246	1	The	the	DT
cord-340028-6oicmeam	246	2	author	author	NN
cord-340028-6oicmeam	246	3	would	would	MD
cord-340028-6oicmeam	246	4	like	like	VB
cord-340028-6oicmeam	246	5	to	to	TO
cord-340028-6oicmeam	246	6	thank	thank	VB
cord-340028-6oicmeam	246	7	Dr.	Dr.	NNP
cord-340028-6oicmeam	246	8	Richard	Richard	NNP
cord-340028-6oicmeam	246	9	Faragher	Faragher	NNP
cord-340028-6oicmeam	246	10	for	for	IN
cord-340028-6oicmeam	246	11	the	the	DT
cord-340028-6oicmeam	246	12	valuable	valuable	JJ
cord-340028-6oicmeam	246	13	suggestions	suggestion	NNS
cord-340028-6oicmeam	246	14	and	and	CC
cord-340028-6oicmeam	246	15	comments	comment	NNS
cord-340028-6oicmeam	246	16	on	on	IN
cord-340028-6oicmeam	246	17	the	the	DT
cord-340028-6oicmeam	246	18	new	new	JJ
cord-340028-6oicmeam	246	19	term	term	NN
cord-340028-6oicmeam	246	20	"	"	``
cord-340028-6oicmeam	246	21	gerolavic	gerolavic	JJ
cord-340028-6oicmeam	246	22	"	"	''
cord-340028-6oicmeam	246	23	to	to	TO
cord-340028-6oicmeam	246	24	describe	describe	VB
cord-340028-6oicmeam	246	25	the	the	DT
cord-340028-6oicmeam	246	26	infections	infection	NNS
cord-340028-6oicmeam	246	27	harmful	harmful	JJ
cord-340028-6oicmeam	246	28	to	to	IN
cord-340028-6oicmeam	246	29	the	the	DT
cord-340028-6oicmeam	246	30	elderly	elderly	JJ
cord-340028-6oicmeam	246	31	,	,	,
cord-340028-6oicmeam	246	32	which	which	WDT
cord-340028-6oicmeam	246	33	did	do	VBD
cord-340028-6oicmeam	246	34	not	not	RB
cord-340028-6oicmeam	246	35	previously	previously	RB
cord-340028-6oicmeam	246	36	exist	exist	VB
cord-340028-6oicmeam	246	37	;	;	:
cord-340028-6oicmeam	246	38	and	and	CC
cord-340028-6oicmeam	246	39	Rachel	Rachel	NNP
cord-340028-6oicmeam	246	40	Stewart	Stewart	NNP
cord-340028-6oicmeam	246	41	for	for	IN
cord-340028-6oicmeam	246	42	edits	edit	NNS
cord-340028-6oicmeam	246	43	,	,	,
cord-340028-6oicmeam	246	44	formatting	format	VBG
cord-340028-6oicmeam	246	45	,	,	,
cord-340028-6oicmeam	246	46	and	and	CC
cord-340028-6oicmeam	246	47	reference	reference	NN
cord-340028-6oicmeam	246	48	management	management	NN
cord-340028-6oicmeam	246	49	.	.	.
cord-340028-6oicmeam	247	1	No	no	DT
cord-340028-6oicmeam	247	2	funding	funding	NN
cord-340028-6oicmeam	247	3	has	have	VBZ
cord-340028-6oicmeam	247	4	been	be	VBN
cord-340028-6oicmeam	247	5	provided	provide	VBN
cord-340028-6oicmeam	247	6	for	for	IN
cord-340028-6oicmeam	247	7	this	this	DT
cord-340028-6oicmeam	247	8	work	work	NN
cord-340028-6oicmeam	247	9	.	.	.
cord-340028-6oicmeam	248	1	Alex	Alex	NNP
cord-340028-6oicmeam	248	2	Zhavoronkov	Zhavoronkov	NNP
cord-340028-6oicmeam	248	3	is	be	VBZ
cord-340028-6oicmeam	248	4	a	a	DT
cord-340028-6oicmeam	248	5	co	co	NN
cord-340028-6oicmeam	248	6	-	-	NN
cord-340028-6oicmeam	248	7	founder	founder	NN
cord-340028-6oicmeam	248	8	of	of	IN
cord-340028-6oicmeam	248	9	Insilico	Insilico	NNP
cord-340028-6oicmeam	248	10	Medicine	Medicine	NNP
cord-340028-6oicmeam	248	11	,	,	,
cord-340028-6oicmeam	248	12	a	a	DT
cord-340028-6oicmeam	248	13	leading	lead	VBG
cord-340028-6oicmeam	248	14	artificial	artificial	JJ
cord-340028-6oicmeam	248	15	intelligence	intelligence	NN
cord-340028-6oicmeam	248	16	company	company	NN
cord-340028-6oicmeam	248	17	specializing	specialize	VBG
cord-340028-6oicmeam	248	18	in	in	IN
cord-340028-6oicmeam	248	19	target	target	NN
cord-340028-6oicmeam	248	20	discovery	discovery	NN
cord-340028-6oicmeam	248	21	and	and	CC
cord-340028-6oicmeam	248	22	small	small	JJ
cord-340028-6oicmeam	248	23	molecule	molecule	NN
cord-340028-6oicmeam	248	24	generation	generation	NN
cord-340028-6oicmeam	248	25	,	,	,
cord-340028-6oicmeam	248	26	and	and	CC
cord-340028-6oicmeam	248	27	Deep	Deep	NNP
cord-340028-6oicmeam	248	28	Longevity	Longevity	NNP
cord-340028-6oicmeam	248	29	,	,	,
cord-340028-6oicmeam	248	30	a	a	DT
cord-340028-6oicmeam	248	31	company	company	NN
cord-340028-6oicmeam	248	32	specializing	specialize	VBG
cord-340028-6oicmeam	248	33	in	in	IN
cord-340028-6oicmeam	248	34	deep	deep	JJ
cord-340028-6oicmeam	248	35	aging	age	VBG
cord-340028-6oicmeam	248	36	clocks	clock	NNS
cord-340028-6oicmeam	248	37	,	,	,
cord-340028-6oicmeam	248	38	multimodal	multimodal	NN
cord-340028-6oicmeam	248	39	age	age	NN
cord-340028-6oicmeam	248	40	predictors	predictor	NNS
cord-340028-6oicmeam	248	41	built	build	VBD
cord-340028-6oicmeam	248	42	using	use	VBG
cord-340028-6oicmeam	248	43	deep	deep	JJ
cord-340028-6oicmeam	248	44	learning	learning	NN
cord-340028-6oicmeam	248	45	.	.	.
cord-340028-6oicmeam	249	1	He	-PRON-	PRP
cord-340028-6oicmeam	249	2	has	have	VBZ
cord-340028-6oicmeam	249	3	multiple	multiple	JJ
cord-340028-6oicmeam	249	4	granted	grant	VBN
cord-340028-6oicmeam	249	5	patents	patent	NNS
cord-340028-6oicmeam	249	6	and	and	CC
cord-340028-6oicmeam	249	7	patent	patent	NN
cord-340028-6oicmeam	249	8	applications	application	NNS
cord-340028-6oicmeam	249	9	on	on	IN
cord-340028-6oicmeam	249	10	deep	deep	JJ
cord-340028-6oicmeam	249	11	aging	age	VBG
cord-340028-6oicmeam	249	12	clocks	clock	NNS
cord-340028-6oicmeam	249	13	,	,	,
cord-340028-6oicmeam	249	14	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	249	15	AGING	aging	NN
cord-340028-6oicmeam	249	16	interventions	intervention	NNS
cord-340028-6oicmeam	249	17	,	,	,
cord-340028-6oicmeam	249	18	generative	generative	JJ
cord-340028-6oicmeam	249	19	chemistry	chemistry	NN
cord-340028-6oicmeam	249	20	,	,	,
cord-340028-6oicmeam	249	21	generative	generative	JJ
cord-340028-6oicmeam	249	22	biology	biology	NN
cord-340028-6oicmeam	249	23	,	,	,
cord-340028-6oicmeam	249	24	and	and	CC
cord-340028-6oicmeam	249	25	artificial	artificial	JJ
cord-340028-6oicmeam	249	26	intelligence	intelligence	NN
cord-340028-6oicmeam	249	27	techniques	technique	NNS
cord-340028-6oicmeam	249	28	.	.	.
cord-340028-6oicmeam	250	1	The	the	DT
cord-340028-6oicmeam	250	2	hallmarks	hallmark	NNS
cord-340028-6oicmeam	250	3	of	of	IN
cord-340028-6oicmeam	250	4	aging	age	VBG
cord-340028-6oicmeam	250	5	Methods	method	NNS
cord-340028-6oicmeam	250	6	for	for	IN
cord-340028-6oicmeam	250	7	structuring	structure	VBG
cord-340028-6oicmeam	250	8	scientific	scientific	JJ
cord-340028-6oicmeam	250	9	knowledge	knowledge	NN
cord-340028-6oicmeam	250	10	from	from	IN
cord-340028-6oicmeam	250	11	many	many	JJ
cord-340028-6oicmeam	250	12	areas	area	NNS
cord-340028-6oicmeam	250	13	related	relate	VBN
cord-340028-6oicmeam	250	14	to	to	IN
cord-340028-6oicmeam	250	15	aging	age	VBG
cord-340028-6oicmeam	250	16	research	research	NN
cord-340028-6oicmeam	250	17	To	to	TO
cord-340028-6oicmeam	250	18	help	help	VB
cord-340028-6oicmeam	250	19	aging	age	VBG
cord-340028-6oicmeam	250	20	populations	population	NNS
cord-340028-6oicmeam	250	21	,	,	,
cord-340028-6oicmeam	250	22	classify	classify	VB
cord-340028-6oicmeam	250	23	organismal	organismal	JJ
cord-340028-6oicmeam	250	24	senescence	senescence	NN
cord-340028-6oicmeam	250	25	Classifying	classify	VBG
cord-340028-6oicmeam	250	26	aging	age	VBG
cord-340028-6oicmeam	250	27	as	as	IN
cord-340028-6oicmeam	250	28	a	a	DT
cord-340028-6oicmeam	250	29	disease	disease	NN
cord-340028-6oicmeam	250	30	in	in	IN
cord-340028-6oicmeam	250	31	the	the	DT
cord-340028-6oicmeam	250	32	context	context	NN
cord-340028-6oicmeam	250	33	of	of	IN
cord-340028-6oicmeam	250	34	ICD-11	ICD-11	NNP
cord-340028-6oicmeam	250	35	Editorial	editorial	NN
cord-340028-6oicmeam	250	36	:	:	:
cord-340028-6oicmeam	251	1	Should	Should	MD
cord-340028-6oicmeam	251	2	We	-PRON-	PRP
cord-340028-6oicmeam	251	3	Treat	treat	VB
cord-340028-6oicmeam	251	4	Aging	age	VBG
cord-340028-6oicmeam	251	5	as	as	IN
cord-340028-6oicmeam	251	6	a	a	DT
cord-340028-6oicmeam	251	7	Disease	Disease	NNP
cord-340028-6oicmeam	251	8	?	?	.
cord-340028-6oicmeam	252	1	Academic	academic	JJ
cord-340028-6oicmeam	252	2	,	,	,
cord-340028-6oicmeam	252	3	Pharmaceutical	Pharmaceutical	NNP
cord-340028-6oicmeam	252	4	,	,	,
cord-340028-6oicmeam	252	5	Healthcare	Healthcare	NNP
cord-340028-6oicmeam	252	6	Policy	Policy	NNP
cord-340028-6oicmeam	252	7	,	,	,
cord-340028-6oicmeam	252	8	and	and	CC
cord-340028-6oicmeam	252	9	Pension	Pension	NNP
cord-340028-6oicmeam	252	10	Fund	Fund	NNP
cord-340028-6oicmeam	252	11	Perspectives	Perspectives	NNPS
cord-340028-6oicmeam	252	12	Aging	age	VBG
cord-340028-6oicmeam	252	13	,	,	,
cord-340028-6oicmeam	252	14	frailty	frailty	NN
cord-340028-6oicmeam	252	15	and	and	CC
cord-340028-6oicmeam	252	16	age	age	NN
cord-340028-6oicmeam	252	17	-	-	HYPH
cord-340028-6oicmeam	252	18	related	relate	VBN
cord-340028-6oicmeam	252	19	diseases	disease	NNS
cord-340028-6oicmeam	252	20	Infection	infection	NN
cord-340028-6oicmeam	252	21	in	in	IN
cord-340028-6oicmeam	252	22	an	an	DT
cord-340028-6oicmeam	252	23	aging	age	VBG
cord-340028-6oicmeam	252	24	population	population	NN
cord-340028-6oicmeam	252	25	Grubeck	Grubeck	NNP
cord-340028-6oicmeam	252	26	-	-	HYPH
cord-340028-6oicmeam	252	27	Loebenstein	Loebenstein	NNP
cord-340028-6oicmeam	252	28	B.	B.	NNP
cord-340028-6oicmeam	252	29	Persistent	persistent	JJ
cord-340028-6oicmeam	252	30	viral	viral	JJ
cord-340028-6oicmeam	252	31	infections	infection	NNS
cord-340028-6oicmeam	252	32	and	and	CC
cord-340028-6oicmeam	252	33	immune	immune	JJ
cord-340028-6oicmeam	252	34	aging	age	VBG
cord-340028-6oicmeam	252	35	Lung	Lung	NNP
cord-340028-6oicmeam	252	36	infections	infection	NNS
cord-340028-6oicmeam	252	37	and	and	CC
cord-340028-6oicmeam	252	38	aging	age	VBG
cord-340028-6oicmeam	252	39	Epidemiology	epidemiology	NN
cord-340028-6oicmeam	252	40	and	and	CC
cord-340028-6oicmeam	252	41	unique	unique	JJ
cord-340028-6oicmeam	252	42	aspects	aspect	NNS
cord-340028-6oicmeam	252	43	of	of	IN
cord-340028-6oicmeam	252	44	aging	age	VBG
cord-340028-6oicmeam	252	45	and	and	CC
cord-340028-6oicmeam	252	46	infectious	infectious	JJ
cord-340028-6oicmeam	252	47	diseases	disease	NNS
cord-340028-6oicmeam	252	48	Characteristics	characteristic	NNS
cord-340028-6oicmeam	252	49	of	of	IN
cord-340028-6oicmeam	252	50	COVID-19	covid-19	JJ
cord-340028-6oicmeam	252	51	infection	infection	NN
cord-340028-6oicmeam	252	52	in	in	IN
cord-340028-6oicmeam	252	53	Beijing	Beijing	NNP
cord-340028-6oicmeam	253	1	The	the	DT
cord-340028-6oicmeam	253	2	Epidemiological	Epidemiological	NNP
cord-340028-6oicmeam	253	3	Characteristics	Characteristics	NNPS
cord-340028-6oicmeam	253	4	of	of	IN
cord-340028-6oicmeam	253	5	an	an	DT
cord-340028-6oicmeam	253	6	Outbreak	outbreak	NN
cord-340028-6oicmeam	253	7	of	of	IN
cord-340028-6oicmeam	253	8	2019	2019	CD
cord-340028-6oicmeam	253	9	Novel	Novel	NNP
cord-340028-6oicmeam	253	10	Coronavirus	Coronavirus	NNP
cord-340028-6oicmeam	253	11	Diseases	Diseases	NNPS
cord-340028-6oicmeam	253	12	(	(	-LRB-
cord-340028-6oicmeam	253	13	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	253	14	)	)	-RRB-
cord-340028-6oicmeam	253	15	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	253	16	Coronavirus	Coronavirus	NNP
cord-340028-6oicmeam	253	17	Outbreak	Outbreak	NNP
cord-340028-6oicmeam	253	18	Analysis	Analysis	NNP
cord-340028-6oicmeam	253	19	of	of	IN
cord-340028-6oicmeam	253	20	Coronavirus	Coronavirus	NNP
cord-340028-6oicmeam	253	21	Estimating	estimate	VBG
cord-340028-6oicmeam	253	22	the	the	DT
cord-340028-6oicmeam	253	23	Asymptomatic	Asymptomatic	NNP
cord-340028-6oicmeam	253	24	Proportion	Proportion	NNP
cord-340028-6oicmeam	253	25	of	of	IN
cord-340028-6oicmeam	253	26	Novel	Novel	NNP
cord-340028-6oicmeam	253	27	Coronavirus	Coronavirus	NNP
cord-340028-6oicmeam	253	28	onboard	onboard	VBD
cord-340028-6oicmeam	253	29	the	the	DT
cord-340028-6oicmeam	253	30	Princess	Princess	NNP
cord-340028-6oicmeam	253	31	Cruises	Cruises	NNPS
cord-340028-6oicmeam	253	32	Ship	ship	NN
cord-340028-6oicmeam	253	33	Causes	cause	NNS
cord-340028-6oicmeam	253	34	of	of	IN
cord-340028-6oicmeam	253	35	Death	death	NN
cord-340028-6oicmeam	253	36	.	.	.
cord-340028-6oicmeam	254	1	Our	-PRON-	PRP$
cord-340028-6oicmeam	254	2	World	World	NNP
cord-340028-6oicmeam	254	3	in	in	IN
cord-340028-6oicmeam	254	4	Data	Data	NNP
cord-340028-6oicmeam	254	5	Estimated	estimate	VBN
cord-340028-6oicmeam	254	6	Influenza	Influenza	NNP
cord-340028-6oicmeam	254	7	Illnesses	Illnesses	NNPS
cord-340028-6oicmeam	254	8	,	,	,
cord-340028-6oicmeam	254	9	Medical	medical	JJ
cord-340028-6oicmeam	254	10	visits	visit	NNS
cord-340028-6oicmeam	254	11	,	,	,
cord-340028-6oicmeam	254	12	Hospitalizations	Hospitalizations	NNPS
cord-340028-6oicmeam	254	13	,	,	,
cord-340028-6oicmeam	254	14	and	and	CC
cord-340028-6oicmeam	254	15	Deaths	death	NNS
cord-340028-6oicmeam	254	16	in	in	IN
cord-340028-6oicmeam	254	17	the	the	DT
cord-340028-6oicmeam	254	18	United	United	NNP
cord-340028-6oicmeam	254	19	States	States	NNP
cord-340028-6oicmeam	254	20	-2017	-2017	:
cord-340028-6oicmeam	254	21	-	-	:
cord-340028-6oicmeam	254	22	2018	2018	CD
cord-340028-6oicmeam	254	23	influenza	influenza	NN
cord-340028-6oicmeam	254	24	season	season	NN
cord-340028-6oicmeam	254	25	for	for	IN
cord-340028-6oicmeam	254	26	the	the	DT
cord-340028-6oicmeam	254	27	China	China	NNP
cord-340028-6oicmeam	254	28	Medical	Medical	NNP
cord-340028-6oicmeam	254	29	Treatment	Treatment	NNP
cord-340028-6oicmeam	254	30	Expert	Expert	NNP
cord-340028-6oicmeam	254	31	Group	Group	NNP
cord-340028-6oicmeam	254	32	for	for	IN
cord-340028-6oicmeam	254	33	Covid-19	Covid-19	NNP
cord-340028-6oicmeam	254	34	*	*	NFP
cord-340028-6oicmeam	254	35	.	.	.
cord-340028-6oicmeam	255	1	Clinical	clinical	JJ
cord-340028-6oicmeam	255	2	Characteristics	characteristic	NNS
cord-340028-6oicmeam	255	3	of	of	IN
cord-340028-6oicmeam	255	4	Coronavirus	Coronavirus	NNP
cord-340028-6oicmeam	255	5	Disease	Disease	NNP
cord-340028-6oicmeam	255	6	2019	2019	CD
cord-340028-6oicmeam	255	7	in	in	IN
cord-340028-6oicmeam	255	8	China	China	NNP
cord-340028-6oicmeam	255	9	Immunosenescence	Immunosenescence	NNP
cord-340028-6oicmeam	255	10	of	of	IN
cord-340028-6oicmeam	255	11	ageing	age	VBG
cord-340028-6oicmeam	255	12	Mechanisms	mechanism	NNS
cord-340028-6oicmeam	255	13	of	of	IN
cord-340028-6oicmeam	255	14	development	development	NN
cord-340028-6oicmeam	255	15	of	of	IN
cord-340028-6oicmeam	255	16	multimorbidity	multimorbidity	NN
cord-340028-6oicmeam	255	17	in	in	IN
cord-340028-6oicmeam	255	18	the	the	DT
cord-340028-6oicmeam	255	19	elderly	elderly	JJ
cord-340028-6oicmeam	255	20	Coronavirus	Coronavirus	NNP
cord-340028-6oicmeam	255	21	puts	put	VBZ
cord-340028-6oicmeam	255	22	drug	drug	NN
cord-340028-6oicmeam	255	23	repurposing	repurposing	NN
cord-340028-6oicmeam	255	24	on	on	IN
cord-340028-6oicmeam	255	25	the	the	DT
cord-340028-6oicmeam	255	26	fast	fast	JJ
cord-340028-6oicmeam	255	27	track	track	NN
cord-340028-6oicmeam	255	28	Research	Research	NNP
cord-340028-6oicmeam	255	29	and	and	CC
cord-340028-6oicmeam	255	30	Development	Development	NNP
cord-340028-6oicmeam	255	31	on	on	IN
cord-340028-6oicmeam	255	32	Therapeutic	therapeutic	JJ
cord-340028-6oicmeam	255	33	Agents	Agents	NNPS
cord-340028-6oicmeam	255	34	and	and	CC
cord-340028-6oicmeam	255	35	Vaccines	Vaccines	NNPS
cord-340028-6oicmeam	255	36	for	for	IN
cord-340028-6oicmeam	255	37	COVID-19	covid-19	CD
cord-340028-6oicmeam	255	38	and	and	CC
cord-340028-6oicmeam	255	39	Related	Related	NNP
cord-340028-6oicmeam	255	40	Human	Human	NNP
cord-340028-6oicmeam	255	41	Coronavirus	Coronavirus	NNP
cord-340028-6oicmeam	255	42	Diseases	Diseases	NNPS
cord-340028-6oicmeam	255	43	Analysis	Analysis	NNP
cord-340028-6oicmeam	255	44	of	of	IN
cord-340028-6oicmeam	255	45	the	the	DT
cord-340028-6oicmeam	255	46	human	human	JJ
cord-340028-6oicmeam	255	47	thymic	thymic	JJ
cord-340028-6oicmeam	255	48	perivascular	perivascular	JJ
cord-340028-6oicmeam	255	49	space	space	NN
cord-340028-6oicmeam	255	50	during	during	IN
cord-340028-6oicmeam	255	51	aging	age	VBG
cord-340028-6oicmeam	255	52	The	the	DT
cord-340028-6oicmeam	255	53	influence	influence	NN
cord-340028-6oicmeam	255	54	of	of	IN
cord-340028-6oicmeam	255	55	age	age	NN
cord-340028-6oicmeam	255	56	on	on	IN
cord-340028-6oicmeam	255	57	T	t	NN
cord-340028-6oicmeam	255	58	cell	cell	NN
cord-340028-6oicmeam	255	59	generation	generation	NN
cord-340028-6oicmeam	255	60	and	and	CC
cord-340028-6oicmeam	255	61	TCR	TCR	NNP
cord-340028-6oicmeam	255	62	diversity	diversity	NN
cord-340028-6oicmeam	255	63	Prevalence	prevalence	NN
cord-340028-6oicmeam	255	64	and	and	CC
cord-340028-6oicmeam	255	65	patterns	pattern	NNS
cord-340028-6oicmeam	255	66	of	of	IN
cord-340028-6oicmeam	255	67	multimorbidity	multimorbidity	NN
cord-340028-6oicmeam	255	68	among	among	IN
cord-340028-6oicmeam	255	69	the	the	DT
cord-340028-6oicmeam	255	70	elderly	elderly	JJ
cord-340028-6oicmeam	255	71	in	in	IN
cord-340028-6oicmeam	255	72	China	China	NNP
cord-340028-6oicmeam	255	73	:	:	:
cord-340028-6oicmeam	255	74	a	a	DT
cord-340028-6oicmeam	255	75	cross	cross	JJ
cord-340028-6oicmeam	255	76	-	-	JJ
cord-340028-6oicmeam	255	77	sectional	sectional	JJ
cord-340028-6oicmeam	255	78	study	study	NN
cord-340028-6oicmeam	255	79	using	use	VBG
cord-340028-6oicmeam	255	80	national	national	JJ
cord-340028-6oicmeam	255	81	survey	survey	NN
cord-340028-6oicmeam	255	82	data	datum	NNS
cord-340028-6oicmeam	255	83	Measuring	measure	VBG
cord-340028-6oicmeam	255	84	multimorbidity	multimorbidity	NN
cord-340028-6oicmeam	255	85	in	in	IN
cord-340028-6oicmeam	255	86	older	old	JJR
cord-340028-6oicmeam	255	87	adults	adult	NNS
cord-340028-6oicmeam	255	88	:	:	:
cord-340028-6oicmeam	255	89	comparing	compare	VBG
cord-340028-6oicmeam	255	90	different	different	JJ
cord-340028-6oicmeam	255	91	data	datum	NNS
cord-340028-6oicmeam	255	92	sources	source	NNS
cord-340028-6oicmeam	255	93	Search	Search	NNP
cord-340028-6oicmeam	255	94	of	of	IN
cord-340028-6oicmeam	255	95	:	:	:
cord-340028-6oicmeam	255	96	Recruiting	recruiting	NN
cord-340028-6oicmeam	255	97	,	,	,
cord-340028-6oicmeam	255	98	Not	not	RB
cord-340028-6oicmeam	255	99	yet	yet	RB
cord-340028-6oicmeam	255	100	recruiting	recruit	VBG
cord-340028-6oicmeam	255	101	,	,	,
cord-340028-6oicmeam	255	102	Available	Available	NNP
cord-340028-6oicmeam	255	103	Studies	Studies	NNPS
cord-340028-6oicmeam	255	104	|	|	:
cord-340028-6oicmeam	255	105	"	"	``
cord-340028-6oicmeam	255	106	Coronavirus	Coronavirus	NNP
cord-340028-6oicmeam	255	107	Infections	Infections	NNPS
cord-340028-6oicmeam	255	108	"	"	''
cord-340028-6oicmeam	255	109	-List	-list	JJ
cord-340028-6oicmeam	256	1	Results	result	NNS
cord-340028-6oicmeam	256	2	-ClinicalTrials.gov	-ClinicalTrials.gov	NNP
cord-340028-6oicmeam	256	3	Centers	Centers	NNPS
cord-340028-6oicmeam	256	4	for	for	IN
cord-340028-6oicmeam	256	5	Disease	Disease	NNP
cord-340028-6oicmeam	256	6	Control	Control	NNP
cord-340028-6oicmeam	256	7	and	and	CC
cord-340028-6oicmeam	256	8	Prevention	Prevention	NNP
cord-340028-6oicmeam	256	9	.	.	.
cord-340028-6oicmeam	257	1	Influenza	Influenza	NNP
cord-340028-6oicmeam	257	2	Antiviral	Antiviral	NNP
cord-340028-6oicmeam	257	3	Medications	Medications	NNPS
cord-340028-6oicmeam	257	4	:	:	:
cord-340028-6oicmeam	257	5	Clinician	clinician	NN
cord-340028-6oicmeam	257	6	Summary	Summary	NNP
cord-340028-6oicmeam	257	7	.	.	.
cord-340028-6oicmeam	258	1	2020	2020	CD
cord-340028-6oicmeam	258	2	Detection	detection	NN
cord-340028-6oicmeam	258	3	and	and	CC
cord-340028-6oicmeam	258	4	control	control	NN
cord-340028-6oicmeam	258	5	of	of	IN
cord-340028-6oicmeam	258	6	influenza	influenza	NN
cord-340028-6oicmeam	258	7	outbreaks	outbreak	NNS
cord-340028-6oicmeam	258	8	in	in	IN
cord-340028-6oicmeam	258	9	well	well	RB
cord-340028-6oicmeam	258	10	-	-	HYPH
cord-340028-6oicmeam	258	11	vaccinated	vaccinate	VBN
cord-340028-6oicmeam	258	12	nursing	nursing	NN
cord-340028-6oicmeam	258	13	home	home	NN
cord-340028-6oicmeam	258	14	populations	population	NNS
cord-340028-6oicmeam	258	15	Influenza	Influenza	NNP
cord-340028-6oicmeam	258	16	virus	virus	NN
cord-340028-6oicmeam	258	17	-	-	HYPH
cord-340028-6oicmeam	258	18	related	relate	VBN
cord-340028-6oicmeam	258	19	critical	critical	JJ
cord-340028-6oicmeam	258	20	illness	illness	NN
cord-340028-6oicmeam	258	21	:	:	:
cord-340028-6oicmeam	258	22	prevention	prevention	NN
cord-340028-6oicmeam	258	23	,	,	,
cord-340028-6oicmeam	258	24	diagnosis	diagnosis	NN
cord-340028-6oicmeam	258	25	,	,	,
cord-340028-6oicmeam	258	26	treatment	treatment	NN
cord-340028-6oicmeam	258	27	Influenza	influenza	NN
cord-340028-6oicmeam	258	28	:	:	:
cord-340028-6oicmeam	258	29	overview	overview	VB
cord-340028-6oicmeam	258	30	on	on	IN
cord-340028-6oicmeam	258	31	prevention	prevention	NN
cord-340028-6oicmeam	258	32	and	and	CC
cord-340028-6oicmeam	258	33	therapy	therapy	NN
cord-340028-6oicmeam	258	34	Vaccine	Vaccine	NNP
cord-340028-6oicmeam	258	35	Potentiation	Potentiation	NNP
cord-340028-6oicmeam	258	36	by	by	IN
cord-340028-6oicmeam	258	37	Combination	Combination	NNP
cord-340028-6oicmeam	258	38	Adjuvants	Adjuvants	NNPS
cord-340028-6oicmeam	258	39	.	.	.
cord-340028-6oicmeam	259	1	Vaccines	vaccine	NNS
cord-340028-6oicmeam	259	2	(	(	-LRB-
cord-340028-6oicmeam	259	3	Basel	Basel	NNP
cord-340028-6oicmeam	259	4	)	)	-RRB-
cord-340028-6oicmeam	259	5	Immunosenescence	Immunosenescence	NNP
cord-340028-6oicmeam	259	6	and	and	CC
cord-340028-6oicmeam	259	7	human	human	JJ
cord-340028-6oicmeam	259	8	vaccine	vaccine	NN
cord-340028-6oicmeam	259	9	immune	immune	JJ
cord-340028-6oicmeam	259	10	responses	response	NNS
cord-340028-6oicmeam	259	11	Long	long	JJ
cord-340028-6oicmeam	259	12	-	-	HYPH
cord-340028-6oicmeam	259	13	term	term	NN
cord-340028-6oicmeam	259	14	use	use	NN
cord-340028-6oicmeam	259	15	of	of	IN
cord-340028-6oicmeam	259	16	oseltamivir	oseltamivir	NN
cord-340028-6oicmeam	259	17	for	for	IN
cord-340028-6oicmeam	259	18	the	the	DT
cord-340028-6oicmeam	259	19	prophylaxis	prophylaxis	NN
cord-340028-6oicmeam	259	20	of	of	IN
cord-340028-6oicmeam	259	21	influenza	influenza	NN
cord-340028-6oicmeam	259	22	in	in	IN
cord-340028-6oicmeam	259	23	a	a	DT
cord-340028-6oicmeam	259	24	vaccinated	vaccinate	VBN
cord-340028-6oicmeam	259	25	frail	frail	JJ
cord-340028-6oicmeam	259	26	older	old	JJR
cord-340028-6oicmeam	259	27	population	population	NN
cord-340028-6oicmeam	259	28	Overview	overview	NN
cord-340028-6oicmeam	259	29	of	of	IN
cord-340028-6oicmeam	259	30	Direct	Direct	NNP
cord-340028-6oicmeam	259	31	-	-	HYPH
cord-340028-6oicmeam	259	32	Acting	Acting	NNP
cord-340028-6oicmeam	259	33	Antiviral	antiviral	JJ
cord-340028-6oicmeam	259	34	Drugs	Drugs	NNPS
cord-340028-6oicmeam	259	35	and	and	CC
cord-340028-6oicmeam	259	36	Drug	Drug	NNP
cord-340028-6oicmeam	259	37	Resistance	Resistance	NNP
cord-340028-6oicmeam	259	38	of	of	IN
cord-340028-6oicmeam	259	39	Hepatitis	Hepatitis	NNP
cord-340028-6oicmeam	259	40	C	C	NNP
cord-340028-6oicmeam	259	41	Virus	Virus	NNP
cord-340028-6oicmeam	259	42	Oseltamivir	Oseltamivir	NNP
cord-340028-6oicmeam	259	43	for	for	IN
cord-340028-6oicmeam	259	44	influenza	influenza	NN
cord-340028-6oicmeam	259	45	in	in	IN
cord-340028-6oicmeam	259	46	adults	adult	NNS
cord-340028-6oicmeam	259	47	and	and	CC
cord-340028-6oicmeam	259	48	children	child	NNS
cord-340028-6oicmeam	259	49	:	:	:
cord-340028-6oicmeam	259	50	systematic	systematic	JJ
cord-340028-6oicmeam	259	51	review	review	NN
cord-340028-6oicmeam	259	52	of	of	IN
cord-340028-6oicmeam	259	53	clinical	clinical	JJ
cord-340028-6oicmeam	259	54	study	study	NN
cord-340028-6oicmeam	259	55	reports	report	NNS
cord-340028-6oicmeam	259	56	and	and	CC
cord-340028-6oicmeam	259	57	summary	summary	NN
cord-340028-6oicmeam	259	58	of	of	IN
cord-340028-6oicmeam	259	59	regulatory	regulatory	JJ
cord-340028-6oicmeam	259	60	comments	comment	NNS
cord-340028-6oicmeam	259	61	Zanamivir	Zanamivir	NNP
cord-340028-6oicmeam	259	62	for	for	IN
cord-340028-6oicmeam	259	63	influenza	influenza	NN
cord-340028-6oicmeam	259	64	in	in	IN
cord-340028-6oicmeam	259	65	adults	adult	NNS
cord-340028-6oicmeam	259	66	and	and	CC
cord-340028-6oicmeam	259	67	children	child	NNS
cord-340028-6oicmeam	259	68	:	:	:
cord-340028-6oicmeam	259	69	systematic	systematic	JJ
cord-340028-6oicmeam	259	70	review	review	NN
cord-340028-6oicmeam	259	71	of	of	IN
cord-340028-6oicmeam	259	72	clinical	clinical	JJ
cord-340028-6oicmeam	259	73	study	study	NN
cord-340028-6oicmeam	259	74	reports	report	NNS
cord-340028-6oicmeam	259	75	and	and	CC
cord-340028-6oicmeam	259	76	summary	summary	NN
cord-340028-6oicmeam	259	77	of	of	IN
cord-340028-6oicmeam	259	78	regulatory	regulatory	JJ
cord-340028-6oicmeam	259	79	comments	comment	NNS
cord-340028-6oicmeam	260	1	Oseltamivir	Oseltamivir	NNP
cord-340028-6oicmeam	260	2	treatment	treatment	NN
cord-340028-6oicmeam	260	3	for	for	IN
cord-340028-6oicmeam	260	4	influenza	influenza	NN
cord-340028-6oicmeam	260	5	in	in	IN
cord-340028-6oicmeam	260	6	adults	adult	NNS
cord-340028-6oicmeam	260	7	:	:	:
cord-340028-6oicmeam	260	8	a	a	DT
cord-340028-6oicmeam	260	9	metaanalysis	metaanalysis	NN
cord-340028-6oicmeam	260	10	of	of	IN
cord-340028-6oicmeam	260	11	randomised	randomised	JJ
cord-340028-6oicmeam	260	12	controlled	control	VBN
cord-340028-6oicmeam	260	13	trials	trial	NNS
cord-340028-6oicmeam	260	14	and	and	CC
cord-340028-6oicmeam	260	15	Baloxavir	Baloxavir	NNP
cord-340028-6oicmeam	260	16	Marboxil	Marboxil	NNP
cord-340028-6oicmeam	260	17	Investigators	Investigators	NNPS
cord-340028-6oicmeam	260	18	Group	Group	NNP
cord-340028-6oicmeam	260	19	.	.	.
cord-340028-6oicmeam	261	1	Baloxavir	Baloxavir	NNP
cord-340028-6oicmeam	261	2	Marboxil	Marboxil	NNP
cord-340028-6oicmeam	261	3	for	for	IN
cord-340028-6oicmeam	261	4	Uncomplicated	uncomplicated	JJ
cord-340028-6oicmeam	261	5	Influenza	Influenza	NNP
cord-340028-6oicmeam	261	6	in	in	IN
cord-340028-6oicmeam	261	7	Adults	Adults	NNPS
cord-340028-6oicmeam	261	8	and	and	CC
cord-340028-6oicmeam	261	9	Adolescents	Adolescents	NNPS
cord-340028-6oicmeam	261	10	Understanding	Understanding	NNP
cord-340028-6oicmeam	261	11	COVID-19	covid-19	VBP
cord-340028-6oicmeam	261	12	new	new	JJ
cord-340028-6oicmeam	261	13	diagnostic	diagnostic	JJ
cord-340028-6oicmeam	261	14	guidelines	guideline	NNS
cord-340028-6oicmeam	261	15	-a	-a	:
cord-340028-6oicmeam	261	16	message	message	NN
cord-340028-6oicmeam	261	17	of	of	IN
cord-340028-6oicmeam	261	18	reassurance	reassurance	NN
cord-340028-6oicmeam	261	19	from	from	IN
cord-340028-6oicmeam	261	20	an	an	DT
cord-340028-6oicmeam	261	21	internal	internal	JJ
cord-340028-6oicmeam	261	22	medicine	medicine	NN
cord-340028-6oicmeam	261	23	doctor	doctor	NN
cord-340028-6oicmeam	261	24	in	in	IN
cord-340028-6oicmeam	261	25	Shanghai	Shanghai	NNP
cord-340028-6oicmeam	262	1	Can	Can	MD
cord-340028-6oicmeam	262	2	physical	physical	JJ
cord-340028-6oicmeam	262	3	activity	activity	NN
cord-340028-6oicmeam	262	4	ameliorate	ameliorate	VB
cord-340028-6oicmeam	262	5	immunosenescence	immunosenescence	RB
cord-340028-6oicmeam	262	6	and	and	CC
cord-340028-6oicmeam	262	7	thereby	thereby	RB
cord-340028-6oicmeam	262	8	reduce	reduce	VB
cord-340028-6oicmeam	262	9	age	age	NN
cord-340028-6oicmeam	262	10	-	-	HYPH
cord-340028-6oicmeam	262	11	related	relate	VBN
cord-340028-6oicmeam	262	12	multi	multi	JJ
cord-340028-6oicmeam	262	13	-	-	JJ
cord-340028-6oicmeam	262	14	morbidity	morbidity	JJ
cord-340028-6oicmeam	262	15	?	?	.
cord-340028-6oicmeam	263	1	Reversal	reversal	NN
cord-340028-6oicmeam	263	2	of	of	IN
cord-340028-6oicmeam	263	3	epigenetic	epigenetic	JJ
cord-340028-6oicmeam	263	4	aging	aging	NN
cord-340028-6oicmeam	263	5	and	and	CC
cord-340028-6oicmeam	263	6	immunosenescent	immunosenescent	NN
cord-340028-6oicmeam	263	7	trends	trend	NNS
cord-340028-6oicmeam	263	8	in	in	IN
cord-340028-6oicmeam	263	9	humans	human	NNS
cord-340028-6oicmeam	263	10	DNA	dna	NN
cord-340028-6oicmeam	263	11	methylation	methylation	NN
cord-340028-6oicmeam	263	12	age	age	NN
cord-340028-6oicmeam	263	13	of	of	IN
cord-340028-6oicmeam	263	14	human	human	JJ
cord-340028-6oicmeam	263	15	tissues	tissue	NNS
cord-340028-6oicmeam	263	16	and	and	CC
cord-340028-6oicmeam	263	17	cell	cell	NN
cord-340028-6oicmeam	263	18	types	type	NNS
cord-340028-6oicmeam	263	19	Vive	Vive	NNP
cord-340028-6oicmeam	263	20	la	la	FW
cord-340028-6oicmeam	263	21	radiorésistance	radiorésistance	FW
cord-340028-6oicmeam	263	22	!	!	.
cord-340028-6oicmeam	263	23	:	:	:
cord-340028-6oicmeam	264	1	converging	converge	VBG
cord-340028-6oicmeam	264	2	research	research	NN
cord-340028-6oicmeam	264	3	in	in	IN
cord-340028-6oicmeam	264	4	radiobiology	radiobiology	NN
cord-340028-6oicmeam	264	5	and	and	CC
cord-340028-6oicmeam	264	6	biogerontology	biogerontology	NN
cord-340028-6oicmeam	264	7	to	to	TO
cord-340028-6oicmeam	264	8	enhance	enhance	VB
cord-340028-6oicmeam	264	9	human	human	JJ
cord-340028-6oicmeam	264	10	radioresistance	radioresistance	NN
cord-340028-6oicmeam	264	11	for	for	IN
cord-340028-6oicmeam	264	12	deep	deep	JJ
cord-340028-6oicmeam	264	13	space	space	NN
cord-340028-6oicmeam	264	14	exploration	exploration	NN
cord-340028-6oicmeam	264	15	and	and	CC
cord-340028-6oicmeam	264	16	colonization	colonization	NN
cord-340028-6oicmeam	264	17	Signaling	Signaling	NNP
cord-340028-6oicmeam	264	18	pathway	pathway	NN
cord-340028-6oicmeam	264	19	cloud	cloud	NN
cord-340028-6oicmeam	264	20	regulation	regulation	NN
cord-340028-6oicmeam	264	21	for	for	IN
cord-340028-6oicmeam	264	22	in	in	IN
cord-340028-6oicmeam	264	23	silico	silico	NN
cord-340028-6oicmeam	264	24	screening	screening	NN
cord-340028-6oicmeam	264	25	and	and	CC
cord-340028-6oicmeam	264	26	ranking	ranking	NN
cord-340028-6oicmeam	264	27	of	of	IN
cord-340028-6oicmeam	264	28	the	the	DT
cord-340028-6oicmeam	264	29	potential	potential	JJ
cord-340028-6oicmeam	264	30	geroprotective	geroprotective	JJ
cord-340028-6oicmeam	264	31	drugs	drug	NNS
cord-340028-6oicmeam	265	1	In	in	IN
cord-340028-6oicmeam	265	2	search	search	NN
cord-340028-6oicmeam	265	3	for	for	IN
cord-340028-6oicmeam	265	4	geroprotectors	geroprotector	NNS
cord-340028-6oicmeam	265	5	:	:	:
cord-340028-6oicmeam	265	6	in	in	IN
cord-340028-6oicmeam	265	7	silico	silico	NN
cord-340028-6oicmeam	265	8	screening	screening	NN
cord-340028-6oicmeam	265	9	and	and	CC
cord-340028-6oicmeam	265	10	in	in	IN
cord-340028-6oicmeam	265	11	vitro	vitro	FW
cord-340028-6oicmeam	265	12	validation	validation	NN
cord-340028-6oicmeam	265	13	of	of	IN
cord-340028-6oicmeam	265	14	signalome	signalome	JJ
cord-340028-6oicmeam	265	15	-	-	HYPH
cord-340028-6oicmeam	265	16	level	level	NN
cord-340028-6oicmeam	265	17	mimetics	mimetic	NNS
cord-340028-6oicmeam	265	18	of	of	IN
cord-340028-6oicmeam	265	19	young	young	JJ
cord-340028-6oicmeam	265	20	healthy	healthy	JJ
cord-340028-6oicmeam	265	21	state	state	NN
cord-340028-6oicmeam	265	22	Artificial	artificial	JJ
cord-340028-6oicmeam	265	23	intelligence	intelligence	NN
cord-340028-6oicmeam	265	24	for	for	IN
cord-340028-6oicmeam	265	25	aging	age	VBG
cord-340028-6oicmeam	265	26	and	and	CC
cord-340028-6oicmeam	265	27	longevity	longevity	NN
cord-340028-6oicmeam	265	28	research	research	NN
cord-340028-6oicmeam	265	29	:	:	:
cord-340028-6oicmeam	265	30	recent	recent	JJ
cord-340028-6oicmeam	265	31	advances	advance	NNS
cord-340028-6oicmeam	265	32	and	and	CC
cord-340028-6oicmeam	265	33	perspectives	perspective	NNS
cord-340028-6oicmeam	265	34	Towards	towards	IN
cord-340028-6oicmeam	265	35	natural	natural	JJ
cord-340028-6oicmeam	265	36	mimetics	mimetic	NNS
cord-340028-6oicmeam	265	37	of	of	IN
cord-340028-6oicmeam	265	38	metformin	metformin	NNP
cord-340028-6oicmeam	265	39	and	and	CC
cord-340028-6oicmeam	265	40	rapamycin	rapamycin	NNP
cord-340028-6oicmeam	265	41	Interventions	Interventions	NNPS
cord-340028-6oicmeam	265	42	to	to	TO
cord-340028-6oicmeam	265	43	restore	restore	VB
cord-340028-6oicmeam	265	44	appropriate	appropriate	JJ
cord-340028-6oicmeam	265	45	immune	immune	JJ
cord-340028-6oicmeam	265	46	function	function	NN
cord-340028-6oicmeam	265	47	in	in	IN
cord-340028-6oicmeam	265	48	the	the	DT
cord-340028-6oicmeam	265	49	elderly	elderly	JJ
cord-340028-6oicmeam	266	1	The	the	DT
cord-340028-6oicmeam	266	2	DrugAge	DrugAge	NNP
cord-340028-6oicmeam	266	3	database	database	NN
cord-340028-6oicmeam	266	4	of	of	IN
cord-340028-6oicmeam	266	5	aging	age	VBG
cord-340028-6oicmeam	266	6	-	-	HYPH
cord-340028-6oicmeam	266	7	related	relate	VBN
cord-340028-6oicmeam	266	8	drugs	drug	NNS
cord-340028-6oicmeam	266	9	org	org	NN
cord-340028-6oicmeam	266	10	:	:	:
cord-340028-6oicmeam	266	11	a	a	DT
cord-340028-6oicmeam	266	12	new	new	JJ
cord-340028-6oicmeam	266	13	,	,	,
cord-340028-6oicmeam	266	14	structured	structured	JJ
cord-340028-6oicmeam	266	15	and	and	CC
cord-340028-6oicmeam	266	16	curated	curated	JJ
cord-340028-6oicmeam	266	17	database	database	NN
cord-340028-6oicmeam	266	18	of	of	IN
cord-340028-6oicmeam	266	19	current	current	JJ
cord-340028-6oicmeam	266	20	therapeutic	therapeutic	JJ
cord-340028-6oicmeam	266	21	interventions	intervention	NNS
cord-340028-6oicmeam	266	22	in	in	IN
cord-340028-6oicmeam	266	23	aging	age	VBG
cord-340028-6oicmeam	266	24	and	and	CC
cord-340028-6oicmeam	266	25	age	age	NN
cord-340028-6oicmeam	266	26	-	-	HYPH
cord-340028-6oicmeam	266	27	related	relate	VBN
cord-340028-6oicmeam	266	28	disease	disease	NN
cord-340028-6oicmeam	266	29	Regulation	regulation	NN
cord-340028-6oicmeam	266	30	of	of	IN
cord-340028-6oicmeam	266	31	yeast	yeast	NN
cord-340028-6oicmeam	266	32	replicative	replicative	JJ
cord-340028-6oicmeam	266	33	life	life	NN
cord-340028-6oicmeam	266	34	span	span	NN
cord-340028-6oicmeam	266	35	by	by	IN
cord-340028-6oicmeam	266	36	TOR	TOR	NNP
cord-340028-6oicmeam	266	37	and	and	CC
cord-340028-6oicmeam	266	38	Sch9	Sch9	NNP
cord-340028-6oicmeam	266	39	in	in	IN
cord-340028-6oicmeam	266	40	response	response	NN
cord-340028-6oicmeam	266	41	to	to	IN
cord-340028-6oicmeam	266	42	nutrients	nutrients	NNP
cord-340028-6oicmeam	266	43	Extension	Extension	NNP
cord-340028-6oicmeam	266	44	of	of	IN
cord-340028-6oicmeam	266	45	chronological	chronological	JJ
cord-340028-6oicmeam	266	46	life	life	NN
cord-340028-6oicmeam	266	47	span	span	NN
cord-340028-6oicmeam	266	48	in	in	IN
cord-340028-6oicmeam	266	49	yeast	yeast	NN
cord-340028-6oicmeam	266	50	by	by	IN
cord-340028-6oicmeam	266	51	decreased	decrease	VBD
cord-340028-6oicmeam	266	52	TOR	TOR	NNP
cord-340028-6oicmeam	266	53	pathway	pathway	NN
cord-340028-6oicmeam	266	54	signaling	signal	VBG
cord-340028-6oicmeam	266	55	Regulation	regulation	NN
cord-340028-6oicmeam	266	56	of	of	IN
cord-340028-6oicmeam	266	57	lifespan	lifespan	NN
cord-340028-6oicmeam	266	58	in	in	IN
cord-340028-6oicmeam	266	59	Drosophila	Drosophila	NNP
cord-340028-6oicmeam	266	60	by	by	IN
cord-340028-6oicmeam	266	61	modulation	modulation	NN
cord-340028-6oicmeam	266	62	of	of	IN
cord-340028-6oicmeam	266	63	genes	gene	NNS
cord-340028-6oicmeam	266	64	in	in	IN
cord-340028-6oicmeam	266	65	the	the	DT
cord-340028-6oicmeam	266	66	TOR	TOR	NNP
cord-340028-6oicmeam	266	67	signaling	signal	VBG
cord-340028-6oicmeam	266	68	pathway	pathway	NN
cord-340028-6oicmeam	266	69	Target	Target	NNP
cord-340028-6oicmeam	266	70	of	of	IN
cord-340028-6oicmeam	266	71	rapamycin	rapamycin	NN
cord-340028-6oicmeam	266	72	activation	activation	NN
cord-340028-6oicmeam	266	73	predicts	predict	VBZ
cord-340028-6oicmeam	266	74	lifespan	lifespan	NN
cord-340028-6oicmeam	266	75	in	in	IN
cord-340028-6oicmeam	266	76	fruit	fruit	NN
cord-340028-6oicmeam	266	77	flies	fly	VBZ
cord-340028-6oicmeam	266	78	TOR	TOR	NNP
cord-340028-6oicmeam	266	79	signaling	signal	VBG
cord-340028-6oicmeam	266	80	and	and	CC
cord-340028-6oicmeam	266	81	rapamycin	rapamycin	NN
cord-340028-6oicmeam	266	82	influence	influence	NN
cord-340028-6oicmeam	266	83	longevity	longevity	NN
cord-340028-6oicmeam	266	84	by	by	IN
cord-340028-6oicmeam	266	85	regulating	regulate	VBG
cord-340028-6oicmeam	266	86	SKN-1	SKN-1	NNP
cord-340028-6oicmeam	266	87	/	/	SYM
cord-340028-6oicmeam	266	88	Nrf	Nrf	NNP
cord-340028-6oicmeam	266	89	and	and	CC
cord-340028-6oicmeam	266	90	DAF-16	DAF-16	NNP
cord-340028-6oicmeam	266	91	/	/	SYM
cord-340028-6oicmeam	266	92	FoxO	FoxO	NNP
cord-340028-6oicmeam	266	93	Rapamycin	Rapamycin	NNP
cord-340028-6oicmeam	266	94	fed	feed	VBN
cord-340028-6oicmeam	266	95	late	late	RB
cord-340028-6oicmeam	266	96	in	in	IN
cord-340028-6oicmeam	266	97	life	life	NN
cord-340028-6oicmeam	266	98	extends	extend	VBZ
cord-340028-6oicmeam	266	99	lifespan	lifespan	NN
cord-340028-6oicmeam	266	100	in	in	IN
cord-340028-6oicmeam	266	101	genetically	genetically	RB
cord-340028-6oicmeam	266	102	heterogeneous	heterogeneous	JJ
cord-340028-6oicmeam	266	103	mice	mouse	NNS
cord-340028-6oicmeam	267	1	Rapamycin	Rapamycin	NNP
cord-340028-6oicmeam	267	2	increases	increase	VBZ
cord-340028-6oicmeam	267	3	lifespan	lifespan	NN
cord-340028-6oicmeam	267	4	and	and	CC
cord-340028-6oicmeam	267	5	inhibits	inhibit	VBZ
cord-340028-6oicmeam	267	6	spontaneous	spontaneous	JJ
cord-340028-6oicmeam	267	7	tumorigenesis	tumorigenesis	NN
cord-340028-6oicmeam	267	8	in	in	IN
cord-340028-6oicmeam	267	9	inbred	inbred	JJ
cord-340028-6oicmeam	267	10	female	female	JJ
cord-340028-6oicmeam	267	11	mice	mouse	NNS
cord-340028-6oicmeam	267	12	Rapamycin	Rapamycin	NNP
cord-340028-6oicmeam	267	13	slows	slow	VBZ
cord-340028-6oicmeam	267	14	aging	age	VBG
cord-340028-6oicmeam	267	15	in	in	IN
cord-340028-6oicmeam	267	16	mice	mouse	NNS
cord-340028-6oicmeam	267	17	New	new	JJ
cord-340028-6oicmeam	267	18	nanoformulation	nanoformulation	NN
cord-340028-6oicmeam	267	19	of	of	IN
cord-340028-6oicmeam	267	20	rapamycin	rapamycin	NNP
cord-340028-6oicmeam	267	21	Rapatar	Rapatar	NNP
cord-340028-6oicmeam	267	22	extends	extend	VBZ
cord-340028-6oicmeam	267	23	lifespan	lifespan	NN
cord-340028-6oicmeam	267	24	in	in	IN
cord-340028-6oicmeam	267	25	homozygous	homozygous	JJ
cord-340028-6oicmeam	267	26	p53-/-mice	p53-/-mice	NNS
cord-340028-6oicmeam	267	27	by	by	IN
cord-340028-6oicmeam	267	28	delaying	delay	VBG
cord-340028-6oicmeam	268	1	carcinogenesis	carcinogenesis	NN
cord-340028-6oicmeam	268	2	Rapamycin	Rapamycin	NNP
cord-340028-6oicmeam	268	3	extends	extend	VBZ
cord-340028-6oicmeam	268	4	maximal	maximal	JJ
cord-340028-6oicmeam	268	5	lifespan	lifespan	NN
cord-340028-6oicmeam	268	6	in	in	IN
cord-340028-6oicmeam	268	7	cancer	cancer	NN
cord-340028-6oicmeam	268	8	-	-	HYPH
cord-340028-6oicmeam	268	9	prone	prone	JJ
cord-340028-6oicmeam	268	10	mice	mouse	NNS
cord-340028-6oicmeam	269	1	Immunostimulatory	immunostimulatory	JJ
cord-340028-6oicmeam	269	2	activity	activity	NN
cord-340028-6oicmeam	269	3	of	of	IN
cord-340028-6oicmeam	269	4	lifespan	lifespan	NN
cord-340028-6oicmeam	269	5	-	-	HYPH
cord-340028-6oicmeam	269	6	extending	extend	VBG
cord-340028-6oicmeam	269	7	agents	agent	NNS
cord-340028-6oicmeam	269	8	Sirolimus	Sirolimus	NNP
cord-340028-6oicmeam	269	9	and	and	CC
cord-340028-6oicmeam	269	10	secondary	secondary	JJ
cord-340028-6oicmeam	269	11	skin	skin	NN
cord-340028-6oicmeam	269	12	-	-	HYPH
cord-340028-6oicmeam	269	13	cancer	cancer	NN
cord-340028-6oicmeam	269	14	prevention	prevention	NN
cord-340028-6oicmeam	269	15	in	in	IN
cord-340028-6oicmeam	269	16	kidney	kidney	NN
cord-340028-6oicmeam	269	17	transplantation	transplantation	NN
cord-340028-6oicmeam	269	18	Sirolimus	Sirolimus	NNP
cord-340028-6oicmeam	269	19	therapy	therapy	NN
cord-340028-6oicmeam	269	20	after	after	IN
cord-340028-6oicmeam	269	21	early	early	JJ
cord-340028-6oicmeam	269	22	cyclosporine	cyclosporine	JJ
cord-340028-6oicmeam	269	23	withdrawal	withdrawal	NN
cord-340028-6oicmeam	269	24	reduces	reduce	VBZ
cord-340028-6oicmeam	269	25	the	the	DT
cord-340028-6oicmeam	269	26	risk	risk	NN
cord-340028-6oicmeam	269	27	for	for	IN
cord-340028-6oicmeam	269	28	cancer	cancer	NN
cord-340028-6oicmeam	269	29	in	in	IN
cord-340028-6oicmeam	269	30	adult	adult	JJ
cord-340028-6oicmeam	269	31	renal	renal	JJ
cord-340028-6oicmeam	269	32	transplantation	transplantation	NN
cord-340028-6oicmeam	269	33	Rejuvenating	rejuvenate	VBG
cord-340028-6oicmeam	269	34	immunity	immunity	NN
cord-340028-6oicmeam	269	35	:	:	:
cord-340028-6oicmeam	269	36	"	"	``
cord-340028-6oicmeam	269	37	anti	anti	JJ
cord-340028-6oicmeam	269	38	-	-	JJ
cord-340028-6oicmeam	269	39	aging	aging	JJ
cord-340028-6oicmeam	269	40	drug	drug	NN
cord-340028-6oicmeam	269	41	today	today	NN
cord-340028-6oicmeam	269	42	"	"	''
cord-340028-6oicmeam	269	43	eight	eight	CD
cord-340028-6oicmeam	269	44	years	year	NNS
cord-340028-6oicmeam	269	45	later	later	RB
cord-340028-6oicmeam	269	46	Validation	validation	NN
cord-340028-6oicmeam	269	47	of	of	IN
cord-340028-6oicmeam	269	48	anti	anti	JJ
cord-340028-6oicmeam	269	49	-	-	JJ
cord-340028-6oicmeam	269	50	aging	aging	JJ
cord-340028-6oicmeam	269	51	drugs	drug	NNS
cord-340028-6oicmeam	269	52	by	by	IN
cord-340028-6oicmeam	269	53	treating	treat	VBG
cord-340028-6oicmeam	269	54	age	age	NN
cord-340028-6oicmeam	269	55	-	-	HYPH
cord-340028-6oicmeam	269	56	related	relate	VBN
cord-340028-6oicmeam	269	57	diseases	disease	NNS
cord-340028-6oicmeam	269	58	Prevention	Prevention	NNP
cord-340028-6oicmeam	269	59	of	of	IN
cord-340028-6oicmeam	269	60	cancer	cancer	NN
cord-340028-6oicmeam	269	61	by	by	IN
cord-340028-6oicmeam	269	62	inhibiting	inhibit	VBG
cord-340028-6oicmeam	269	63	aging	age	VBG
cord-340028-6oicmeam	269	64	An	an	DT
cord-340028-6oicmeam	269	65	anti	anti	JJ
cord-340028-6oicmeam	269	66	-	-	JJ
cord-340028-6oicmeam	269	67	aging	aging	JJ
cord-340028-6oicmeam	269	68	drug	drug	NN
cord-340028-6oicmeam	269	69	today	today	NN
cord-340028-6oicmeam	269	70	:	:	:
cord-340028-6oicmeam	269	71	from	from	IN
cord-340028-6oicmeam	269	72	senescence	senescence	NN
cord-340028-6oicmeam	269	73	-	-	HYPH
cord-340028-6oicmeam	269	74	promoting	promote	VBG
cord-340028-6oicmeam	269	75	genes	gene	NNS
cord-340028-6oicmeam	269	76	to	to	IN
cord-340028-6oicmeam	269	77	anti	anti	JJ
cord-340028-6oicmeam	269	78	-	-	JJ
cord-340028-6oicmeam	269	79	aging	aging	JJ
cord-340028-6oicmeam	269	80	pill	pill	NN
cord-340028-6oicmeam	269	81	Aging	aging	NN
cord-340028-6oicmeam	269	82	and	and	CC
cord-340028-6oicmeam	269	83	immortality	immortality	NN
cord-340028-6oicmeam	269	84	:	:	:
cord-340028-6oicmeam	269	85	quasiprogrammed	quasiprogrammed	NNP
cord-340028-6oicmeam	269	86	senescence	senescence	NN
cord-340028-6oicmeam	269	87	and	and	CC
cord-340028-6oicmeam	269	88	its	-PRON-	PRP$
cord-340028-6oicmeam	269	89	pharmacologic	pharmacologic	JJ
cord-340028-6oicmeam	269	90	inhibition	inhibition	NN
cord-340028-6oicmeam	269	91	Selective	selective	JJ
cord-340028-6oicmeam	269	92	Effects	effect	NNS
cord-340028-6oicmeam	269	93	of	of	IN
cord-340028-6oicmeam	269	94	mTOR	mtor	NN
cord-340028-6oicmeam	269	95	Inhibitor	Inhibitor	NNP
cord-340028-6oicmeam	269	96	Sirolimus	Sirolimus	NNP
cord-340028-6oicmeam	269	97	on	on	IN
cord-340028-6oicmeam	269	98	Naïve	Naïve	NNP
cord-340028-6oicmeam	269	99	and	and	CC
cord-340028-6oicmeam	270	1	CMV	CMV	NNP
cord-340028-6oicmeam	270	2	-	-	HYPH
cord-340028-6oicmeam	270	3	Specific	specific	JJ
cord-340028-6oicmeam	270	4	T	t	NN
cord-340028-6oicmeam	270	5	Cells	cell	NNS
cord-340028-6oicmeam	270	6	Extending	extend	VBG
cord-340028-6oicmeam	270	7	Its	-PRON-	PRP$
cord-340028-6oicmeam	270	8	Applicable	applicable	JJ
cord-340028-6oicmeam	270	9	Range	range	NN
cord-340028-6oicmeam	270	10	Beyond	Beyond	NNP
cord-340028-6oicmeam	270	11	Immunosuppression	Immunosuppression	NNP
cord-340028-6oicmeam	270	12	Paradoxical	paradoxical	JJ
cord-340028-6oicmeam	270	13	aspects	aspect	NNS
cord-340028-6oicmeam	270	14	of	of	IN
cord-340028-6oicmeam	270	15	rapamycin	rapamycin	NN
cord-340028-6oicmeam	270	16	immunobiology	immunobiology	NN
cord-340028-6oicmeam	270	17	in	in	IN
cord-340028-6oicmeam	270	18	transplantation	transplantation	NN
cord-340028-6oicmeam	270	19	Type	type	NN
cord-340028-6oicmeam	270	20	1	1	CD
cord-340028-6oicmeam	270	21	interferons	interferon	NNS
cord-340028-6oicmeam	270	22	and	and	CC
cord-340028-6oicmeam	270	23	the	the	DT
cord-340028-6oicmeam	270	24	virus	virus	NN
cord-340028-6oicmeam	270	25	-	-	HYPH
cord-340028-6oicmeam	270	26	host	host	NN
cord-340028-6oicmeam	270	27	relationship	relationship	NN
cord-340028-6oicmeam	270	28	:	:	:
cord-340028-6oicmeam	270	29	a	a	DT
cord-340028-6oicmeam	270	30	lesson	lesson	NN
cord-340028-6oicmeam	270	31	in	in	IN
cord-340028-6oicmeam	270	32	détente	détente	FW
cord-340028-6oicmeam	270	33	SARS	SARS	NNP
cord-340028-6oicmeam	270	34	coronavirus	coronavirus	NN
cord-340028-6oicmeam	270	35	and	and	CC
cord-340028-6oicmeam	270	36	innate	innate	JJ
cord-340028-6oicmeam	270	37	immunity	immunity	NN
cord-340028-6oicmeam	270	38	Inhibitors	Inhibitors	NNP
cord-340028-6oicmeam	270	39	of	of	IN
cord-340028-6oicmeam	270	40	mTOR	mTOR	NNP
cord-340028-6oicmeam	270	41	in	in	IN
cord-340028-6oicmeam	270	42	aging	aging	NN
cord-340028-6oicmeam	270	43	and	and	CC
cord-340028-6oicmeam	270	44	cancer	cancer	NN
cord-340028-6oicmeam	270	45	Gerosuppression	Gerosuppression	NNP
cord-340028-6oicmeam	270	46	in	in	IN
cord-340028-6oicmeam	270	47	confluent	confluent	JJ
cord-340028-6oicmeam	270	48	cells	cell	NNS
cord-340028-6oicmeam	271	1	Dual	Dual	NNP
cord-340028-6oicmeam	271	2	mTORC1	mTORC1	NNP
cord-340028-6oicmeam	271	3	/	/	SYM
cord-340028-6oicmeam	271	4	C2	C2	NNP
cord-340028-6oicmeam	271	5	inhibitors	inhibitor	NNS
cord-340028-6oicmeam	271	6	suppress	suppress	VBP
cord-340028-6oicmeam	271	7	cellular	cellular	JJ
cord-340028-6oicmeam	271	8	geroconversion	geroconversion	NN
cord-340028-6oicmeam	271	9	(	(	-LRB-
cord-340028-6oicmeam	271	10	a	a	DT
cord-340028-6oicmeam	271	11	senescence	senescence	NN
cord-340028-6oicmeam	271	12	program	program	NN
cord-340028-6oicmeam	271	13	)	)	-RRB-
cord-340028-6oicmeam	271	14	Decreased	decrease	VBD
cord-340028-6oicmeam	271	15	Cytomegalovirus	Cytomegalovirus	NNP
cord-340028-6oicmeam	271	16	infection	infection	NN
cord-340028-6oicmeam	271	17	after	after	IN
cord-340028-6oicmeam	271	18	antilymphocyte	antilymphocyte	NNP
cord-340028-6oicmeam	271	19	therapy	therapy	NN
cord-340028-6oicmeam	271	20	in	in	IN
cord-340028-6oicmeam	271	21	sirolimus	sirolimus	NN
cord-340028-6oicmeam	271	22	-	-	HYPH
cord-340028-6oicmeam	271	23	treated	treat	VBN
cord-340028-6oicmeam	271	24	renal	renal	JJ
cord-340028-6oicmeam	271	25	transplant	transplant	NN
cord-340028-6oicmeam	271	26	patients	patient	NNS
cord-340028-6oicmeam	271	27	Sirolimus	Sirolimus	NNP
cord-340028-6oicmeam	271	28	enhances	enhance	VBZ
cord-340028-6oicmeam	271	29	the	the	DT
cord-340028-6oicmeam	271	30	magnitude	magnitude	NN
cord-340028-6oicmeam	271	31	and	and	CC
cord-340028-6oicmeam	271	32	quality	quality	NN
cord-340028-6oicmeam	271	33	of	of	IN
cord-340028-6oicmeam	271	34	viralspecific	viralspecific	NNP
cord-340028-6oicmeam	271	35	CD8	CD8	NNP
cord-340028-6oicmeam	271	36	+	+	CC
cord-340028-6oicmeam	271	37	T	t	NN
cord-340028-6oicmeam	271	38	-	-	HYPH
cord-340028-6oicmeam	271	39	cell	cell	NN
cord-340028-6oicmeam	271	40	responses	response	NNS
cord-340028-6oicmeam	271	41	to	to	IN
cord-340028-6oicmeam	271	42	vaccinia	vaccinia	NN
cord-340028-6oicmeam	271	43	virus	virus	NN
cord-340028-6oicmeam	271	44	vaccination	vaccination	NN
cord-340028-6oicmeam	271	45	in	in	IN
cord-340028-6oicmeam	271	46	rhesus	rhesus	NNP
cord-340028-6oicmeam	271	47	macaques	macaque	NNS
cord-340028-6oicmeam	271	48	mTOR	mTOR	NNP
cord-340028-6oicmeam	271	49	inhibition	inhibition	NN
cord-340028-6oicmeam	271	50	improves	improve	VBZ
cord-340028-6oicmeam	271	51	immune	immune	JJ
cord-340028-6oicmeam	271	52	function	function	NN
cord-340028-6oicmeam	271	53	in	in	IN
cord-340028-6oicmeam	271	54	the	the	DT
cord-340028-6oicmeam	271	55	elderly	elderly	JJ
cord-340028-6oicmeam	271	56	TORC1	TORC1	NNP
cord-340028-6oicmeam	271	57	inhibition	inhibition	NN
cord-340028-6oicmeam	271	58	enhances	enhance	VBZ
cord-340028-6oicmeam	271	59	immune	immune	JJ
cord-340028-6oicmeam	271	60	function	function	NN
cord-340028-6oicmeam	271	61	and	and	CC
cord-340028-6oicmeam	271	62	reduces	reduce	VBZ
cord-340028-6oicmeam	271	63	infections	infection	NNS
cord-340028-6oicmeam	271	64	in	in	IN
cord-340028-6oicmeam	271	65	the	the	DT
cord-340028-6oicmeam	271	66	elderly	elderly	JJ
cord-340028-6oicmeam	271	67	NVP	NVP	NNP
cord-340028-6oicmeam	271	68	-	-	HYPH
cord-340028-6oicmeam	271	69	BEZ235	BEZ235	NNP
cord-340028-6oicmeam	271	70	,	,	,
cord-340028-6oicmeam	271	71	a	a	DT
cord-340028-6oicmeam	271	72	novel	novel	JJ
cord-340028-6oicmeam	271	73	dual	dual	JJ
cord-340028-6oicmeam	271	74	phosphatidylinositol	phosphatidylinositol	NN
cord-340028-6oicmeam	271	75	3-kinase	3-kinase	CD
cord-340028-6oicmeam	271	76	/	/	SYM
cord-340028-6oicmeam	271	77	mammalian	mammalian	JJ
cord-340028-6oicmeam	271	78	target	target	NN
cord-340028-6oicmeam	271	79	of	of	IN
cord-340028-6oicmeam	271	80	rapamycin	rapamycin	NN
cord-340028-6oicmeam	271	81	inhibitor	inhibitor	NN
cord-340028-6oicmeam	271	82	,	,	,
cord-340028-6oicmeam	271	83	elicits	elicit	VBZ
cord-340028-6oicmeam	271	84	multifaceted	multifaceted	JJ
cord-340028-6oicmeam	271	85	antitumor	antitumor	JJ
cord-340028-6oicmeam	271	86	activities	activity	NNS
cord-340028-6oicmeam	271	87	in	in	IN
cord-340028-6oicmeam	271	88	human	human	JJ
cord-340028-6oicmeam	271	89	gliomas	glioma	NNS
cord-340028-6oicmeam	271	90	Effect	effect	NN
cord-340028-6oicmeam	271	91	of	of	IN
cord-340028-6oicmeam	271	92	RTB101	rtb101	NN
cord-340028-6oicmeam	271	93	on	on	IN
cord-340028-6oicmeam	271	94	Illness	Illness	NNP
cord-340028-6oicmeam	271	95	Associated	Associated	NNP
cord-340028-6oicmeam	271	96	With	with	IN
cord-340028-6oicmeam	271	97	Respiratory	respiratory	JJ
cord-340028-6oicmeam	271	98	Tract	tract	NN
cord-340028-6oicmeam	271	99	Infections	infection	NNS
cord-340028-6oicmeam	271	100	in	in	IN
cord-340028-6oicmeam	271	101	the	the	DT
cord-340028-6oicmeam	271	102	Elderly	Elderly	NNP
cord-340028-6oicmeam	271	103	Search	Search	NNP
cord-340028-6oicmeam	271	104	of	of	IN
cord-340028-6oicmeam	271	105	:	:	:
cord-340028-6oicmeam	271	106	Rad001	rad001	ADD
cord-340028-6oicmeam	271	107	,	,	,
cord-340028-6oicmeam	271	108	Certican	Certican	NNP
cord-340028-6oicmeam	271	109	,	,	,
cord-340028-6oicmeam	271	110	Rapamycin	Rapamycin	NNP
cord-340028-6oicmeam	271	111	Metformin	Metformin	NNP
cord-340028-6oicmeam	271	112	as	as	IN
cord-340028-6oicmeam	271	113	a	a	DT
cord-340028-6oicmeam	271	114	Tool	tool	NN
cord-340028-6oicmeam	271	115	to	to	IN
cord-340028-6oicmeam	271	116	Effect	effect	NN
cord-340028-6oicmeam	271	117	of	of	IN
cord-340028-6oicmeam	271	118	"	"	``
cord-340028-6oicmeam	271	119	Nicotinamide	Nicotinamide	NNP
cord-340028-6oicmeam	271	120	Mononucleotide	Mononucleotide	NNP
cord-340028-6oicmeam	271	121	"	"	''
cord-340028-6oicmeam	271	122	(	(	-LRB-
cord-340028-6oicmeam	271	123	NMN	NMN	NNP
cord-340028-6oicmeam	271	124	)	)	-RRB-
cord-340028-6oicmeam	271	125	on	on	IN
cord-340028-6oicmeam	271	126	Cardiometabolic	Cardiometabolic	NNP
cord-340028-6oicmeam	271	127	Function	Function	NNP
cord-340028-6oicmeam	271	128	Effects	effect	NNS
cord-340028-6oicmeam	271	129	of	of	IN
cord-340028-6oicmeam	271	130	Nicotinamide	Nicotinamide	NNP
cord-340028-6oicmeam	271	131	Riboside	Riboside	NNP
cord-340028-6oicmeam	271	132	on	on	IN
cord-340028-6oicmeam	271	133	Metabolism	Metabolism	NNP
cord-340028-6oicmeam	271	134	and	and	CC
cord-340028-6oicmeam	271	135	Vascular	Vascular	NNP
cord-340028-6oicmeam	271	136	Function	Function	NNP
cord-340028-6oicmeam	271	137	Nicotinamide	Nicotinamide	NNP
cord-340028-6oicmeam	271	138	Riboside	Riboside	NNP
cord-340028-6oicmeam	271	139	and	and	CC
cord-340028-6oicmeam	271	140	Metabolic	Metabolic	NNP
cord-340028-6oicmeam	271	141	Health	Health	NNP
cord-340028-6oicmeam	271	142	Nicotinamide	Nicotinamide	NNP
cord-340028-6oicmeam	271	143	Riboside	Riboside	NNP
cord-340028-6oicmeam	271	144	in	in	IN
cord-340028-6oicmeam	271	145	Systolic	Systolic	NNP
cord-340028-6oicmeam	271	146	Heart	Heart	NNP
cord-340028-6oicmeam	271	147	Failure	Failure	NNP
cord-340028-6oicmeam	271	148	Acute	Acute	NNP
cord-340028-6oicmeam	271	149	nicotinamide	nicotinamide	NN
cord-340028-6oicmeam	271	150	riboside	riboside	NN
cord-340028-6oicmeam	271	151	supplementation	supplementation	NN
cord-340028-6oicmeam	271	152	improves	improve	VBZ
cord-340028-6oicmeam	271	153	redox	redox	JJ
cord-340028-6oicmeam	271	154	homeostasis	homeostasis	NN
cord-340028-6oicmeam	271	155	and	and	CC
cord-340028-6oicmeam	271	156	exercise	exercise	NN
cord-340028-6oicmeam	271	157	performance	performance	NN
cord-340028-6oicmeam	271	158	in	in	IN
cord-340028-6oicmeam	271	159	old	old	JJ
cord-340028-6oicmeam	271	160	individuals	individual	NNS
cord-340028-6oicmeam	271	161	:	:	:
cord-340028-6oicmeam	271	162	a	a	DT
cord-340028-6oicmeam	271	163	double	double	JJ
cord-340028-6oicmeam	271	164	-	-	HYPH
cord-340028-6oicmeam	271	165	blind	blind	JJ
cord-340028-6oicmeam	271	166	cross	cross	NN
cord-340028-6oicmeam	271	167	-	-	HYPH
cord-340028-6oicmeam	271	168	over	over	RP
cord-340028-6oicmeam	271	169	study	study	NN
cord-340028-6oicmeam	271	170	Chronic	Chronic	NNP
cord-340028-6oicmeam	271	171	nicotinamide	nicotinamide	NN
cord-340028-6oicmeam	271	172	riboside	riboside	NN
cord-340028-6oicmeam	271	173	supplementation	supplementation	NN
cord-340028-6oicmeam	271	174	is	be	VBZ
cord-340028-6oicmeam	271	175	welltolerated	welltolerate	VBN
cord-340028-6oicmeam	271	176	and	and	CC
cord-340028-6oicmeam	271	177	elevates	elevate	VBZ
cord-340028-6oicmeam	271	178	NAD	NAD	NNP
cord-340028-6oicmeam	271	179	+	+	CC
cord-340028-6oicmeam	271	180	in	in	IN
cord-340028-6oicmeam	271	181	healthy	healthy	JJ
cord-340028-6oicmeam	271	182	middle	middle	NN
cord-340028-6oicmeam	271	183	-	-	HYPH
cord-340028-6oicmeam	271	184	aged	aged	JJ
cord-340028-6oicmeam	271	185	and	and	CC
cord-340028-6oicmeam	271	186	older	old	JJR
cord-340028-6oicmeam	271	187	adults	adult	NNS
cord-340028-6oicmeam	271	188	Plaque	plaque	VB
cord-340028-6oicmeam	271	189	Inflammation	inflammation	NN
cord-340028-6oicmeam	271	190	and	and	CC
cord-340028-6oicmeam	271	191	Dysfunctional	dysfunctional	JJ
cord-340028-6oicmeam	271	192	HDL	HDL	NNP
cord-340028-6oicmeam	271	193	in	in	IN
cord-340028-6oicmeam	271	194	AIM	aim	NN
cord-340028-6oicmeam	271	195	-	-	HYPH
cord-340028-6oicmeam	271	196	HIGH	HIGH	NNP
cord-340028-6oicmeam	271	197	Treatment	Treatment	NNP
cord-340028-6oicmeam	271	198	of	of	IN
cord-340028-6oicmeam	271	199	HDL	HDL	NNP
cord-340028-6oicmeam	271	200	to	to	TO
cord-340028-6oicmeam	271	201	Reduce	reduce	VB
cord-340028-6oicmeam	271	202	the	the	DT
cord-340028-6oicmeam	271	203	Incidence	Incidence	NNP
cord-340028-6oicmeam	271	204	of	of	IN
cord-340028-6oicmeam	271	205	Vascular	vascular	JJ
cord-340028-6oicmeam	271	206	Events	event	NNS
cord-340028-6oicmeam	271	207	HPS2-THRIVE	hps2-thrive	CD
cord-340028-6oicmeam	272	1	Interacting	interact	VBG
cord-340028-6oicmeam	272	2	NAD	NAD	NNP
cord-340028-6oicmeam	273	1	+	+	CC
cord-340028-6oicmeam	274	1	and	and	CC
cord-340028-6oicmeam	274	2	Cell	cell	NN
cord-340028-6oicmeam	274	3	Senescence	senescence	NN
cord-340028-6oicmeam	274	4	Pathways	pathway	NNS
cord-340028-6oicmeam	274	5	Complicate	complicate	VBP
cord-340028-6oicmeam	275	1	Antiaging	Antiaging	NNP
cord-340028-6oicmeam	275	2	Therapies	Therapies	NNP
cord-340028-6oicmeam	275	3	Molecular	Molecular	NNP
cord-340028-6oicmeam	275	4	immune	immune	JJ
cord-340028-6oicmeam	275	5	www.aging-us.com	www.aging-us.com	ADD
cord-340028-6oicmeam	276	1	AGING	age	VBG
cord-340028-6oicmeam	276	2	pathogenesis	pathogenesis	NN
cord-340028-6oicmeam	276	3	and	and	CC
cord-340028-6oicmeam	276	4	diagnosis	diagnosis	NN
cord-340028-6oicmeam	276	5	of	of	IN
cord-340028-6oicmeam	277	1	COVID-19	COVID-19	NNP
cord-340028-6oicmeam	277	2	Nicotinamide	Nicotinamide	NNP
cord-340028-6oicmeam	277	3	Riboside	Riboside	NNP
cord-340028-6oicmeam	277	4	Augments	augment	VBZ
cord-340028-6oicmeam	277	5	the	the	DT
cord-340028-6oicmeam	277	6	Aged	Aged	NNP
cord-340028-6oicmeam	277	7	Human	Human	NNP
cord-340028-6oicmeam	277	8	Skeletal	Skeletal	NNP
cord-340028-6oicmeam	277	9	Muscle	Muscle	NNP
cord-340028-6oicmeam	277	10	NAD	NAD	NNP
cord-340028-6oicmeam	277	11	+	+	CC
cord-340028-6oicmeam	277	12	Metabolome	Metabolome	NNP
cord-340028-6oicmeam	277	13	and	and	CC
cord-340028-6oicmeam	277	14	Induces	induce	VBZ
cord-340028-6oicmeam	277	15	Transcriptomic	Transcriptomic	NNP
cord-340028-6oicmeam	277	16	and	and	CC
cord-340028-6oicmeam	277	17	Anti	anti	JJ
cord-340028-6oicmeam	277	18	-	-	JJ
cord-340028-6oicmeam	277	19	inflammatory	inflammatory	JJ
cord-340028-6oicmeam	277	20	Signatures	signature	NNS
cord-340028-6oicmeam	277	21	Head	Head	NNP
cord-340028-6oicmeam	277	22	to	to	IN
cord-340028-6oicmeam	277	23	Head	Head	NNP
cord-340028-6oicmeam	277	24	Comparison	Comparison	NNP
cord-340028-6oicmeam	277	25	of	of	IN
cord-340028-6oicmeam	277	26	Short	Short	NNP
cord-340028-6oicmeam	277	27	-	-	HYPH
cord-340028-6oicmeam	277	28	Term	Term	NNP
cord-340028-6oicmeam	277	29	Treatment	Treatment	NNP
cord-340028-6oicmeam	277	30	with	with	IN
cord-340028-6oicmeam	277	31	the	the	DT
cord-340028-6oicmeam	277	32	NAD(+	nad(+	CD
cord-340028-6oicmeam	277	33	)	)	-RRB-
cord-340028-6oicmeam	278	1	Precursor	Precursor	NNP
cord-340028-6oicmeam	278	2	Nicotinamide	Nicotinamide	NNP
cord-340028-6oicmeam	278	3	Mononucleotide	Mononucleotide	NNP
cord-340028-6oicmeam	278	4	(	(	-LRB-
cord-340028-6oicmeam	278	5	NMN	NMN	NNP
cord-340028-6oicmeam	278	6	)	)	-RRB-
cord-340028-6oicmeam	278	7	and	and	CC
cord-340028-6oicmeam	278	8	6	6	CD
cord-340028-6oicmeam	278	9	Weeks	week	NNS
cord-340028-6oicmeam	278	10	of	of	IN
cord-340028-6oicmeam	278	11	Exercise	Exercise	NNP
cord-340028-6oicmeam	278	12	in	in	IN
cord-340028-6oicmeam	278	13	Obese	obese	JJ
cord-340028-6oicmeam	278	14	Female	female	JJ
cord-340028-6oicmeam	278	15	Mice	mouse	NNS
cord-340028-6oicmeam	278	16	Pharmacological	pharmacological	JJ
cord-340028-6oicmeam	278	17	inhibition	inhibition	NN
cord-340028-6oicmeam	278	18	of	of	IN
cord-340028-6oicmeam	278	19	nicotinamide	nicotinamide	NN
cord-340028-6oicmeam	278	20	phosphoribosyltransferase/	phosphoribosyltransferase/	HYPH
cord-340028-6oicmeam	278	21	visfatin	visfatin	FW
cord-340028-6oicmeam	278	22	enzymatic	enzymatic	JJ
cord-340028-6oicmeam	278	23	activity	activity	NN
cord-340028-6oicmeam	278	24	identifies	identify	VBZ
cord-340028-6oicmeam	278	25	a	a	DT
cord-340028-6oicmeam	278	26	new	new	JJ
cord-340028-6oicmeam	278	27	inflammatory	inflammatory	JJ
cord-340028-6oicmeam	278	28	pathway	pathway	NN
cord-340028-6oicmeam	278	29	linked	link	VBN
cord-340028-6oicmeam	278	30	to	to	IN
cord-340028-6oicmeam	278	31	NAD	NAD	NNP
cord-340028-6oicmeam	278	32	CD38	CD38	NNP
cord-340028-6oicmeam	278	33	Is	be	VBZ
cord-340028-6oicmeam	278	34	Robustly	robustly	RB
cord-340028-6oicmeam	278	35	Induced	induce	VBN
cord-340028-6oicmeam	278	36	in	in	IN
cord-340028-6oicmeam	278	37	Human	Human	NNP
cord-340028-6oicmeam	278	38	Macrophages	Macrophages	NNPS
cord-340028-6oicmeam	278	39	and	and	CC
cord-340028-6oicmeam	278	40	Monocytes	Monocytes	NNPS
cord-340028-6oicmeam	278	41	in	in	IN
cord-340028-6oicmeam	278	42	Inflammatory	Inflammatory	NNP
cord-340028-6oicmeam	278	43	Conditions	condition	NNS
cord-340028-6oicmeam	279	1	The	the	DT
cord-340028-6oicmeam	279	2	Clinical	clinical	JJ
cord-340028-6oicmeam	279	3	Potential	potential	NN
cord-340028-6oicmeam	279	4	of	of	IN
cord-340028-6oicmeam	279	5	Senolytic	Senolytic	NNP
cord-340028-6oicmeam	279	6	Drugs	Drugs	NNP
cord-340028-6oicmeam	279	7	Cardiac	Cardiac	NNP
cord-340028-6oicmeam	279	8	glycosides	glycoside	NNS
cord-340028-6oicmeam	279	9	are	be	VBP
cord-340028-6oicmeam	280	1	broad	broad	JJ
cord-340028-6oicmeam	280	2	-	-	HYPH
cord-340028-6oicmeam	280	3	spectrum	spectrum	NN
cord-340028-6oicmeam	280	4	senolytics	senolytic	NNS
cord-340028-6oicmeam	280	5	Senolytics	Senolytics	NNP
cord-340028-6oicmeam	280	6	decrease	decrease	VBP
cord-340028-6oicmeam	280	7	senescent	senescent	JJ
cord-340028-6oicmeam	280	8	cells	cell	NNS
cord-340028-6oicmeam	280	9	in	in	IN
cord-340028-6oicmeam	280	10	humans	human	NNS
cord-340028-6oicmeam	280	11	:	:	:
cord-340028-6oicmeam	281	1	preliminary	preliminary	JJ
cord-340028-6oicmeam	281	2	report	report	NN
cord-340028-6oicmeam	281	3	from	from	IN
cord-340028-6oicmeam	281	4	a	a	DT
cord-340028-6oicmeam	281	5	clinical	clinical	JJ
cord-340028-6oicmeam	281	6	trial	trial	NN
cord-340028-6oicmeam	281	7	of	of	IN
cord-340028-6oicmeam	281	8	Dasatinib	Dasatinib	NNP
cord-340028-6oicmeam	281	9	plus	plus	CC
cord-340028-6oicmeam	281	10	Quercetin	Quercetin	NNPS
cord-340028-6oicmeam	281	11	in	in	IN
cord-340028-6oicmeam	281	12	individuals	individual	NNS
cord-340028-6oicmeam	281	13	with	with	IN
cord-340028-6oicmeam	281	14	diabetic	diabetic	JJ
cord-340028-6oicmeam	281	15	kidney	kidney	NN
cord-340028-6oicmeam	281	16	disease	disease	NN
cord-340028-6oicmeam	281	17	Effect	Effect	NNP
cord-340028-6oicmeam	281	18	of	of	IN
cord-340028-6oicmeam	281	19	Flavonoids	Flavonoids	NNP
cord-340028-6oicmeam	281	20	on	on	IN
cord-340028-6oicmeam	281	21	Upper	Upper	NNP
cord-340028-6oicmeam	281	22	Respiratory	respiratory	JJ
cord-340028-6oicmeam	281	23	Tract	tract	NN
cord-340028-6oicmeam	281	24	Infections	Infections	NNPS
cord-340028-6oicmeam	281	25	and	and	CC
cord-340028-6oicmeam	281	26	Immune	Immune	NNP
cord-340028-6oicmeam	281	27	Function	function	NN
cord-340028-6oicmeam	281	28	:	:	:
cord-340028-6oicmeam	282	1	A	a	DT
cord-340028-6oicmeam	282	2	Systematic	Systematic	NNP
cord-340028-6oicmeam	282	3	Review	Review	NNP
cord-340028-6oicmeam	282	4	and	and	CC
cord-340028-6oicmeam	282	5	Meta	Meta	NNP
cord-340028-6oicmeam	282	6	-	-	HYPH
cord-340028-6oicmeam	282	7	Analysis	Analysis	NNP
cord-340028-6oicmeam	282	8	2	2	CD
cord-340028-6oicmeam	282	9	years	year	NNS
cord-340028-6oicmeam	282	10	of	of	IN
cord-340028-6oicmeam	282	11	calorie	calorie	NN
cord-340028-6oicmeam	282	12	restriction	restriction	NN
cord-340028-6oicmeam	282	13	and	and	CC
cord-340028-6oicmeam	282	14	cardiometabolic	cardiometabolic	JJ
cord-340028-6oicmeam	282	15	risk	risk	NN
cord-340028-6oicmeam	282	16	(	(	-LRB-
cord-340028-6oicmeam	282	17	CALERIE	CALERIE	NNP
cord-340028-6oicmeam	282	18	)	)	-RRB-
cord-340028-6oicmeam	282	19	:	:	:
cord-340028-6oicmeam	282	20	exploratory	exploratory	JJ
cord-340028-6oicmeam	282	21	outcomes	outcome	NNS
cord-340028-6oicmeam	282	22	of	of	IN
cord-340028-6oicmeam	282	23	a	a	DT
cord-340028-6oicmeam	282	24	multicentre	multicentre	NN
cord-340028-6oicmeam	282	25	,	,	,
cord-340028-6oicmeam	282	26	phase	phase	NN
cord-340028-6oicmeam	282	27	2	2	CD
cord-340028-6oicmeam	282	28	,	,	,
cord-340028-6oicmeam	282	29	randomised	randomise	VBN
cord-340028-6oicmeam	282	30	controlled	control	VBN
cord-340028-6oicmeam	282	31	trial	trial	NN
cord-340028-6oicmeam	283	1	The	the	DT
cord-340028-6oicmeam	283	2	role	role	NN
cord-340028-6oicmeam	283	3	of	of	IN
cord-340028-6oicmeam	283	4	intermittent	intermittent	JJ
cord-340028-6oicmeam	283	5	fasting	fasting	NN
cord-340028-6oicmeam	283	6	and	and	CC
cord-340028-6oicmeam	283	7	meal	meal	NN
cord-340028-6oicmeam	283	8	timing	timing	NN
cord-340028-6oicmeam	283	9	in	in	IN
cord-340028-6oicmeam	283	10	weight	weight	NN
cord-340028-6oicmeam	283	11	management	management	NN
cord-340028-6oicmeam	283	12	and	and	CC
cord-340028-6oicmeam	283	13	metabolic	metabolic	JJ
cord-340028-6oicmeam	283	14	health	health	NN
cord-340028-6oicmeam	283	15	Effects	effect	NNS
cord-340028-6oicmeam	283	16	of	of	IN
cord-340028-6oicmeam	283	17	Intermittent	intermittent	JJ
cord-340028-6oicmeam	283	18	Fasting	fast	VBG
cord-340028-6oicmeam	283	19	on	on	IN
cord-340028-6oicmeam	283	20	Health	Health	NNP
cord-340028-6oicmeam	283	21	,	,	,
cord-340028-6oicmeam	283	22	Aging	aging	NN
cord-340028-6oicmeam	283	23	,	,	,
cord-340028-6oicmeam	283	24	and	and	CC
cord-340028-6oicmeam	283	25	Disease	Disease	NNP
cord-340028-6oicmeam	283	26	Regulatory	Regulatory	NNP
cord-340028-6oicmeam	283	27	T	T	NNP
cord-340028-6oicmeam	283	28	cells	cell	NNS
cord-340028-6oicmeam	283	29	and	and	CC
cord-340028-6oicmeam	284	1	Foxp3	foxp3	JJ
cord-340028-6oicmeam	284	2	Inhibition	Inhibition	NNP
cord-340028-6oicmeam	284	3	of	of	IN
cord-340028-6oicmeam	284	4	HDAC9	HDAC9	NNP
cord-340028-6oicmeam	284	5	increases	increase	VBZ
cord-340028-6oicmeam	284	6	T	T	NNP
cord-340028-6oicmeam	284	7	regulatory	regulatory	JJ
cord-340028-6oicmeam	284	8	cell	cell	NN
cord-340028-6oicmeam	284	9	function	function	NN
cord-340028-6oicmeam	284	10	and	and	CC
cord-340028-6oicmeam	284	11	prevents	prevent	VBZ
cord-340028-6oicmeam	284	12	colitis	colitis	NN
cord-340028-6oicmeam	284	13	in	in	IN
cord-340028-6oicmeam	284	14	mice	mouse	NNS
cord-340028-6oicmeam	284	15	Sirtuin-1	Sirtuin-1	NNP
cord-340028-6oicmeam	285	1	targeting	targeting	NN
cord-340028-6oicmeam	285	2	promotes	promote	VBZ
cord-340028-6oicmeam	286	1	Foxp3	foxp3	JJ
cord-340028-6oicmeam	286	2	+	+	CC
cord-340028-6oicmeam	286	3	Tregulatory	tregulatory	JJ
cord-340028-6oicmeam	286	4	cell	cell	NN
cord-340028-6oicmeam	286	5	function	function	NN
cord-340028-6oicmeam	286	6	and	and	CC
cord-340028-6oicmeam	286	7	prolongs	prolong	VBZ
cord-340028-6oicmeam	286	8	allograft	allograft	NN
cord-340028-6oicmeam	286	9	survival	survival	NN
cord-340028-6oicmeam	286	10	Are	be	VBP
cord-340028-6oicmeam	286	11	There	there	RB
cord-340028-6oicmeam	287	1	Reliable	Reliable	NNP
cord-340028-6oicmeam	287	2	Biomarkers	Biomarkers	NNPS
cord-340028-6oicmeam	287	3	for	for	IN
cord-340028-6oicmeam	287	4	Immunosenescence	Immunosenescence	NNP
cord-340028-6oicmeam	287	5	and	and	CC
cord-340028-6oicmeam	287	6	Inflammaging	Inflammaging	NNP
cord-340028-6oicmeam	287	7	Deep	Deep	NNP
cord-340028-6oicmeam	287	8	biomarkers	biomarker	NNS
cord-340028-6oicmeam	287	9	of	of	IN
cord-340028-6oicmeam	287	10	human	human	JJ
cord-340028-6oicmeam	287	11	aging	aging	NN
cord-340028-6oicmeam	287	12	:	:	:
cord-340028-6oicmeam	287	13	application	application	NN
cord-340028-6oicmeam	287	14	of	of	IN
cord-340028-6oicmeam	287	15	deep	deep	JJ
cord-340028-6oicmeam	287	16	neural	neural	JJ
cord-340028-6oicmeam	287	17	networks	network	NNS
cord-340028-6oicmeam	287	18	to	to	IN
cord-340028-6oicmeam	287	19	biomarker	biomarker	NN
cord-340028-6oicmeam	287	20	development	development	NN
cord-340028-6oicmeam	287	21	Machine	machine	NN
cord-340028-6oicmeam	287	22	Learning	learn	VBG
cord-340028-6oicmeam	287	23	on	on	IN
cord-340028-6oicmeam	287	24	Human	Human	NNP
cord-340028-6oicmeam	287	25	Muscle	Muscle	NNP
cord-340028-6oicmeam	287	26	Transcriptomic	Transcriptomic	NNP
cord-340028-6oicmeam	287	27	Data	Data	NNP
cord-340028-6oicmeam	287	28	for	for	IN
cord-340028-6oicmeam	287	29	Biomarker	Biomarker	NNP
cord-340028-6oicmeam	287	30	Discovery	Discovery	NNP
cord-340028-6oicmeam	287	31	and	and	CC
cord-340028-6oicmeam	287	32	Tissue	tissue	NN
cord-340028-6oicmeam	287	33	-	-	HYPH
cord-340028-6oicmeam	287	34	Specific	Specific	NNP
cord-340028-6oicmeam	287	35	Drug	drug	NN
cord-340028-6oicmeam	287	36	Target	Target	NNP
cord-340028-6oicmeam	287	37	Identification	identification	NN
cord-340028-6oicmeam	287	38	Deep	deep	JJ
cord-340028-6oicmeam	287	39	learning	learning	NN
cord-340028-6oicmeam	287	40	enables	enable	VBZ
cord-340028-6oicmeam	287	41	rapid	rapid	JJ
cord-340028-6oicmeam	287	42	identification	identification	NN
cord-340028-6oicmeam	287	43	of	of	IN
cord-340028-6oicmeam	287	44	potent	potent	JJ
cord-340028-6oicmeam	287	45	DDR1	DDR1	NNP
cord-340028-6oicmeam	287	46	kinase	kinase	NN
cord-340028-6oicmeam	287	47	inhibitors	inhibitor	NNS
cord-340028-6oicmeam	288	1	Genome	genome	NN
cord-340028-6oicmeam	288	2	-	-	HYPH
cord-340028-6oicmeam	288	3	wide	wide	JJ
cord-340028-6oicmeam	288	4	methylation	methylation	NN
cord-340028-6oicmeam	288	5	profiles	profile	NNS
cord-340028-6oicmeam	288	6	reveal	reveal	VBP
cord-340028-6oicmeam	288	7	quantitative	quantitative	JJ
cord-340028-6oicmeam	288	8	views	view	NNS
cord-340028-6oicmeam	288	9	of	of	IN
cord-340028-6oicmeam	288	10	human	human	JJ
cord-340028-6oicmeam	288	11	aging	aging	NN
cord-340028-6oicmeam	288	12	rates	rate	NNS
cord-340028-6oicmeam	288	13	Human	human	JJ
cord-340028-6oicmeam	288	14	microbiome	microbiome	NN
cord-340028-6oicmeam	288	15	aging	age	VBG
cord-340028-6oicmeam	288	16	clocks	clock	NNS
cord-340028-6oicmeam	288	17	based	base	VBN
cord-340028-6oicmeam	288	18	on	on	IN
cord-340028-6oicmeam	288	19	deep	deep	JJ
cord-340028-6oicmeam	288	20	learning	learning	NN
cord-340028-6oicmeam	288	21	and	and	CC
cord-340028-6oicmeam	288	22	tandem	tandem	NN
cord-340028-6oicmeam	288	23	of	of	IN
cord-340028-6oicmeam	288	24	permutation	permutation	NN
cord-340028-6oicmeam	288	25	feature	feature	VBP
cord-340028-6oicmeam	288	26	importance	importance	NN
cord-340028-6oicmeam	288	27	and	and	CC
cord-340028-6oicmeam	288	28	accumulated	accumulate	VBN
cord-340028-6oicmeam	288	29	local	local	JJ
cord-340028-6oicmeam	288	30	effects	effect	NNS
cord-340028-6oicmeam	288	31	.	.	.
cord-340028-6oicmeam	289	1	bioRxiv	biorxiv	RB
cord-340028-6oicmeam	290	1	Deep	deep	JJ
cord-340028-6oicmeam	290	2	Aging	Aging	NNP
cord-340028-6oicmeam	290	3	Clocks	clock	NNS
cord-340028-6oicmeam	290	4	:	:	:
cord-340028-6oicmeam	291	1	The	the	DT
cord-340028-6oicmeam	291	2	Emergence	emergence	NN
cord-340028-6oicmeam	291	3	of	of	IN
cord-340028-6oicmeam	291	4	AI	AI	NNP
cord-340028-6oicmeam	291	5	-	-	HYPH
cord-340028-6oicmeam	291	6	Based	base	VBN
cord-340028-6oicmeam	291	7	Biomarkers	Biomarkers	NNPS
cord-340028-6oicmeam	291	8	of	of	IN
cord-340028-6oicmeam	291	9	Aging	age	VBG
cord-340028-6oicmeam	291	10	and	and	CC
cord-340028-6oicmeam	291	11	Longevity	Longevity	NNP
cord-340028-6oicmeam	291	12	UK	UK	NNP
cord-340028-6oicmeam	291	13	National	National	NNP
cord-340028-6oicmeam	291	14	Health	Health	NNP
cord-340028-6oicmeam	291	15	Service	Service	NNP
cord-340028-6oicmeam	291	16	.	.	.
cord-340028-6oicmeam	292	1	SARS	SARS	NNP
cord-340028-6oicmeam	292	2	(	(	-LRB-
cord-340028-6oicmeam	292	3	severe	severe	JJ
cord-340028-6oicmeam	292	4	acute	acute	JJ
cord-340028-6oicmeam	292	5	respiratory	respiratory	JJ
cord-340028-6oicmeam	292	6	syndrome	syndrome	NN
cord-340028-6oicmeam	292	7	)	)	-RRB-
cord-340028-6oicmeam	293	1	Insilico	Insilico	NNP
cord-340028-6oicmeam	293	2	Medicine	Medicine	NNP
cord-340028-6oicmeam	293	3	publishes	publish	VBZ
cord-340028-6oicmeam	293	4	molecular	molecular	JJ
cord-340028-6oicmeam	293	5	structures	structure	NNS
cord-340028-6oicmeam	293	6	for	for	IN
cord-340028-6oicmeam	293	7	the	the	DT
cord-340028-6oicmeam	293	8	key	key	JJ
cord-340028-6oicmeam	293	9	protein	protein	NN
cord-340028-6oicmeam	293	10	target	target	NN
cord-340028-6oicmeam	293	11	of	of	IN
cord-340028-6oicmeam	294	1	2019-nCoV	2019-ncov	LS
cord-340028-6oicmeam	294	2	Potential	Potential	NNP
cord-340028-6oicmeam	294	3	COVID-2019	COVID-2019	NNP
cord-340028-6oicmeam	294	4	3C	3c	NN
cord-340028-6oicmeam	294	5	-	-	HYPH
cord-340028-6oicmeam	294	6	like	like	JJ
cord-340028-6oicmeam	295	1	Protease	Protease	NNP
cord-340028-6oicmeam	295	2	Inhibitors	Inhibitors	NNP
cord-340028-6oicmeam	295	3	Designed	design	VBN
cord-340028-6oicmeam	295	4	Using	use	VBG
cord-340028-6oicmeam	295	5	Generative	Generative	NNP
cord-340028-6oicmeam	295	6	Deep	deep	JJ
cord-340028-6oicmeam	295	7	Learning	learning	NN
cord-340028-6oicmeam	295	8	Approaches	approach	VBZ
cord-340028-6oicmeam	295	9	How	how	WRB
cord-340028-6oicmeam	295	10	to	to	TO
cord-340028-6oicmeam	295	11	improve	improve	VB
cord-340028-6oicmeam	295	12	R&D	r&d	NN
cord-340028-6oicmeam	295	13	productivity	productivity	NN
cord-340028-6oicmeam	296	1	:	:	:
cord-340028-6oicmeam	296	2	the	the	DT
cord-340028-6oicmeam	296	3	pharmaceutical	pharmaceutical	JJ
cord-340028-6oicmeam	296	4	industry	industry	NN
cord-340028-6oicmeam	296	5	's	's	POS
cord-340028-6oicmeam	296	6	grand	grand	JJ
cord-340028-6oicmeam	296	7	challenge	challenge	NN
cord-340028-6oicmeam	296	8	Acute	acute	JJ
cord-340028-6oicmeam	296	9	respiratory	respiratory	JJ
cord-340028-6oicmeam	296	10	infections	infection	NNS
cord-340028-6oicmeam	296	11	are	be	VBP
cord-340028-6oicmeam	296	12	world	world	NN
cord-340028-6oicmeam	296	13	's	's	POS
cord-340028-6oicmeam	296	14	third	third	JJ
cord-340028-6oicmeam	296	15	leading	leading	JJ
cord-340028-6oicmeam	296	16	cause	cause	NN
cord-340028-6oicmeam	296	17	of	of	IN
cord-340028-6oicmeam	296	18	death	death	NN
cord-340028-6oicmeam	296	19	Network	network	NN
cord-340028-6oicmeam	296	20	-	-	HYPH
cord-340028-6oicmeam	296	21	based	base	VBN
cord-340028-6oicmeam	296	22	drug	drug	NN
cord-340028-6oicmeam	296	23	repurposing	repurpose	VBG
cord-340028-6oicmeam	296	24	for	for	IN
cord-340028-6oicmeam	296	25	novel	novel	JJ
cord-340028-6oicmeam	296	26	coronavirus	coronavirus	NN
cord-340028-6oicmeam	296	27	2019-nCoV	2019-ncov	CD
cord-340028-6oicmeam	296	28	/	/	SYM
cord-340028-6oicmeam	296	29	SARS	SARS	NNP
cord-340028-6oicmeam	296	30	-	-	HYPH
cord-340028-6oicmeam	296	31	CoV-2	CoV-2	NNP